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Cerebral small vessel disease (SVD) is associated with increased risks of stroke and 
dementia, however the mechanisms remain unclear. Low cerebral blood flow (CBF) 
has long been suggested and accepted, but clinical evidence is conflicting. On the 
other hand, growing evidence suggests that increased intracranial pulsatility due to 
vascular stiffening might be an alternative mechanism. Pulse-gated phase-contrast 
MRI is an imaging technique that allows measuring of CBF contemporaneously with 
pulsatility in multiple vessels and cerebrospinal fluid (CSF) spaces. The overall aim 
of this thesis was to provide an overview of existing clinical evidence on both 
hypotheses, to test the reproducibility of CBF and pulsatility measures in phase-
contrast MRI, and to explore the relationship between CBF and intracranial 
pulsatility and SVD features in a group of patients with minor stroke and SVD 
changes on brain imaging.  
I first systematically reviewed and meta-analysed clinical studies that have assessed 
CBF or intracranial pulsatility in SVD patients. There were 38 studies (n=4006) on 
CBF and 27 (n=3356) on intracranial pulsatility. Most were cross-sectional, and 
longitudinal studies were scarce. There were large heterogeneities in patient 
characteristics and indices used particularly for measuring and calculating pulsatility. 
Methods to reduce bias such as blinding and the expertise of structural image readers 
were generally poorly reported, and many studies did not account for the impact of 
confounding factors (e.g. age, vascular risk factors and disease severity) on CBF or 
pulsatility. Evidence for falling CBF predating SVD was not supported by 
longitudinal studies; high pulsatility in one large artery such as internal carotid 
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arteries (ICA) or middle cerebral arteries might be related to SVD, but studies that 
measured arteries, veins and CSF in the same patients were very limited and the 
reliability of some pulsatility measures, especially in CSF, needs to be tested.  
In order to test the reproducibility of the CBF and intracranial pulsatility measures, I 
repeated 2D phase-contrast MRI scans of vessels and CSF on healthy volunteers 
during two visits. I also compared the ICA pulsatility index derived from the MRI 
flow waveform to that from the Doppler ultrasound velocity waveform in patients 
with minor stroke and SVD features. In 10 heathy volunteers (age 35.2±9.78 years), 
the reproducibility of CBF and vascular pulsatility indices was good, with within-
subject coefficients of variability (CV) less than 10%; whereas CSF flow and 
pulsatility measures were generally less reproducible (CV>20%). In 56 patients (age 
67.8±8.27 years), the ICA pulsatility indices in Doppler ultrasound and MRI were 
acceptably well-correlated (r=0.5, p<0.001) considering the differences in the two 
techniques.  
We carried out a cross-sectional study aiming to recruit 60 patients with minor stroke 
and SVD features. We measured CBF and intracranial pulsatility using phase-
contrast MRI, as well as aortic augmentation index (AIx) using a SphygmoCor 
device. I first investigated the relationship between intracranial measures, and 
systemic blood pressure or aortic AIx, and then focused on how the intracranial 
haemodynamic measures related to two main SVD features (white matter 
hyperintensities (WMH) and perivascular spaces (PVS)). We obtained usable data 
from 56/60 patients (age 67.8±8.27 years), reflecting a range of SVD burdens. After 
the adjustment for age, gender, and history of hypertension, higher pulsatility in the 
venous sinuses was associated with lower diastolic blood pressure and lower mean 
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arterial pressure (e.g. diastolic blood pressure on straight sinus pulsatility index (PI): 
β=-0.005, P=0.029), but not with aortic AIx. Higher aortic AIx was associated with 
low ICA PI (β=-0.011, P=0.040). Increased pulsatility in the venous sinuses, not low 
CBF, was associated with greater WMH volume (e.g. superior sagittal sinus PI: 
β=1.29, P=0.005) and more basal ganglia PVS (e.g. odds ratio=1.379 per 0.1 increase 
in superior sagittal sinus PI) after the adjustment for age, gender and blood pressure.  
The thesis is the first to summarise the literature on CBF and intracranial pulsatility 
in SVD patients, addressed the major limitations of current clinical studies of SVD, 
and also assessed CBF and intracranial pulsatility contemporaneously in well-
characterised patients with SVD features. The overall results of the thesis challenge 
the traditional hypothesis of the cause and effect between low CBF and SVD, and 
suggest that increased cerebrovascular pulsatility, which might be due to intrinsic 
cerebral small vessel pathologies rather than just aortic stiffness, is important for 
SVD. More importantly, this pilot study also provides a reliable methodology for 
measuring intracranial pulsatility using phase-contrast MRI for future longitudinal or 
larger multicentre studies, and shows that intracranial pulsatility could be used as a 
secondary outcome in clinical trials of SVD. However, future research is required to 
elucidate the implication of venous pulsatility and to fully explore the passage of 
pulse wave transmission in the brain. Overall, this thesis advances knowledge and 
suggest potential targets for future SVD studies in terms of mechanisms, prevention 





Stroke and dementia are amongst the largest threats to our ageing society. A disease 
that affects small vessels in the brain is responsible for nearly half of dementia and 
1/5 of all strokes. As current technology is still not developed enough to directly 
visualise these vessels, the small vessel disease (SVD) is mainly diagnosed from 
lesions visible with brain imaging. There have been various theories on how these 
SVD lesions happen: the diseased small vessels might reduce the amount of blood 
entering the brain, or become stiffer which might be harmful for both vessels and 
brain tissues. 
In this thesis, I first reviewed all papers that measured brain blood flow or brain 
vascular health in patients who had SVD. I found that these studies were mostly not 
powerful enough to support their theories. They were generally rather small, or 
overlooked the fact that patients’ SVD might be largely due to age. They also 
measured the brain vessel health, or SVD differently, which makes a combined 
analysis very difficult.  
Then we carried out a new study, with the aim of setting up a standardised method 
for measuring blood flow and vascular function using a brain scanner. We tested 
these methods on healthy volunteers and made sure these measures are reliable. 
We then recruited 60 patients who had mini stroke and SVD changes in their brains. 
We measured the blood flow and brain vascular function using the tested methods, 
and also assessed their SVD burden. Eventually we obtained complete data on 56 
patients (40 male; age 67.95±8.69 years). We found that patients who had a worse 
brain vascular function had more severe SVD. This relationship still existed after we 
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considered the impact of age, gender and blood pressure. How this  brain vascular 
dysfunction happened was still unknown, but was related to lower blood pressure in 
our study. However, we did not find low total blood flow being associated with SVD.  
Our results suggest that vascular dysfunction that is related to stiffer vessel walls 
might be able to explain how SVD develops. Our current and next step is to measure 
brain blood flow and the vascular function in SVD patients in the long term and in 
more patients, and to examine whether any drugs could improve brain vascular 
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Chapter 1: Introduction 
As people live longer, stroke and dementia have become a great burden to the aging 
society. Worldwide, 47 million people were estimated to be living with dementia, 
and the number is expected to increase to 132 million by 2050.1 Every year, 15 
million people had a stroke, from which 5 million died and another 5 million are left 
disabled.2 Up to 45% of dementias (alone or in addition to Alzheimer’s disease 
(AD)), 25% of ischaemic strokes and a large proportion of haemorrhagic strokes are 
associated with a type of cerebrovascular disease, small vessel disease (SVD).3, 4 In 
addition, silent burden of SVD on brain imaging is very commonly seen in the 
elderly and could substantially worsen cognitive function and cause psychiatric and 
physical disabilities.4-6  
Theoretically, SVD are pathologies in perforating cerebral arterioles, capillaries, and 
venules. As currently, it is difficult to visualise small vessels in vivo, SVD is mostly 
diagnosed on brain imaging. Generally and in this thesis, the term “SVD” refers to a 
series of imaging changes in white matter and subcortical grey matter that are 
thought to result from the small vessel pathologies.(Figure 1) These features include 
recent small subcortical infarcts, lacunes, white matter hyperintensities (WMH), 
prominent perivascular spaces (PVS), cerebral microbleeds (CMB) and 





Figure 1 Key features of small vessel disease, including lacunar infarct, lacunes, 
white matter hyperintensities, enlarged perivascular spaces, and cerebral microbleeds. 
These features could be seen in the centrum semiovale, basal ganglia and sometimes 
in the brain stem. For brevity, only lesions in the centrum semiovale and basal 
ganglia are illustrated here. This figure is adapted from a figure in Prof Joanna M 
Wardlaw’s presentation in Chinese Stroke Association Inaugural Conference (2015, 





Figure 2 STRIVE: STandards for Reporting and Imaging of Small Vessel Disease: 
example findings (upper), schematic representations (middle) and a summary of 
imaging characteristics (lower) of MRI features for changes related to small vessel 
disease (SVD).7 The typical imaging features of SVD include recent small 
subcortical infarcts, white matter hyperintensities (WMH), lacunes, perivascular 
spaces (PVS), and cerebral microbleeds (CMB). A recent small subcortical infarct is 
an oval or tubular lesion of less than 20mm in diameter and appears hyperintense on 
diffusion-weighted imaging (DWI), T2-weighted (T2W), fluid-attenuated inversion 
recovery (FLAIR) sequences. WMH are punctuate or confluent lesions 
symmetrically distributed in the subcortical areas with hyperintense signals on T2W 
and FLAIR. A lacune is a round or oval subcortical lesion of usually 3-15 mm in 
diameter with fluid-filled signals on MRI, which is hyperintense on T2W but 
hypointense on T1W and FLAIR. It is consistent with a previous acute subcortical 
infarct or haemorrhage. A haemorrhagic lacune is hypointense on gradient-recalled 
echo (GRE) and susceptibility-weighted imaging (SWI). PVS are fluid-filled spaces 
that run along the course of a vessel. Thus on MRI, visible PVS are linear or oval 
fluid signals of usually less than 2 mm in diameter. CMB are small (generally 2–5 
mm in diameter, but sometimes up to 10 mm) areas of signal void with associated 
blooming on GRE or SWI sequences.7 This figure is a copy from a previous paper 7 




The importance of SVD has not been recognised until the generalised use of MRI in 
clinical routine and research during the last three decades. In older studies, vascular 
dementia was often referred to as “multiple-infarct dementia” or “post-stroke 
dementia”.3 The Hachinski’s ischaemic score was designed to distinguish vascular 
dementia and AD, which is based on the history of vascular risk factors, and 
presence and clinical characteristics of strokes.8 However, these terms and the 
Hachinski’s scale are imprecise and misleading, since a large proportion of patients 
with vascular dementia did not have a previous stroke. In vascular dementia, those 
who had SVD lesions without overt acute symptoms are even more common than 
those who had a stroke.3 SVD also appears in other types of dementia, such as AD. 
Almost half of patients with clinical probable AD had mixed pathology.9  
SVD could also present with acute symptoms, which is known as the lacunar stroke, 
or small-vessel-disease stroke if using the Trial of Org 10172 in Acute Stroke 
Treatment (TOAST) classification. Lacunar stroke is largely under-researched. Few 
if any other clinical trials particularly targeted lacunar stroke or treated it separately, 
apart from the Secondary Prevention of Small Subcortical Strokes (SPS3) trial which 
showed that long-term dual antiplatelet therapy was harmful to patients with lacunar 
stroke.10  
Despite the important association between SVD and dementia and stroke, the 
underlying mechanisms of SVD remain unknown, which greatly limits the 
prevention and treatment of SVD. Various mechanisms have been suggested. The 
advances in imaging techniques have also brought new insights into mechanisms of 
SVD. In this chapter, I will first describe the main imaging features and the historical 
perspectives of SVD. Then I will talk about emerging theories and evidence on SVD 
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mechanisms. As this thesis focuses on “ischaemic” SVD, I will mainly focus on 
lacunar infarct, WMH, and PVS.  
 
What is small vessel disease?  
Lacunar infarct 
Lacunar ischaemic stroke is defined as a stroke that is attributable to a recent small 
subcortical infarct less than 1.5 (or, some say, 2) cm diameter in white matter, basal 
ganglia, pons or brainstem, and is consistent with a lacunar clinical syndrome.11 It is 
also worth noting that a lacunar clinical syndrome could be due to either ischaemia 
or a small haemorrhage.12 On MRI, an acute lacunar infarct is shown as hyperintense 
on diffusion-weighted imaging (DWI) with a lowered apparent diffusion coefficient 
value, hyperintense on T2-weighted (T2W) and fluid-attenuated inversion recovery 
(FLAIR), hypointense on T1-weighted (T1W), and hypoattenuated on CT.(Figure 2)  
Since Fisher’s autopsy study in patients who had a history of hypertension and stroke, 
lacunar infarct has been generally thought to result from occlusion of deep 
perforating arteries.13 However, this phenomenon was rarely seen on imaging. In 
contrast, an imaging study on lacunar stroke discovered that some lacunar stroke 
lesions were not at the end of but surrounding the occluded artery, and there was also 
signal indicating thrombus in the arteriole lumen and blood products in and around 
the vessel wall. This finding suggested that some lacunar infarct lesions might be due 
to a leakage of the vessel wall rather than the traditional understanding of an 
occluded arteriole.14 A recent imaging study supported that patients with lacunar 
stroke had diffused blood brain barrier (BBB) impairment compared with those with 
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cortical stroke.15 These results indicated that lacunar infarct might be more complex 
than the simple paradigm described in Fisher’s original study.   
Lacune 
The French term “lacune” originally refers to small round holes in brain subcortical 
areas.16 In the 1960s, C. Miller Fisher used this term to describe those subcortical 
cavitated lesions on brain autopsy which he thought were healed lacunar infarcts.13 
Therefore in SVD research, it is very common that terms like “lacunar infarction”, 
“lacunar stroke” and “silent brain infarct” were used to refer to the cerebrospinal 
fluid (CSF)-filled cavities on brain MRI or autopsy.17 In fact, lacunes are not always 
“ischaemic”. They can also be the residual lesion of a small haemorrhage.18 Also, it 
is common that many non-cavitated lacunar ischaemic strokes were not counted as 
‘lacunar infarcts’.  
Lacunes of presumed vascular origin are round or ovoid, subcortical, fluid-filled 
cavities, with a diameter of 3-15 mm.(Figure 2) These can occur without any prior 
symptoms, but can also result from a previous acute small subcortical infarct or 
haemorrhage.7 PVS could also mimic lacunes when they are more than 3 mm in 
diameter.19 Large PVS might have also been miscounted as lacunes in many 
studies.20 Although many lacunes might have lacked acute symptoms, when present 
in larger numbers, they are associated with dementia, cognitive impairment, gait 
disturbance and an increased risk of stroke.21-23 In the general elderly population, the 
prevalence of lacunes ranges from 8% to 28% (mean age = 50-75 years).22 
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White matter hyperintensities 
WMH of presumed vascular origin are very common in older individuals and 
regarded as the typical sign of SVD. Symptoms of WMH develop insidiously, such 
as cognitive impairment, dementia, and depression;4 but the presence of WMH is 
associated with triple the risk of stroke, double the risk of dementia and higher risk 
of death.24 WMH are usually symmetrically and bilaterally distributed in the white 
matter including pons and brain stem, and also occur in deep grey matter. They 
appear hyperintense to the normal brain on T2W or FLAIR MRI, and can be patchy 
or confluent depending on their stage in development and severity.(Figure 2) 
Imaging-pathology studies on WMH were very limited and mostly were carried out 
when MRI was not very well developed. Thus the underlying pathology of WMH 
was not fully understood.25 Demyelination, loss of oligodendrocytes and axonal 
damage were often reported. Diffusion tensor imaging (DTI) studies provided 
indirect evidence for axonal damage and impaired white matter integrity in WMH.26 
Indeed, recent evidence indicates that WMH are rather heterogeneous, perhaps 
reflecting different disease stages. Reduced density of glia and vacuolation were 
observed in severe WMH suggesting end-stage disease.27 Autopsy MRI studies also 
found oedema that suggests leakage of fluid from the impaired BBB in and around 
WMH.28, 29 Although these ‘white’ lesions have until now been treated as if they 
were all the same, different degrees of ‘whiteness’ might indicate different ‘stages of 
formation’ - some very white WMH are probably at the end stage of disease and 
irreversible once demyelination or axonal damage have happened; some perhaps less 
white lesions might be reversible if they are mainly interstitial fluid imbalances 
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before permanent tissue damage has occurred.25 These observations remain to be 
confirmed in larger studies.  
Perivascular spaces 
PVS are the extension of the subarachnoid spaces that surround cerebral 
microvessels.30 They are fluid-filled spaces that follow the course of a vessel through 
the brain parenchyma.30(Figure 1) PVS are usually microscopic and not detected on 
CT or conventional MRIs. When enlarged, PVS are commonly seen as hyperintense 
on T2W MRI, either punctuate with a diameter less than 3 mm if imaged 
perpendicular to the course of the vessel, or linear if imaged parallel to the course of 
the vessel.31(Figure 2) PVS are most frequent in the inferior parts of the basal 
ganglia and centrum semiovale but can also occur in the brainstem. Though 3 mm 
has generally been considered as the cut-off diameter for distinguishing PVS from 
lacunes,19 occasional PVS could be larger and even cause a mass effect.7 PVS 
usually do not have a hyperintense rim on T2W or FLAIR images unless passing 
through a WMH area, which can help the discrimination between PVS and lacunes.  
Whether enlarged PVS should be regarded as ‘lesions’ is still controversial, as their 
clinical significance remains unclear. Although a few PVS can be normal,32 the 
numbers of PVS increased with advancing age and other features of SVD.20, 33-35 In 
some studies, more PVS were associated with increased risk of dementia or worse 
cognitive function or hypertension.19, 36, 37 The mechanisms underlying enlarged PVS 
are not well understood. In normal ageing and other neurological diseases like 
multiple sclerosis, PVS are associated with inflammatory markers.38 In SVD, it 
might be a sign of an impaired BBB.15 There is also a hypothesis that visible PVS are 
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associated with blockage of drainage of interstitial fluid (ISF),39 which might be 
attributed to increased vessel stiffness, as arterial pulsatility is thought to be a key 
driver of ISF drainage.40  
 
What causes SVD?  
Traditional risk factors 
Increasing age is significantly associated with SVD features. Modifiable risk factors 
including hypertension, hypercholesterolaemia, smoking and diabetes mellitus are 
also thought to be key risk factors in the pathogenesis of SVD, particularly 
hypertension. However, the relationship between these risk factors and SVD is 
complex. Lipohyalinosis, the typical vascular pathology of SVD, has long been 
thought to result from hypertension. The theory is supported by clinical evidence 
showing that hypertension is more prevalent in patients with WMH and that higher 
blood pressure was associated with more severe WMH.41 A recent study showed that 
vascular risk factors and large artery disease explained only 2% of the variance in 
WMH, leaving 98% of the variance unexplained, providing further evidence that 
WMH are mostly non-athromatous.42 This finding may give a clue as to why risk 
factor modifications so far have very limited effects on preventing WMH progression.  
Low cerebral blood flow 
The narrowing of small vessel lumen seen in the pathology studies led to the 
suggestion that low blood flow might be the cause of WMH, and that complete 
occlusion of the vessel would cause an acute lacunar infarct.4 The “chronic 
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hypoperfusion” hypothesis was supported by some animal studies which showed that 
white matter tract and glial cells were vulnerable to global ischaemia.43, 44 Many 
animal models of SVD are also based on chronic occlusion or stenosis of carotid 
arteries which is thought to reduce CBF. However, there is limited and  rather 
conflicting evidence in human studies. No direct association between carotid artery 
stenosis and lacunar stroke or WMH has been found in humans.45, 46 Furthermore, the 
relationship between CBF and WMH is not consistent across clinical studies. In 
some cross-sectional studies, low CBF was significantly related to more WMH, 
whereas in other studies, no such relationship was found.47, 48 These studies had 
different study designs, sample sizes and locations where low CBF was detected and 
most were cross-sectional. There are few longitudinal studies. Thus it is unclear 
whether there is a causal relationship between low CBF and WMH in humans. 
Endothelium dysfunction  
Common small vessel pathologies and BBB impairment were found in both 
clinically evident and covert SVD features, suggesting that SVD should be regarded 
as a whole-brain disease rather than be treated separately as individual conditions. 
An early endothelial failure has been suggested as a main precipitator of SVD,11 as 
the endothelium is the main component of the BBB. The impaired endothelium 
would enable plasma fluid components and blood cells to enter the vessel wall, 
leading to the disintegration of the vessel wall and fibrin deposition. If this happens 
at arterioles where there is smooth muscle, the components deposited in the arteriolar 
wall could result in both dilation and narrowing of the vessel lumen and vessel wall 
thickening, which would eventually precipitate inflammation, platelet adhesion, 
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luminal occlusion and thus a traditional infarct. Whereas at the capillary level where 
there is no smooth muscle between the endothelium and brain tissue, the leaky BBB 
would cause direct damage to the tissue, such as oedema and demyelination in white 
matter tracts.(Figure 3) 
 
 
Figure 3 Example of endothelial damage at the arteriole and capillary level. In the 
arterioles, the blood component would infiltrate into the tunica media (smooth 
muscle) and induce fibrin deposition and vessel wall disintegration, causing 
segmental narrowing or dilation of the vessel lumen. The impaired endothelial cells 
could also trigger platelet adhesion and aggregation. Eventually, these multiple 
factors would cause occlusion of the arteriole lumen and a traditional infarct. With 
the fibrin deposition in the vessel wall, the vessels would stiffen and be less able to 
compensate the cardiac pulsatile energy, thus increasing the pulsatility in the vessels 
and in turn exacerbating the endothelial damage. At the capillary level where there is 
no smooth muscle, but only pericytes and the basement membrane, between the 
endothelium and brain tissue, the impaired endothelial cells result in a leaky blood 
brain barrier, thus causing direct damage to the tissue, such as glial oedema and 
demyelination in white matter tracts. At both arteriole and capillary levels, the 
increased pulsatility might damage the fluid exchange between the interstitial spaces 
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and the perivascular spaces, leading to enlarged perivascular spaces and possibly 
impaired metabolite clearance from the brain cells.  
 
 
Increased vascular pulsatility  
But how does the endothelial function fail? It is likely that the cause of endothelial 
dysfunction is multi-factorial. Various factors have been suggested, including 
increasing age,49 inflammation50, 51 and salt intake11, 52. The impaired endothelium 
would cause the infiltration of the blood component into the tunica media (smooth 
muscle) and induce fibrin deposition and vessel wall disintegration, causing 
segmental narrowing or dilating of the vessel lumen and vessel stiffening.(Figure 3)  
It is hypothesized that stiffened vessels should be less able to dampen the pressure 
and pulsatility, leading to more pulsatile energies dissipating in the brain, which in 
turn could exacerbate and cause more endothelial damage. Growing evidence has 
shown that increased vascular pulsatility is related to endothelial dysfunction.53 At 
the microvascular level, high pulsatile flow along with increased sheer stress reduced 
the expression of endothelial tight junction markers, thus deteriorating the BBB.54 
Studies on endothelial cells in other organs showed that high pulsatility could also 
induce endothelial inflammatory responses, such as via activating the toll-like 
receptor 2 /NF-κB pathway.55 Furthermore, increased pulsatility could hamper the 
perivascular clearance pathway. In experimental models, the normal arterial pulse 
has been identified as a key factor in facilitating fluid drainage from the interstitium 
to the PVS and thence to the extracerebral CSF and venous system.40 PVS become 
enlarged and visible on MRI in patients with hypertension, and are associated with 
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other SVD features like WMH and lacunar stroke,7, 33 and with inflammation.56 Some 
clinical studies have observed high pulsatility in large cerebral arteries, such as the 
internal carotid artery (ICA) or middle cerebral arteries (MCA), was associated with 
WMH,57-59 but so far no clinical studies have assessed the relationship with PVS.    
However, there is also suggestion that increased aortic stiffness might be the source 
of the high intracranial pulsatility and in turn be the cause of SVD.53, 59 It is 
hypothesized that as the aorta becomes stiffer with older age or hypertension and is 
less able to buffer the high cardiac pulsatile energy, the impedance difference 
between high resistance peripheral arteries and central arteries becomes smaller, thus 
the excessive cardiac pulsatile energy would be more easily transmitted into “high-
flow and low-resistance” organs such as the brain and the kidney. Various studies 
have shown the association between aortic stiffness and WMH,60, 61 but most of the 
data supporting this theory is based on “healthy” populations. And very few studies 
have directly compared the aortic stiffness and intracranial pulsatility.  
Moreover, in studies that measured intracranial pulsatility, most only assessed one 
(or at most two) main artery by ultrasound. Cerebral veins and CSF are also thought 
to be important compartments for compensating arterial pulse pressure,62 since the 
sum of the brain volume, CSF, and intracranial blood is constrained within the 
skull.63 Few studies have assessed pulsatility in the cerebral arteries, veins, and CSF 
contemporaneously in the same subjects,64 and none has investigated how pulsatility 
in these multiple components related to aortic stiffness. 
Pulse-gated phase-contrast MRI is an imaging technique that is able to detect flow 
and pulsatility in the major cerebral vessels and CSF spaces. Previous studies showed 
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higher pulsatility in cerebral veins in patients with vascular dementia compared to 
healthy elderly controls,64 and altered CSF pulsatility in the aqueduct in patients with 
age-related depression compared to age-matched healthy volunteers.65 No studies 
have compared vascular and CSF pulsatility contemporaneously with CBF, with 





Aim of the thesis 
The aim of this thesis is to provide an overview of clinical evidence on CBF and 
intracranial pulsatility in subjects with SVD features, and then to set up a reliable 
method of CBF and pulsatility measurement and analysis. We will test this method in 
a pilot study with a group of typical patients who have SVD imaging changes, 
investigate the relationship between CBF and intracranial pulsatility, and SVD 
features, and explore how systemic measures such as blood pressure (BP) and aortic 





Chapter 2A: Cerebral blood flow in small vessel disease: a 
systematic review and meta-analysis 
The content of chapter 2A is a systematic review on cerebral blood flow in patients 
with small vessel disease, which has already been published in 2016. It is also part of 
the two systematic reviews in this thesis that I have undertaken for an overview of 
existing clinical evidence on changes of intracranial haemodynamic in small vessel 
disease. This chapter will be presented as the original publication, but supplementary 
materials will be added into the published manuscript for the comprehensiveness. 
Since the original search of the systematic review was undertaken before December 
2015, I updated the search from December 2015 to September 2017 while writing up 
this thesis. As the new studies were generally small and are not suitable for meta-
analysis, they were listed in a table following the original paper.  
Although I was the first author of this paper, various colleagues have contributed to 
the work of this systematic review. Authors’ contributions are listed as following: Dr 
Stephen D Makin (S.D.M.) and Prof Joanna M Wardlaw (J.M.W.) conceived the idea 
of the study. Yulu Shi (Y.S.) and J.M.W. designed the study. Y.S. did the data search 
and extracted data and statistical analyses. Dr Anton J. M. de Craen (A.J.M.D.C.) 
(now deceased), Dr Mark A van Buchem (M.A.VB.), and Dr Mirjam I Geerlings 
(M.I.G.) provided unpublished data for two longitudinal studies. J.M.W. cross-
checked the data. Y.S. drafted the report and designed the tables and figures. J.M.W., 
M.J.T., S.M., I.M., A.J.M.D.C., M.A.VB., and M.I.G. revised the report. All authors 
approved the manuscript.   
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Cerebral blood flow in small vessel disease: a systematic 
review and meta-analysis 
Introduction 
White matter hyperintensities (WMHs) are commonly seen on brain magnetic 
resonance imaging (MRI) in older people and are considered as one of the core 
neuroimaging findings of cerebral small vessel disease (SVD). They are defined as 
patchy or confluent hyperintensities on T2-weighted or FLAIR images, without 
cavitation, in subcortical white or deep grey matter regions.7 WMHs are associated 
with increasing age and vascular risk factors such as hypertension and diabetes.66 
Although the aetiology is not completely understood, chronic hypoperfusion is 
thought to be a key mechanism,67 perhaps resulting from narrowing of the arteriolar 
lumena secondary to lipohyalinosis and arteriolosclerosis. Based on this theory, 
mechanically-induced hypoperfusion models, for example partial or complete carotid 
artery occlusion, are used to create pathology that appears to mimic human SVD. 
However, no direct association between carotid artery stenosis and lacunar stroke or 
WMH has been found in human studies.45 
Additionally, the relationship between CBF and WMH is not consistent across 
human studies. In some cross-sectional studies, low CBF was significantly related to 
more WMHs, whereas in other studies, no such relationship was found.47, 48 These 
studies had different study designs, sample sizes and locations where low CBF was 
detected and most were cross-sectional. There are few longitudinal studies. Thus it is 
unclear whether there is causal relationship between low CBF and WMHs in humans, 
or whether there is region specificity.  
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We sought to establish if WMH were related to changes in CBF levels, or whether 
differences in CBF might be related to potential confounders such as age and tissue 
loss. We systematically reviewed the available longitudinal and cross-sectional 
studies in humans, performed a meta-analysis of cross-sectional studies to assess the 
overall effect size of CBF differences by WMH burden in different brain regions, 
assessed study quality and performed sensitivity analyses on important confounders.         
 
Methods 
We performed this review according to the MOOSE guidelines68  and a pre-specified 
protocol. We conducted a literature search of MEDLINE and EMBASE from 1946 
up to December 2015, using the Ovid Web Gateway. We used exploded headings 
related to Small Vessel Disease (i.e. small vessel disease, white matter 
hyperintensities, white matter lesion, leukoaraiosis, lacune, lacunar infarct) and 
Cerebral Blood Flow (i.e. cerebral blood flow, brain blood flow, brain perfusion, 
cerebral hypoperfusion) with the Boolean operator AND.  English and non-English 
literature were sought. Additional records were identified by hand searching from 
January 1990-December 2015 of Stroke and Journal of Cerebral Blood Flow & 
Metabolism. We also checked references cited in reviews and primary papers.  
 
Eligibility criteria  
We sought longitudinal and cross-sectional primary research studies assessing CBF 
in subjects with cerebral SVD.7 Studies measuring cerebral blood flow velocity 
(CBFv) using Doppler ultrasound techniques were also considered eligible. We 
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excluded studies targeting unilateral or bilateral severe carotid stenosis or occlusion, 
studies in children, animal studies, duplicate publications, conference abstracts, and 
cross-sectional studies from which we could not extract either absolute values of 
CBF or correlation/regression coefficients.   
 
Data extraction and analysis 
We screened all potentially relevant full papers and extracted data using a 
standardised form.  All data were cross-checked by a second reviewer (JMW). From 
those that met the inclusion criteria, we extracted data on study population 
characteristics, study design, SVD and CBF measurement techniques and units. We 
assessed the study quality using a checklist devised on the basis of the Strengthening 
the Reporting of Observational Studies in Epidemiology (STROBE) statement 
(www.equator-network.org) and a checklist in a previous paper,69 including factors 
such as study population and bias control. (Table 1)  
 
Table 1 The 9-point study quality checklist applied to all included studies 
Clearly reported study population (stroke, aging cohort, etc)? yes/no (1/0) 
Clearly defined inclusion criteria? yes/no (1/0) 
Prospective study? yes/no (1/0) 
Reported drop-out (how the final sample was reached)? yes/no (1/0) 
Adjusted/matched for risk factors (including age)?  yes/no (1/0) 
Reported number of & expertise of observers of SVD image? yes/no (1/0) 
Observers blinded to clinical data? yes/no (1/0) 
Clearly defined SVD? yes/no (1/0) 
Clearly described CBF measurement? yes/no (1/0) 
Overall score  /9 





For cross-sectional studies which reported means and standard deviations (SDs) of 
CBF, we extracted data on CBF in disease and control groups or according to SVD 
burden. Means and SDs were extracted from text or tables where available, or from 
graphs where necessary. For cross-sectional studies where only qualitative data for 
the association between CBF and WMH were available, we included the studies in 
the review but not in the meta-analysis: we noted the statistical methods, coefficients, 
P values and other covariates included in the regression.  
For longitudinal studies, we also listed follow-up durations and primary results 
extracted from the papers, and contacted the authors to request unpublished data on 
baseline and follow-up CBF and WMH volume.  
 
Data transformation and analysis 
All studies reporting means and SDs were included for meta-analysis. For studies 
that divided patients into more than two grades of WMH severity, we combined the 
means and SDs of groups to create a single pair-wise comparison using formulae 
from the Cochrane handbook (http://handbook.cochrane.org). We condensed data 
into new groups “negative to mild WMHs” indicating none to mild including 
multiple punctuate WMHs (eg. Fazekas deep WMH score 0 to1), and “moderate to 
severe WMHs” as beginning to large confluent WMHs (eg. Fazekas deep WMH 




Equation 1 Equations for calculating combined means and SDs 
  Group 1 
(e.g. 
males) 
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As most studies measured CBF in several regions of interest (ROIs), such as 
different grey matter and white matter regions, we conducted subgroup analysis by 
brain region. Due to various units of CBF being used in different papers, we 
calculated the standardised mean differences (SMD) and 95% confidence intervals 
(CI) for comparisons using a random-effect model. Sensitivity analyses were carried 
out for subjects with/without dementia and by age matching between study groups, 
as both strongly influence CBF. Meta-analyses were conducted using the Cochrane 
Collaboration’s Review Manager (Revman Version 5.3). We assessed for 
heterogeneity by calculating the I2 statistic and publication bias using a funnel plot.   
 
Results 
A total of 2843 publications were initially identified, of which 75 were potentially 
eligible and were selected for further review. We ultimately included 38 articles and 
excluded: conference abstracts (6), those where we were unable to access the full text 
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(6) or that had no analysable data (18), duplicate publications including the same 
participant population (3), and studies of severe carotid stenosis or occlusion 
(4).(Figure 4) Note that although presence of arterial diseases was an inclusion 
criterion of Second Manifestations of ARTerial disease-magnetic resonance 
(SMART-MR) study, carotid arterial stenosis or occlusion was not one of the criteria: 
here patients with carotid artery stenosis were included, but they only represented a 
small proportion of participants, thus we included the study70 in our review. The 38 
studies included a total of 4006 participants: 4/38 were longitudinal and 34/38 were 
cross-sectional.  
Some papers are from the same studies: van der Veen et al.70 and Bisschops et al.71 
from the SMART-MR study; Ten Dam et al.72 and van Es et al.73 from the 
Prospective Study of the Elderly at Risk (PROSPER) trial; Vernooij et al.74 and 
Claus et al.75 from the Rotterdam Scan Study. We were careful to count each 




Figure 4 PRISMA diagram of literature search 
  
Records identified through 
database searching  
(n =2843) 
Additional records identified 
through hand search  
(n = 2) 
Records after duplicates removed  
(n =2602) 
Records excluded  
(n = 2527) 
Full-text articles assessed for 
eligibility  
(n = 75) Full-text articles excluded (37): 
Conference abstract (6) 
No access to full text (6) 
No analysable numeric data or 
graphs (18) 
Duplicate publications (3) 
Severe carotid stenosis or 
occlusion (4) 
Studies included in the review  
(n = 38) 
Studies included in quantitative 
synthesis (meta-analysis) 
(n = 24) 
Studies included in the 
review but not available for 
meta-analysis (n=14): 
Longitudinal studies (4) 
Cross-sectional studies (10) 
37 
 
Characteristics of included studies 
Cross-sectional studies 
34 cross-sectional studies were included.(Table 2) 24/34 were suitable for meta-
analysis. 6/24 studies used patients with dementia plus WMH as disease groups. Of 
these six studies, two included AD,76, 77 the other four focused on vascular dementia 
including subcortical vascular dementia,78 multi-infarct dementia (MID),79, 80 and 
Binswanger’s disease.47 AD was diagnosed based on the criteria of the National 
Institute of Neurological and Communicative Disorders and Stroke, and the 
Alzheimer’s disease and Related Disorders Association (NINCDS/ADRDA) for 
probable AD. Vascular dementia diagnosis varied: CT/MRI evidence, DSM-III-R 
criteria,47, 79, 80 Hachinski ischaemia scores,79 and the criteria of the State of 
California Alzheimer’s Disease Diagnostic and Treatment Centres.78 In the 18/24 
studies of  non-demented subjects, 11 compared CBF between subjects having 
WMHs and normal controls with no or mild WMHs,81-91 one study performed the 
comparison between patients with depression (DSM-IV criteria) plus WMHs vs no 
WMHs,92 and the other four papers examined the differences in CBF across grades 
of WMH severity.48, 93-95 Of these four studies, two used Fazekas WMH rating 
scores,48, 95 the other two used self-designed rating systems similar to Fazekas’s 
method.93, 94 Two studies recruited patients with acute ischaemic symptoms: in Nezu 
et al.,81 patients presented with minor ischaemic stroke and brain scans were 
performed at least three weeks after onset; Huynh et al. only included TIA patients 
and brain scans were done acutely.81  
In the other 10/34 studies which only reported association analysis, two were 
population-based studies,74, 96 the other nine hospital-based studies included patients 
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with cerebrovascular risk factors,73, 97, 98 heart failure,99 dementia,100 and manifest 
arterial diseases.71   
 
Longitudinal studies  
Four longitudinal prospective studies, including 1079 participants, were 
included.(Table 2) Three were hospital-based70, 72, 101 and one from a population-
based aging study.102 Among these four studies, Bernbaum et al. recruited 
participants who presented acute minor stroke symptoms or transient ischaemic 
attack (TIA) and had baseline MRI within 48hrs after the onset.101 The other three 
studies did not include acute patients. The follow-up durations ranged from 1.5 to 7.7 
years. Kraut et al. compared the patterns of long-term CBF change in patients with 
progressive WMHs to those with stable WMHs,102 whereas the other three studies 
performed regression analyses between CBF and WMH data without subdividing 




Table 2 Characteristics of all included studies 
Study Sample 
size 
Participants (Baseline) Age 




Longitudinal studies (4) 
    Bernbaum 2015101 40 High risk TIA or minor 
ischaemic stroke 
61.0±11.0 DCS PWI ml/100 g/min 
    van der Veen 201570 575 Manifest arterial diseases* 57.0±10.0 Phase-contrast 
MRI 
ml/100 ml/min 
    Kraut 2008102 74 Progressive WMH 70.0±6.9 PET Not shown 
Stable WMH 67.1±7.0 
    Ten Dam 200772 390 history of vascular disease or 




Cross-sectional studies (34) 
   Cognitive impairment/Dementia (6) 
Kimura, N. 201276 98 late-onset AD with WMH 78.6±5.1 SPECT ml/100 g/min 
AD without WMH 77.4±5.0 
Schuff 200978 26 subcortical vascular dementia  77.0±8.0  ASL ml/100 g/min 
cognitively normal 73.0±8.0 




Yamaji 199777 32 AD with WMH  71.6±3.1 PET ml/100 ml/min 
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AD without WMH 71.0±4.3 
Kawamura 199379 40 MID 64.4±10.2 Xenon CT ml/100 g/min 
no WMH 67.2±10.5 
Kobari 199080 20 MID  68.1±12.0 Xenon CT ml/100 g/min 
neurologically normal controls 52.3±5.7 
   No cognitive impairment (18) 
Wagner 2015103 36 Extensive WMH 71.0 ASL ml/100 g/min 
No or mild WMH 67.0 
 Fu 201493 56 WMH Grade 3ƚ 68.1±8.1 Xenon CT ml/100 g/min 
WMH Grade 2 68.9±7.7 
WMH Grade 1 64.5±5.8 
WMH Grade 0 65.3±6.3 
Nezu 201281 18 lacunar stroke with severe 
WMHs 
76.0 PET ml/100 g/min 
lacunar stroke with mild WMH 74.0 
Huynh 2008104 35 TIA with moderate to severe 
WMH 
77.1±6.0 CT perfusion ml/100 g/min 
  TIA with mild WMH 62.6±16.3 
De Bastos-Leite 200894 21 WMH Grade 3ƚ 77.7±5.7 ASL ml/100 ml/min 
WMH Grade 2 74.4±4.6 
WMH Grade 1 74.0±5.0 
Zheng 200682 35 asymptomatic WMH  69.7±8.9 SPECT ml/g/min 
no WMH 67.1±6.9 
Ramli 200683 42 leukoraiosis on CT  70.19 CT perfusion ml/100 g/min 
no leukoaraiosis on CT 69.86 
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Kimura, M. 200392 20 depression (remission) with 
WMH 
78.5±5.1 SPECT ml/100 g/min 
depression (remission) without 
WMH 
77.4±5.0 
Cui 200384 98 WMH 70.0 TCD, SPECT cm/s 
no WMH 66.0 
O'Sullivan 200285 36 WMH 68.9±9.2 PET ml/100 g/min 
no WMH 72.7±7.7 
Yao 200086 10 extensive WMH 75.0±5.0 Xenon CT ml/100 g/min 
no WMH 72.0±5.0 
Markus 200087 17 Leukoraiosis  63.3±12.3 MRI Contrast ml/100 g/min 
no leukoraiosis 68.3±7.3   
Oishi 199988  45 WMH 66.8±8.4 Xenon CT ml/100 g/min 
no WMH 65.1±8.5 
Hatazawa 199789 33 asymptomatic WMH 71.3±8.6 PET ml/100 ml/min 
no WMH 68.5±10.2 
Miyazawa 199795 135 WMH Grade IVǂ 71.90±8.17 Xenon CT ml/100 g/min 
WMH Grade III 69.00±8.08 
WMH Grade II 67.30±9.87 
WMH Grade I 64.20±5.55 
WMH Grade 0 57.3±12.0 
Kuwabara 199648 24 hypertensive with moderate to 
severe leukoraiosisǂ  
67.0±9.0 PET ml/100 ml/min 





normotensive control 60.0±12.0 
Kobayashi 199190 246 apparent PVWMH 67.0±6.1 Xenon CT ml/100 g/min 
no or mild PVWMH 60.0±8.2 
Fazekas 198891 23 WMH  58.8±5.3 Xenon CT ml/100 g/min 
no WMH 58.2±2.8 
Studies only showing correlation/regression coefficients (10) 
Crane 2015105 26 Mild to severe WMH 73.3±8.8 ASL ml/100 g/min 
Alosco 201399 69 Heart failure with WMH 68.55±8.07 Doppler 
ultrasound  
cm/s 
Heliopoulos 201297 52 Hypertension with WMH 71.4±4.5 Doppler 
ultrasound  
cm/s 
van Es 201073 447 Cerebrovascular risk factors 






Vernooij 200874 892 Population-based  67.5±5.5 Phase-contrast 
MRI 
ml/100 g/min 
Bisschops 200471 228 Manifest arterial diseases* 59.0 Phase-contrast 
MRI 
ml/min 
Tzourio 200196 628 Population-based  68.9±2.9 Doppler 
ultrasound  
m/s 
Ott 1997100 40 Mixed dementia 72.8±8.7 SPECT %rCBF relative 
to cerebellum 
Claus 199675 60 Non-demented WMH 65.0-85.0§ SPECT %rCBF relative 
to cerebellum 
Isaka 199498 28 Cerebrovascular risk factors 67.8 Xenon CT ml/100 ml/min 
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without neurological deficits 
SD: standard deviation; CBF: cerebral blood flow; TIA: transient ischaemic attack; DCS-PWI: dynamic susceptibility contrast perfusion-
weighted imaging; MRI: magnetic resonance imaging; AD: Alzheimer’s disease; MID: multi-infarct dementia; BD: Binswanger’s disease; 
WMH: white matter hyperintensities; SPECT: Single-photon emission computed tomography;  ASL: Arterial spin labelling MRI; PET: 
positron emission tomography; TCD: Transcranial Doppler; CT: computed tomography; PVWMH: periventricular white matter 
hyperintensities; rCBF: regional cerebral blood flow.  
* Include manifest coronary artery disease, cerebrovascular disease, peripheral arterial disease or an abdominal aortic aneurysm.  
ƚ Fazekas WMH score;  






Figure 5 Quality assessment of included papers 
 
The average study quality score was 6/9. Scores were mainly lost for not reporting 
the drop-outs (25/38), no adjustment or matching for risk factors (including age) 
(17/38), not reporting expertise of image observers (20/38) and not using blinding 
(25/38). (Figure 5) 
 
Assessment of CBF measurement methods 
Three studies used phase-contrast MRI,70-74 seven used positron emission 
tomography (PET),47, 48, 77, 81, 85, 89, 102 six used single-photon emission computerized 
tomography (SPECT),75, 76, 82, 84, 92, 100 two used MRI contrast,87, 101 two used arterial 




































Quality assessment of included papers
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used CT perfusion83, 104 to assess CBF. Four studies measured CBFv in the MCA 
using transcranial Doppler ultrasound (TCD).84, 96, 97  
Meta-analysis of differences in CBF by WMH burden 
Meta-analysis using SMD in CBF was only possible for 24 cross-sectional studies. 
22 brain regions were extracted, but sufficient data were available from only 11 
regions which were used by at least three studies and were selected for the primary 
meta-analysis. These included: global brain mean CBF, basal ganglia, cortical grey 
matter (total, frontal, temporal, parietal and occipital gray matter) and white matter 
(total, frontal and occipital white matter, centrum semiovale). Most data were 
available for frontal grey matter; few studies provided white matter data.  
Figure 6 shows the results of and meta-analyses of global and cortical CBF, and 
Figure 7 shows the results of white matter CBF. Patients with more severe WMH had 
lower CBF than patients with mild WMH, globally and in most grey and white 
matter regions (e.g. mean global CBF: SMD -0.71, 95% CI -1.12, -0.30; total grey 
matter: SMD -0.50, 95% CI -0.97, -0.03; total white matter: SMD -1.16, 95% CI -
1.08, -0.53), except in the basal ganglia (SMD -1.25, 95% CI -2.53, 0.30) and 
occipital white matter (SMD -0.45, 95% CI -0.96, 0.05) where the difference in CBF 
did not reach significance.(Figure 6 and Figure 7) No studies in the meta-analysis 
separated normal appearing white matter (NAWM) and WMH. However, there were 
heterogeneities between studies for most of these comparisons that were not due to 
publication bias.(Figure 8) One study found that CBF in patients with lacunar 
lesions was lower than in those without, however, the result was not adjusted for 




Figure 6 Forest plot showing standard mean differences in global and grey matter 
CBF in patients with WMH in dementia & non-dementia studies. CBF in different 





Figure 7 Forest plot showing standard mean differences in white matter CBF in 
patients with WMH in dementia & non-dementia studies. CBF in different brain 






Figure 8 Funnel plot of all include data in meta-analysis. The symmetrical 




Sensitivity analysis of dementia and age  
We repeated the meta-analyses after excluding studies that included patients with 
dementia and then further excluded studies without age-matching. In most grey and 
white matter regions, the differences in CBF between subjects with high and low 
WMH burdens attenuated and were no longer significant, except for mean global 
brain CBF and the centrum semiovale. Most of the trends in the comparisons were 
still the same, apart from temporal grey matter.(Figure 9)  
We were not able to do a sensitivity analysis for vascular risk factors. Only one study, 
Ibayashi et al., used hypertensive but neurologically normal patients as the control 
group, and found lower CBF in patients with Binswanger’s dementia compared to 
the control group;47 none of the other studies matched or adjusted for vascular risk 






Figure 9 Sensitivity analysis: SMD of CBF in different brain areas in patients with 
moderate to severe WMH against those with negative to mild WMH. In each brain 
area, we showed the SMD of CBF in all studies, after excluding dementia studies and 
furthermore excluding studies without age-matching [number of studies] (number of 
participants). SMD: standard mean difference; CBF: cerebral blood flow; GM: grey 






Cross-sectional studies that provided data on associations between 
CBF and SVD features 
Among the 10 cross-sectional papers which only performed association analysis, 
three studies did not find an association between CBF and WMH burden.75, 98, 100 
Four studies reported that CBF was negatively related to WMH severity.71, 73, 74, 105 
Negative correlation between WMH features and CBFv were found in three studies, 
of which one assessed CBFv in ICA,97 and the other two in MCA.96, 99 Amongst all 
10 studies, six adjusted for covariates such as age, gender, and other vascular risk 










Results P Values Adjusted for other 






Mean CBF in cluster 
(LAP, SC, accumbens, 
AC and OF) and 
Fazekas score 
Rho=-0.55 0.006 Age, gender 
Mean CBF in cluster 
(LAI and OF) and 
Fazekas score 
Rho=-0.49 0.015 
Mean CBF in cluster 








CBFv and  WMH 
volume 













CCA-PSV and WMH 
score 
r=-0.256 0.067 No 
   CCA-EDV and WMH 
score 
r=-0.205 0.144  
   CCA-MFV and WMH 
score 
r=-0.134 0.342  




   ICA-EDV and WMH 
score 
r=-0.324 0.019  
   ICA-MFV and WMH 
score 











   TCBF and WMH 
volume 






WMH volume and 
tCBF 
0.03*  NS Age, gender 
WMH volume and 
TCBF 

















Quartiles of mean 
CBFv and WMH 





OR=1.6 (2nd quartile) 0.11 






Perfusion score and 
PVWMH 
score 
r=-0.17 0.3 No 
   Perfusion score and 
SCWMH score 







CBF and grades of 
severity of WMH 
-1.7§ (Frontal lobe) NS age, gender, type of 





NS ventricle-to-brain ratio 






PVWMH score and 
baseline CBF  
r=-0.364 NS No 
LAP: left anterior putamen; SC: subcallosal; AC: anterior caudate; OF: orbital frontal; LAI: left anterior insula; LOF: left orbital; FP: 
frontal pole; CBFv: cerebral blood flow velocity (measured by Doppler ultrasound ); WMH: white matter hyperintensities; BMI: Body 
mass index; CCA: common carotid artery; ICA: internal carotid artery; PSV: peak systolic velocity; EDV: end-diastolic velocity; MFV: 
mean-flow velocity; tCBF: total cerebral blow flow in ml/min; TCBF: cerebral blood flow per 100 ml brain volume; total brain perfusion: 
tCBF divided by brain volume; S.D.: standard deviation; lnWMH: natural log transformed white matter hyperintensities volume; IMT: 
intima media thickness; OR: odds ratio; PVWMH: periventricular white matter hyperintensities; SCWMH: subcortical white matter 
hyperintensities; NS: not significant; SPET: single-positron emission tomography.  
* Difference in lnWMH volume per S.D. increase of tCBF;  
ƚ Difference in lnWMH volume per S.D. decrease in TCBF;  
ǂ Difference in WMH per 100 ml/min increase in tCBF;  




Table 4 summarises the results of four longitudinal studies. The largest study (575 
subjects), Van der Veen et al. found that high WMH volume at baseline was 
significantly associated with falling CBF over 3.9 years follow-up.70 Ten dam et al. 
demonstrated in 390 subjects that a decline in global CBF over 2.75 years was 
associated with a progression in periventricular WMH (PVWMH) but not in deep 
WMH (DWMH).70 A small study (n=40) found low CBF in regions that developed 
WMH over 1.5 years follow-up (baseline WMH volume 9.21±11.87 ml).101 In 
contrast to the other findings of falling CBF over time, Kraut et al. demonstrated in 
74 subjects that CBF increased in some brain areas (right inferior temporal gyrus, 
right anterior cingulate, and the left superior temporal gyrus) over 7.7 years in 
patients with progressive WMH.102 Falling CBF was observed more in the posterior 
regions including right inferior parietal lobule and right occipital pole but was not 






Table 4 Results of longitudinal studies 
 Bernbaum 2015101 Van der veen 201570 Kraut 
2008*102 
Ten Dam 200772 
Sample size 40 575 74 390 
Follow-up time (years) 1.5 3.9 7.7 2.75 
CBF at baseline 16.0±0.2 ƚ (ml/100 
g/min) 
52.3±9.8 (ml/100 ml/min) NA 520.0±88.0 (ml/min) 
at follow-up NA NA 504.0±92.0 (ml/min) 
WMH (ml) at baseline 9.21±11.87 2.86±5.44 5.27±9.60 




Coefficient NA NA NA TWMH: OR=1.02 [95%CI: 
0.86, 1.21]; 
PVWMH: OR=1.03 [95%CI: 
0.87, 1.21] 
TWMH: OR=0.88 [95%CI: 
0.74, 1.06] 
P value NS 
bCBF and 
ΔWMH volume 
Coefficient OR=0.61 [95%CI: 
0.57, 0.65] 
PVWMH: Bǂ=0.00 [95%CI: -0.06, 0.05] 
DWMH: Bǂ =0.04 [95%CI: -0.04, 0.12] 
NA 
P value <0.001 NS 
bWMH volume 
and ΔCBF 
Coefficient NA PVWMH: B§ =-0.61 [95%CI: -1.32, 0.10] 
DWMH: B§ =-0.92 [95%CI: -1.56, -0.28] 
NA 
P value PVWMH: NS 
DWMH: <0.05  
ΔWMH volume 
and ΔCBF 




PVWMH: OR=1.32 [95%CI: 
1.06, 1.66]; 
DWMH: OR=1.00 [95%CI: 
0.79, 1.25] 
P value NS TWMH: NS 
PVWMH: 0.015 
DWMH: NS 
Adjusted for other variables Age, sex, diabetes, 
hypertension 
Age, sex, follow-up periods, baseline WMHs, 
cardiovascular risk factors, IMT, carotid 
stenosis >50%, non lacunes 
Age, sex, baseline atrophy, 
treatment allocation, baseline 
CBF 
CBF: cerebral blood flow; WMH: white matter hyperintensities; PVWMH: periventricular white matter hyperintensities; DWMH: deep 
white matter hyperintensities; TWMH: total white matter hyperintensities; bCBF: baseline CBF; bWMH: baseline white matter 
hyperintensities; ΔWMH: change of white matter hyperintensities; ΔCBF: change of cerebral blood flow; OR: odds ratio; CI: confidence 
interval; NA: not available; NS: not significant; IMT: intima media thickness.  
No numeric data were available from this paper, as statistical parametric mapping methods were used as the image analysis tool; 
ƚ CBF of tissues which were normal appearing white matter at baseline but became WMH at follow-up; 
ǂ % change in PVWMH or DWHMs-natural log transformed (% intracranial volume, ICV) per decrease in baseline CBF; 





WMHs are often considered to be a consequence of chronic hypoperfusion. However, 
while this review of all available published and some unpublished data show that 
high WMH load is associated with lower CBF, they do not strongly support 
causation. In cross-sectional studies, low CBF was observed in most of the patients 
with more WMHs. However, the association was dampened after removing non-age 
matched subjects and those with dementia, which suggests that the underlying 
association is between reduced CBF and age or dementia rather than just WMH. One 
longitudinal study (n=575) also showed a correlation between high baseline WMH 
volume and decrease in CBF over time, questioning whether a CBF decline causes 
the tissue loss or vice versa.70  
 
The strengths of this systematic review include the use of well-established guidelines 
for meta-analysis, cautious exclusion of duplicate data, thorough analysis of different 
study types and sensitivity analysis of clinically-important subgroups. Some studies 
provided more than one comparison but we avoided double-counting the total 
number of participants. We used every piece of data we could obtain. Studies that 
recruited subjects with AD, heart failure, and depression but compared CBF between 
patients with and without SVD were also included. Moreover, we included papers in 
non-English languages, including three papers in Chinese. As most studies measured 
regional CBF in different brain areas, we carefully chose regions that were 




There are some limitations of the review which in most part reflect the limitation of 
the literature. Firstly, there are differences between studies in terms of study design 
and imaging methods which we tried to harmonise to enable comparisons. 
Longitudinal studies were rare. Data for white matter regions such as centrum 
semiovale or immediate periventricular white matter were limited or lacking. CBF 
was obtained by different techniques and varied by technique. However, it is 
important to note that meta-analysis compares the magnitude of association within 
one study with that within the others, rather than making direct comparisons of CBF 
between studies. There are also differences in patient populations: most studies chose 
patients without neurological symptoms or from community-based populations, 
whereas three studies recruited patients with acute onset of TIA or minor stroke. Two 
studies used acute brain MRI as baseline imaging.101, 104 Image analysis methods 
differed and few if any studies differentiated normal tissue from WMH in the ROIs, 
thus including more tissue affected by lesions in subjects with high WMH burdens 
than with few WMH – an obvious confound if measuring CBF. Secondly, as some 
studies divided subjects into different severity groups, we converted them into pair-
wise comparisons in the form of low WMHs versus high WMHs. Therefore it is 
possible that disease groups in the original pair-wise studies might include some 
patients with mild lesions. Thirdly, the sample sizes of the studies included in meta-
analyses were small – the whole analysis of 24 studies included 1161 patients (mean 
48/study or 24/group). Only a few studies used age-matched controls. Patients with 
more severe WMHs were in general significantly older than those who had mild or 
no WMH, introducing an obvious confound; we addressed this in sensitivity analyses 
but these were underpowered for meta-regression. In addition, only one study 
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matched for important confounders like vascular risk factors so that sensitivity 
analysis for risk factors was not possible, and of course hypertension was generally 
more prevalent in severe WMH groups. Moreover, data for other imaging changes 
like lacunes or lacunar lesions are lacking.90  
 
The meta-analysis demonstrated that CBF measured concurrently was significantly 
lower in patients with more severe WMH. Cross-sectional studies which only did 
regression/correlation analyses also showed an association between high WMH 
burden and low CBF. However, the differences between groups in most brain regions 
were largely attenuated by excluding dementia and non-age-matched studies, except 
global mean CBF and CBF in centrum semiovale which remained significant and the 
point estimate did not move. These results suggest that disease severity and age 
confound the relationship between WMH and CBF, which was again supported by 
results from longitudinal studies showing that high burden of WMH predated falling 
CBF.70 Additionally, in regression/correlation-only cross-sectional studies where a 
negative association between WMH and CBF was found, the correlation tends to be 
significant in more severe patients.96  
 
These results indicate that the reduced CBF in patients with WMH might reflect a 
reduction in the blood supply required by the tissue, due to reduced neuronal activity, 
or atrophy with fewer cells. As most included studies recorded CBF in cortical grey 
matter, these associations between reduced CBF and cortical atrophy should not be 
overlooked. Cortical atrophy is known to occur with the aging process. Results from 
a large cohort study demonstrated that baseline brain atrophy predicted a decline in 
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total CBF over time.106 There are many imaging studies reporting an association 
between cortical atrophy and WMH severity.107 However there is little information 
about cortical volume from included studies. Although data for white matter are 
limited, CBF in frontal and occipital white matter regions changed in a similar way 
as in grey matter. Results in DWMH and in PVWM differed: a longitudinal study 
showed that decreasing CBF over time was related to the progression of PVWMH 
rather than to that of DWMH,72 which is in agreement with a cross-sectional study 
showing depressed CBF only in NAWM in periventricular regions.85 The 
contradictory results from white matter indicate that there might be differential 
vulnerabilities for DWMH and PVWMH as these two brain areas are in different 
sections of the arteriolar tree.85 However, such a suggestion is not supported by 
available data - studies indicate that PVWMH and DWMH are on a continuum in 
terms of location.108  
 
The limitation of resting CBF is that it only provides information of a cut-off time 
point at which CBF might still be relatively preserved or compensated especially in 
the early stage of the disease.109 One of the included studies showed a reduced CBF 
response to hypercapnia in non-demented hypertensive patients with leukoaraiosis 
while resting CBF was shown to be unaffected.48 Many other mechanisms have been 
suggested, such as the reduced cerebral vascular reactivity which represents the 
dilatory ability of brain vessels, or increased vascular pulsatility.53, 110 Risk factors 
such as hypertension alter the structure of penetrating arterioles by promoting 
lipohyalinosis and vessel wall thickening, which has led to the suggestion that 
cerebral arterioles might stiffen and thus cause a decrease in vasodilatory capacity or 
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become less able to buffer the pulsatile arterial pressure. Further studies are required 
to investigate how blood flow responsiveness (not just resting CBF) varies across 
different vessels and tissues (NAWM, WMHs and grey matter), and how it changes 
over the course of the disease. 
 
Conclusion  
In conclusion, despite large heterogeneities across included studies and the cross-
sectional nature of most studies, this systematic review showed that CBF was 
negatively related to WMH severity. The results of this systematic review suggest 
that hypoperfusion in the whole brain and low cortical blood flow is more likely a 
consequence of WMH than the cause. However, whether WMH are due to focal 
ischaemia in particular white matter tissues and whether the development of 
PVWMH and DWMH differ in mechanisms still remain unanswered. This 
systematic review emphasizes that more data are needed for white matter, especially 
separate data for NAWM and WMH. Future studies should obtain longitudinal data 
from white matter as well as grey matter, have larger sample sizes, include 
appropriate control groups, stratify by and adjust for important covariates such as age, 
important risk factors like hypertension, clinical diagnosis, (including the type of 
dementia if relevant) by different features and severities of SVD, and by cognitive 
status. In addition, if studying patients with acute stroke, it would be better to avoid 
the acute phase after stroke for imaging assessments to avoid effects of the acute 
stroke interfering with the study of WMH. Moreover, investigation of alternative 
mechanisms such as impaired CVR, increased cerebrovascular pulsatility, and effects 
63 
 
of blood-brain barrier changes should be pursued in parallel with CBF measurement 
to provide new perspectives on treatment for SVD. 
 
 
Updates of search after being published  
Since the original search for this systematic review was undertaken before December 
2015, I updated the search from December 2015 to September 2017 when writing up 
this thesis. Six studies were identified, including four cross-sectional studies111-114 
(n=269, median=31, range 22-185) and two longitudinal studies (n=290)115, 116. As 
most studies are not suitable for a meta-analysis and had very small sample sizes, I 
summarised the results in Table 5. Most of the cross-sectional studies found an 
association between WMH and low CBF in the white matter rather than in the 
cortical grey matter or global CBF, after the adjustment for age. In one longitudinal 
study with AD patients (n=38), those who had a higher burden of WMH at baseline 
showed a more severe CBF decline during a two-year follow-up.115 In the other 
longitudinal study (n=252), white matter CBF at baseline was neither associated with 
baseline WMH burden or WMH progression over five years. 116 These results, 
especially those of the longitudinal studies, are not only consistent with the original 
conclusion that low global or cortical blood flow is unlikely the cause of WMH, but 
in addition further question the cause and effect between WMH and low blood flow 




Table 5 Summary of studies on CBF and SVD since December 2015 
 sample 
size 







Summary of results Adjusted or 




252 community-dwelling elderly 
population 
75 5  DSC Baseline CBF not associated with 
baseline WMH volume or WMH 




38 Alzheimer's disease with 
WMH at baseline (n=24) 
77.2± 7.9 2  SPECT more severe CBF decline in the 
cingulate gyrus, parahippocampal 
gyrus and frontal gyrus 
no 
  Alzheimer's disease without 
WMH at baseline (n=14) 
74.9 ± 6.8 2     
Cross-sectional studies  
Bahrani A, 
2017111  
26  77.8 ± 6.8 - ASL parietal periventricular WMH volume 
associated with lower CBF frontal, 




36 SVD (n=23) not known - ASL lower CBF in the right centrum 
semiovale  
not known 
  No SVD (n=13) not known -    
Hashimoto 
T, 2016112 
22 lacunar stroke with ≥ 5 
CMBs) 
69±7 - PET lower CBF in the centrum semiovale, 
but not in the cortex or basal ganglia 
yes 
  lacunar stroke with < 5 
CMBs) 
68±8 -    
van Dalen 
J.W. 2016114 
185 community-dwelling elderly 
population 
77±2 - ASL WMH volume associated with 
reduced WMH CBF but not grey 
matter or NAWM CBF 
yes 
CBF: cerebral blood flow; SVD: small vessel disease; WMH: white matter hyperintensities; DSC: dynamic susceptibility contrast; SPECT: single photon emission 




Chapter 2B: Intracranial pulsatility in patients with cerebral small 
vessel disease: a systematic review  
Introduction  
Increasing evidence suggests that increased vascular pulsatility might be an 
alternative mechanism of SVD. Autopsy studies showed lipohyalinosis or 
arteriolosclerosis in the small arteries in the vicinity of “lacunes”,13 WMH117  or 
microbleeds.118 Aging and hypertension are important risk factors for SVD,119 both 
of which are associated with loss of elasticity in the vessel walls. It is possible that 
the stiffened vessel walls would be less able to dampen the arterial pressure pulse via 
the Windkessel effect, leading to high pulsatility being transmitted into the brain and 
causing or exacerbating vessel and brain tissue damage.120  
Some large cohort studies have shown a relationship between increased aortic 
pulsatility and lacunar infarcts or WMH volume 60, 61 However, fewer studies 
assessed pulsatility in the intracranial vessels. Doppler ultrasound and MRI are two 
main techniques that have been used to measure intracranial pulsatility. Doppler 
ultrasound measures the real-time blood flow velocity in the large arteries, mainly 
ICA and MCA if using TCD. Pulsatility was generally calculated using Gosling’s 
equation (pulsatility index, PI = (peak systolic velocity – peak diastolic 
velocity)/mean velocity)).121 There have been cross-sectional studies showing that 
high ICA57 (n=700) or MCA122 (n=159) PI was associated with larger WMH volume. 
However, the limitation of ultrasound is that it only assesses pulsatility in one 
particular artery at a time and does not provide information on smaller arterioles, 
CSF or venous pulsatility.  
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Phase-contrast MRI can quantify fluid velocity and flow in the intracranial arteries, 
veins, and CSF. It has mostly been used in disorders such as hydrocephalus that 
present with abnormal CSF dynamics123  with few studies in SVD. Vascular PI was 
also used in MRI studies, calculated using similar equations to ultrasound (flow was 
used instead of velocity), but indices reported for pulsatility in CSF vary.124, 125 It is 
unclear which measures are most relevant and reliable for quantifying intracranial 
pulsatility in SVD patients.  
Furthermore, it is uncertain if high pulsatility and SVD were both simply the result of 
exposure to vascular risk factors, since some studies also did not adjust for age or 
important risk factors when assessing the relationship between intracranial pulsatility 
and SVD.124 Also, WMH are commonly used by studies to represent SVD burden,57, 
124, 125 and it is not known whether high pulsatility was also related to other features 
of SVD, such as lacunar stroke or enlarged PVS.  
In order to provide a complete summary of all knowledge to date on intracranial 
pulsatility in patients with SVD, in this chapter, wewill systematically review papers 
that used either ultrasound or MRI to measure cerebral pulsatility in SVD with a 
view to performing a meta-analysis. We aimed to determine if there was an 
association between pulsatility and SVD, the magnitude of any association, whether 
it was cross-sectional or measured pulsatility and SVD progression longitudinally, 
and if any individual SVD features were more strongly associated with pulsatility 
than others.  
Several colleagues have contributed to the work mentioned in this chapter. I 
conceived the idea of this systematic review and designed the search and data 
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analysis plan. Dr Michael J Thrippleton (M.J.T.) helped revise the searching strategy. 
I undertook the search, data extraction, data analysis and then drafted the paper. 
M.J.T., Prof Ian Marshall and Prof Joanna M Wardlaw double checked the result of 
data extraction, revised the drafts and helped with the table/figure design. “We” in 
this chapter, wherever mentioned, indicates the above-mentioned people including 
myself.    
 
Methods 
We performed this review according to the MOOSE guidelines for meta-analysis of 
observational studies.68 We conducted a literature search of Ovid MEDLINE and 
Embase from 1946 up to April 2017 using the Ovid Web Gateway. We searched 
terms related to pulsatility and SVD in all contents of the papers using the strategy: 
“Pulsatility” or “Resistance” or “Velocity” or “cerebrospinal fluid pulsatility” or 
“Phase-contrast MRI” and “Cerebral small vessel disease” or “White matter 
hyperintensities” or “Leukoaraiosis” English and non-English literature were sought. 
Additional records were identified by hand from relevant reviews, primary papers 
and from the authors’ publication lists. The search and screening was done by myself 
and cross-checked with a second person if there was any uncertainty. We defined 
SVD features according to the STRIVE Guideline.7  
Eligibility Criteria 
We included papers that reported primary results of studies that: 1. recruited 
participants with SVD features; 2. assessed resting-state intracranial pulsatility 
(including ICA) using any imaging technique; 3. assessed the relationship between 
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intracranial pulsatility and SVD. We only included studies that focused on sporadic 
SVD in this review as the mechanisms for hereditary SVDs might differ. We 
excluded review papers, abstracts, and papers that used pharmacological, CO2 or 
other stimuli without providing pre-stimulus data. 
Data extraction  
We extracted data on participant characteristics, study design, MRI or Doppler 
technicalities, location and type of pulsatility indices assessed. For studies that 
compared pulsatility between groups and reported means and SDs, we extracted the 
results of the comparisons from text or tables where available, or from graphs where 
necessary; for those that performed association analysis such as correlation or 
regression models, we extracted the statistical methods, coefficients, P values and 
confounding factors or covariates (if any) that were adjusted for. For studies that 
performed both non-adjusted and adjusted analysis, we only included the adjusted 
results. We assessed the study quality using a checklist devised on the basis of the 











Table 6 Checklist for quality assessment 
Prospective study?  yes/no (1/0) 
Clearly reported study population (stroke, 
aging cohort, etc.)? 
yes/no (1/0) 
Clearly defined inclusion criteria?  yes/no (1/0) 
Clearly defined SVD?  yes/no (1/0) 
Clearly reported MRI acquisition and 
image processing?  
yes/no (1/0) 
Observers blinded to clinical data?  reported/not reported (1/0) 
Reported number of & expertise of 
observers of SVD images? 
 reported/not reported (1/0) 
Adjusted/matched for risk factors 
(including age)?  
 yes/no (1/0) 
Reported drop-out (how the final sample 
was reached)? 
 yes/no (1/0) 
Reported participants’ demographics and 
vascular risk factors/medical conditions 
yes/no (1/0) 
Overall score (/10)  
The 10 point study quality checklist applied to all included studies. It was devised 
using influences from the STROBE statement (https://www.strobe-statement.org/) 






Statistical analysis  
We displayed the results of comparisons between groups using forest plots in the 
Cochrane Collaboration’s Review Manager (Revman Version 5.3) and used SMD to 
represent the difference between groups. We did not include data from studies that 
did not provide standard deviations, because the SMD is inestimable without 
standard deviations. In this review, we were not able to perform robust meta-analyses 
because of the limited data and the large heterogeneity in study populations and 
pulsatility measures. Therefore, in the forest plot we did not calculate overall effect 
sizes. For studies that divided patients into more than two grades of WMH severity, 
we combined the means and SD of groups to create a single pair-wise comparison 
using formulae from the Cochrane handbook which I described in chapter 2A. We 
condensed data into new groups “mild WMHs” indicating none to punctuate WMHs 
(e.g. Fazekas deep WMH score 0 to 1), and “severe WMHs” as confluent WMHs 
(e.g. Fazekas deep WMH score 2 to 3).(Equation 1 in Chapter 2A) 
 
Results  
The search strategy identified 518 papers, of which 48 were potentially eligible and 
27 were ultimately selected for further review.(Figure 10) We excluded reviews (3), 
drug trials without providing baseline information on pulsatility and SVD (2), non-
SVD (sporadic) study (8), studies that used stimulus only (2) or did not assess 
intracranial pulsatility (6). One MRI study compared CSF pulsatility between 
patients with late-life depression and age-matched healthy volunteers but we 
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included the results in the forest plot because patients had higher WMH burden than 
the healthy volunteers.65  
 




Records identified through 
database searching  
(n = 510) 
Additional records identified 
through hand search  
(n = 8) 
Records after duplicates removed  
(n = 496) 
Abstracts screened  
(n = 78) 
Records excluded 
through titles  
(n = 418) 
Full-text articles assessed 
for eligibility  
(n = 49) 19 articles excluded: 
Review (3); 
Drug trial (2); 
Non-SVD (6); 
Use stimulus (2); 
No intra-cranial 
pulsatility measures (6) 
Studies included  
(n = 30) 
MRI studies 
(n = 7) 
Ultrasound studies 
(n = 22) 
Conference abstracts  
(n = 29) 
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Characteristics of included studies 
Twenty-seven (n=3356) were included, of which 20 used ultrasound57, 59, 97, 122, 124, 
127-142  and seven used MRI to measure pulsatility,58, 64, 65, 125, 143, 144 26/27 were cross-
sectional and one was a clinical trial of cilostazol141  from which we only extracted 
the data obtained at baseline.  
Doppler ultrasound studies  
Table 7 summarises patient characteristics from 20 ultrasound studies (n=2935) with 
sample sizes ranging from 9 to 700 (median=107). Fourteen used WMH (if MRI 
used for structural brain imaging) or white matter hypoattenuation (if CT used) to 
represent SVD burden. Two studies included patients with stroke: one compared 
pulsatility between lacunar and non-lacunar ischaemic stroke,133 and one compared 
pulsatility between patients with lacunar stroke (according to TOAST classification) 
and age- and sex-matched healthy controls.138  One study included patients with 
multi-infarct dementia130  and one recruited patients with cerebral amyloid 
angiopathy (CAA).137 (Table 7)  
Three studies assessed pulsatility in the ICA (cervical), seventeen in the MCA, one in 
the basilar artery, one in the posterior cerebral artery (PCA) and one in the central 
retinal artery. Most studies calculated PI using Gosling’s equation. One study one 





Table 7 Patient characteristics of Ultrasound studies 
First Author Subjects/disease  Sample 
size 
Group Age (years) Vessels of interest 
Sanahuja 2016136 Type 2 Diabetes 202 Higher SVD score (n=21)  MCA 
   Lower SVD score (n=181)   
Del Brutto 2015139 Community 70 Mild WMH (n=42) 72.2±5.5 MCA ,Vertebral 
artery 
    77.4±7.34  
Ghorbani 2015140 Patients who had 
SVD on imaging 
104 Patients who had WMH or 
lacunar infarct on MRI 
68.4 MCA 
   Patients who had no lesion on 
MRI  
62.6  
Turk 2015129 Leukoraiosis  96 Leukoaraiosis (n=52) 54.9±8.3 ICA 
   Age and sex-matched healthy 
volunteers (n=44) 
52.39±7.34  
Aribisala 201457 Lothian birth cohort 
1936 
700 - 70 ICA 




Patients who visited 
neurosonology lab 
439 - 63.47±14.94 MCA 
Purkayastha 2014134 Patients with 
vascular risk factors 
48 - 75±7 MCA 
Han 2014141 Lacunar stroke  130 - 64.7 MCA 
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Webb 201259 TIA or minor stroke 110 Fazekas 3 (n=25) 74.9±7.9 MCA 
   Fazekas 2 (n=24) 68.5±11  
   Fazekas 1 (n=21) 66.5±12  
   Fazekas 0 (n=30) 53±15  
Mok 2012122 Community 205 With severe WMH 74±6 MCA 
   without severe WMH  69±6  
Heliopoulos 201297 Hypertensive 
patients  
52 - 71.4±4.5 MCA 
Bettermann 2012142 Patients with WMH 26 Patients with WMH 63.5±11.25 MCA 
   Control without WMH  55.07±7.91  
Rodriguez 2010133 Ischaemic stroke 186 Lacunar (n=35) 69.7±10.8 MCA 
   Non-lacunar (n=151) 71.6±8.1  
Tanaka 2009127 Diabetic patients 122 Hypertensive (n=43) 66.9±9.8 ICA 
   Non hypertensive (n=79) 62.0±11.0  
Smith 2008137 CAA 20 CAA (n=11) 73.5±7.4 Basilar artery 
   Healthy volunteers (n=9) 70.9±7.9  
Kidwell 2001131 Retrospective review 
in patients who had 
both TCD and MRI 
55 - 62(range 28-
98) 
MCA 





116 - 74.44±6.35 MCA 




   age and sex-matched controls 
(n=64) 
69.7±8.8  
Biedert 1995130 Dementia 78 Multi-infarct dementia (n=19) Age range 60-
69 for all  
MCA, basilar 
artery 
   AD (n=23)   
   age-matched healthy 
volunteers (n=36) 
  
MCA: middle cerebral artery; SVD: small vessel disease; WMH: white matter hyperintensities; MRI: magnetic resonance imaging; ICA: 






MRI studies  
Patient characteristics and scanner information of seven MRI studies (n=421, range 
35-101, median=51) are shown in Table 8. Three studies recruited patients with 
dementia or cognitive impairment, including idiopathic dementia,124 AD,64 vascular 
dementia64 and mild cognitive impairment.143 Only one reported the diagnosis 
criteria for Alzheimer’s disease and vascular dementia.64 One study recruited patients 
with the late onset major depressive disorder.65 Three studies recruited healthy 
volunteers (age range: 43-82; 18-75; 62-82 years).58, 125, 144 (Table 8)  
All seven studies used phase-contrast MRI. Four studies used 1.5 Tesla and three 
used 3 Tesla scanners. All studies used retrospective gated phase-contrast MRI: four 
used peripheral pulse- and two used electrocardiogram (ECG)- gating; four studies 
reported the numbers of time points measured per cardiac cycle, among which three 
used 32 whereas one used 16 time points.(Table 8)
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Groups Age (years) Scanner and sequences TE/TR 
(ms) 






101 - 44.7±17.8 
(range 18-75) 
GE 3 Tesla; 
Retrospectively peripheral 
pulse-gated 2-D phase 
contrast cine sequences 







37 - 71±6 Philips 3 Tesla; 
Retrospectively peripheral 
pulse or ECG-gated 2-D 




70 cm/s for 
arteries and 
7 cm/s for 
CSF 
32 
Jolly 201358 Healthy 
volunteers 
35 - 65.67±9.31 
(range 43-82) 
Siemens 3 Tesla; 
Retrospectively ECG-
gated 2-D phase contrast 
cine sequences 
6.9/26.5  Arteries 75 
cm/s, veins 
40 cm/s, 








71 significant WHM 
(n=42) 
74±5 GE 1.5 Tesla; 
Retrospectively ECG-















48 AD (n=12) 76±4 Siemens 1.5 Tesla; 
Retrospectively ECG-
gated 2-D phase contrast 
cine sequences 
7/29  Arteries 75 
cm/s, veins 
40 cm/s, 























71.0±6.54 Philips 1.5 Tesla; 
Retrospectively peripheral 
pulse-gated 2-D phase 


















78 Fazekas 0 (n=10) 71±8 1.5 Tesla; Retrospectively 
ECG-gated 2-D phase 
contrast cine sequences 
7/29 ms Not 
mentioned 
Not 
mentioned Fazekas 1(n=18) 75±8 
Fazekas 2 (n=24) 76±7 




cc: cardiac cycle; TE: Echo time; TR: repetition time; Venc: velocity encoding parameter; ECG: electrocardiogram; WMH: white matter 




There were large differences between studies as to where flow was measured. Figure 
11 shows the ROIs used in these studies. Six included the ICA(s);58, 64, 124, 125, 143, 144 
in posterior circulation five chose the basilar artery58, 64, 124, 125, 143 and one selected 
the vertebral arteries144; four studied pulsatility in the venous sinuses;58, 64, 124, 143 six 
measured CSF flow, among which one selected the cervical subarachnoid spaces,144 
one selected tentorial incisura,64 and four measured the cerebral aqueduct.58, 65, 125, 143 
In total, three studies measured flow or pulsatility across the cerebral arteries, veins 
and the CSF system.64, 65, 143 (Figure 11) 
 
Figure 11 Regions of interest for flow measurement used in phase-contrast MRI 
studies included in this review. *Anders Wahlin et al. selected the vertebral arteries 





The average quality score of 27 studies was 6.85/10. 26/27 studies were prospective. 
However, seven studies did not report participants’ demographic information or 
general health condition. Only about half of the studies adjusted or matched for risk 
factors (15/27) or reported the expertise of observers of structural MRI (15/27). Less 
than half of the studies reported dropout (12/27) or use of blinding in structural 
image analysis (11/27).  (Figure 12)  
 


















Reported MRI acquisition and imaging…
Blinding
Reported expertise of observer
Adjusted/matched for risk factors
Reported drop-out
Reported participants’ demographics


















Quality assessment of included studies
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Result of comparisons of pulsatility measures  
Doppler ultrasound studies  
Three studies (n=356, median=96) compared arterial PI between patients with 
different WMH severities. One study examined the ICA, one chose MCA, and one 
chose both MCA and basilar artery. PI was generally higher in patients with more 
severe WMH in the ICA,129 MCA122, 130 and the basilar artery130  (e.g. in MCA: 
SMD= 3.24, 95% CI [2.4, 4.07]), although the result for ICA did not reach statistical 
significance (SMD= 0.38, 95% CI[-0.02, 0.79]).130 2/3 of the studies were age-
matched129, 130  and one of them also matched for gender.129 (Figure 13A)  
Two studies looked at other SVD features. One study (n=167) showed that patients 
with lacunar stroke (TOAST) had higher PI in the central retinal artery compared to 
age- and sex-matched healthy controls (SMD=0.35, 95% CI[0.03, 0.66]).129 (Figure 
13B) One study of CAA (n=20) found that patients with CAA had a significantly 
higher PI in PCA than non-age-matched healthy elderly controls (SMD=1.07, 95% 
CI[0.12, 2.03]).129 (Figure 13C) 
MRI studies  
Three phase-contrast MRI studies (n=124, median=50) performed comparisons of 
cerebrovascular or CSF pulsatility between patients with different WMH severities. 
None of them corrected for age. The indices for pulsatility included PI, stroke 
volume, and the delay between waveform peaks. The trend in all the comparisons is 
that higher arterial or venous PI (e.g. arterial PI: SMD=0.93, 95% CI[0.40, 1.47]),124 
larger arterial or venous or CSF stroke volume (e.g. CSF stroke volume: SMD=1.58, 
95% CI[0.64, 2.52])64 was associated with more WMH, although some results did 
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not reach a statistical significance (e.g. venous PI: SMD=0.18, 95% CI[-0.33, 
0.69]).124 (Figure 13D)  
Two studies (n=110) calculated the delay between waveform systolic peaks. There 
was no significant difference in arterial-venous (n=60, SMD= 0.95% CI[-0.51, 
0.51])64 or arterial-aqueduct peak delays (n=51, SMD=0.49, 95% CI[-0.07, 1.06])65 




Figure 13 Forest plots of studies that compared pulsatility (using Doppler ultrasound 
or MRI) between SVD and control groups. *indicates studies that matched for age.  
A-C: Pulsatility was measured by Doppler ultrasound. A. Comparison of vascular 
pulsatility between patients with severe and mild white matter hyperintensities 
(WMH); B. Comparison of central retinal artery pulsatility between patients with 
SVD-stroke (TOAST classification) and healthy volunteers; C. Comparison of 
posterior cerebral artery pulsatility between patients with cerebral amyloid 
angiopathy (CAA) and healthy volunteers;  
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D and E: pulsatility was measured by phase-contrast MRI. D. Comparison of 
vascular or CSF pulsatility between patients with severe and mild WMH; E. 
Comparison of flow waveform peak delays between patients with severe and mild 
WMH. It is worth noting that, in forest plot E, shorter peak delay is suggested by the 
authors to represent higher intracranial stiffness. 
 
 
Results of studies that performed regression or correlation analysis 
Table 9 summarises studies that performed regression or correlation analysis, 
including 13 Doppler ultrasound (n=9-700, median=116) and three MRI studies 
(n=35-100, median=37). 14/16 studies adjusted for covariates, of which twelve 
included age. No studies adjusted for blood pressure although five considered the 
history of hypertension.  
Doppler ultrasound studies 
Two studies measured ICA and eleven measured MCA. Most studies (apart from 
two127, 132) reported a significant association between increased ICA or MCA PI and 
more WMH after adjustment for age. One (n=186) found that higher MCA PI was 
predictive of having a lacunar infarct (vs other types of infarct).133 One paper (n=159) 
mentioned that they did not find a significant association between MCA PI and 
microbleeds or lacunes, although no detailed information was provided.122  
One study (n=9) found that higher brain tissue displacement, which was used for 
representing brain tissue pulsatility, was significantly correlated with larger WMH 




All three MRI studies adjusted for age. Two assessed WMH volume: increased 
WMH volume was found to be significantly associated with higher CSF systolic 
peak velocity in one study (n=101, β= -124.903, P=0.041),125 but not with arterial or 
venous pulsatility (pulse amplitude, pulse width or PI) in the other (n=35).58  
One study (n=37) found that increased arterial PI and cervical CSF pulsatility were 
associated with smaller brain volume in healthy volunteers.144 (Table 9)  
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Table 9 Results of correlation analyses in MRI and Ultrasound studies  




Variables (y~x) Coefficient  P value  Adjustment for 
confounding factors 
Ultrasound studies 
ICA        
Aribisala 201457 700 Multiple variable 
regression  
WMH volume ~ ICA PI β=0.09 0.016 Age, sex, ICV, HBp 
history 
Tanaka 2009127 122 Multivariate regression 
analysis  
WMH volume ~ ICA PI not shown >0.05 Age 
MCA        
Brutto 2015139 70 Generalised linear 
model 
WMH severity ~ MCA PI β=0.065, 95% CI[-
0.084, 0.177 ] 
0.474 Age, sex, the 
cardiovascular health 
status 





439 Multiple ordinal 
regression  
DWMH score~ MCA PI OR 17.994, 95% 
CI [6.875, 47.11] 




failure, obesity, peripheral 
artery disease, alcoholism, 
IMT 
   PVH score ~ MCA PI OR 5.739, 95% CI 
[2.288, 14.397] 
<0.001  
   Basal ganglia score ~ MCA PI OR 11.844,  95% 




Han 2014145 130 Pearson correlation  WMH volume ~ MCA PI R=0.195 0.026 No 
Purkayastha 
2014134 
48 Multivariable linear 
regression  
WMH/ICV~ MCA PI OR 1.25, 95% CI 
[0.14, 2.09] 
<0.01 Age, sex, race, DM, HBp 
Webb 201259 110 Ordinal regression  WMH score ~ MCA PI Beta = 4.33 P=0.037 Age, sex, physiology 
Mok 2012122 159* Multiple logistic 
regression  
Severe WMH (vs without severe 
WMH) ~ MCA PI 
OR=1.33, 95% CI 
[1.04,1.70] per 0.1 








186 Multivariate logistic 
analysis  
Lacunar infarct (vs non-lacunar) ~ 
MCA PI 
OR=8.13, 95% CI 
[1.17, 56.27] 





116 Multiple linear 
regression 
Leukoaraiosis severity score ~MCA 
PI 
β=-0.108 0.353 Age, sex, vascular risk 
factors, cognitive 
performance, blood flow 
velocity in MCA 
Kidwell 2001131 55 Multivariate regression  WMH score ~ MCA PI 0.71 P<0.05 Age, sex, HBp, coronary 
artery disease 
Brain tissue pulsatility 
Ternifi 2014128 9 Non-parametric 
spearman correlation 
WMH volume ~ Max BTD ρ=-0.86 <0.001 No 
   WMH volume ~ Mean BTD ρ=-0.72 <0.001 No 
MRI studies  
Beggs 2016125 101 Multiple linear 
regression  
total WMH volume ~ CSF peak 
negative velocity 
β =-124.903 P=0.041 Age 
Wåhlin 2014144 37 Ordinary linear 
regression  
Total brain volume ~ arterial PI β = -0.42 P<0.01 Age, ICV, arterial net flow 
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   Total brain volume ~ CSF flow 
volume pulsatility 
β = -0.44 P<0.01 Age, ICV, arterial net flow 
Jolly 201358 35 Partial correlation  WMH volume ~ pulse wave 
amplitude in arteries or venous 
sinuses 
not shown P>0.05 Age 
   WMH volume ~ pulse width in 
arteries or sinuses 
not shown P>0.05 Age 
   WMH volume ~ PI in arteries or 
venous sinuses 
not shown P>0.05 Age 
WMH: white matter hyperintensities; CSF: cerebrospinal fluid; PI: pulsatility index; ICA: internal carotid artery; ICV: intracranial volume; 
BTD: brain tissue displacement; MCA: middle cerebral artery; DWI: diffusion-weighted imaging; SD: standard deviation; CI: confidence 
interval; DWMH: deep white matter hyperintensities; PVH: periventricular white matter hyperintensities; OR: odds ratio; DM: diabetes 
mellitus; IMT: intima-media thickness; HBp: hypertension. BMI: body mass index.  




We identified 27 studies that assessed intracranial pulsatility in relation to SVD 
including 3356 SVD subjects. Most studies found a significant association between 
increased intracranial pulsatility and SVD. However, these studies showed 
considerable heterogeneity with regard to participants’ characteristics, adjustment for 
covariates, image acquisitions, vessels of interest, and pulsatility measures. About 
half of the studies gave little detail on control of bias, such as the use of blinding, or 
on the expertise in SVD image assessment. We were not able to perform meta-
analyses due to the substantial heterogeneities and limited data.  
The limitations of the literature include that SVD features differed or were assessed 
differently across studies. Most studies used WMH volume or semi-quantitative 
score to represent SVD burden. Only half of the papers reported the expertise of the 
observers doing the SVD rating. Three studies used symptomatic lacunar ischaemic 
stroke as the SVD feature: two referred to subcortical infarct on imaging whereas one 
used the definition of “small vessel disease” in the TOAST classification. Although 
there might be some overlap between the two definitions, “small vessel disease” in 
TOAST involves clinical features and consideration of vascular risk factors and does 
not necessarily need imaging evidence.146 Studies that assessed pulsatility in relation 
to other SVD features including lacunes,122 microbleeds122 or atrophy144 were rather 
scant and some lacked details of the analysis. Although some have hypothesised that 
perivascular spaces become enlarged and more visible in the presence of high 
pulsatile flow,39, 40 so far no studies have reported the relationship between 
cerebrovascular pulsatility and perivascular spaces visibility.  
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A third of papers provided little detail on patients’ demographic or health 
characteristics. Age and blood pressure are thought to influence intracranial 
pulsatility147, 148  and are also important risk factors of SVD,11  therefor they should 
be adjusted for in relevant studies. Most studies that performed correlation or 
regression analysis have adjusted for age, but in studies that performed comparisons 
of WMH, patients with more severe WMH were significantly older than those with 
mild WMH.59, 124, 142, 143 Very few studies accounted for blood pressure in their 
analyses although some included history of hypertension as a covariate.   
Indices used to represent pulsatility also varied. Most studies focused on ICA or 
MCA. When calculating vascular PI, both MRI and ultrasound studies applied 
Gosling’s equation. However, some MRI scanners only collected flow value at 16 
time points in the cardiac cycle,65, 143 and low temporal resolution might affect the 
accuracy of the PI value as the peak flow might have been missed. Although the 
reliability of Gosling’s PI in representing vascular resistance has been questioned,149 
there is evidence that ICA and MCA PI are well correlated with cerebrovascular 
reactivity measured using CO2 stimulus or invasive monitoring.150, 151 The agreement 
between PI derived from MRI and from ultrasound was generally moderate.152, 153 
Two studies measured brain tissue pulsatility using ultrasound or BOLD MRI, but 
both had a very small sample sizes thus the validity needs to be tested in larger 
samples.128, 154  
Apart from including large arteries, four MRI studies also considered pulsatility in 
veins and CSF. According to Windkessel theory, the venous system and CSF are also 
important components in compensating for arterial pressure.62 Two studies calculated 
venous PI58, 124  and one measured venous stroke volume.64 CSF pulsatility 
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assessment varied in terms of both locations and indices. There is so far no accepted 
definition of pulsatility in CSF, although stroke volume seemed to be the most used. 
Futures studies need to test the reliability of different measures and also select ones 
that provide more relevant measurements of pulsatility. In addition, one MRI study 
measured the delay between arterial peak and venous sinus peak whereas another 
looked at the delay between arterial blood and aqueduct CSF pulsations. These two 
measures also might be non-comparable, as it has been suggested CSF pulse through 
the aqueduct is associated with capillary expansion whereas the venous pulse at neck 
level relates more directly to arterial expansion.62 So far no studies have measured 
pulsatility in smaller vessels than MCA. Techniques such as 4D phase-contrast MRI 
or 7-T MRI which enables the assessment in multiple vessels including perforating 
arteries,155, 156 or ultra-fast magnetic resonance encephalography which might be able 
to measure pulsatility in glymphatic system,157 could be considered by future SVD 
studies.  
Despite these heterogeneities, generally most cross-sectional studies have found that 
arterial or venous pulsatility was associated with worse SVD, although the 
relationship could be confounded by risk factors, particularly age and blood pressure. 
For ICA, one community based-study (n=700) with all participants aged 70 years 
that adjusted for age and other medical covariates found increased ICA PI to be 
independently associated with larger WMH volume,57 whereas in another study of 
diabetic patients the significance of the association disappeared after adjustment for 
age.127 The relationship between increased MCA PI and WMH or lacunar infarct was 
found in most studies after adjustment for confounding factors. We are unable to 
draw conclusions on the relationship between CSF pulsatility and WMH because of 
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different indices and locations used in each study, but the trend seems to be that 
larger CSF stroke volume is related to more WMH. It was also impossible to 
conclude if any specific SVD features are more associated with pulsatility due to the 
very limited data on any features other than WMH.  
This is the first study to comprehensively summarise studies that have measured 
intracranial pulsatility in relation to SVD. The strengths included a systematic search 
including papers in non-English languages and a careful assessment of all included 
studies. However, we were not able to perform a meta-analysis due to many sources 
of heterogeneity, or to pool the results of association analyses as regression analyses 
were performed differently in each study.  
In conclusion, most of the data support a cross-sectional association between SVD 
and higher pulsatility in large intracranial arteries such as MCA and ICA, although 
whether a specific SVD feature is more related to high intracranial pulsatility 
remains unknown, and it is not known if high pulsatility leads to more WMH or 
more WMH leads to higher pulsatility. Therefore, methodologically robust 
longitudinal studies are required to establish the cause and effect. Future studies 
should clearly define participants’ clinical features, use blinding, improve expertise 
in SVD assessment, and adjust for relevant covariates. Agreement on reliable 
measures of intracranial pulsatility is also needed to allow for better comparison 
between studies, especially for CSF pulsatility. Although Doppler ultrasound might 
be affordable and more widely used, MRI techniques enable assessment of pulsatility 
in multiple and smaller vessels and in different types of brain tissues, which therefore 
should be encouraged in future studies.  
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Chapter 3: Method: a reproducibility analysis of phase-contrast 
MRI in healthy volunteers and an observational study on cerebral 
blood flow and intracranial pulsatility in patients with SVD 
Introduction 
As I mentioned in Chapters one and two, some studies have investigated the 
relationship between cerebrovascular/CSF pulsatility and WMH in patients with 
dementia (such as G.A. Bateman et al. 2008, n=48)64 or healthy volunteers (Clive B 
Beggs et al. 2016, n=101)125. However, so far, there are no studies that have assessed 
the intracranial pulsatility in stroke patients who had SVD. Thus we recruited a 
group of patients with minor non-disabling ischaemic stroke in whom SVD features 
are common. In the following chapters, I will first assess the reproducibility of 
cerebral blood flow (CBF) and intracranial pulsatility measured by MRI using data 
from healthy volunteers, and then investigate the association between CBF and 
intracranial pulsatility measures and SVD features in stroke patients.  
This chapter is a method-chapter. I will introduce the methods that we used in the 
data collection and data analysis, including recruitment of subjects and imaging 
techniques, which apply to the results presented in chapter 4 and 5. When assessing 
the relationship between cerebral haemodynamics and SVD features, I will mainly 
focus on WMH and PVS, as they are thought to be the most relevant SVD 
presentations to increased pulsatility and the most commonly seen features in the 
patient group in our study.  
It is worth noting that the work related to chapter 3 to chapter 5 involves 
collaboration from various people. The contributions are listed below. Dr Michael J 
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Thrippleton (MJT) and myself (YS) recruited the healthy volunteers for the 
reproducibility study. The main study involving SVD patients was originally 
designed by Prof Joanna M Wardlaw (JMW). Dr Gordon Blair (GB), Dr Fergus 
Doubal (FD) and JMW recruited patients with SVD for the main study. GB and a 
group of radiographers helped scanned the patients. GB (a neurologist trainee) did 
the Doppler ultrasound scans. GB, Iona Hamilton and myself did the radial pulse 
tonometry. Dr David Alexander Dickie (DAD) helped with structural image 
processing and generated the automatic masks for brain tissues. MJT processed the 
primary phase-contrast images from the MRI scanner. I manually corrected the brain 
tissue masks, drew regions of interest (ROI) on processed flow images and carried 
out further flow data processing and statistical analyses. I also did all the visual 
rating for WMH and PVS and then cross-checked with JMW. “We” in this chapter 
and the following chapter 4 to chapter 6 indicates the relevant people in the above-
mentioned list or the whole team.    
Methods 
Subject recruitment   
We recruited healthy volunteers and patients with a past history of minor stroke 
following Research Ethics Committee approvals (ref. 14/HV/0001 and 14/EM/1126) 
and according to the principles expressed in the Declaration of Helsinki. Written 
informed consent was obtained from all participants. 
In order to assess the reproducibility of flow and pulsatility measured by phase-
contrast MRI, we recruited healthy volunteers from the surrounding area who had no 
cardiovascular disease, stroke, hypertension, migraine, anxiety disorders or panic 
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attacks. We also excluded those who had a known family history of intracranial 
aneurysms, subarachnoid haemorrhage, arteriovenous malformation, or who had 
contraindications to MRI. Healthy volunteers were asked to attend two phase-
contrast scanning sessions in the same scanner and using the same sequences within 
one week. As the two scan sessions were not on the same day, I used the term 
“reproducibility” to describe the analysis of agreement between measures derived 
from the two scans.  
We recruited patients prospectively with a symptomatic minor (i.e. non-disabling) 
ischaemic stroke presenting to the NHS Lothian stroke service between October 
2014 and April 2016. NHS Lothian covers three major hospitals and is managed by 
one centralised team of stroke physicians. Diagnosis and classification of stroke were 
based on the combination of clinical presentation and appearance on MR brain 
imaging with DWI and other relevant diagnostic sequences, and was carefully 
crossed-checked by a panel of experts in stroke (FD and JMW). ‘Non-disabling’ was 
defined as not requiring assistance in activities of daily living. We excluded patients 
with disabling stroke, poorly-controlled diabetes mellitus, poorly-controlled 
hypertension, and any psychiatric illness that would limit compliance with study 
procedures. We also excluded patients with a known family history of intracranial 
aneurysms, subarachnoid haemorrhage, arteriovenous malformation, and those with 
contraindications to MRI. 
Imaging protocols 
All participants were imaged on the same 1.5 tesla MRI scanner (Signa HDxt, 
General Electric, Milwaukee, WI, USA) using an 8-channel phased-array head coil. 
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We acquired velocity images using a 2-D cine phase-contrast pulse sequence with 
retrospective peripheral pulse gating, as described previously.147, 158 Figure 14 
illustrates the slices and regions we selected for flow measurements in phase-contrast 
MRI. Vascular flow (TR/TE=9/5 ms, 25° flip angle, 256 x 128 matrix, 2 signal 
averages) was determined in the distal cervical ICA, vertebral arteries, and internal 
jugular veins axially, superior to the carotid bifurcation where the ICA walls are 
parallel. We measured venous sinus flow (TR/TE=9/5 ms (approx.), 25° flip angle, 
256 x 128 matrix, 2 signal averages) in the superior sagittal sinus, straight sinus, and 
transverse sinuses. A coronal-oblique slice that intersected the superior sagittal sinus 
at about 2cm above the torcular and through the midpoint of straight sinus was 
selected. We also measured CSF flow through slices perpendicular to the cerebral 
aqueduct (TR/TE=11/6.5 ms (approx.), 20° flip angle, 256 x 256 matrix, 2 signal 
averages) and axially at C2-C3 level (TR/TE=11/7 ms (approx.), 20° flip angle, 256 
x 128 matrix, 3 signal averages).(Figure 14) 
All velocities were measured at 32 time points during the cardiac cycle, with velocity 
encoding value set to 70 cm/s for neck arteries, 50 cm/s for dural venous sinuses, 10 
cm/s for the aqueduct CSF, and 6 cm/s for the cervical CSF. Views per segment were 




Figure 14 Locations sampled with phase-contrast MRI, and example flow waveforms 
of selected vessels and cerebrospinal fluid (CSF) spaces in one standardised cardiac 
cycle. Thick color lines on the sagittal image indicate the locations of slices for 
phase-contrast MRI scans. Arrows indicate the directions of flow. In each waveform, 
dashed lines in the same colour as the flow curve point to the time of peak flow, 
while red dashed lines in all waveforms show the time of arterial peak flow. For the 
arterial flow waveform, we combined the flow from both internal carotid arteries 
(ICA) and both vertebral arteries in this example, but we calculated PI for the ICAs 
and vertebral arteries separately in the analyses. A: arteries including both ICA and 
vertebral arteries; B: superior sagittal sinus; C: straight sinus; D: transverse sinus; E: 
internal jugular vein; F: cerebral aqueduct; G: cervical subarachnoid space.   
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We acquired structural images using the following sequences: 3D T1W imaging 
(inversion recovery-prepared spoiled gradient echo (SPGR), sagittal acquisition, 
TR/TE/TI=9.6/4.0/500 ms, 8° flip angle, 25.6 x 25.6 cm FoV, 192 × 192 acquisition 
matrix, 160 x 1.3 mm slices), axial T2W (TR/TE=7000/90 ms, 24 x 24 cm FoV, 
PROPELLER acquisition with matrix size 384, 1.5 signal averages, 36 x 4 mm 
contiguous slices), axial FLAIR (TR/TE/TI=8000/100/2000, 24 x 24 cm FoV, 320 × 
256 acquisition matrix, 36 x 4 mm contiguous slices), axial GRE (TR/TE=900/15 ms, 
20° flip angle, 24 x 24 cm FoV, 384 × 256 acquisition matrix, 36 x 4 mm contiguous 
slices).  
We performed ICA Doppler ultrasound on patients on a portable SonoSite 
MicroMaxx ultrasound machine (Sonasite, USA).The blood flow velocity readings 
were obtained in the supine position at rest and 10 minutes after patients finished the 
MRI scan. We measured peak systolic and end diastolic blood flow velocities from 
the ICA and averaged the right and left velocities. We calculated the ICA PI, and the 
resistance index (RI) using the following equations: Gosling’s equation: PI= 
(Velocitymax – Velocitymin) / Velocitymean;
121 Pourcelot’s equation: RI= (Velocitymax-
Velocitymin) / Velocitymax).
159   
We also measured the aortic augmentation index (AIx) to represent aortic stiffness in 
patients. In order to estimate the aortic AIx, we performed the radial artery pulse 
wave analysis using a tonometry device (SphygmoCor, Sydney, Australia). We 
obtained the radial artery pressure waveform via a transducer with a small sensor that 
could non-invasively detect the pulse of the radial artery. The aortic pressure 
waveform was then estimated from the radial artery pressure waveform using a 
mathematical formula that was reported in a previous study and is now generally 
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accepted.160 The aortic AIx was calculated as the aortic augmentation pressure 
divided by the aortic pulse pressure and was then normalised to a heart rate of 75 
bpm, because it is sensitive to heart rate.161(Figure 15) Indeed, the aortic AIx is a 
measure of aortic wave reflection. In young and healthy vessels, the reflected wave 
arrives back at the route of the aorta during systole. When vessels stiffen with aging 
or vascular risk factors, the speed of travel of the reflected wave becomes faster thus 
the reflected wave arrives back to the aorta during systolic ejection, which generates 
a higher pressure peak (augmentation pressure) after the first systolic peak.162 
Therefore, in many studies, aortic AIx was used to estimate aortic stiffness.161, 162  
There are other measures for estimating aortic stiffness, such as the carotid-femoral 
pulse wave velocity which is suggested by some researchers as the gold standard. 
However, we chose the radial artery tonometry because it is more comfortable for 
our patients and easier to carry out in the setting of our study. This study was 
primarily designed for measuring cerebrovascular function using MRI, thus patients 
needed to be scanned for about 75 minutes in the MRI scanner including 25 minutes 
for phase-contrast imaging, 20 minutes for CVR acquisition (not discussed in this 
thesis) and 30 minutes for structural image acquisitions. In addition to the MRI scan, 
we also performed other exams such as the retinal photography, carotid ultrasound, 
and pulse wave analysis. Thus the radial artery tonometry which does not require 
undressing, as opposed to the carotid-femoral artery evaluation, was more acceptable 




Figure 15 Example of aortic pressure waveform with aortic systolic pressure, aortic 
diastolic pressure, inflection point where the forward aortic wave merges with the 
reflected wave. The aortic pressure waveform is estimated from a radial pressure 
waveform in the radial artery tonometry using a mathematical formulas.154 The 
augmentation pressure is the difference between the systolic pressure and the 
pressure at the inflection point. The aortic augmentation index is calculated as the 
ratio between the augmentation pressure and pulse pressure. As the augmentation 
index is sensitive to the heart rate, it is then normalised to a heart rate of 75 bpm.155 
Imaging processing 
Structural imaging analysis 
All imaging analysts (DAD, MJT, YS, JMW) were blinded to patients’ clinical data 
and haemodynamic measures generated from the phase-contrast MRI. Structural 
image acquisitions were co-registered within each subject.163 WMH were 
automatically calculated by a validated software which first diffeomorphically 
registering a white matter probability map to each subject using T1W image data. 
The probability map was previously created from 313 volunteers aged 18-96 
years.164 The diffeomorphic registration was performed using the symmetric image 
normalisation algorithm within Advanced Normalisation Tools version 2.1.0 on a 
Linux Red Hat Server.165 This provided a “clean” estimate of the white matter for 
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each subject, e.g., a white matter surface without gaps/ holes created by WMH. 
Hyperintense outliers were identified on FLAIR by transforming each voxel to a 
standard (z) score.166 Voxels with z≥1.5 and within the estimated white matter 
surface were initially defined as WMH. Final WMH estimates were defined by 3D 
Gaussian smoothing to reduce noise and account for partial volumes around WMH 
edges. WMH masks were then manually corrected for each participant and stroke 
lesions were excluded manually according to STRIVE guidelines7 and supervision 
from an experienced neuroradiologist (JMW). A stroke lesion on FLAIR was defined 
as a hyperintense area with a corresponding increased signal on patient’s previous 
DWI scan and/or compatible with relevant stroke symptoms. Normal appearing 
tissues including cortical grey matter, subcortical grey matter, white matter, and 
cerebellum were segmented using within subject T1 intensity data and population 
specific probability maps, which gives the brain volume.167 Intracranial volume (ICV) 
was calculated in two stages: firstly by running FSL's Brain Extraction Tool on the 
GRE image from each patient; secondly, hypointense outliers (generally skull and 
bone in GRE) were automatically removed via Z scores. Any hypointensities within 
the cranial vault (e.g., microbleeds) were refilled using the MATLAB fill holes 
function. Finally, ICVs were checked and edited by trained image analysts (YS) 
overseen by a consultant neuroradiologist (JMW).  
As well as quantitative volumetrics, periventricular and deep WMH were assessed 
using clinical scoring with the Fazekas scale from 0-3 (Deep WMH: 0 =absent,1 = 
punctuate foci, 2 =beginning of confluence, 3= large confluent areas; periventricular 
WMH: 0= absent, 1= “caps” or pencil-thin lining, 2= smooth “halo”, 3= irregular 
periventricular signal extending into the deep white matter).168(Figure 16) Total 
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Fazekas score was generated from the sum of the two. We also rated the PVS7 in 
both basal ganglia and centrum semiovale according to a validated semiquantitative 
scale from 0-4 (0=no visible PVS; 1= <10 PVS; 2= 11-20 PVS; 3= 21-40 PVS; 4= > 
40 PVS).33, 36(Figure 17) 
 
 
Figure 16 Fazekas score for deep white matter hyperintensities (DWMH) and 
periventricular white matter hyperintensities (PVWMH). DWMH: 0 =absent,1 = 
punctuate foci, 2 =beginning of confluence, 3= large confluent areas; PVWMH: 0= 
absent, 1= “caps” or pencil-thin lining, 2= smooth “halo”, 3= irregular 
periventricular signal extending into the deep white matter. Images were from 







Figure 17 Visual rating score for perivascular spaces (PVS) in basal ganglia and 
centrum semiovale. 0=no visible PVS; 1= <10 PVS; 2= 11-20 PVS; 3= 21-40 PVS; 




Flow and pulsatility measurements 
4-D velocity and magnitude images from each selected slices showing the flow in a 
cardiac cycle were generated from the scanner. To determine the flow values, I 
manually drew ROIs around the ICAs, vertebral arteries, internal jugular veins, 
venous sinuses, aqueduct, and cervical subarachnoid spaces on an averaged 
magnitude image of the correspondent slice of each patient. Then the background 
phase error was corrected by carefully placing background ROIs close to but not 
including the studied ROIs and then subtracted the mean velocity of the background 
ROIs.169 (Figure 18-Figure 21) The sums of the flow in ICAs and vertebral arteries 
on both sides gave the value of total arterial flow. The sum of the flow in transverse 
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sinuses and internal jugular veins on both sides represented total transverse sinus and 
internal jugular vein flow respectively. For each vessel, the PI was calculated from 
an adapted Gosling’s equation ((Flowmaximum – Flow minimum)/Flowmean). We also 













Figure 18 Example of regions of interests for vessels at the cervical level on 
magnitude image. RICA: right internal carotid artery; LICA: left internal carotid 
artery; RIJV: right internal jugular vein; LIJV: left internal jugular vein; RVA: right 















Figure 19 Example of regions of interest for cervical CSF on magnitude image. CSF: 














Figure 20 Example of regions of interest for dural venous sinuses on magnitude 
image. SSS: superior sagittal sinus; ROI: region of interest; TS: transverse sinus. We 














Figure 21 Example of regions of interest for the aqueduct on magnitude image. ROI: 
region of interest. 
 
We calculated the total net CSF flow in the aqueduct and cervical subarachnoid 
space, by integrating positive and negative flow values in caudal and cranial 
directions, the stroke volume by averaging the absolute flow volume in both 
directions. We defined the systolic phase in the CSF space as the caudal phase, as 
during the systolic phase the CSF is expected to leave the cranial space and returns to 
the cranial space in diastole;62 hence the diastolic phase represented the cranial phase. 
We calculated the duration of the systolic phase in CSF spaces. These methods for 
CSF data processing were similar to those reported in a previous study.124  
We normalised flow waveforms in all vessels and CSF spaces to one standardised 
cardiac cycle. We measured the time delay between systolic pulse wave peaks in 
arteries and veins or CSF spaces to estimate the timing of pulse wave at each point 




The sample size was determined to detect an effect in a similar vascular function 
measure called cerebrovascular reactivity (CVR), since very little data were available 
for PI or RI in veins or CSF. We estimated from the literature that it would be 
possible to detect a relative difference in CVR of 25%, standard deviation 40%, 
between those with high SVD scores and low SVD scores with 80% power and alpha 
level 0.05. This estimated a sample size of 40 participants, however, we aimed to 
include 60 patients to allow for technical failures or patient withdrawal from the 
procedure, for multivariate analysis and to increase the possibility of detecting 
effects on the other vascular function measures. 
I performed all statistical analyses using Rstudio version 1.0.136 (RStudio Inc, 
Boston, MA) and SPSS version 21 (SPSS Inc, Chicago, IL). All the detailed 







Chapter 4: Reproducibility analysis of CBF and intracranial 
pulsatility and comparability of internal carotid artery pulsatility 
indices between MRI and Doppler ultrasound 
Introduction  
Reduced CBF and increased intracranial pulsatility have been suggested as the 
underlying mechanisms of SVD. Recently, a few studies have used phase-contrast 
MRI to measure CBF, CSF flow and pulsatility in patients who had SVD features 
such as WMH or vascular dementia.64, 65, 143 As I showed in the systematic reviews in 
Chapter 2, higher intracranial pulsatility and low CBF was found to be associated 
with higher SVD burden in cross-sectional studies, which indicates that they might 
be used as potential secondary endpoints in future clinical trials of SVD, or be 
followed-up in the long term as the longitudinal relationship between these measures 
and SVD remains largely unknown. However, the indices of intracranial pulsatility 
used by these studies, such as the stroke volume, net flow, duration of systole and 
peak velocities of CSF, varied substantially. It is unclear how reproducible these 
measures are or which of these measures are more reliable.   
Different from the heterogeneities in CSF measures, the cerebrovascular PI and RI 
calculated from blood flow waveforms were more consistently used by previous 
studies.124, 144 These two measures were adapted from the Gosling’s PI and 
Pourcelot’s RI equations in the Doppler ultrasound, although in Doppler ultrasound 
they were calculated from the velocity waveforms. As Doppler ultrasound has 
already been a well-established method in detecting blood velocity, the PI and RI is 
widely used in research59, 122, 128, 129 and the clinical routine. However, it is yet 
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unknown whether the flow-based MRI pulsatility indices are comparable to their 
counterparts in Doppler ultrasound.  
Thus, in this chapter, I aim to assess the reproducibility of CBF, CSF flow, and 
pulsatility measures in a group of healthy volunteers who had repeated phase-
contrast MRI scans; and to assess the comparability of ICA pulsatility indices in MRI 
and Doppler ultrasound in our patients who had SVD.  
 
Methods  
The recruitment of participants and image processing have been described in Chapter 
3. All the measures were normally distributed. Thus for statistical analyses, 
descriptive statistics will be presented as mean ± SD. I used paired-samples t-test to 
test the differences within participants. A statistical significance is defined as p < 
0.05. No multi-test corrections were applied in these t-tests, as these data were 
mainly for descriptive purposes. The within-subject coefficient of variation (within-
subject CV = √𝑀𝑒𝑎𝑛(𝑆𝐷𝑖/𝑚𝑒𝑎𝑛𝑖)2, i indicates each participant) and Bland-Altman 
plots were used to estimate the reproducibility. The between-subject CV was 




), i indicates each participants, n represents the 
total number of participants). I calculated the CVs for all the measures apart from the 
total net CSF flow. As theoretically, the value of the net CSF flow in a cardiac cycle 
is zero, the CV calculation is non-applicable, but the reproducibility of the net CSF 
flow will be demonstrated in the Bland-Altman plots. The comparability between 
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MRI and Doppler ultrasound pulsatility indices was tested by Bland-Altman plots 
and Pearson’s correlation analysis. 
Results 
Ten healthy volunteers (6 males, mean age=35.2±9.8 years, range 22-50 years) were 
included and finished two visits of phase- contrast MRI scans (median duration 
between scan = 6 days). Nine completed scans for arteries, dural venous sinuses, 
cerebral aqueduct and cervical subarachnoid spaces, whereas one did not have 
complete data for venous sinuses due to technical issues.  
60 patients who had minor non-disabling ischaemic stroke and SVD were recruited, 
of which 56 (67.80±8.27 years, 40 males) had both MRI and Doppler ultrasound data. 
Four patients did not have complete MRI data: one due to claustrophobia, one due to 
an incidental finding of a subdural hematoma, and two had pulse gating issues during 
the scan. The other details of the patients will be discussed in the next chapter.  
 
Summary of flow and pulsatility measures at two visits in healthy 
volunteers  
Means and SDs of CBF and intracranial pulsatility measures for each visit are shown 
in Table 9. Total arterial flow (ICA + vertebral arteries; 776.90 ±125.33 ml/min) was 
similar to but higher than flow in the internal jugular veins (597.47±195.05 ml/min) 
or transverse sinuses (638.62±113.78 ml/min). PI and RI were highest in the arteries 
(e.g. ICA PI = 1.00±0.15), followed by internal jugular veins (PI = 0.32±0.08), and 
lowest in dural venous sinuses (e.g. superior sagittal sinus PI = 0.57±0.30). The net 
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CSF flow was larger in the cervical subarachnoid space (-1.02±4.74 ml/min) than in 
the aqueduct (0.04±0.01 ml/min), as was the stroke volume (0.58±0.20 ml in cervical 
CSF vs 0.04±0.01 ml in the aqueduct). Here and throughout the thesis, for the net 
CSF flow, the positive value indicates flow in the caudal direction and the negative 
value indicates the cranial direction. The waveform peak delay with reference to the 
arterial peak was relatively short in the cervical subarachnoid (0.04±0.05 s), followed 
by the internal jugular vein (0.11±0.10 s) and straight sinus (0.12±0.13 s), and 
longest in the transverse sinus (0.20±0.15 s), superior sagittal sinus (0.20±0.15 s), 
and aqueduct (0.21±0.05 s). There were no statistically significant differences 
between two visits in any of these measures. (Table 10) 
Table 10 Summary of flow and pulsatility measures at two visits in healthy 
volunteers  
 
Visit 1 (n=10) Visit 2 (n=10) 
Average of two 
visits 
P value 
Cerebral blood flow (ml/min) 
Total arterial flow 772.65 ± 121.55 781.15 ± 128.85 776.90 ±125.33 0.89 
Total internal 
jugular vein flow 
615.02 ± 190.48 579.91 ± 197.97 597.47±195.05 0.71 
Total transverse 
sinus flow 
664.60 ± 118.58 612.64 ± 102.39 638.62±113.78 0.36 
Pulsatility/resistance index 
ICA PI 1.03 ± 0.16 0.98 ± 0.14 1.00±0.15 0.47 
ICA RI 0.62 ± 0.06 0.69 ± 0.05 0.61±0.06 0.36 
Vertebral PI 1.43 ± 0.25 1.33 ± 0.21 1.38±0.23 0.36 
Vertebral RI 0.72 ± 0.05 0.69 ± 0.04 0.70±0.04 0.35 
Superior sagittal 
sinus PI* 
0.33 ± 0.09 0.32 ± 0.10 0.57±0.30 0.83 
Superior sagittal 
sinus RI* 
0.28 ± 0.06 0.28 ± 0.07 0.42±0.16 0.80 
Straight sinus PI* 0.32 ± 0.08 0.32 ± 0.07 0.29±0.09 0.94 
Straight sinus RI* 0.28 ± 0.06 0.27 ± 0.05 0.26±0.07 0.92 
Transverse sinus PI* 0.29 ± 0.07 0.29 ± 0.11 0.33±0.09 0.98 
Transverse sinus 
RI* 
0.26 ± 0.06 0.26 ± 0.08 0.28±0.07 1.00 
Internal jugular vein 
PI 
0.60 ± 0.32 0.54 ± 0.29 0.32±0.08 0.65 
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Internal jugular vein 
RI 
0.44 ± 0.16 0.40 ± 0.15 0.27±0.06 0.59 
CSF flow and pulsatility  
Total net aqueduct 
CSF flow (ml/min)# 
0.42 ± 0.41 0.60 ± 0.34 0.51±0.39 0.30 
Aqueduct CSF 
stroke volume (ml) 
0.04 ± 0.01 0.04 ± 0.01 0.04±0.01 0.51 
Aqueduct CSF 
systolic duration (s) 
0.51 ± 0.07 0.51 ± 0.07 0.51±0.07 0.96 
Total net cervical 
CSF flow (ml/min)# 
-1.06 ± 4.79 -0.98 ± 4.46 -1.02±4.74 0.97 
Cervical CSF stroke 
volume (ml) 
0.61 ± 0.20 0.56 ± 0.19 0.58±0.20 0.59 
Cervical CSF 
systolic duration (s) 
0.41 ± 0.10 0.41 ± 0.09 0.41±0.10 0.88 
Waveform peak delay (s) (with reference to arterial peak) 
Superior sagittal 
sinus* 
0.24 ± 0.15 0.16 ± 0.14 0.20±0.15 0.25 
Straight sinus* 0.14 ± 0.13 0.10 ± 0.12 0.12±0.13 0.50 
Transverse sinus* 0.23 ± 0.15 0.17 ± 0.15 0.20±0.15 0.46 
Internal jugular vein 0.10 ± 0.09 0.11 ± 0.11 0.11±0.10 0.74 
Aqueduct CSF 0.22 ± 0.05 0.20 ± 0.05 0.21±0.05 0.37 
Cervical CSF 0.05 ± 0.04 0.03 ± 0.06 0.04±0.05 0.46 
ICA: internal carotid arteries; PI: pulsatility index; RI: resistance index; CSF: 
cerebrospinal fluid. 
* n=9. One subject did not have complete data of venous sinus during one visit. 
# For net CSF flow in either the aqueduct or the cervical subarachnoid space, positive 




Reproducibility of flow and pulsatility measures in healthy volunteers  
The within-subject and between-subject CVs were shown in Table 10. The within-
subject CVs were generally lower than 10% in blood flow measures and pulsatility 
indices in the vessels, apart from PI in the internal jugular veins (CV=10.04%) and 
the straight sinus (CV=11.01%). In CSF measures, the duration of the systole in both 
cervical CSF and aqueduct CSF had a CV of less than 10%. Stroke volumes in both 
aqueduct (CV%=18.02%) and cervical CSF (CV%=11.62%) had a reasonably good 
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reproducibility. CV% of peak delay were generally larger than 30% (ranging from 
34.52-62.96%), apart from 14.38% in the aqueduct-artery delay. (Table 10) 
The between-subject CVs of flow and pulsatility measures were mostly larger than 
20% (21.96-165.10%). In the ICA and vertebral arteries, the variations of arterial 
flow and pulsatility indices (7.12-21.96%) were smaller than in veins or CSF spaces. 
All the between-subject CVs were not adjusted for age. (Table 11) 
Table 11 Within-subject and between-subject coefficients of variance of flow and 
pulsatility measures in healthy volunteers 




Cerebral blood flow (ml/min) 
Total arterial flow 4.49 21.96 
Total internal jugular vein 
flow 
7.65 45.12 
Total transverse sinus flow 6.29 23.33 
Pulsatility/resistance index 
ICA PI 6.47 19.41 
ICA RI 3.96 12.39 
Vertebral PI 8.23 21.07 
Vertebral RI 3.78 7.12 
Internal jugular vein PI 10.04 74.20 
Internal jugular vein RI 8.69 52.04 
Transverse sinus PI 9.89 41.68 
Transverse sinus RI 8.82 35.93 
Superior sagittal sinus PI 9.98 38.97 
Superior sagittal sinus RI 9.05 32.81 
Straight sinus PI 11.01 30.72 
Straight sinus RI 9.85 27.97 
CSF flow and pulsatility  
Total net aqueduct CSF flow 
(ml/min)* 
- - 
Aqueduct CSF stroke 
volume (ml) 
18.02 45.08 
Aqueduct CSF systolic 
duration (s) 
6.47 17.66 




Cervical CSF stroke volume 
(ml) 
11.62 45.20 
Cervical CSF systolic 
duration (s) 
9.86 30.89 
Waveform peak delay (s) (with reference to arterial peak) 
Superior sagittal sinus 40.08 81.33 
Straight sinus 62.96 83.75 
Transverse sinus 34.52 89.74 
Internal jugular vein 45.47 117.35 
Aqueduct CSF 14.38 28.64 
Cervical CSF 47.63 165.10 
CV: coefficient of variation; ICA: internal carotid arteries; PI: pulsatility index; RI: 
resistance index; CSF: cerebrospinal fluid. All the CVs were not adjusted for age. 
*Theoretically, the mean values of net CSF flow in the aqueduct and cervical 
subarachnoid spaces are zero, thus the calculation of CV is non-applicable. The 






Bland-Altman plots of the above-mentioned flow and pulsatility measures are shown 
in Figure 22 to Figure 25. In Figure 22 and Figure 23, the limits of agreement were 
generally small for CBF and pulsatility/resistance indices for arteries and veins. In 
Figure 24, the limits of agreements for total net CSF flow and stroke volume in both 
cerebral aqueduct and cervical subarachnoid space were large although the mean 
differences were about zero, which represents a poor reproducibility. For the systolic 
duration in both cervical and aqueduct CSF, the limits of agreement and mean 
differences were relatively small. Figure 25 shows that the reproducibility of 
waveform peak delays was generally poor with large limits of agreements apart from 
in the aqueduct, which is consistent with the results in Table 10. No particular trend 
was observed between the means of two measures (X-axis) and the mean differences 




Figure 22 Bland-Altman plots showing the reproducibility of cerebral blood flow in the arteries, transverse sinuses and internal jugular 
veins. Data points represent the mean value of two visits (X-axis) and the difference between two visits (value at visit one minus value at 
visit two, Y-axis); dashed lines show the mean difference between the two measurements and the mean difference ± 1.96 × standard 





Figure 23 Bland-Altman plots showing the reproducibility of pulsatility index (PI) 
and resistance index (RI) in the vessels including: internal carotid arteries (ICA), 
vertebral arteries, superior sagittal sinus, straight sinus, transverse sinuses, and 
internal jugular veins. Data points represent the mean value of two visits (X-axis) 
and the difference between two visits (value at visit one minus value at visit two, Y-
axis); dashed lines show the mean difference between two measurements and the 
mean difference ± 1.96 × standard deviation (SD); the solid lines indicate the zero 





Figure 24 Bland-Altman plots showing the reproducibility of CSF flow and 
pulsatility measures in the cerebral aqueduct and cervical subarachnoid space. Data 
points represent the mean value of two visits (X-axis) and the difference between two 
visits (value at visit one minus value at visit two, Y-axis); dashed lines show the 
mean difference between two measurements and the mean difference ± 1.96 × 
standard deviation (SD); the solid lines indicate the zero lines of the mean 




Figure 25 Bland-Altman plots showing the reproducibility of peak delays from 
arteries to veins and CSF spaces. Data points represent the mean value of two visits 
(X-axis) and the difference between two visits (value at visit one minus value at visit 
two, Y-axis); dashed lines show the mean difference between two measurements and 
the mean difference ± 1.96 × standard deviation (SD); the solid lines indicate the 
zero lines of the mean differences. The SDs of the differences are shown under the 




Comparability between Doppler ultrasound and MRI measurements in 
ICA pulsatility indices  
In Figure 26, a direct comparison of waveforms shows that the ICA flow waveform 
reconstructed from phase contrast MRI and blood velocity waveform in Doppler 
ultrasound shared a similar shape. Both images were from the same patient.  
 
Figure 26 Blood flow waveform derived from MRI (left) and velocity waveform 




Table 12 shows the mean PI and RI from both MRI (PI 1.27±0.31; RI 0.69±0.07) and 
Doppler ultrasound (PI 1.53±0.38; RI 0.72±0.07). Paired-sample t-tests showed that 
MRI measures were smaller than those in Doppler ultrasound (PI: P<0.001; RI: 
P=0.002).  
 
Table 12 ICA PI and RI in phase contrast MRI and Doppler ultrasound 
 Phase-contrast 
MRI 
Doppler ultrasound P value 
ICA PI 1.27±0.31 1.53±0.38 <0.001 
ICA RI 0.69±0.07 0.72±0.07 0.002 
ICA: internal carotid arteries; PI: pulsatility index; RI: resistance index. P values 
from paired-samples t-tests. 
 
 In the correlation analysis, there was a reasonably good correlation between PI (r = 
0.45) and RI (r = 0.47) measured by MRI and Doppler ultrasound considering the 
differences in the two techniques. (Figure 27) 
In Figure 28, the Bland-Altman plots demonstrate that the limits of agreement for 
both PI and RI were relatively small, especially for RI, representing a good 
comparison between the two. The PI and RI in MRI were lower than that measured 



















Figure 27 Correlation between phase contrast MRI and Doppler ultrasound measurements in pulsatility index (PI; left) and resistance index 
(RI; right) of internal carotid arteries (ICA). In both techniques, values of ICA PI and RI were averaged from both sides. r coefficients and 
















Figure 28 Bland-Altman plots showing the comparability between Doppler ultrasound and MRI measurements of pulsatility index (left) 
and resistance index (right) in the internal carotid arteries (ICA). Data points represent the mean value of two measurements (X-axis) and 
the difference between the two measurements (MRI- Doppler ultrasound, Y-axis); dashed lines show the mean difference between the two 
measurements and the mean difference ± 1.96 × standard deviation (SD); the solid lines indicate the zero lines of the mean differences. The 





The results of this chapter show that in ten healthy volunteers (35.2±9.78 years), the 
blood flow and pulsatility measures in large intracranial arteries and veins were 
highly reproducible with within-subject CV of 3.78%-11.10%. In CSF flow and 
pulsatility measures, stroke volume and systolic duration of both cervical and 
aqueduct CSF were more reproducible (within-subject CV% = 6.47-18.02%) than the 
total net CSF flow (within-subject CV% >70%). Waveform peak delays in veins and 
CSF had poor reproducibility with large within-subject CV (34.52%-62.96%) apart 
from the artery-aqueduct delay (CV%=14.38%). Between-subject variations of all 
flow and pulsatility measures were generally large. When comparing ICA pulsatility 
indices measured by MRI to that measured by Doppler ultrasound in 56 patients 
(67.80±8.27 years) with minor stroke and SVD, the shape of flow waveform in MRI 
was similar to velocity waveform in Doppler ultrasound, and the pulsatility indices 
calculated from these waveforms were reasonably correlated (PI: r=0.45; RI: r=0.47; 
both P<0.01). PI and RI in MRI were slightly lower than those in Doppler ultrasound.  
 
There are some limitations of this study. First, the within-subject variability might 
come from various sources, such as the variability of the participants’ physical 
conditions as they were not scanned on the same day and were repositioned. Indeed, 
rather than measuring the repeatability of the scan acquisition and imaging 
processing, the aim of this study is to estimate whether the whole scan and imaging 
processing procedure could be reproduced in longitudinal studies such as clinical 
trials or in multicentre studies, and the results showed good reproducibility of the 
flow and pulsatility measures in such scenarios. Second, the sample size (n=10) of 
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healthy volunteers was small which limits the power of statistical analysis, although 
in previous literature the sample sizes for repeatability analysis were generally 
around 10. Third, as I focus on blood flow and pulsatility measures in this thesis, the 
comparison between velocity in both MRI and Doppler ultrasound was not included 
in this chapter. However, several previous studies have discussed this topic and 
generally showed good correlations between the two methods in blood velocity.170-172 
Fourth, due to the limitations of our Doppler ultrasound, we were not able to measure 
cerebral vessels other than ICAs in our patient group, thus the comparisons of 
pulsatility indices were only available for ICAs. 
 
The value of total arterial flow (776.90 ±125.33 ml/min) in this study was in 
agreement with other studies in young healthy volunteers (700±100 ml/min, n=8, 
mean age=21 years;173 776±150 ml/min, n=20, mean age=31 years;174 715 ml/min, 
n=12, mean age=32±10 years175). Total internal jugular vein flow (597.47±195.05 
ml/min in our study) was also generally smaller than total arterial flow in these 
studies (550±138 ml/min;174 298 ml/min175). The net flow rate and stroke volume of 
CSF was also similar to the values reported by other studies in healthy volunteers 
using either manual or automatic ROIs (aqueduct flow: 0.6 ml/min;175 0.305±0.145 
ml/min, n=23, 21-39 years;176 aqueduct stroke volume: 0.04±0.02 ml, n=21, mean 
age=40.8±18.7 years;175 cervical CSF flow: -2.7 ml/min175) (positive value indicates 
flow in the caudal direction and negative indicates flow in the cranial direction). We 
found large between-subject variations in all these flow and pulsatility measures, 




Our results of high reproducibility in arterial and internal jugular flow in healthy 
volunteers are also consistent with previous studies.173-175 In one study, the repeated 
scans were conducted on the same day consecutively without repositioning,173 while 
in the other study the gap between both scans ranged from 7 to 110 days,174 which 
suggests that the total arterial and internal jugular flow measured by MRI are highly 
reproducible even in a long-term follow-up. One 4D flow MRI showed a high 
reproducibility of dural venous sinus flow (ml/cardiac cycle) in healthy volunteers 
(n=10, mean age=36±14 years),178 but otherwise 2-D phase contrast MRI studies on 
venous sinuses were scant. We showed small variability between scans in venous 
flow metrics, despite the fact that large veins may collapse and be too small to 
generate reliable ROIs when subjects lie in a supine position, which could limit the 
accuracy and also increase the variability of flow values.179, 180  
 
Studies that have assessed the reproducibility of CSF flow are limited, but in general 
CSF had higher within-subject (between-scan) variability than arterial or venous 
flow regardless of the time gap between scans and the location of CSF (Foramen 
Magnum or aqueduct).174, 175 Among various CSF measures, stroke volumes showed 
a higher reproducibility than other measures such as peak systolic velocity or total 
net flow.181, 182 We also showed that durations of systole (duration of caudal flow) in 
the CSF flow waveform had a reasonably good reproducibility which had not yet 
been studied previously. Thus the stroke volume and the temporal characteristics of 
the CSF flow waveform might be more adequate than net flow for reproducibility 
and long-term follow-up purposes. There are substantial variabilities in waveform 
peak delay measures, which might be because these waveforms were collected from 
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different cardiac cycles with variable heart rates and the temporal resolution of MRI 
scanner is low. So far there is no consensus on how to calculate the waveform peak 
form delay. In this thesis, the waveform peak delays were calculated from a 
normalised cardiac cycle. I also attempted averaging the heart rates of two scan 
sessions (e.g. aqueduct and arteries) to estimate the peak delay between the two 
waveforms, which gives very similar results to what was currently shown in this 
thesis. The implication of the waveform delays remains unclear. It was interpreted as 
an indicator of pulse wave transmission velocity in some studies.65 However, our 
results suggest that caution should be taken when interpreting a single measure of 
waveform peak delays.      
 
The difference between the reproducibility of blood flow and CSF measures might 
be due to several reasons. The small size of the aqueduct makes the velocity or flow 
measurements susceptible to the partial volume effect. A previous study of 2D phase-
contrast MRI showed that a measurement accuracy of within 10% required at least 
16 voxels in the cross section of ROI when measuring vessels.183 In our study the 
ROIs of aqueduct generally had less than 10 voxels due to the low resolution. 
Although ROIs of cervical CSF have larger areas, the low velocity in cervical CSF 
and the difficulty in distinguishing CSF from neighbouring tissues might have 
contributed to the variability of CSF flow measures. Background correction could be 
another source of the variability in CSF measures, which we used for reducing the 
impact of background noises on flow measures. Although background correction 
brought the mean CSF flow significantly closer to physiological expected values, it 
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substantially increased the intra-subject CV% of mean CSF flow from 17% 
to158%.175  
 
So far there are no studies that have assessed the reproducibility of cerebrovascular 
pulsatility and resistance index calculated from MRI flow waveforms. Objectively, 
the MRI flow waveform had a similar shape to the velocity waveform from the 
Doppler ultrasound in the same patient, both of which had similar peaks and slopes at 
the similar timing in a cardiac cycle. Quantitatively, this study also showed a good 
reproducibility and a small inter-visit variation of both vascular pulsatility indices. 
The two indices are generally calculated in Doppler ultrasound using blood velocity 
waveform. We compared the ICA pulsatility indices in the MRI with those in 
Doppler ultrasound (performed immediately after MRI) in patients who had stroke 
and SVD, and showed a reasonable correlation between them (r=0.45-0.47). Usually 
an r coefficient of around 0.5 would be seen as a “moderate” correlation, in our case, 
we classified the correlation as “reasonably good” considering the difference 
between the two techniques and that we used a portable Doppler ultrasound machine 
which is not the optimal type of the technology. The Bland-Altman plots also 
showed similar results, as the difference between the two values (e.g. for PI mostly 
within ±0.5) were small compared to the averaged value (PI mostly within 1.0-1.8). 
Both MRI and ultrasound pulsatility indices gave similar relative value, although the 
MRI waveform represents the average of multiple waveforms and takes the whole 
vessel as an example, whereas the Doppler ultrasound only samples the centre of a 
vessel. MRI-generated ICA PI and RI were slightly lower than in Doppler ultrasound, 
which was consistent with a previous study (n=14, healthy volunteers, mean 
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age=33±3.8 years).172 The same previous study found a moderate correlation in PI 
(r=0.36) and RI (r=0.39) between MRI and Doppler ultrasound.172 Some other 
studies performed the similar comparisons in different vessels such as small cerebral 
arteries near an aneurysm152 or MCA,153 and showed heterogeneous results (r=0.14-
0.35, n=4, animal study;152 r=0.69-0.81, n=11, healthy volunteers, mean age=31 
years153). In general, these data suggest that measurements of pulsatility indices in 
MRI are comparable to Doppler ultrasound given the differences between two 
technologies.  
 
There are limitations and strengths in both techniques. Doppler ultrasound is more 
accessible and has high temporal resolution, but it does not provide information 
about the whole cross section of the vessels, which could cause potential 
measurement bias, has limited access to more intracranial vessels, is strongly user-
dependent, and the position of where measures were performed may vary during the 
follow-up; whereas although phase-contrast MRI is more expensive and non-portable 
and has relatively low time-resolution, it enables measurements in more vessels at a 
time such as venous sinuses and ever smaller vessels if using high-field techniques, 
is less user-dependent and more consistent with the slices selected for flow detection.   
 
In conclusion, flow and pulsatility measures in the arteries and veins, CSF stroke 
volume and systolic duration in phase-contrast MRI had generally good 
reproducibility in consideration of future follow-up. In patients with mild stroke and 
SVD, ICA PI and RI by phase-contrast MRI (calculated from flow waveform) and by 
Doppler ultrasound (calculated from velocity waveform) have reasonable 
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comparability. Higher spatial and temporal resolution of phase-contrast MRI may 
increase the specificity and accuracy, and thus the reproducibility of the vascular 






Chapter 5: An observational study of CBF and intracranial 
pulsatility in patients with SVD– Results  
Introduction  
SVD increases with age and increases the risk of stroke.24 A quarter of ischaemic 
strokes are lacunar.22, 184 WMH are commonly seen in stroke patients, regardless of 
the stroke aetiology.185, 186 Some studies have assessed the CBF, or intracranial 
pulsatility in patients with some SVD features, such as in vascular dementia,124 or 
“healthy” volunteers.58 However, vascular risk factors were generally not well 
controlled for in the literature as I showed in Chapter 2; and few studies have 
addressed vascular and CSF pulsatility contemporaneously with CBF in stroke 
patients in whom SVD is common. Also, there is lack of studies that have 
investigated the relationship between extracranial vascular haemodynamic measures 
and intracranial pulsatility. Furthermore, in most previous studies, SVD burden was 
represented by WMH whereas PVS was rarely mentioned, despite the hypothesis that 
PVS visibility increases when cerebral interstitial fluid dynamic is impaired and is 
related to arterial pulsation.40 Thus we carried out a cross-sectional study in patients 
with minor ischaemic stroke and SVD features, assessed the CBF and intracranial 
pulsatility using phase-contrast MRI, in an attempt to address the above-mentioned 
questions in this pilot study.  
This chapter will be divided into 5 sections. In Chapter 5A, I will summarise the 
characteristics of the patients and the haemodynamic measures, then investigate how 
these haemodynamic measures are related to age and stroke subtype (lacunar vs 
cortical), and examine whether there is any relationship between intracranial and 
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extracranial measures including systemic (brachial) BP and aortic stiffness. In 
Chapter 5B, I will investigate the association between CBF and the main SVD 
features (WMH and PVS). Chapter 5C will be focusing on pulsatility in brain vessels 
as well as aortic stiffness and WMH or PVS. Then in Chapter 5D, I will investigate 
how the CSF pulsatility and waveform peak delays relate to WMH and PVS. Lastly, 
in Chapter 5E, I will explore how cerebrovascular pulsatility relates to CBF; and as 
ICAs are responsible for transmitting most of the pulse into the intracranial space, I 
will also look at how PI in the veins is related to ICA PI. 
 
Methods  
The details of patient recruitment and image processing methods have been described 
in Chapter 3. For statistical analysis, categorical variables were presented as numbers 
and percentage, such as the history of vascular risk factors, numbers of patients under 
each Fazekas score or PVS score; continuous variables that are normally distributed 
were presented as mean ± SD, including BP and all flow and pulsatility measures; 
continuous variables that were non-normally distributed were presented as medians 
and ranges, including the WMH volume and WMH/ICV ratio. Differences in 
continuous variables between Fazekas groups or PVS score groups were assessed by 
the analysis of variance (ANOVA) and illustrated using boxplots. Figure 29 shows 








Figure 29 Example of a typical boxplot, which includes the median, values at the 25% 
and 75% quartile (Q1, Q3), inter-quartile range (IQR), upper and lower limit, and 
outliers. The upper limit is defined as Q3 + 1.5 × IQR, and the lower limits is defined 
as Q1 – 1.5 × IQR. An outlier is a data point that is located outside the range within 
the lower and upper limit. 
 
When assessing the relationships between variables, I will use linear regression 
models if the outcome variable is continuous, such as haemodynamic measures and 
the WMH/ICV ratio; ordinal regression models if the outcome is categorical and 
ordinal, such as PVS scores. In the regression models where the WMH/ICV is used 
as the outcome variable, I will natural log transform the WMH/ICV in order to obtain 
normally distributed residuals in the models. Histogram review and Q-Q plots were 
used to check the normality of distributions of residuals for each model. Also to note 
that, although the WMH volume and Fazekas scores are both validated measures for 
representing WMH burden, only WMH volume will be used in regression models as 
it is a quantitative measure whereas Fazekas scores are based on visual rating, but I 
will also investigate whether haemodynamic measures differ when stratifying by 
Fazekas scores. In Chapter 5E where I am going to assess the association between 
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ICA pulsatility and other haemodynamic measures, I will use only PI to represent 
vascular pulsatility rather than repeating the analyses using RI again, as PI and RI are 
calculated similarly.  
As the final sample size for data analyses is 56, the number of covariates that are 
allowed in each multiple regression model is limited to three. Age, gender and mean 
arterial pressure (MAP) will be adjusted for in most models but there are also 
exceptions. When BP is used as the main predictor variable, history of hypertension 
will be used instead of MAP to avoid collinearities. In Chapter 5E, when assessing 
the relationship between intracranial haemodynamic measures, I will adjust for 
WMH volume (instead of gender) as it might be a strong confounding factor. Non-
standardised β coefficients will be presented as the results of linear regression 
models, whereas odds ratios (OR) will be used in ordinal regression models. 
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Chapter 5A: Summary of patient characteristics and intracranial 
haemodynamic measures 
Patient characteristics 
Table 13 summarises the basic demographics, past medical history and SVD features 
of the patients. We recruited 60 patients, of whom 56 (40% male; mean age 
67.8±8.27 years old) had analysable MRI data. One patient did not complete the MRI 
scan due to claustrophobia and another due to a finding of a subdural hematoma. I 
excluded data from another two patients because of the poor finger pulse signal 
during the phase-contrast MRI scan.  
The stroke subtype was lacunar in 36/56 and cortical in 20/56 patients. Overall, 6/56 
patients had a past history of stroke and 42/56 were hypertensive, 31/56 patients 
were taking antihypertensive treatment before the stroke, 51/56 used statins and 
51/56 used antiplatelet agents. The supine BP immediately after the MRI scan was 
138.62±21.6/81.02±12.04 mmHg. 35/56 patients had lacunes and 8/56 had CMBs. 
Median WMH volume was 10.74 ml (range 1.40-74.97 ml), representing median 
0.77% (range 0.11-5.17%) of ICV. According to the Fazekas scale, most patients 
(43/56) had mild to moderate WMH (total Fazekas 1-4). Most patients also had mild 
to moderate PVS: 51/56 scored 0-3 in PVS (i.e. the number of PVS <40) in the basal 
ganglia, and 48/56 scored 0-3 in PVS in the centrum semiovale. 
Vascular risk factors and most SVD features including CMBs, WMH burden, and 
PVS did not differ between lacunar and cortical stroke, apart from that lacunes are 




Table 13 Summary of patient characteristics 
 
Overall (n=56) Lacunar (n=36) Cortical (n=20) 
Demographic and health condition 
Age (years)  67.80±8.27 67.36±8.32 68.60±8.32 
Sex = male (%) 40 (71.4) 29 (80.6) 11 (55.0) 
History of stroke (%) 6 (10.7) 5 (13.9) 1 (5.0) 
Diabetes (%) 7 (12.5) 4 (11.1) 3 (15.0) 
AF (%) 5 (8.9) 2 (5.6) 3 (15.0) 
Hyperlipidaemia (%) 37 (66.1) 23 (63.9) 14 (70.0) 




Systolic   138.62±21.60 138.33±22.86 138.50±19.27 




Never 22 (39.3) 16 (44.4) 6 (30.0) 
Current smoker  10 (17.9) 6 (16.7) 4 (20.0) 
Quit less than 1 
year 
3 (5.4) 2 (5.6) 1 (5.0) 
Quit more than 1 
year 
21 (37.5) 12 (33.3) 9 (45.0) 
SVD related measures    
Presence of lacune (%) 35 (62.5) 27 (75.0) 8 (40.0) 
Presence of CMB (%) 8 (14.3) 6 (16.7) 2 (10.0) 






8.12 [3.31, 74.97] 
ICV volume (ml)  1478.77±134.48 1484.33±126.38 1468.76±150.89 
WMH/ICV (%) 
(median [range]) 
0.77 [0.11, 1.21] 0.92 [0.11, 4.53] 0.60 [0.21, 5.17] 
PVWMH Fazekas score (%) 
0 0 (0) 0 0 
1 27 (48.2) 15 (41.7) 12 (60.0) 
2 17 (30.4) 12 (33.3) 5 (25.0) 
3 12 (21.4) 9 (25.0) 3 (15.0) 
DWMH Fazekas score (%) 
0 4 (7.1) 3 (8.3) 1 (5.0) 
1 26 (46.4) 14 (38.9) 12 (60.0) 
2 16 (28.6) 12 (33.3) 4 (20.0) 
3 10 (17.9) 7 (19.4) 3 (15.0) 
Total Fazekas score (%) 
1 4 (7.1) 3 (8.3) 1 (5.0) 
2 20 (35.7) 10 (27.8) 10 (50.0) 
3 9 (16.1) 6 (16.7) 3 (15.0) 
4 10 (17.9) 7 (19.4) 3 (15.0) 
5 4 (7.1) 4 (11.1) 0 (0) 
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AF: atrial fibrillation; SVD: small vessel disease; CMB: cerebral microbleeds; WMH: 
white matter hyperintensities; ICV: intracranial volume; PVWMH: periventricular 
white matter hyperintensities; DWMH: deep white matter hyperintensities; PVS: 
perivascular spaces.  
*Results in bold represent p<0.05. P values were from paired-samples t-tests. No 
multi-test corrections were used in this table since it is mainly for descriptive 
purposes. 
 
Summary of CBF and pulsatility measures 
As shown in Table 14, mean total cerebral arterial flow was 645.32±113.00 ml/min 
or 60.17±9.52 ml/min per 100 ml brain volume. Mean total transverse sinus flow was 
562.67±117.00 ml/min or 51.98±11.34 per 100 ml brain volume, and mean total 
internal jugular vein flow was 521.98±163.56 ml/min or 48.12±14.82 per 100 ml 
brain volume. 
PI was highest in the arteries (e.g. 1.27±0.31 in ICA), followed by internal jugular 
veins (0.94±0.52) and lowest in venous sinuses (e.g. 0.58±0.24 in superior sagittal 
sinus). RI followed the same pattern as PI and was generally smaller than PI in the 
same vessel. 
6 9 (16.1) 6 (16.7) 3 (15.0) 
Basal ganglia PVS score (%) 
0 0 (0) 0 0 
1 19 (33.9) 9 (25.0) 10 (50.0) 
2 21 (37.5) 16 (44.4) 5 (25.0) 
3 12 (21.4) 8 (22.2) 4 (20.0) 
4 4 (7.1) 3 (8.3) 1 (5.0) 
Centrum semiovale PVS score (%) 
0 0 (0) 0 0 
1 11 (19.6) 5 (13.9) 6 (30.0) 
2 17 (30.4) 10 (27.8) 7 (25.0) 
3 20 (35.7) 14 (38.9) 6 (30.0) 
4 8 (14.3) 7 (19.4) 1 (5.0) 
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Total net CSF flow was 0.20±0.78 ml/min (positive value indicates flow towards the 
caudal direction) in the aqueduct and -1.73±4.46 ml/min (a negative value indicates 
flow towards the cranial direction) in the cervical subarachnoid space. Flow 
waveform peak delays (with reference to arterial peak) were significantly different 
across veins and CSF spaces, being shortest in the cervical subarachnoid space 
(0.0451±0.0797 s), followed by the internal jugular vein (0.1127±0.1045 s), 
transverse sinus (0.1173±0.0931 s), straight sinus (0.1253±0.1061 s), superior 




Table 14 Summary of extra- and intra- cranial haemodynamic measures 
 Mean ± SD 
(n=56) 
Aortic measures 
 Aortic augmentation index 24.81±9.69 
CBF  
Total arterial flow (ml/min) 654.32±113.00 
 Total transverse sinuses flow (ml/min) 562.67±117.00 
Total internal jugular flow (ml/min) 521.98±163.56 
Total arterial flow (ml/min/100 ml brain volume) 60.17±9.52 
Total transverse sinus flow (ml/min/100 ml brain volume) 
51.98±11.34 
Total internal jugular flow (ml/min/100 ml brain volume) 48.12±14.82 
Pulsatility indices in brain vessels 
ICA PI  1.27±0.31 
ICA RI 0.69±0.07 
Vertebral artery PI 1.48±0.38 
Vertebral artery RI 0.74±0.09 
Superior sagittal sinus PI 0.58±0.24 
Superior sagittal sinus RI 0.43±0.13 
Straight sinus PI 0.52±0.19 
Straight sinus RI 0.41±0.11 
Transverse sinus PI 0.53±0.21 
Transverse sinus RI 0.41±0.12 
Internal jugular vein PI 0.94±0.52 
Internal jugular vein RI 0.61±0.21 
CSF flow and pulsatility measures 
Total aqueduct CSF flow (ml/min)* 0.20±0.78 
Aqueduct stroke volume (ml) 0.06±0.04 
Duration of systolic phase in aqueduct (s) 0.46±0.07 
Total cervical CSF flow (ml/min)* -1.73±4.46 
Cervical CSF stroke volume (ml) 0.48±0.21 
Duration of systolic phase in Cervical CSF (s) 0.36±0.07 
Waveform peak delays (with reference to arterial peak)  
Superior sagittal sinus (s)  0.16±0.10 
Straight sinus (s) 0.13±0.10 
Transverse sinus (s) 0.12±0.09 
Internal jugular vein (s)  0.11±0.10 
Aqueduct (s) 0.18±0.07 
Cervical CSF (s) 0.05±0.08 
SD: standard deviation; CBF: cerebral blood flow; ICA: internal carotid artery; PI: 
pulsatility index; RI: resistance index; CSF: cerebrospinal fluid. 
* For the CSF flow, a positive value indicates flow towards the caudal direction, 
whereas a negative value indicates flow towards the cranial direction.  
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The association between CBF, pulsatility measures, and age and 
stroke subtype  
Table 15 shows the results of univariate linear regression between CBF or pulsatility 
measures, and age and stroke subtypes. To note that, for CBF, in order to adjust for 
the potential confounding effect of brain atrophy, only the values normalised to the 
brain volume (ml/min/100 ml brain volume) will be used in further analyses; for CSF 
pulsatility and waveform peak delays, only the ones that were well reproducible 
(defined as within-subject CV < 20%, see Table 10 in Chapter 4) will be used, 
including the stroke volumes, systolic durations, aqueduct-to-artery peak delay and 
internal jugular vein-to-artery peak delay. 
Aortic AIx significantly increased with age (0.407 increase per year, p=0.01). There 
was no significant association between age and CBF in either arteries or veins.  In 
general, pulsatility indices in most vessels increased with age, although it only 
reached statistical significance in the straight sinus (both PI and RI. e.g. PI: 0.008 
increase per year, p=0.014) and ICA (RI: 0.003 increase per year, p=0.015).  
There were no significant associations between the aqueduct and cervical CSF 
pulsatility measures and age. None of the CBF or pulsatility measures was associated 








Age (years) Lacunar stroke (vs cortical) 
Outcomes β 95% CI P value β 95% CI P 
value Aortic stiffness 
Aortic 
augmentation index 
0.407 [0.107, 0.707] 0.010 -3.247 [-8.646, 2.151] 0.233 
CBF (ml/min/100 ml brain volume) 
Total arterial flow -0.262 [-0.568, 0.044] 0.091 2.459 [-2.871, 7.789] 0.359 
Total transverse 
sinus flow 
-0.012 [-0.386, 0.362] 0.949 -3.799 [-10.113, 2.514] 0.233 
Total internal 
jugular vein flow  
-0.391 [-0.868, 0.086] 0.106 -0.048 [-8.410, 8.313] 0.991 
Pulsatility indices in brain vessels 
ICA PI 0.009 [-0.001, 0.019] 0.078 0.002 [-0.170, 0.175] 0.978 
Superior sagittal 
sinus PI 
0.007 [-0.001, 0.015] 0.074 0.020 [-0.115, 0.155] 0.772 
Straight sinus PI 0.008 [0.002, 0.014] 0.014 0.059 [-0.049, 0.168] 0.277 
Transverse sinus PI 0.005 [-0.002, 0.012] 0.141 0.048 [-0.070, 0.166] 0.421 
Internal jugular 
vein PI 
-0.001 [-0.018, 0.017] 0.940 0.137 [-0.157, 0.431] 0.354 
ICA RI 0.003 [0.001, 0.005] 0.015 0.005 [-0.037, 0.046] 0.829 
Superior sagittal 
sinus RI 
0.004 [0.000, 0.008] 0.074 0.020 [-0.051, 0.091] 0.572 
Straight sinus RI 0.004 [0.001, 0.008] 0.020 0.040 [-0.022, 0.102] 0.201 
Transverse sinus RI 0.003 [-0.001, 0.007] 0.153 0.033 [-0.035, 0.102] 0.333 
Internal jugular 
vein RI 
-0.001 [-0.008, 0.005] 0.687 0.049 [-0.067, 0.164] 0.401 
CSF pulsatility measures 
Aqueduct stroke 
volume 
0 [-0.0004, 0.002] 0.160 -0.011 [-0.032, 0.010] 0.288 
Aqueduct systolic 
duration  
-0.001 [-0.004, 0.001] 0.269 -0.015 [-0.055, 0.025] 0.45 
Cervical CSF stroke 
volume  
0 [-0.007, 0.007] 0.932 -0.017 [-0.134, 0.101] 0.777 
Cervical CSF 
systolic duration 
-0.001 [-0.003, 0.001] 0.308 0 [-0.04, 0.04] 0.961 
Waveform peak delays 
Aqueduct-artery 
peak delay 




-0.002 [-0.005,0.002] 0.332 0.006 [-0.053,0.065] 0.837 
Results in bold represent P value <0.05. CBF: cerebral blood flow; ICA: internal 




The association between intracranial haemodynamic measures 
and BP 
Table 16 shows the relationship between intracranial haemodynamic measures and 
systemic BP measures. Pulsatility indices in some veins significantly increased with 
lower diastolic BP (e.g. straight sinus PI: β=-0.005, p=0.028) and lower MAP (e.g. 
Internal jugular vein PI: β=-0.012, p=0.019) but not with systolic BP. There were no 
significant associations between pulsatility indices and systolic BP or pulse pressure.  
There were no significant associations between CSF stroke volumes or systolic 
durations and any BP measurements. Also, the waveform peak delay (with reference 
to the arterial peak) in either aqueduct CSF or internal jugular vein was not 





Table 16  The associations between intracranial haemodynamic measures and BP  
 
Predictor variables (in separate models adjusted for age, gender and history of hypertension) 
 Systolic BP Diastolic BP Pulse pressure Mean arterial pressure 
 
β 95% CI P β 95% CI P β 95% CI P β 95% CI P value 
Outcome variables (in separate models) 
CBF (ml/min/100 ml brain volume) 
Arterial flow 0.097 [-0.021,0.215] 0.11 0.222 [0.021,0.424] 0.03 0.041 [-0.116,0.198] 0.60 0.192 [0.014,0.37] 0.04 
Transverse sinus flow -0.032 [-0.159,0.095] 0.61 0.111 [-0.109,0.331] 0.32 -0.117 [-0.28,0.046] 0.16 0.032 [-0.163,0.228] 0.74 
Internal jugular vein 
flow 
0.006 [-0.182,0.194] 0.95 0.051 [-0.278,0.379] 0.76 -0.018 [-0.264,0.227] 0.88 0.031 [-0.259,0.32] 0.83 
Pulsatility indices in brain vessels 
ICA PI 0.002 [-0.002,0.006] 0.26 0.002 [-0.005,0.009] 0.57 0.003 [-0.002,0.008] 0.29 0.003 [-0.003,0.009] 0.36 
Superior sagittal sinus 
PI 
0.001 [-0.002,0.004] 0.70 -0.002 [-0.008,0.003] 0.37 0.002 [-0.002,0.006] 0.24 -0.001 [-0.005,0.004] 0.74 
Straight sinus PI -0.001 [-0.004,0.001] 0.23 -0.005 [-0.009,-0.001] 0.03 0 [-0.003,0.003] 0.97 -0.004 [-0.007,0] 0.06 
Transverse sinus PI 0 [-0.002,0.003] 0.84 -0.003 [-0.008,0.001] 0.16 0.002 [-0.001,0.006] 0.19 -0.001 [-0.006,0.003] 0.48 
Internal jugular vein 
PI 
-0.006 [-0.012,0.001] 0.10 -0.015 [-0.026,-0.003] 0.01 0.001 [-0.01,0.008] 0.76 -0.012 [-0.022,-0.002] 0.02 
ICA RI 0.001 [0,0.001] 0.25 0 [-0.001,0.002] 0.75 0.001 [0,0.002] 0.20 0.001 [-0.001,0.002] 0.44 
Superior sagittal sinus 
RI 
0 [-0.001,0.002] 0.76 -0.002 [-0.004,0.001] 0.26 0.001 [-0.001,0.003] 0.21 -0.001 [-0.003,0.002] 0.62 
Straight sinus RI -0.001 [-0.002,0.001] 0.40 -0.002 [-0.005,0] 0.05 0 [-0.002,0.002] 0.74 -0.002 [-0.004,0] 0.11 
Transverse sinus RI 0 [-0.001,0.002] 0.83 -0.002 [-0.005,0.001] 0.17 0.001 [-0.001,0.003] 0.18 -0.001 [-0.003,0.002] 0.49 
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Internal jugular vein 
RI 
-0.002 [-0.005,0.001] 0.12 -0.007 [-0.010,-0.002] 0.01 0 [-0.004,0.003] 0.96 -0.005 [-0.009,-0.001] 0.02 
CSF pulsatility  
Aqueduct CSF stroke 
volume 
0 [0,0.001] 0.483 0 [-0.001,0.001] 0.618 0 [0,0.001] 0.16 0 [-0.001,0.001] 0.95 
Aqueduct CSF 
systolic duration 
-0.001 [-0.002,0] 0.096 -0.001 [-0.003,0.001] 0.188 -0.001 [-0.002,0] 0.24 -0.001 [-0.002,0] 0.10 
Cervical CSF stroke 
volume 
0 [-0.003,0.003] 0.985 0 [-0.005,0.005] 0.926 0 [-0.004,0.004] 0.98 0 [-0.004,0.004] 0.99 
Cervical CSF systolic 
duration 
0 [-0.001,0.001] 0.925 0.001 [-0.001,0.002] 0.292 0 [-0.001,0.001] 051 0 [-0.001,0.002] 0.51 
Waveform peak delays 
Aqueduct-artery peak 
delay  
0 [-0.001,0] 0.271 -0.001 [-0.002,0.001] 0.200 0 [-0.001,0.001] 0.63 -0.001 [-0.002,0] 0.19 
Internal jugular vein-
artery peak delay 
0.001 [-0.001,0.002] 0.267 0.002 [-0.001,0.004] 0.142 0 [-0.001,0.002] 0.72 0.001 [-0.001,0.004] 0.15 




The association between cerebrovascular pulsatility measures 
and aortic stiffness 
Table 17 shows the associations between CBF or intracranial pulsatility and aortic 
AIx. There were no significant associations between aortic AIx and CBF (e.g. arterial 
flow: β=0.136, p=0.36). Higher aortic AIx was significantly associated with lower 
ICA PI (β=-0.011, p=0.04). There was no significant association between aortic AIx 
and venous pulsatility indices.  
None of the CSF pulsatility measures or waveform peak delays were associated with 




Table 17  The associations between CBF, cerebrovascular pulsatility, and aortic AIx 
 
Aortic AIx (predictor variable) 
 
β 95% CI P value 
Outcome variables (in separate models*) 
CBF (ml/min/100 ml brain volume) 
Arterial flow 0.215 [-0.115,0.546] 0.197 
Transverse sinus flow 0.102 [-0.262, 0.466] 0.576 
Internal jugular vein flow 0.419 [-0.109, 0.948] 0.117 
Pulsatility indices in brain vessels 
ICA PI -0.011 [-0.022, -0.001] 0.040 
Superior sagittal sinus PI 0.004 [-0.005, 0.012] 0.396 
Straight sinus PI 0.002 [-0.005, 0.009] 0.533 
Transverse sinus PI 0.004 [-0.003, 0.012] 0.255 
Internal jugular vein PI -0.007 [-0.026,0.012] 0.456 
ICA RI -0.002 [-0.005, 0.001] 0.117 
Superior sagittal sinus RI 0.002 [-0.003, 0.007] 0.382 
Straight sinus RI 0.001 [-0.003, 0.005] 0.552 
Transverse sinus RI 0.002 [-0.002, 0.007] 0.292 
Internal jugular vein RI -0.004 [-0.011, 0.004] 0.299 
CSF pulsatility  
Aqueduct CSF stroke 
volume 
0 [-0.002,0.001] 0.740 
Aqueduct CSF systolic 
duration 
0.001 [-0.002,0.003] 0.644 
Cervical CSF stroke 
volume 
0.001 [-0.007,0.009] 0.886 
Cervical CSF systolic 
duration 
-0.002 [-0.004,0.001] 0.197 
Waveform peak delays 
Aqueduct-artery peak 
delay  
-0.001 [-0.004,0.001] 0.349 
Internal jugular vein-
artery peak delay 
-0.001 [-0.005,0.003] 0.633 
*All models were adjusted for age, gender and mean arterial pressure. Results in bold 
represent P value <0.05. CBF: cerebral blood flow; ICA: internal carotid artery; PI: 
pulsatility index; RI: resistance index; CSF: cerebrospinal fluid. 
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Chapter 5B: The associations between CBF and SVD features 
The association between CBF and WMH  
Univariate comparisons of CBF according to Fazekas scores 
Figure 30 and  
Table 18 shows the univariate comparisons of arterial and venous flow according to 
the total Fazekas score. There were no significant differences in any CBF value 
across Fazekas groups. (e.g. total arterial flow total Fazekas 1-2 vs 3-4 vs 5-6 was 
62.62±10.65 vs 58.27±8.31 vs 58.43±8.57 ml/min/100 ml brain volume, p=0.25).  
CBF also did not differ across either periventricular (Table 18) or deep WMH 




Figure 30 Boxplots showing the comparisons of CBF (ml/min/100 ml brain volume) 
in arteries and veins according to total Fazekas score. P values were from ANOVA. 
Sample sizes in each group: Fazekas score 1-2 (n=24); 3-4 (n=19); 5-6 (n=13). 




Table 18 CBF according to total Fazekas scores 
Total Fazekas score 
CBF (ml/min/100 ml 
brain volume) 
1-2 (n=24) 3-4 (n=19) 5-6 (n=13) P value 
Total arterial flow  62.62±10.65 58.27±8.31 58.43±8.57 0.25 
Total transverse sinus 
flow  
53.98±10.31 49.80±9.65 51.46±15.17 0.49 
Total internal jugular 
flow  
51.28±13.32 46.14±11.72 45.20±20.62 0.39 





Table 19 CBF according to periventricular WMH Fazekas scores 
 
Fazekas score for periventricular WMH 
CBF (ml/min/100 ml brain volume) 1 (n=27) 2 (n=17) 3 (n=12) P value 
Total arterial flow  62.24±10.62 57.47±8.11 59.34±8.27 0.26 
Total transverse sinus  flow  53.51±10.28 49.36±9.60 52.24±15.57 0.50 
Total internal jugular flow  51.39±12.96 43.89±12.21 46.78±20.70 0.25 
P values were from ANOVA. 
 
Table 20 CBF according to deep WMH Fazekas scores 
 
Fazekas score for deep WMH 
CBF (ml/min/100 ml brain volume) 0 (n=4) 1 (n=26) 2 (n=16) 3 (n=10) P value  
Total arterial flow  65.26±19.88 60.67± 8.47 59.57± 8.12 57.80± 9.69 0.61 
Total transverse sinus flow  48.63± 11.35 54.32± 9.97 48.89± 8.94 52.16± 17.19 0.46 
Total internal jugular flow  45.82± 27.40 51.85± 8.47 43.82± 15.85 46.25± 19.86 0.36 
P values were from ANOVA. 
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Linear regression analyses of CBF on WMH volume  
Table 21 demonstrates the results of linear regression analysis between CBF and 
WMH volume (normalised to ICV). There were no significant associations between 
CBF and WMH, especially after the adjustment for age, gender and MAP (e.g. 
arterial flow: β=-0.018, p=0.153). Older age was significantly associated with larger 




Table 21 The associations between CBF and WMH 
ln WMH/ICV ratio as the outcome (linear regression) 
Non-adjusted linear regression  Multiple linear regression 
Predictors  β  95% CI P value  Predictors  β 95% CI P value 
Total arterial flow 
(ml/min/100 ml 
brain volume) 
-0.024 [-0.050, 0.002] 0.065  Total arterial flow -0.018 [-0.042, 0.007] 0.153 
 Age 0.056 [0.028, 0.084] <0.001 
 MAP 0.012 [-0.005, 0.028] 0.157 
 gender 0.029 [-0.463, 0.522] 0.153 
Total transverse 
sinus  flow 
(ml/min/100 ml 
brain volume) 
-0.009 [-0.031, 0.013] 0.403  Total transverse 
sinus  flow 
-0.011 [-0.033, 0.012] 0.34 
 Age 0.059 [0.032, 0.087] <0.001 
 MAP 0.009 [-0.007, 0.024] 0.277 
 gender -0.061 [-0.644, 0.522] 0.834 




-0.011 [-0.028, 0.005] 0.173  Total internal 
jugular vein flow 
-0.004 [-0.020, 0.011] 0.573 
 Age 0.059 [0.031, 0.088] <0.001 
 MAP 0.008 [-0.007, 0.024] 0.291 
 gender 0.059 [-0.447, 0.565] 0.816 
Results in bold represent P value <0.05.   
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The association between CBF and PVS  
Univariate comparisons of CBF according to PVS scores  
Figure 31 and Figure 32 demonstrate the results of CBF stratified by PVS score in 
the basal ganglia and centrum semiovale. There were no significant differences in 
any CBF measures across basal ganglia (Figure 31) or centrum semiovale (Figure 
32) PVS scores.  
The details of the comparisons are shown in Table 22 and Table 23 below the 






Figure 31 Boxplots showing the comparisons of blood flow (ml/min/100 ml brain 
volume) in arteries and veins according to basal ganglia perivascular space (PVS) 
score. P values were from ANOVA. Sample sizes in each group: PVS score 1 (n=19); 
2 (n=21); 3 (n=12); 4 (n=4). Arterial CBF included blood flow in the internal carotid 
arteries and vertebral arteries. 
 
 
Table 22 CBF according to basal ganglia PVS score 
Basal ganglia PVS score 
CBF (ml/min/100 
ml brain volume 
1 (n=19) 2 (n=21) 3 (n=12) 4 (n=4) P  
Total arterial flow  59.28±9.86 59.30±7.45 61.60±12.31 64.70±10.34 0.69 
Total transverse 
sinus flow  
52.42±11.31 49.45±10.93 52.97±11.95 60.13±11.42 0.37 
Total internal 
jugular flow  
47.31±13.90 44.88±15.69 51.05±15.11 60.21±9.00 0.25 





Figure 32 Boxplots showing the comparisons of blood flow (ml/min/100 ml brain 
volume) in arteries and veins according to centrum semiovale perivascular space 
(PVS) score. P values were from ANOVA. Sample sizes in each group: PVS score 1 
(n=11); 2 (n=16); 3 (n=20); 4 (n=8). Arterial CBF included blood flow in the internal 
carotid arteries and vertebral arteries. 
 
 
Table 23 CBF according to centrum semiovale PVS score 








61.40±7.88 59.47±12.61 60.51±7.18 59.11±10.71 0.94 
Total transverse 
sinus flow  
53.78±9.26 52.78±13.00 50.52±10.25 51.42±14.24 0.88 
Total internal 
jugular flow  
44.72±11.44 48.75±17.61 49.54±13.93 47.93±16.67 0.86 
P values were from ANOVA. 
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Ordinal regression analyses of CBF on PVS 
Table 24 and Table 25 show the results of logistic ordinal regression models between 
CBF and PVS in the basal ganglia and centrum semiovale. No significant 
associations between CBF and PVS in either location were observed, apart from the 
almost negligible association between higher internal jugular vein flow and higher 
PVS score in the basal ganglia (OR=1.047, 95% CI [1.005, 1.09]). PVS in both basal 
ganglia and centrum semiovale significantly increased with older age (OR≈1.1 per 






Table 24 Association between CBF and PVS in the basal ganglia 
PVS score in basal ganglia as outcome 
Non-adjusted ordinal regression  Multiple ordinal regression 
Predictors OR 95% CI  Predictors OR 95% CI 
Total arterial flow (per 
ml/min/100 ml brain volume) 
1.027 [0.973, 1.084]  Total arterial flow  1.067 [0.999, 1.138] 
 Age (per year) 1.137 [1.055, 1.227] 
 MAP (per mmHg) 1.015 [0.978, 1.054] 
 Gender (male) 1.171 [0.357, 3.836] 
Total Transverse sinus  flow (per 
ml/min/100 ml brain volume) 
1.011 [0.969, 1.056]  Total Transverse 
sinus flow  
1.03 [0.975, 1.089] 
 Age  1.117 [1.041, 1.199] 
 MAP  1.025 [0.986, 1.064] 
 Gender (male) 1.46 [0.378, 5.646] 
Total Internal jugular vein flow 
(per ml/min/100 ml brain 
volume) 
1.018 [0.985, 1.053]  Total Internal 
jugular vein flow  
1.047 [1.005, 1.09] 
 Age  1.143 [1.060, 1.234] 
 MAP 1.024 [0.987, 1.062] 
 Gender 1.435 [0.426, 4.832] 




Table 25 Association between CBF and PVS in the centrum semiovale 
Centrum semiovale PVS score as outcome 
Non-adjusted ordinal regression  Multiple ordinal regression 
Predictors OR 95% CI  Predictors OR 95% CI 
Total arterial flow  (per 
ml/min/100 ml brain volume) 
0.993 [0.945, 1.042]  Total arterial flow   1.013 [0.958, 1.072] 
 Age (per year)  1.087 [1.013, 1.166] 
 MAP (per mmHg) 1.008 [0.970, 1.047] 
 Gender (Male) 3.01 [0.835, 10.847] 
Total transverse sinus  flow (per 
ml/min/100 ml brain volume) 
0.984 [0.944, 1.027]  Total transverse sinus 
flow   
1.01 [0.959, 1.065] 
 Age  1.084 [1.013, 1.161] 
 MAP  1.01 [0.975, 1.047] 
 Gender (Male) 3.327 [0.716, 15.451] 
Total internal jugular vein flow 
(per ml/min/100 ml brain 
volume) 
1.009 [0.978, 1.042]  Total internal jugular 
vein flow 
1.024 [0.990, 1.060] 
 Age  1.094 [1.022, 1.172] 
 MAP  1.009 [0.973, 1.045] 
 Gender (Male) 3.438 [0.961, 12.302] 
Results in bold represent results that do not overlap with the null value (OR=1)
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Chapter 5C: The associations between aortic AIx, cerebrovascular 
pulsatility and SVD features 
The association between cerebrovascular pulsatility and WMH 
Univariate comparisons of cerebrovascular pulsatility according to 
Fazekas scores  
Figure 33 and Table 26 show the results of cerebrovascular PI and RI stratified by 
total Fazekas scores. PI and RI in all venous sinuses was significantly higher, 
incrementally, in patients with higher total Fazekas score (e.g. in the superior sagittal 




Figure 33 Boxplot showing the univariate comparisons of pulsatility and resistance 
index in the arteries to veins according to total Fazekas score. P values were from 
ANOVA and were marked bold when less than 0.05. Sample sizes in each group: 




Table 26 Aortic augmentation index and cerebrovascular pulsatility according to 
total Fazekas score 
  Total Fazekas score 
 1-2 (n=24) 3-4 (n=19) 5-6 (n=13) P value 
Aortic augmentation 
index 
22.04±11.43 26.50±7.28 27.46±8.57 0.174 
ICA PI 1.24±0.30 1.25±0.33 1.34±0.29 0.66 
Vertebral artery PI 1.43±0.34 1.51±0.44 1.54±0.38 0.66 
Superior sagittal sinus 
PI 
0.48±0.12 0.60±0.24 0.73±0.32 0.007 
Straight sinus PI 0.45±0.11 0.57±0.24 0.59±0.20 0.05 
Transverse sinus PI 0.45±0.12 0.57±0.24 0.63±0.24 0.03 
Internal jugular vein PI 0.94±0.50 0.88±0.62 1.03±0.44 0.76 
ICA RI 0.68±0.07 0.69±0.07 0.72±0.08 0.15 
Vertebral artery RI 0.72±0.08 0.75±0.10 0.77±0.09 0.18 
Superior sagittal sinus 
RI 
0.38±0.07 0.45±0.13 0.50±0.16 0.005 
Straight sinus RI 0.37±0.07 0.43±0.13 0.45±0.12 0.03 
Transverse sinus RI 0.37±0.08 0.43±0.14 0.46±0.14 0.02 
Internal jugular vein RI 0.62±0.18 0.58±0.24 0.65±0.19 0.63 




Table 27 and Table 28 show the results of cerebrovascular PI and RI stratified by 
periventricular and deep WMH Fazekas scores. PI and RI were significantly higher 
in patients with higher periventricular Fazekas score (e.g. in the superior sagittal 
sinus, the PI in Fazekas 1 vs 2 vs 3 was 0.48±0.14 vs 0.62±0.23 vs 0.75±0.33, 
P=0.003).(Table 27) However, patients who had different deep WMH Fazekas scores 
did not differ in PI or RI in any vessels. (Table 28) 
 
Table 27 Cerebrovascular pulsatility according to periventricular Fazekas scores 
 
Fazekas score for periventricular WMH 
1 (n=27) 2 (n=17) 3 (n=12) P value 
ICA PI 1.23±0.29 1.26±0.34 1.36±0.29 0.44 
Vertebral artery PI 1.42±0.34 1.52±0.45 1.56±0.39 0.505 
Superior sagittal sinus 
PI  
0.48±0.14 0.62±0.23 0.75±0.33 0.003 
Straight sinus PI 0.45±0.11 0.57±0.26 0.61±0.19 0.024 
Transverse sinus PI 0.45±0.14 0.58±0.24 0.65±0.24 0.013 
Internal jugular vein PI 0.93±0.49 0.89±0.63 1.05±0.45 0.724 
ICA RI 0.67±0.07 0.69±0.07 0.72±0.07 0.148 
Vertebral artery RI 0.72±0.08 0.76±0.10 0.78±0.09 0.178 
Superior sagittal sinus 
RI  
0.38±0.08 0.46±0.12 0.51±0.17 0.005 
Straight sinus RI 0.37±0.07 0.43±0.14 0.46±0.11 0.026 
Transverse sinus RI 0.36±0.09 0.44±0.13 0.47±0.14 0.018 
Internal jugular vein RI 0.61±0.18 0.58±0.25 0.66±0.20 0.629 




Table 28 Cerebrovascular pulsatility according to deep WMH Fazekas scores 
  Fazekas score for deep WMH 
 0 (n=4) 1 (n=26) 2 (n=16) 3 (n=10) P 
value ICA PI 1.04±0.24 1.25±0.28 1.33±0.37 1.30±0.27 0.41 
Vertebral artery 
PI 
1.28±0.40 1.48±0.40 1.54±0.40 1.48±0.31 0.71 
Superior sagittal 
sinus PI 
0.49±0.10 0.53±0.19 0.60±0.29 0.71±0.27 0.18 
Straight sinus PI 0.42±0.11 0.50±0.21 0.54±0.18 0.58±0.20 0.50 
Transverse sinus 
PI 
0.47±0.17 0.49±0.16 0.56±0.27 0.63±0.22 0.28 
Internal jugular 
vein PI 
0.77±0.31 0.99±0.52 0.92±0.65 0.92±0.43 0.88 
ICA RI 0.62±0.07 0.68±0.07 0.70±0.08 0.71±0.07 0.19 
Vertebral artery 
RI 
0.70±0.13 0.74±0.10 0.76±0.09 0.77±0.08 0.53 
Superior sagittal 
sinus RI 
0.39±0.06 0.41±0.10 0.44±0.16 0.50±0.13 0.25 
Straight sinus RI 0.35±0.08 0.39±0.12 0.42±0.11 0.44±0.11 0.42 
Transverse sinus 
RI 
0.37±0.11 0.39±0.10 0.42±0.15 0.46±0.12 0.39 
Internal jugular 
vein RI 
0.54±0.18 0.64±0.19 0.59±0.26 0.59±0.17 0.78 






Linear regression analyses of aortic AIx and cerebrovascular pulsatility 
on WMH volume  
In univariate regression models, higher aortic AIx (β=0.026, P=0.040), pulsatility 
indices in the ICA (e.g. PI: β=0.841, P=0.038), superior sagittal sinus (e.g. PI: 
β=1.594, P=0.002), straight sinus (e.g. PI: β=1.399, P=0.028), and transverse sinuses 
(e.g. PI: β=1.654, P=0.004) were all significantly associated with large WMH 
volume.  
After the adjustment for age, gender and MAP, the associations remained significant 
only in the superior sagittal sinus (e.g. PI: β=1.287, P=0.005) and transverse sinuses 
(e.g. PI: β=1.364, P=0.008) remained significant, but not in the ICA or with aortic 
AIx. There was no significant association between pulsatility in the internal jugular 
veins and WMH. (Table 29)
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Table 29 Association between aortic augmentation index, cerebrovascular pulsatility, and WMH 
ln WMH/ICV ratio as the outcome (linear regression) 
Univariate linear regression models  Multiple linear regression models 




0.026 [0.001,0.051] 0.040  Aortic augmentation 
index 
0.011 [-0.019,0.040] 0.462 
    Age 0.059 [0.030, 0.087] <0.001 
    MAP 0.006 [-0.012,0.023] 0.512 
    Gender 0.193 [-0.373, 0.760] 0.496 
ICA PI 0.841 [0.050, 1.633] 0.038  ICA PI 0.435 [-0.293, 1.163] 0.236 
 Age 0.057 [0.030, 0.085] <0.001 
 MAP 0.007 [-0.009, 0.023] 0.374 
 Gender 0.062 [-0.428, 0.553] 0.799 
Vertebral 
artery PI 
0.332 [-0.323, 0.986] 0.314  Vertebral artery PI 0.090 [-0.492, 0.673] 0.757 
 Age 0.061 [0.033, 0.089] <0.001 
 MAP 0.292 [-0.007, 0.024] 0.292 




1.594 [0.636, 2.552] 0.002  Superior sagittal sinus 
PI 
1.287 [0.402, 2.172] 0.005 
 Age 0.055 [0.029, 0.081] <0.001 
 MAP 0.009 [-0.005, 0.024] 0.210 
 Gender 0.244 [-0.226, 0.715] 0.302 
Straight sinus 
PI 
1.399 [0.159, 2.640] 0.028  Straight sinus PI 0.900 [-0.311, 2.111] 0.142 
 Age 0.056 [0.028, 0.084] <0.001 
 MAP 0.011 [-0.005, 0.027] 0.160 
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 Gender 0.150 [-0.342, 0.641] 0.544 
Transverse 
sinus PI 
1.654 [0.545, 2.762] 0.004  Transverse sinus PI 1.364 [0.366, 2.362] 0.008 
 Age 0.056 [0.031, 0.082] <0.001 
 MAP 0.010 [-0.005, 0.025] 0.173 
 Gender 0.199 [-0.270, 0.668] 0.398 
Internal 
jugular vein PI 
0.104 [-0.376, 0.583] 0.667  Internal jugular vein PI 0.204 [-0.227, 0.635] 0.347 
 Age 0.062 [0.035, 0.089] <0.001 
 MAP 0.011 [-0.006, 0.027] 0.200 
 Gender 0.106 [-0.386, 0.598] 0.667 
ICA RI 4.326 [1.132, 7.520] 0.038  ICA RI 2.267 [-0.778, 5.312] 0.141 
     Age 0.055 [0.027, 0.083] <0.001 
     MAP 0.007 [-0.009, 0.023] 0.375 
     Gender 0.091 [-0.393, 0.576] 0.707 
Vertebral 
artery RI 
2.437 [-0.240, 5.114] 0.074  Vertebral artery RI 0.094 [-1.519, 3.401] 0.446 
     Age 0.059 [0.031, 0.087] <0.001 
     MAP 0.008 [-0.008, 0.024] 0.312 




2.878 [1.044, 4.713] 0.003  Superior sagittal sinus 
RI 
2.281 [0.589, 3.973] 0.009 
    Age 0.055 [0.029, 0.081] <0.001 
    MAP 0.010 [-0.005, 0.024] 0.196 
    Gender 0.223 [-0.250, 0.696] 0.349 
Straight sinus 
RI 




    Age 0.056 [0.028, 0.084] <0.001 
 
    MAP 0.011 [-0.005, 0.027] 0.176 
 
    Gender 0.136 [-0.353, 0.624] 0.579 
Transverse 
sinus RI 
2.664 [0.745, 4.583] 0.007  Transverse sinus RI 2.154 [0.431, 3.876] 0.015 
    Age 0.057 [0.031, 0.083] <0.001 
    MAP 0.010 [-0.005, 0.025] 0.186 




0.226 [-0.996, 1.448] 0.712 
 
 Internal jugular vein RI 0.600 [-0.497, 1.698] 0.277 
 Age 0.063 [0.036, 0.090] <0.001 
 MAP 0.011 [-0.005, 0.028] 0.183 
 Gender 0.107 [-0.383, 0.597] 0.664 




The association between cerebrovascular pulsatility and PVS 
Univariate comparisons of cerebrovascular pulsatility according to PVS 
scores  
Figure 34 and Table 30 show that aortic AIx, and PI and RI in most vessels were 
significantly and incrementally higher in patients with higher basal ganglia PVS 
score (e.g. in the superior sagittal sinus, the PI in PVS score 1 vs 2 vs 3 vs 4 was 
0.50±0.22 vs 0.53±0.19 vs 0.69±0.26 vs 0.87±0.25, P=0.006).  
Figure 34 Boxplot showing univariate comparisons of pulsatility and resistance index 
in the arteries to veins according to the basal ganglia PVS score. P values were from 
ANOVA and were marked bold when less than 0.05. Sample sizes in each group: 




Table 30 Aortic augmentation index and cerebrovascular pulsatility according to 
basal ganglia PVS score 
Basal ganglia PVS score 





19.42±11.50 26.50±6.86 28.25±8.48 31.25±6.80 0.016 
ICA PI 1.18±0.23 1.33±0.37 1.19±0.23 1.54±0.29 0.09 
Vertebral artery 
PI 
1.46±0.39 1.50±0.36 1.42±0.46 1.64±0.28 0.79 
Superior sagittal 
sinus PI 
0.50±0.22 0.53±0.19 0.69±0.26 0.87±0.25 0.006 
Straight sinus PI 0.43±0.15 0.54±0.21 0.57±0.18 0.74±0.14 0.011 
Transverse sinus 
PI 
0.45±0.17 0.51±0.19 0.63±0.25 0.73±0.19 0.025 
Internal jugular 
vein PI 
0.95±0.56 0.90±0.41 0.89±0.67 1.27±0.53 0.62 
ICA RI 0.66±0.06 0.71±0.08 0.68±0.07 0.78±0.05 0.02 
Vertebral artery 
RI 
0.73±0.09 0.75±0.08 0.74±0.12 0.81±0.06 0.49 
Superior sagittal 
sinus RI 
0.39±0.12 0.41±0.11 0.49±0.13 0.58±0.10 0.01 
Straight sinus RI 0.35±0.09 0.42±0.11 0.44±0.10 0.54±0.08 0.007 
Transverse sinus 
RI 
0.36±0.10 0.40±0.12 0.46±0.13 0.52±0.10 0.04 
Internal jugular 
vein RI 
0.62±0.20 0.60±0.19 0.57±0.25 0.75±0.20 0.53 




Figure 35 and Table 31 show that there were no significant associations between PI 
or RI and centrum semiovale PVS score (e.g. in the superior sagittal sinus, the PI in 
PVS score 1 vs 2 vs 3 vs 4 was 0.53±0.25 vs 0.60±0.29 vs 0.57±0.25 vs 0.62±0.12, 
P=0.86).  
Figure 35 Boxplot showing univariate comparisons of pulsatility and resistance index 
in the arteries to veins according to the centrum semiovale PVS score. P values were 
from ANOVA. Sample sizes in each group: PVS score 1 (n=11); 2 (n=17); 3 (n=20); 





Table 31 Aortic augmentation index and cerebrovascular pulsatility according to 
centrum semiovale PVS score 
Centrum semiovale PVS score 





24.00±11.53 21.47±12.12 25.73±5.84 30.75±7.01 0.15 
ICA PI 1.24±0.28 1.22±0.25 1.28±0.32 1.36±0.44 0.77 
Vertebral 
artery PI 




0.53±0.25 0.60±0.28 0.57±0.25 0.62±0.12 0.86 
Straight sinus 
PI 
0.49±0.18 0.52±0.19 0.54±0.23 0.54±0.11 0.92 
Transverse 
sinus PI 
0.51±0.22 0.51±0.19 0.57±0.26 0.53±0.28 0.80 
Internal 
jugular vein PI 
1.04±0.71 0.82±0.39 1.04±0.58 0.83±0.33 0.53 
ICA RI 0.69±0.08 0.68±0.07 0.69±0.07 0.71±0.08 0.74 
Vertebral 
artery RI 




0.41±0.12 0.44±0.14 0.43±0.14 0.46±0.08 0.82 
Straight sinus 
RI 
0.39±0.12 0.40±0.11 0.41±0.13 0.42±0.07 0.93 
Transverse 
sinus RI 
0.40±0.12 0.39±0.11 0.43±0.15 0.41±0.05 0.82 
Internal 
jugular vein RI 
0.63±0.23 0.56±0.19 0.65±0.23 0.58±0.17 0.60 




Ordinal regression analyses of aortic AIx, cerebrovascular pulsatility on 
PVS  
PVS in the basal ganglia 
Higher aortic AIx and higher pulsatility in all venous sinuses were significantly 
associated with higher PVS score in the basal ganglia, in both non-adjusted (e.g. 
OR=1.532, 95%CI [1.120, 2.095] per 0.1 increase in straight sinus PI) and models 
adjusted for age, gender and MAP (OR=1.502, 95%CI [1.085, 2.079] per 0.1 
increase in straight sinus PI). However, PI in the arteries or internal jugular veins 
were not associated with basal ganglia PVS. Older age was significantly associated 
with more PVS in all models (OR≈1.1 per year older).(Table 32) 
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Table 32 The associations between aortic AIx, cerebrovascular pulsatility and PVS in basal ganglia 
PVS score in the basal ganglia as outcome variable 
Univariate ordinal regression  Multiple ordinal regression 
Predictors OR 95% CI  Predictors OR 95% CI 
Aortic AIx (per unit) 1.032 [1.032, 1.171]  Aortic AIx 1.028 [1.028, 1.221] 
   Age (per year) 1.096 [1.021, 1.176] 
   MAP (per mmHg) 1.003 [0.964, 1.045] 
   Gender (male) 3.017 [0.716, 12.718] 
ICA PI (per 0.1) 1.079 [0.926, 1.257]  ICA PI  1.001 [0.847, 1.182] 
 Age 1.107 [1.032, 1.186] 
 MAP 1.021 [0.983, 1.061] 
 Gender 0.99 [0.316, 3.105] 
Vertebral artery PI (per 0.1) 1.008 [0.885, 1.148]  Vertebral artery PI  0.956 [0.832, 1.098] 
 Age  1.113 [1.037, 1.193] 
 MAP  1.021 [0.985, 1.060] 
 Gender  1.025 [0.322, 3.257] 
Superior sagittal sinus PI 
(per 0.1) 
1.42 [1.113, 1.812]  Superior sagittal 
sinus PI  
1.379 [1.061, 1.792] 
 Age  1.092 [1.018, 1.172] 
 MAP  1.026 [0.988, 1.066] 
 Gender 1.552 [0.455, 5.296] 
Straight sinus PI (per 0.1) 
 
1.532 [1.120, 2.095]  Straight sinus PI 1.502 [1.085, 2.079] 
    Age 1.084 [1.009, 1.164] 
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    MAP 1.038 [0.997, 1.082] 
    Gender 1.48 [0.440, 4.974] 
Transverse sinus PI (per 
0.1) 
1.444 [1.112, 1.877]  Transverse sinus PI  1.426 [1.086, 1.873] 
 Age 1.099 [1.025, 1.179] 
 MAP 1.028 [0.989, 1.069] 
 Gender 1.386 [0.416, 4.618] 
Internal jugular vein PI (per 
0.1) 
1.008 [0.913, 1.112]  Internal jugular vein 
PI  
1.034 [0.924, 1.156] 
 Age 1.108 [1.035, 1.186] 
 MAP 1.025 [0.986, 1.064] 
 Gender 1.039 [0.327, 3.296] 
ICA RI (per 0.1) 1.853 [0.942, 3.645]  ICA RI  1.335 [0.641, 2.783] 
 Age 1.099 [1.025, 1.179] 
 MAP 1.018 [0.981, 1.057] 
 Gender 1.028 [0.328, 3.224] 
Vertebral artery RI (per 0.1) 1.305 [0.757, 2.249]  Vertebral artery RI  0.993 [0.553, 1.784] 
 Age 1.107 [1.032, 1.187] 
 MAP 1.022 [0.985, 1.060] 
 Gender 0.989 [0.315, 3.108] 
Superior sagittal sinus RI 
(per 0.1) 
1.835 [1.182, 2.848]  Superior sagittal 
sinus RI  
1.73 [1.078, 2.774] 
 Age 1.093 [1.019, 1.172] 
 MAP 1.027 [0.988, 1.066] 
 Gender 1.472 [0.437, 4.957] 
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Straight sinus RI (per 0.1) 2.14 [1.266, 3.619]  Straight sinus RI  2.061 [1.183, 3.593] 
    Age 1.085 [1.011, 1.165] 
    MAP 1.036 [0.995, 1.079] 
    Gender 1.422 [0.425, 4.759] 
Transverse sinus RI (per 
0.1) 
1.804 [1.168, 2.787]  Transverse sinus RI  1.768 [1.121, 2.789] 
 Age 1.1 [1.026, 1.18] 
 MAP 1.027 [0.988, 1.068] 
 Gender 1.344 [0.407, 4.442] 
Internal jugular vein RI (per 
0.1) 
0.996 [0.782, 1.268]  Internal jugular vein 
RI  
1.075 [0.823, 1.405] 
 Age 1.109 [1.036, 1.188] 
 MAP 1.024 [0.986, 1.064] 
 Gender 1.03 [0.326, 3.261] 
Results in bold represent results that do not overlap with the null value (OR=1).   
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PVS in the centrum semiovale 
Higher aortic AIx was significantly associated with higher centrum semiovale PVS 
score in the adjusted model (OR=1.080, 95% CI [1.008, 1.156] per unit change in 
aortic AIx) but not in the non-adjusted model. There were no associations between 
pulsatility indices in any brain vessels and centrum semiovale PVS score. Older age 
was significantly associated with higher PVS in the centrum semiovale (OR≈1.1 per 




Table 33 Associations between aortic AIx, cerebrovascular pulsatility and PVS in centrum semiovale 
PVS score in the centrum semiovale as outcome variable 
Univariate ordinal regression  Multiple ordinal regression 
Predictors OR 95% CI  Predictors OR 95% CI 
Aortic AIx 1.047 [0.996, 1.101]  Aortic AIx 1.080 [1.008, 1.156] 
   Age (per year) 1.062 [0.992, 1.136] 
   MAP (per mmHg) 0.001 [0.952, 1.030] 
   Gender (male) 6.869 [1.536, 30.721] 
ICA PI (per 0.1) 1.025 [0.881, 1.193]  ICA PI 0.968 [0.824, 1.138] 
   Age (per year) 1.084 [1.013, 1.161] 
   MAP (per mmHg) 1.012 [0.977, 1.049] 
   Gender (male) 2.834 [0.826, 9.723] 
Vertebral artery PI (per 0.1) 0.957 [0.850,1.079]  Vertebral artery PI 0.928 [0.820,1.050] 
   Age 1.091 [1.019,1.169] 
   MAP 1.010 [0.975,1.046] 
   Gender (male) 2.834 [0.829,9.693] 
Superior sagittal sinus PI (per 
0.1) 
1.048 [0.864, 1.273]  Superior sagittal sinus PI  1.061 [0.859, 1.311] 
   Age 1.077 [1.007, 1.152] 
   MAP 1.011 [0.976, 1.047] 
   Gender (male) 3.081 [0.856, 11.089] 
Straight sinus PI (per 0.1) 1.129 [0.901, 1.415]  Straight sinus PI  1.129 [0.875, 1.456] 
 
   Age 1.069 [0.997, 1.147] 
 




   Gender 3.119 [0.896, 10.866] 
Transverse sinus PI (per 0.1) 1.038 [0.844, 1.278]  Transverse sinus PI  1.053 [0.843, 1.315] 
   Age 1.078 [1.009, 1.153] 
   MAP 1.011 [0.976, 1.047] 
   Gender (male) 2.986 [0.842, 10.589] 
Internal jugular vein PI (per 
0.1) 
1.025 [0.881, 1.193]  Internal jugular vein PI  0.968 [0.824, 1.138] 
 Age 1.084 [1.013, 1.161] 
 MAP 1.012 [0.977, 1.049] 
  Gender (male) 2.834 [0.826, 9.723] 
ICA RI (per 0.1) 1.047 [0.586, 1.872]  ICA RI  0.898 [0.494, 1.633] 
   Age 1.083 [1.013, 1.159] 
   MAP 1.012 [0.977, 1.048] 
   Gender (male) 2.733 [0.799, 9.340] 
Vertebral artery RI (per 0.1) 0.876 [0.530, 1.449]  Vertebral artery RI 0.761 [0.447, 1.297] 
   Age 1.091 [1.018, 1.170] 
   MAP 1.012 [0.977, 1.048] 
   Gender (male) 2.603 [0.756, 8.959] 
Superior sagittal sinus RI (per 
0.1) 
1.121 [0.777, 1.619]  Superior sagittal sinus RI  1.151 [0.773, 1.715] 
   Age 1.076 [1.006, 1.151] 
   MAP 1.011 [0.976, 1.047] 
   Gender 3.139 [0.879, 11.212] 
Straight sinus RI (per 0.1) 1.236 [0.828, 1.844]  Straight sinus RI  1.209 [0.778, 1.878] 
 
   Age 1.071 [0.999, 1.148] 
 




   Gender (male) 3.034 [0.879, 10.476] 
Transverse sinus RI (per 0.1) 1.084 [0.761, 1.543]  Transverse sinus RI  1.108 [0.760, 1.615] 
   Age 1.078 [1.009, 1.153] 
   MAP 1.011 [0.976, 1.048] 
   Gender 3.009 [0.852, 10.627] 
Internal jugular vein RI (per 
0.1) 
0.976 [0.783, 1.216]  Internal jugular vein RI  1.045 [0.828, 1.318] 
   Age 1.083 [1.013, 1.157] 
   MAP 1.013 [0.977, 1.050] 
   Gender (male) 2.858 [0.831, 9.825] 





Chapter 5D: The associations between CSF pulsatility, waveform 
peak delays, and SVD features 
CSF pulsatility, waveform peak delays, and WMH 
Univariate comparisons of CSF pulsatility and waveform delays 
according to Fazekas scores 
Figure 36 and Table 34 show the univariate comparisons of CSF pulsatility and 
waveform peak delays across total Fazekas scores. Aqueduct-to-artery and internal 
jugular vein-to-artery peak delay significantly shortened with higher total Fazekas 
score (e.g. the aqueduct-to-artery peak delay in total Fazekas 1-2 vs 3-4 vs 5-6 was 
0.21±0.07 vs 0.17±0.06 vs 0.16±0.08 s, p=0.047). Otherwise, there were no 





Figure 36 Boxplots showing comparisons of the CSF pulsatility and waveform peak 
delays according to total Fazekas scores. P values were from ANOVA and were 
marked bold when less than 0.05. Sample sizes in each group: Fazekas 1-2 (n=24); 3-
4 (n=19); 5-6 (n=13). CSF: cerebrospinal fluid; IJV: internal jugular vein.
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 Table 34 CSF pulsatility and waveform peak delays according to total Fazekas score 
 
Total Fazekas score 
1-2 (n=24) 3-4 (n=19) 5-6 (n=13) P value 
Aqueduct CSF stroke volume (ml) 0.06±0.05 0.06±0.03 0.06±0.03 0.987 
Aqueduct CSF systolic duration (s) 0.47±0.06 0.46±0.09 0.45±0.07 0.788 
Cervical CSF stroke volume (ml) 0.51±0.21 0.48±0.20 0.43±0.22 0.503 
Cervical CSF systolic duration (s) 0.37±0.06 0.34±0.07 0.38±0.08 0.143 
Internal jugular vein to artery waveform peak 
delay (s) 
0.16±0.09 0.07±0.12 0.09±0.08 0.011 
Aqueduct CSF to artery waveform peak delay (s) 0.21±0.07 0.17±0.06 0.16±0.08 0.047 






Table 35 and Table 36 demonstrate the CSF pulsatility and waveforms peak delays 
stratified by periventricular and deep Fazekas score. There were no significant 
differences in CSF pulsatility and waveform peak delays across Fazekas groups, 
either in periventricular or deep WMH, apart from the cervical CSF systolic duration 






Table 35 CSF pulsatility and waveform peak delays according to periventricular WMH Fazekas scores 
 Fazekas score for periventricular WMH 
 1 (n=27) 2 (n=17) 3 (n=12) P value 
Aqueduct stroke volume (ml) 0.06± 0.05 0.06±0.03 0.06±0.03 0.927 
Aqueduct systolic duration (s) 0.47±0.06 0.45±0.09 0.45±0.08 0.754 
Cervical CSF stroke volume (ml) 0.50±0.20 0.47±0.22 0.44±0.22 0.695 
Cervical CSF systolic duration (s) 0.38±0.07 0.32±0.05 0.38±0.08 0.025 
Internal jugular vein to artery waveform peak delay (s) 0.13±0.12 0.09±0.10 0.10±0.07 0.427 
Aqueduct CSF to artery waveform peak delay (s) 0.20±0.07 0.17±0.06 0.16±0.08 0.093 
P values were from ANOVA. Results in bold represent p<0.05.  
 
Table 36 CSF pulsatility and waveform peak delays according to deep WMH Fazekas scores 
  Fazekas score for deep WMH 
 0 (n=4) 1 (n=26) 2 (n=16) 3 (n=10) P value 
Aqueduct stroke volume (ml) 0.07± 0.06 0.05±0.04 0.06±0.03 0.06±0.03 0.735 
Aqueduct systolic duration (s) 0.45±0.01 0.46±0.06 0.48±0.09 0.44±0.06 0.536 
Cervical CSF stroke volume (ml) 0.33±0.17 0.53±0.22 0.45±0.18 0.48±0.23 0.298 
Cervical CSF systolic duration (s) 0.38±0.10 0.36±0.05 0.34±0.09 0.39±0.06 0.370 
Internal jugular vein to artery waveform peak delay (s) 0.16±0.03 0.13±0.11 0.09±0.11 0.07±0.08 0.220 
Aqueduct CSF to artery waveform peak delay (s) 0.19±0.06 0.20±0.08 0.18±0.06 0.15±0.08 0.297 




Linear regression analyses of CSF pulsatility or waveform peak delays 
on WMH volume 
Table 37 demonstrates that there were no significant associations between CSF 
pulsatility or waveform peak delays and WMH volume (normalised to ICV) in either 
univariate or multiple regression models. Age was significantly associated with 
larger WMH volume in all models.   
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Table 37 The associations between CSF pulsatility and waveform peak delays and WMH volume 
WMH/ICV ratio as outcome (linear regression) 
Non-adjusted models  Models adjusted for age, MAP, and gender 




2.697 [-3.943, 9.337] 0.419  Aqueduct CSF stroke volume -0.038 [-6.038, 5.961] 0.990 
    Age 0.062 [0.034, 0.090] <0.001 
    MAP 0.008 [-0.008, 0.024] 0.300 




-0.974 [-4.503, 2.556] 0.582  Aqueduct CSF systolic 
duration 
0.321 [-2.982, 3.624] 0.884 
    Age 0.062 [0.034, 0.089] <0.001 
    MAP 0.009 [-0.008, 0.025] 0.298 
    Gender 0.076 [-0.442, 0.593] 0.760 
Cervical CSF 
stroke volume 
-0.57 [-1.77,0.631] 0.345  Cervical CSF stroke volume -0.549 [-1.579, 0.48] 0.289 
    Age 0.062 [0.035, 0.089] <0.001 
    MAP 0.0080 [-0.007, 0.024] 0.295 




-1.899 [-5.554, 1.756] 0.302  Cervical CSF systolic duration -1.021 [-4.228, 2.186] 0.526 
    Age 0.06 [0.033, 0.088] <0.001 
    MAP 0.009 [-0.007, 0.024] 0.277 








    Age 0.063 [0.036, 0.090] <0.001 
 
    MAP 0.057 [-0.443, 0.556] 0.304 
 





-1.252 [-3.638, 1.134] 0.297  Internal jugular vein-Artery 
peak delay 
-0.965 [-3.107, 1.177] 0.370 
    Age 0.061 [0.034, 0.088] <0.001 
    MAP 0.129 [-0.370, 0.628] 0.231 
    Gender 0.01 [-0.006, 0.026] 0.606 
Results in bold represent p<0.05. 
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CSF pulsatility, waveform peak delays, and PVS 
Univariate comparisons of CSF pulsatility and waveform peak delays 
according to PVS scores  
Figure 37 and Figure 38 shows that CSF pulsatility and waveform peak delays did 
not differ across PVS scores in either basal ganglia (Figure 37) or centrum 




Figure 37 Boxplot showing the univariate comparisons of CSF pulsatility and 
waveform peak delays according to basal ganglia PVS score. P values were from 
ANOVA. Sample sizes in each group: PVS score 1 (n=19); 2 (n=21); 3 (n=12); 4 





Figure 38 Boxplot showing the univariate comparisons of CSF pulsatility and 
waveform peak delays according to centrum semiovale PVS score. P values were 
from ANOVA. Sample sizes in each group: PVS score 1 (n=11); 2 (n=20); 3 (n=20); 




Table 38 CSF pulsatility and waveform peak delays according to basal ganglia PVS score 
 Basal ganglia PVS score  
 1 (n=19) 2 (n=21) 3 (n=12) 4 (n=4) P value 
Aqueduct stroke volume (ml) 0.12±0.10 0.10±0.06 0.12±0.08 0.09±0.05 0.67 
Aqueduct systolic duration (s) 0.47±0.05 0.47±0.09 0.44±0.06 0.40±0.04 0.15 
Cervical CSF stroke volume (ml) 0.49±0.22 0.51±0.19 0.43±0.23 0.38±0.21 0.56 
Cervical CSF systolic duration (s) 0.38±0.08 0.35±0.07 0.36±0.05 0.35±0.06 0.66 
Internal jugular vein to artery waveform peak delay (s) 0.09±0.10 0.12±0.12 0.14±0.09 0.12±0.09 0.70 
Aqueduct CSF to artery waveform peak delay (s) 0.18±0.08 0.19±0.06 0.20±0.08 0.13±0.09 0.49 
P values were from ANOVA. Results in bold represent p<0.05.  
Table 39 CSF pulsatility and waveform peak delays according to centrum semiovale PVS score 
 Centrum semiovale PVS score 
 1 (n=11) 2 (n=17) 3 (n=20) 4 (n=8) P value 
Aqueduct stroke volume (ml) 0.12±0.07 0.12±0.10 0.10±0.05 0.14±0.08 0.51 
Aqueduct systolic duration (s) 0.45±0.03 0.45±0.06 0.48±0.09 0.43±0.07 0.36 
Cervical CSF stroke volume (ml) 0.54±0.16 0.43±0.24 0.48±0.17 0.49±0.27 0.59 
Cervical CSF systolic duration (s) 0.37±0.06 0.35±0.07 0.36±0.07 0.37±0.07 0.88 
Internal jugular vein to artery waveform peak delay (s) 0.09±0.09 0.11±0.10 0.13±0.10 0.13±0.15 0.81 
Aqueduct CSF to artery waveform peak delay (s) 0.15±0.06 0.19±0.07 0.21±0.08 0.16±0.07 0.20 
P values were from ANOVA. 
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Ordinal regression analyses of CSF pulsatility or waveform peak 
delays on PVS 
Table 40 and Table 41 show the results of ordinal regression models between CSF 
pulsatility measures, waveform peak delays, and PVS scores in the basal ganglia 
(Table 40) or centrum semiovale (Table 41).  
CSF pulsatility (stroke volume, systolic duration) or waveform peak delays (in the 
aqueduct or internal jugular veins) were not significantly associated with PVS scores 
in either location. 
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Table 40 The associations between CSF pulsatility and waveform peak delays and PVS in the basal ganglia 
Basal ganglia PVS score as outcome 
Non-adjusted models  Models adjusted for age, MAP, and gender 
Predictors OR 95% CI  Predictors OR 95% CI 
Aqueduct CSF stroke 
volume (per 0.01 ml) 
0.984 [0.919, 1.054]  Aqueduct CSF stroke volume 0.944 [0.869, 1.026] 
 Age (per year) 1.127 [1.047, 1.214] 
 MAP (per mmHg) 1.021 [0.983, 1.060] 
 Gender (Male) 1.287 [0.392, 4.223] 
Aqueduct CSF systolic 
duration (per 0.1 s) 
0.615 [0.316, 1.197]  Aqueduct CSF systolic duration 0.672 [0.326, 1.386] 
 Age 1.107 [1.034, 1.185] 
 MAP 1.017 [0.980, 1.056] 
 Gender (Male) 1.243 [0.367, 4.205] 
Cervical CSF stroke 
volume (per 0.01 ml) 
0.278 [0.025, 3.124]  Cervical CSF stroke volume 0.313 [0.026, 3.793] 
 Age 1.107 [1.034, 1.185] 
 MAP 1.021 [0.984, 1.059] 
 Gender (Male) 1.015 [0.322, 3.202] 
Cervical CSF systolic 
duration (per 0.1 s) 
0.664 [0.323, 1.366]  Cervical CSF systolic duration 0.71 [0.335, 1.503] 
 Age 1.105 [1.032, 1.183] 
 MAP 1.022 [0.985, 1.061] 
 Gender (Male) 0.983 [0.315, 3.071] 
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Aqueduct - Artery peak 
delay (per 0.01 s) 
0.977 [0.910, 1.049]  Aqueduct - Artery peak delay 0.983 [0.907, 1.064] 
 Age 1.107 [1.035, 1.185] 
 MAP 1.021 [0.984, 1.059] 
 Gender (Male) 1.098 [0.317, 3.801] 
Internal jugular vein - 
Artery peak delay (per 
0.01 s) 
1.021 [0.976, 1.068]  Internal jugular vein - Artery 
peak delay 
1.035 [0.984, 1.088] 
 Age 1.115 [1.041, 1.196] 
 MAP 1.014 [0.976, 1.054] 
 Gender (Male) 0.865 [0.268, 2.790] 




Table 41 The associations between CSF pulsatility and waveform peak delays and PVS in the centrum semiovale 
Centrum semiovale PVS score as outcome 
Non-adjusted models  Models adjusted for age, MAP, and gender 
Predictors OR 95% CI  Predictors OR 95% CI 
Aqueduct CSF stroke 
volume (per 0.01 ml) 
1.005 [0.943, 1.070]  Aqueduct CSF stroke volume  0.986 [0.925, 1.052] 
   Age (per year) 1.083 [1.013, 1.159] 
   MAP (per mmHg) 1.011 [0.976, 1.047] 
   Gender (Male) 2.932 [0.840, 10.235] 
Aqueduct CSF systolic 
duration (per 0.1 s) 
1.056 [0.557, 2.004]  Aqueduct CSF systolic duration  1.064 [0.529, 2.136] 
   Age  1.081 [1.012, 1.155] 
   MAP 1.012 [0.976, 1.049] 
   Gender (Male) 2.693 [0.758, 9.571] 
Cervical CSF stroke 
volume (per 0.01 ml) 
0.799 [0.080, 7.991]  Cervical CSF stroke volume  0.98 [0.095, 10.120] 
   Age 1.081 [1.011, 1.155] 
   MAP 1.011 [0.976, 1.047] 
   Gender (Male) 2.773 [0.814, 9.446] 
Cervical CSF systolic 
duration (per 0.1 s) 
1.009 [0.539, 2.099]  Cervical CSF systolic duration 1.024 [0.631, 2.615] 
   Age 1.094 [1.015, 1.161] 
   MAP 1.009 [0.974, 1.046] 
    Gender (Male) 3.438 [0.855, 10.043] 
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Aqueduct - Artery peak 
delay (per 0.01 s) 
1.035 [0.965, 1.110]  Aqueduct - Artery peak delay 1.028 [0.952, 1.111] 
   Age 1.08 [1.011, 1.153] 
   MAP 1.014 [0.978, 1.052] 
    Gender (Male) 2.316 [0.616, 8.702] 
Internal jugular vein - 
Artery peak delay (per 
0.01s) 
1.026 [0.980, 1.075]  Internal jugular vein - Artery 
peak delay 
1.028 [0.978, 1.081] 
   Age 1.084 [1.015, 1.158] 
   MAP 1.009 [0.974, 1.046] 
   Gender (Male) 2.448 [0.701, 8.544] 





Chapter 5E: The associations between intracranial haemodynamic 
measures 
Cerebrovascular pulsatility and CBF  
Table 42 shows the association between pulsatility and CBF in the same vessels. 
Arterial PI was averaged from PI in the ICAs and vertebral arteries, as the arterial 
flow was the sum of blood flow in the four arteries. Higher arterial PI was 
significantly associated with lower arterial flow (β＝-8.59, p=0.047), although the p 
value was not corrected for multiple testing.(Table 42) I also illustrated this 
association in Figure 39, although the coefficient in the figure was from non-adjusted 
models (β＝-9.784, p=0.029).  
However, CBF in the transverse sinuses and internal jugular veins were not 
associated with pulsatility indices in the correspondent vessels (e.g. transverse sinus: 






Table 42 The associations between vascular pulsatility and flow 




Arterial PI Transverse sinus PI Internal jugular vein PI 
Arterial flow  β＝-8.59 [-17.09, -0.099]*, p=0.047 - - 
Transverse sinus 
flow  
- β＝1.50 [-14.44, 17.44]*, p=0.851 - 
Internal jugular 
vein flow 
- - β＝-0.31 [-8.50, 7.88]*, p=0.94 




Figure 39 The association between arterial flow and arterial pulsatility (univariate) 
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ICA and venous pulsatility  
Results in Table 43 show that pulsatility in all the venous sinuses and the internal 
jugular veins were significantly associated with ICA pulsatility (e.g. superior sagittal 
sinus: β=0.247, p=0.019; internal jugular veins: β=0.622, p=0.007), after the 
adjustment for age, MAP and WMH volume.(Table 43) I also illustrated these 
associations in the scatterplots in Figure 40 where all results were from univariate 
regression models (e.g. superior sagittal sinus: β=0.287, p=0.005; internal jugular 
vein: β=0.52, p=0.023).  
 
Table 43 The associations between ICA pulsatility and pulsatility in veins and CSF 
 ICA PI as predictor variable (in separate models*) 
 β 95% CI P value 
Superior sagittal sinus PI 0.247 [0.043,0.451] 0.019 
Straight sinus PI 0.298 [0.152,0.444] <0.001 
Transverse sinus PI 0.264 [0.088,0.441] 0.004 
Internal jugular vein PI 0.622 [0.179,1.064] 0.007 
*All models were adjusted for age, MAP and WMH volume. Results in bold 




Figure 40 The associations between ICA pulsatility and venous pulsatility 
(univariate). A: superior sagittal sinus pulsatility index (PI) vs ICA PI; B: straight 
sinus PI vs ICA PI; C: transverse sinus PI vs ICA PI; D: internal jugular vein PI vs 







Chapter 6: Cross-sectional study of CBF and intracranial 
pulsatility in SVD patients - Discussion 
Summary of results 
This chapter is the discussion of the results presented in chapter 5. The main findings 
of this study were summarised in Figure 41. In Chapter 5A, I aimed to summarise the 
haemodynamic measures we obtained from patients and investigate how these 
measures related to age, stroke subtype, SVD features as well as to systemic 
measures. I included data from 56 patients (age 67.8 ± 8.3 years) with minor stroke 
and SVD features on brain imaging. 36 patients had a lacunar and 20 had a cortical 
stroke. Most patients were hypertensive and had mild to moderate SVD burden 
according to Fazekas score and PVS score. Age, vascular risk factors, and most SVD 
features did not differ between lacunar and cortical stroke. Older age was associated 
with higher aortic AIx and higher pulsatility indices in most brain vessels, but not 
with CBF (ml/min/100 brain volume) or CSF pulsatility. Stroke subtype was not 
associated with any intracranial or extracranial haemodynamic measures. Higher 
diastolic BP and MAP was associated with higher arterial blood flow but not with the 
venous flow. Lower diastolic BP and MAP were significantly associated with higher 
pulsatility indices in venous sinuses. Higher aortic AIx was associated with lower 
ICA pulsatility indices, but not with pulsatility in the veins or CSF.     
Then, in Chapter 5B-5D, I investigated the role of intracranial measures and aortic 
stiffness in WMH and PVS. Higher aortic AIx was associated with larger WMH 
volume, but the association disappeared after the adjustment for age and other 
covariates. Higher aortic AIx was also associated with higher PVS score in the basal 
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ganglia but not centrum semiovale. Neither arterial nor venous flow was associated 
with WMH or PVS. High PI and RI in the venous sinuses were significantly 
associated with higher WMH burden and basal ganglia PVS score (not centrum 
semiovale), which was independent of age, gender, and blood pressure. Shorter 
aqueduct-to-artery and artery-to-internal jugular vein delays were observed in 
patients with higher Fazekas score but not associated with WMH volume or PVS 
scores. We did not observe significant associations between CSF pulsatility and 
WMH or PVS. (Figure 41) 
In order to better understand the implications of cerebrovascular pulsatility, in 
Chapter 5E, I assessed the association between PI and blood flow in the same vessels, 
and between venous and arterial PI. It was only in arteries but not veins that higher 
pulsatility was associated with lower CBF. PI in all the venous sinuses and internal 
jugular veins were significantly associated with arterial pulsatility. (Figure 41) 





Figure 41 Summary of associations between extracranial and intracranial 
haemodynamic measures, and SVD features. All models were adjusted for age, 
gender and MAP. WMH burden was calculated as WMH volume, and semi-
quantitative scores (0-4) were used for PVS. Results of RI were similar to PI (see 
Chapter 5). For simplicity, only results of PI were shown here. SVD: small vessel 
disease; PVS: perivascular spaces; WMH: white matter hyperintensities; ICA: 
internal carotid artery; Bp: blood pressure; AIx: augmentation index; PI: pulsatility 





In this study, we recruited a group of representative patients with minor stroke in 
whom SVD is very common. All these patients underwent a careful assessment of 
stroke classification by a panel of stroke specialists. We took various approaches to 
reduce the biases in every step of the analysis. For image processing, we used a well-
established and validated method for brain tissue segmentation, including masks for 
total brain volume, ICV, and WMH volume. All these masks were automatically 
generated, and then corrected manually by a neurologist and cross-checked by an 
experienced neuroradiologist, who also cross-checked all the visual rating scores of 
SVD features. All the image analysts were blinded to any clinical or flow/pulsatility 
data. Although both visual rating and volumetric measurements of WMH were 
included in the analysis, most of the conclusions were based on the results using 
WMH volumes, because there is an inherent ceiling effect in the visual rating 
methods such as Fazekas scores which limits the differentiation for severe WMH. 
We also adjusted for necessary covariates in the statistical analysis. The other 
strengths include a thorough assessment of the flow and pulsatility in cerebral 
arteries, veins and CSF in a single session, and for the first time assessed the 
relationship between PVS and pulsatility in humans.  
 
Weaknesses 
Weaknesses include the sample size (n=56) that limited the power for very 
comprehensive multivariate analysis. However, as we mentioned previously, this is a 
pilot study that mainly aimed to set up a reliable methodology for future studies, 
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such as sample size estimation for larger studies or long-term follow-ups. The second 
weakness is that we included both lacunar stroke and cortical stroke, although both 
groups had WMH and PVS. The reason was that patients who had minor stroke, 
regardless of the aetiologies, are a typical group that could be affected by SVD 
pathologies. However, it is possible that including both stroke subtypes could lead to 
a potential selection bias. The third limitation is that some patients were under anti-
hypertensive treatments such as angiotensin converting enzyme inhibitors (ACEIs) 
that have vasoactive effects, which may reduce the vessel stiffness and PI. However, 
our sample size is not powerful enough for a sensitivity analysis that could address 
the impact of these medications on our final results, which could be considered in 
future larger studies. There are also some other weaknesses in the methodology. We 
had limited assessment for aortic stiffness. We obtained the aortic pressure waveform 
via the estimation from the radial artery tonometry, which is a widely accepted and 
most common method, and calculated the aortic AIx to represent the aortic stiffness. 
However, aortic AIx is a measure of aortic wave reflection and is related to aortic 
pulse wave velocity (another indicator of aortic stiffness) which we did not have in 
this study. We were also not able to measure smaller cerebral vessels (e.g. 
penetrating arteries) due to limited MRI resolution or to acquire independent CBF 
measures for different tissues. All the associations that we assessed were cross-
sectional, thus we were not able to address any causal relationships between 
variables in this study. Lastly, all the p values that were provided in this thesis were 
not corrected for multiple testing such as Bonferroni adjustment. It is possible that 
some p values that were just close to 0.05 might not survive multi-testing corrections. 
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However, an important aim of this study is to generate new hypotheses for future 
research, of which the validity could be tested in suitable powered larger studies. 
 
Haemodynamic measures and their relation to age and stroke 
subtype 
The value of total arterial flow was 645.32±113.00 ml/min (60.17±9.52 ml/min per 
100 ml brain volume), which is consistent with values reported in other studies with 
elderly populations (n=36, age≈70 years, mean arterial flow=580-710 ml/min;64 
n=60, age 65.67±9.31 year, 709±135 ml/min58). Venous flow in the transverse 
sinuses and internal jugular veins were in general smaller than in the arteries, 
consisting of 75-80% of total blood flow, as reported in the literature.187 The 
difference between arterial inflow and internal jugular outflow might be due to a 
small amount of blood draining through extra-jugular venous systems such as 
vertebral, cavernous region or deep neck veins, which was not recorded in our 
study.158, 188  
Some previous cross-sectional studies showed a yearly CBF decrease of 4.8-6.3 
ml/min (n=250-447, age 19-88 years).73, 189 However, the decreasing CBF (ml/min) 
might be largely confounded by the brain volume which also decreased with age.73, 74 
In the PROSPER study (n=447, age=75±3 years) the relationship between CBF and 
age disappeared after using ml/min/100 ml brain volume instead of ml/min, which is 
consistent with our finding. These results suggest that some studies may have 
overestimated the decline in CBF with age, and that future studies which aim to 
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investigate the role of CBF in any pathology related to ageing should normalise the 
CBF to the brain volume.     
We found that aortic AIx and pulsatility indices in some brain vessels were 
significantly associated with older age. Aortic AIx is a measure of pulse wave 
reflection and an indirect indicator of aortic stiffness. Although increasing evidence 
has shown that the aorta stiffens with ageing,120 the relationship between aortic AIx 
and age varied in the literature. Aortic AIx increased with age in some studies with 
small population or patients with coronary artery diseases (n=41-67, age≈30-50 
years);190, 191 whereas in some large-scale studies with healthy populations (n=4001-
4561, age 18-90 years), the relationship seemed nonlinear: it increased before 60 
years old but plateaued afterwards.192, 193 However, these studies were all cross-
sectional and therefore were possibly confounded by including healthier older and 
less healthy young subjects. In our study, all patients had had a stroke, and 
hypertension was very common, which was more complicated than normal ageing. 
The vascular risk factors might co-associate with age, which we were not able to 
untangle fully with a small sample size.  
Previous studies on age and cerebrovascular pulsatility were scarce. One study (n=78, 
age 20-85 years) showed that both ICA PI and RI increased with age.194 One study 
found that healthy elderly (n=12, age 71±9 years) had smaller CSF stroke volume in 
the aqueduct and cervical subarachnoid spaces compared with healthy young 
volunteers (n=12, age 27.5±4.4 years) but no differences in waveform peak delay 
between groups.147 However we did not find any linear association between CSF 
flow or pulsatility and age.  
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None of the extra- and intra-cranial haemodynamic measures were associated with 
stroke subtype (lacunar vs cortical). As I showed previously, patients with lacunar 
and cortical stroke did not differ between most SVD features (except lacunes) or any 
vascular risk factors, suggesting a similar cerebrovascular disease burden.  
 
The association between extracranial and intracranial measures 
The relationship between CBF and blood pressure is complex and nonlinear. In a 
brain with an intact autoregulation system, CBF remains relatively constant across a 
wide range of cerebral perfusion pressure (60-150 mmHg) and systemic arterial 
pressure.195 However in this study, we found a positive relationship between CBF 
and diastolic and mean arterial pressure. As the CBF autoregulation is thought to be 
achieved primarily by small arteries and arterioles, it is likely that pathologies in the 
small vessels might result in a failed or compromised CBF autoregulation, such as in 
patients with SVD. A previous study showed that in patients with chronic 
hypertension (n=13, age 44-64 years), the lower end of the plateau of CBF 
autoregulation shifted to a higher blood pressure,196 suggesting an impaired 
autoregulation and that a lowered blood pressure might possibly cause an insufficient 
blood supply to brain tissues. 
This is the first study that has addressed the relations between pulsatility in various 
cerebral vessels concurrently with CSF and haemodynamic measures in the systemic 
circulation. Some studies have measured one single type of brain artery, such as 
ICAs or MCAs. In the Lothian Birth cohort study (n=694, age 72.6±0.7 years), 
higher ICA PI (averaged from both sides) was associated with higher systolic BP, 
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lower diastolic BP, and higher pulse pressure. It is worth noting that a longitudinal 
rise in pulse pressure between 69 and 72 years was due to falling diastolic BP, since 
systolic BP did not change.57 In another two studies (n=165-334, age 19-86 years) 
that assessed MCA, higher MCA PI was associated with higher pulse pressure but no 
results for other brachial BP measures were shown.197, 198 Although in our study, the 
association between lower diastolic BP and higher pulsatility indices was only 
significant in the straight sinus and the internal jugular vein but not in the ICA, the 
overall trend between diastolic BP and cerebrovascular pulsatility was consistent 
across all brain vessels and with the literature.  
Apart from systemic BP measures, I also investigated how intracranial pulsatility 
indices were related to aortic AIx. There is a hypothesis that in normal ageing, as the 
aorta stiffens more than peripheral arteries with age, excessive pulsatile power would 
be more easily transmitted forward and dissipated into the peripheral circulation.120 
Interestingly, we found a contrasting result in the ICA: higher aortic AIx was 
associated with lower ICA pulsatility, despite that both measures showed a similar 
trend with age. Likewise, another study (n=159, age 61±1.1 years) observed that 
decreasing aortic AIx was associated with increasing impedance in the carotid artery 
but decreasing impedance in distal peripheral circulation.199 Aortic AIx is an 
indicator of aortic wave reflection, which is theoretically determined by the 
impedance mismatch between central and peripheral arteries. According to an 
analysis on the physical principle of wave reflection, the reflection ratio in a central 
artery is expressed as (Zdist-Zprox)/ (Zdist+Zprox) where Zdist indicates distal impedance 
and Zprox means impedance in the proximal.
200 According to this equation, the 
magnitude of the reflected wave back to the aorta is dependent on the ratio between 
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the impedance at proximal and distal arteries. Thus the increased impedance in the 
proximal artery, such as in the ICA, might result in a smaller reflected wave that 
returns to the aorta. These results also raise a concern that aortic AIx is a complex 
measure which might not be sensitive in detecting aortic stiffness in the elderly, 
which has been discussed in other studies.120, 201   
Very few studies have assessed aortic stiffness and pulsatility in vessels more 
downstream than ICA. One study (n=100, age≈50-80 years) showed that high MCA 
PI is associated with high aortic pulse wave velocity,59 but we did not find a 
significant association between venous pulsatility and aortic AIx. The association 
between higher aortic AIx and PVS in the basal ganglia might suggest a relationship 
between aortic stiffness and pulsatility in distal cerebral vessels, as enlarged PVS are 
hypothesised to be the result of a fluid blockage in the perivascular spaces due to 
abnormal pulsatility in deep arterioles.59 Furthermore, we also showed that higher 
aortic AIx was associated with shorter artery-to-aqueduct systolic peak delay which 
was also suggested as an indicator of microvascular pathologies.65 However, the 
cause and effect between aortic stiffness and high pulsatility in distal cerebral vessels 
is unclear: whether it is high distal impedance that causes a high reflected wave in 
the aorta or it is the less dampened pulse from stiffened aorta that was transmitted 
into the distal vessels is not known. We were unable to address the question in this 
study.  
We showed that the higher aortic AIx was not associated with WMH volume after 
the adjustment for age and other covariates. In the literature, the relationship between 
aortic AIx and WMH was found in some202, 203 but not in other studies,60 despite the 
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varying sample sizes and participants population across the studies. These results 
might suggest that aortic stiffness is part of, but not necessarily the cause of WMH.          
  
The associations between intracranial measures and SVD features  
Age was prominently associated with both WMH and PVS in all analyses, which is 
not surprising and emphasizes the importance of the adjustment for age in any SVD-
related analysis. The barely existing association between total CBF and WMH in our 
patients is detected only in arteries and disappeared when corrected for age, which is 
consistent with previous evidence from both large-scale cross-sectional and 
longitudinal studies.126 However, it is noteworthy that we were unable to measure 
CBF in white matter and grey matter separately. The effect on regional CBF in white 
matter and grey matter might differ. A cross-sectional analysis from the Third 
International Stroke Trial (IST-3) (n=115) showed that higher total SVD score was 
associated with lower CBF in the white matter.204 Thus techniques that enable the 
detection of CBF in different tissues especially in the white matter should be 
encouraged and would better clarify the role of CBF in SVD.    
The relationship between ICA pulsatility and WMH partly reflects a co-association 
with age, which is consistent with a previous study (n=122, age 63.73±10.85 
years).127 In other studies such as the Lothian Birth Cohort (n=694, age 72.6±0.7 
years), high ICA PI remained associated with WMH after the adjustment for age.57 
Similarly, we also did not find associations between ICA pulsatility and PVS, despite 
the suggestion in animal studies and mathematical models that arterial pulsatility is 
the key driver of fluid dynamics in perivascular spaces.40, 205 The wide age range and 
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the small size of our study may have made it difficult for us to untangle the 
confounding effect of age on ICA PI-SVD, a relationship which appears to be 
inherently weaker than venous PI-SVD. We did not find any significant association 
between vertebral artery pulsatility and WMH or PVS, perhaps reflecting the low 
flow volume in the vertebral arteries. 
Unlike in the arteries, we found that the PI and RI in the superior sagittal and 
transverse sinuses remained associated with WMH, which is independent of age and 
MAP. The relationship between high venous sinus pulsatility and white matter 
damage was supported in some studies in other diseases. In patients with idiopathic 
dementia (n=60, age 75±8 years), those with more severe WMH had higher superior 
sagittal sinus PI;124 in a healthy population (n=70, 43-82 years) where most 
participants had mild or negligible WMH, high venous PI was associated with white 
matter microstructural damage although not with total WMH volume.58  
This study is the first to observe the relationship between increased cerebrovascular 
pulsatility and basal ganglia PVS in humans. Other indirect clinical evidence comes 
from a population-based study (n=1009, age 68±8 years) which showed that higher 
systemic (brachial) pulse pressure was associated with PVS.206 We also found that 
high PI and RI was only associated with basal ganglia but not centrum semiovale 
PVS, which might reflect known differences in the arterioles in the two regions. This 
result is consistent with apparent differences in associations of PVS in the two 
locations. Some studies suggest that basal ganglia PVS may be more associated with 
inflammation,56 hypertension207 or lacunar stroke,33 and centrum semiovale PVS 
more with cerebral amyloid angiography.207 A theoretical mathematical model also 
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shows that in hypertension, the arteriolar pressure in the basal ganglia was higher 
than in cortical vessels.208  
However, despite the hypothetical differences in PVS in these two locations, they are 
co-associated with each other.33 A previous study showed that the visual rating score 
for PVS in the centrum semiovale had a higher intra- and inter-observer variability 
than PVS in the basal ganglia, which might partly be due to more WMH in the 
centrum semiovale that makes it difficult to rate PVS and more slices that contain 
PVS in the centrum semiovale. Thus before more data and detailed studies are 
available, it might be too early to conclude on the differences in the mechanisms of 
PVS in the two areas. We suggest that future studies should collect information on 
both sites. There is a suggestion that different SVD features share a common 
pathology and should be regarded as a “whole-brain” disease.119 Total PVS (basal 
ganglia and centrum semiovale combined) are associated with WMH.33 PVS and 
WMH are both associated with an impaired BBB.209 Increased cerebrovascular 
pulsatility may be affecting cerebral interstitial fluid drainage accounting for the 
increased visibility of PVS and worse WMH, providing further support for a shared 
aetiology between PVS and WMH, although it is uncertain whether PVS precede, 
follow, or appear concurrently with WMH. 
We did not find associations between CSF stroke volumes or systolic durations and 
SVD features. The association between CSF pulsatility and WMH was conflicting in 
previous studies: present in some125, 143 but not others58. Theoretically, PVS might be 
related to perivascular CSF pulsatility driven by arterial pulse, but the indices we 
used here were not designed to detect this pulse at the microscopic level. Some 
researchers hypothesise that the CSF flow in the aqueduct represents flow in the 
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capillary bed and shorter artery-to-aqueduct peak delay might indicate capillary 
dysfunction.65 However, we did not find associations between any peak delays with 
WMH volume nor with PVS score. 2D phase-contrast MRI has limited temporal 
resolution and the reliability of the pulse wave peak delays requires more research. 
Improved imaging techniques with high temporal and spatial resolution that enable 
detection of small vessels in more detail, or that identifies intracranial pulsation with 
higher sensitivity would benefit further research.  
 
The implication of cerebrovascular pulsatility  
Although no studies have directly compared cerebral vascular pulsatility and CBF, 
one study showed a higher ICA pulsatility and lower arterial flow in patients with 
WMH compared to healthy controls.129 These findings are in agreement with the 
trend for both measures in our study and the inverse association between arterial 
pulsatility and arterial flow. These results also led to the suggestion that increased 
vascular stiffness might locally affect the blood flow, which maybe eventually result 
in a reduced CBF at the end stage of the disease.  
The implication of venous pulsatility remains unclear. It is still not known how the 
changes in the pulsatility in the large vessels relates to pathologies in small vessels. 
On one hand, it is possible that the increased pulsatility detected in the large vessels, 
especially in the large veins, was a result of high cardiac pulse that could not be 
sufficiently buffered in the stiffened small vessels. On the other hand, the increased 
pulsatility in large vessels, regardless of the source, could in turn lead to high 
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pulsatile energy being transmitted into small vessels, exacerbate endothelial damages 
and impair the perivascular clearance pathway.  
Although the association between PI (and RI) and SVD features was only significant 
in the venous sinuses but not arteries, it might not necessarily suggest a particular 
significance of the venous pathology. The non-significant PI-SVD relationship after 
the adjustment of age might be due to our small sample size. The pulsatility in the 
arteries and veins were significantly correlated. Pulsatility in the venous sinuses 
might indicate inefficient dampening of the arterial pulse, and perhaps is a more 
sensitive measure in reflecting the compliance of the whole brain.210 However, the 
details of the passage of pulse transmission through the older brain are largely under-
researched. One hypothesis suggests that the systolic arterial expansion produces a 
pressure wave within the CSF spaces, which is then partly transmitted into the major 
dural sinuses via arachnoid granulations.62, 211 We found that the systolic peak delay 
time from arteries was shortest to cervical CSF, followed by the transverse and 
straight sinuses, then the superior sagittal sinus, similar to the pattern of cardiac pulse 
transmission (from skull base to the cortex) observed in another study using ultra-fast 
magnetic resonance encephalography.157  
Venous pulsatility could also be partly from capillaries. Increased capillary 
pulsatility from the less dampened arterial pulse could be transmitted to veins 
through blood flow or inward expansion.62 However, the relationship between 
capillary and venous pulsatility is uncertain. As a sufficient venous backpressure is 
also important for maintaining a constant capillary flow,62 venous pathologies could 
in turn result in increased capillary pulsatility. Indeed, there are autopsy studies 
(n=13, age>60 years) showing a collagenous thickening in periventricular venules 
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which was related to PVWMH severity,212 but it is unknown whether the venule 
damage was caused by excessive pressure filtered from the arteries or was an 
intrinsic pathology. It is likely that pathologies in the arterioles and venules coexist. 
Future SVD studies including pathology, clinical or any models, should consider 
both arteries and veins.  
 
Conclusion  
This is the first study to investigate the flow and pulsatility in the main cerebral 
arteries, veins, and CSF concurrently, and compared them to both WMH and PVS in 
patients with minor ischaemic stroke. It is also the first comprehensive study to look 
at the relationship between intracranial and systemic haemodynamic measures. Our 
results suggest that aortic AIx is related to lower ICA pulsatility, but might not 
necessarily be the cause of WMH. The finding of no significant association between 
low CBF and WMH challenges the traditional hypothesis that low CBF is the cause 
of WMH, but is consistent with the overall message from longitudinal data which 
indicates that high WMH burden precedes low CBF. WMH and basal ganglia PVS 
are closely associated with cerebrovascular pulsatility. Although the implication of 
venous sinus pulsatility requires further research, this study confirms the role for 
increased intracranial pulsatility in SVD, as well as suggesting that venous PI 
specifically is important in SVD, thus advancing knowledge in the field and 
identifying potential targets for future studies of mechanism, treatment, and 
prevention of SVD. 
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Chapter 7: General discussion 
Summary of the results  
In this thesis, I summarised the current evidence of clinical studies on CBF and 
intracranial pulsatility in SVD, developed a method to measure CBF and pulsatility 
using phase-contrast MRI, and then applied this method in 60 patients with minor 
ischaemic stroke and SVD imaging features. The results of the systematic reviews 
question the cause and effect between reduced global CBF and SVD, and suggest 
increased intracranial pulsatility as an alternative mechanism of SVD. The 
systematic reviews also highlighted the importance on the adjustment of important 
covariates such as age and blood pressure in SVD studies, and called for more 
studies of high quality and longitudinal data.  
Then in the cross-sectional study, I showed that the MRI CBF and pulsatility 
measures were well reproducible and comparable to that in the Doppler ultrasound. 
The results again did not support an association between low global CBF and SVD, 
but suggest that increased cerebrovascular pulsatility plays an important role in the 
pathophysiology of WMH and PVS, thus advancing the current understanding of 
SVD mechanisms and providing potential targets for SVD prevention and treatment. 
More importantly, this thesis sets up a reliable methodology for futures SVD studies 
to measure CBF and intracranial pulsatility using phase contrast MRI, and to use 





The thesis has several strengths. First, I carried out two comprehensive systematic 
reviews of clinical studies, which not only summarised the results of previous studies, 
but also addressed the potential limitations of the current evidence. Second, we 
showed that phase-contrast MRI had high reproducibility and good comparability 
with Doppler ultrasound in measuring cerebrovascular pulsatility, which provides 
strong evidence for cerebrovascular pulsatility to be used as a secondary outcome for 
monitoring cerebrovascular function in future longitudinal studies and clinical trials. 
The results of the associations between the flow and pulsatility and SVD features 
also allow us to estimate sample sizes for further studies. Third, in the cross-sectional 
study, I used various approaches to control the potential biases, including the use of 
blinding (to clinical and flow data) and validated methods in the structural image 
processing, cross-checking of the visual rating scores with an experienced 
neuroradiologist. Fourth, all statistical analyses were carefully performed. Age was 
adjusted wherever possible in the statistical analyses, including in the systematic 
reviews and the cross-sectional study. We also adjusted for gender and blood 
pressure in all the multiple variable analyses. In all the statistical models, the 
numbers of covariates were carefully selected according to the sample size, with 
avoidance of any collinearity between covariates. 
 
Weaknesses 
The first limitation is the relatively small sample sizes in both systematic reviews 
and our own study, which limited more comprehensive statistical analyses. However, 
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the sample sizes of the systematic reviews actually reflect the limitation of previous 
studies. Second, all associations assessed in this thesis were cross-sectional. We were 
not able to address the cause and effect between predictor and outcome variables, 
which requires longitudinal studies. However, one of the aims of this pilot study was 
to set up a reliable measure of CBF and intracranial pulsatility and use it in future 
clinical trials or for long-term follow ups. Indeed, after this study, we have already 
applied this method in 27 patients in the ongoing Lacunar Intervention Trial 1 
(LACI-1) funded by the Alzheimer’s Society.213(protocol has been published, see 
Appendix) This technique will also be used in several larger multicentre studies (e.g. 
Investigate and Treat SVDs with centres from Edinburgh, Oxford, Munich, 
Maastricht, and Utrecht; Leduc study of sleep and sporadic SVDs with centres from 
Edinburgh and Toronto). Thus the longitudinal relationship between CBF, pulsatility, 
and SVD could be addressed in these future studies with larger populations.  
 
Implications for future research  
Most of the previous studies and our study only measured the global CBF. However, 
the relationship between the local CBF or blood flow in the penetrating arteries, or at 
an even more microscopic level and SVD changes remained unknown. We showed 
that increased arterial pulsatility was associated with lower arterial blood flow, 
indicating that stiffened vessels might potentially limit local CBF. Thus, it is likely 
that, at the end stage of the disease if the brain small vessels stiffen diffusely, the 
CBF in patients with SVD would eventually drop, as shown in some studies that 
recruited patients with very severe SVD or vascular dementia. But at earlier stages of 
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the disease, such as in our study, where most patients had mild to moderate WMH or 
PVS burden, the global CBF might be compensated by the not-yet-exhausted 
cerebrovascular autoregulation. Nevertheless, it is still not impossible that, at the 
microscopic level, limited local blood supply due to impaired arteriole autoregulation 
could be one of the factors that lead to brain tissue damage. Animal studies have 
showed that white matter and glial cells were vulnerable to low blood flow. Imaging 
methods such as arterial-spin labelling MRI and dynamic contrast-enhanced MRI 
that have higher spatial resolution and can localise CBF measurement to specific 
tissues might benefit future studies. On the other hand, the oxygen metabolism of 
brain tissues is not simply related to blood flow, but also (maybe more importantly) 
to the flow-metabolism coupling.214 In a capillary with a disturbed flow, high CBF 
might even show a low oxygen availability and cause reperfusion injury to brain 
tissues.214 Thus only measuring CBF is not enough for understanding the 
pathophysiology of SVD.   
Increasing evidence has revealed that early cerebral endothelial dysfunction might be 
a precipitator of SVD. Various mechanisms have been suggested to be related to the 
endothelial failure, of which increased intracranial pulsatility is supported by 
growing data. This study for the first time showed the association between increased 
venous sinus pulsatility and PVS, which is considered as a possible marker of the 
impaired BBB.15 PVS might also play an important role in the metabolite clearance 
in the central nervous system via the glymphatic system.215 However PVS was still 
relatively under-researched. Also, whether PVS in different locations have separate 
physiology is unclear. Therefore, more animal and human studies on PVS are needed.  
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The implication of high pulsatility in the venous sinuses also requires more research: 
whether it is due to the venous pathologies, or whether because it is a more sensitive 
indicator of intracranial pulsatility or pulsatility in small penetrating arteries is 
unclear. We suggest that future pathology and pathophysiology studies, or 
mathematical models, of SVD, should include both arteries and veins whenever 
possible. Brain imaging techniques with higher resolution, such as 7T MRI scanners 
might also be helpful. In addition, the reproducibility of CSF measures in our study 
was mostly poor, which might be due to the difficulty in measuring CSF with low 
flow. Future studies that use techniques with higher temporal and spatial resolution 
might facilitate better CSF measurements and generate more reliable data. Apart 
from clinical studies, animal studies might have its advantages in elucidating the 
relationship between intracranial pulsatility, and endothelial dysfunction and 
perivascular spaces at the microscopic level.     
We found a complicated relationship between aortic stiffness and intracranial 
haemodynamics. We did not find aortic AIx to be associated with venous sinus 
pulsatility, but instead an inverse relationship with ICA pulsatility. In addition, aortic 
AIx was associated with basal ganglia PVS but not with WMH. AIx is a complex 
measure that is an indicator of aortic wave reflection, which is associated with aortic 
stiffness but also related to other factors such as impedance mismatch between 
proximal and distal arteries. After all, these results might suggest that aortic stiffness 
has contributed to the increased intracranial pulsatility and cerebral small vessel 
damage, but might not be the single reason. The reduced diastolic pressure was also 
associated with increased ICA and venous pulsatility. For patients who had SVD, the 
stiffened small vessels could be the main source of the high intracranial pulsatility. 
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However, restricted by the limited assessment of aortic stiffness and spatial 
resolution of phase contrast MRI, we were not able to assess other indices of aortic 
stiffness such as aortic pulse wave velocity and pulsatility in smaller penetrating 
cerebral vessels, which could be considered in future studies. 
In addition, future studies should examine the long-term effect of high intracranial 
pulsatility on patients’ cognition, recurrent stroke, disabilities, and the progression of 
different SVD lesions, in order to better understand the cause and effect between 
pulsatility and SVD, and to seek potential treatment and prevention of SVD.  
 
Implications for treatment and prevention of SVD 
Currently, the management of traditional modifiable risk factors is still the main 
approach for treating or preventing SVD, despite the fact that most of these 
treatments have not yet shown desired effects on long-term outcomes. 
Antihypertensive treatment produced contradicting results: it reduced WMH 
progression in some observational studies216 but showed little or no effect in 
randomized controlled trials.217, 218 There is a suggestion that ACEIs and angiotensin 
receptor blocker (ARBs) are superior to other antihypertensive drugs in reducing 
arterial stiffness,219 but clinical trials on either Perindopril or Telmisartan (on top of 
other antihypertensive drugs) did not show significant effects on long-term SVD 
progression. Although hypertension has been reported to be highly associated with 
SVD, other factors may be involved, or be influenced by genetic factors,220 but more 
evidence is required. Nevertheless, lowering blood pressure too much could be 
potentially harmful. With an impaired cerebral autoregulation, reducing blood 
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pressure might also reduce the CBF, thus caution needs to be taken when lowering 
blood pressure in patients who had severe SVD, prior strokes and in older patients.221, 
222 Most lipid-lowering treatment had also neutral results in preventing WMH, like 
pravastatin,223 but statins might have other therapeutic effects including anti-
inflammatory and pro-endothelial activities.224 Some small studies showed that 
physical exercise might be able to prevent age-related arterial stiffness in healthy 
individuals,225, 226 and aerobic exercise could improve cardiovascular function related 
to arterial stiffness after stroke.227 However, the required intensity, frequency and 
duration of physical exercise remains unknown, and it might not be suitable for all 
age groups.219 Smoking is another well-known modifiable risk factor for SVD and 
dementia and increases arterial stiffness.228, 229 Although so far there is no evidence 
on smoking cessation for preventing SVD progression, quitting smoking greatly 
reduces the risk of stroke.230    
Prevention and treatment of SVD in the future should consider targeting the BBB, 
brain endothelium and microvascular function. There are multiple potential 
endothelial targets, such as the nitric oxide/cyclic guanosine monophosphate (cGMP) 
systems and prostacyclin/cyclic adenosine monophosphate (cAMP) system which 
might also improve the BBB integrity.224 Therefore interventions that could induce 
cAMP or cGMP or reduce their degradation appear promising. There are several 
licensed drugs that have these properties such as some nitric oxide donors and 
phosphodiesterase (PDE)-5 inhibitors.224 Dipyridamole has been licensed in the 
secondary prevention of stroke in addition to the mono-antiplatelet therapy.224, 231  
Other PDE-5 inhibitors, such as sildenafil, is used to reduce the vascular resistance in 
the pulmonary circulation in pulmonary hypertension. In animal models of stroke, 
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sildenafil improved the vascular density and endothelial cell proliferation, although 
clinical data are lacking.232 Many other drugs are still in development. More 
laboratory studies are required. But meantime, management of traditional risk factors 
according to guidelines should still be encouraged. 
   





1. World Alzheimer Report 2015. The Global Impact of Dementia. 
2. Mackay J and Mensah GA. The atlas of heart disease and stroke. World health 
organization and Center for disease control and prevention. [Last accessed on 2013 Feb 14]. 
3. Gorelick PB, Scuteri A, Black SE, et al. Vascular contributions to cognitive 
impairment and dementia: a statement for healthcare professionals from the american heart 
association/american stroke association. Stroke. 2011; 42: 2672-713. 
4. Pantoni L. Cerebral small vessel disease: from pathogenesis and clinical 
characteristics to therapeutic challenges. Lancet Neurol. 2010; 9: 689-701. 
5. Herrmann LL, Le Masurier M and Ebmeier KP. White matter hyperintensities in late 
life depression: a systematic review. J Neurol Neurosurg Psychiatry. 2008; 79: 619-24. 
6. de Laat KF, Tuladhar AM, van Norden AG, Norris DG, Zwiers MP and de Leeuw 
FE. Loss of white matter integrity is associated with gait disorders in cerebral small vessel 
disease. Brain. 2011; 134: 73-83. 
7. Wardlaw JM, Smith EE, Biessels GJ, et al. Neuroimaging standards for research into 
small vessel disease and its contribution to ageing and neurodegeneration. Lancet Neurol. 
2013; 12: 822-38. 
8. Hachinski VC, Iliff LD, Zilhka E, et al. Cerebral blood flow in dementia. Arch 
Neurol. 1975; 32: 632-7. 
9. Snyder HM, Corriveau RA, Craft S, et al. Vascular contributions to cognitive 
impairment and dementia including Alzheimer's disease. Alzheimer's and Dementia. 2015; 
11: 710-7. 
10. Investigators SPS, Benavente OR, Hart RG, et al. Effects of clopidogrel added to 
aspirin in patients with recent lacunar stroke. N Engl J Med. 2012; 367: 817-25. 
11. Wardlaw JM, Smith C and Dichgans M. Mechanisms of sporadic cerebral small 
vessel disease: insights from neuroimaging. Lancet Neurol. 2013; 12: 483-97. 
12. Mori E, Tabuchi M and Yamadori A. Lacunar syndrome due to intracerebral 
hemorrhage. Stroke. 1985; 16: 454-9. 
13. Fisher CM. Lacunes: Small, Deep Cerebral Infarcts. Neurology. 1965; 15: 774-84. 
14. Wardlaw JM, Dennis MS, Warlow CP and Sandercock PA. Imaging appearance of 
the symptomatic perforating artery in patients with lacunar infarction: occlusion or other 
vascular pathology? Ann Neurol. 2001; 50: 208-15. 
15. Wardlaw JM, Doubal F, Armitage P, et al. Lacunar stroke is associated with diffuse 
blood-brain barrier dysfunction. Ann Neurol. 2009; 65: 194-202. 
16. Durand-Fardel M. Traité du Ramolissment du Cerveau. . Baillière. Paris, 1843. 
17. Potter GM, Marlborough FJ and Wardlaw JM. Wide variation in definition, 
detection, and description of lacunar lesions on imaging. Stroke. 2011; 42: 359-66. 
18. Franke CL, van Swieten JC and van Gijn J. Residual lesions on computed 
tomography after intracerebral hemorrhage. Stroke. 1991; 22: 1530-3. 
19. Hernandez Mdel C, Piper RJ, Wang X, Deary IJ and Wardlaw JM. Towards the 
automatic computational assessment of enlarged perivascular spaces on brain magnetic 
resonance images: a systematic review. J Magn Reson Imaging. 2013; 38: 774-85. 
20. Potter GM, Doubal FN, Jackson CA, et al. Enlarged perivascular spaces and cerebral 
small vessel disease. Int J Stroke. 2015; 10: 376-81. 
21. Snowdon DA, Greiner LH, Mortimer JA, Riley KP, Greiner PA and Markesbery 
WR. Brain infarction and the clinical expression of Alzheimer disease. The Nun Study. 
JAMA. 1997; 277: 813-7. 
22. Vermeer SE, Longstreth WT, Jr. and Koudstaal PJ. Silent brain infarcts: a systematic 
review. Lancet Neurol. 2007; 6: 611-9. 
232 
 
23. Vermeer SE, Prins ND, den Heijer T, Hofman A, Koudstaal PJ and Breteler MM. 
Silent brain infarcts and the risk of dementia and cognitive decline. N Engl J Med. 2003; 
348: 1215-22. 
24. Debette S and Markus HS. The clinical importance of white matter hyperintensities 
on brain magnetic resonance imaging: systematic review and meta-analysis. BMJ. 2010; 
341: c3666. 
25. Wardlaw JM, Valdes Hernandez MC and Munoz-Maniega S. What are white matter 
hyperintensities made of? Relevance to vascular cognitive impairment. J Am Heart Assoc. 
2015; 4: 001140. 
26. Madden DJ, Bennett IJ, Burzynska A, Potter GG, Chen NK and Song AW. 
Diffusion tensor imaging of cerebral white matter integrity in cognitive aging. Biochim 
Biophys Acta. 2012; 1822: 386-400. 
27. Munoz DG, Hastak SM, Harper B, Lee D and Hachinski VC. Pathologic correlates 
of increased signals of the centrum ovale on magnetic resonance imaging. Arch Neurol. 
1993; 50: 492-7. 
28. Black S, Gao F and Bilbao J. Understanding white matter disease: imaging-
pathological correlations in vascular cognitive impairment. Stroke. 2009; 40: S48-52. 
29. Feigin I and Popoff N. Neuropathological Changes Late in Cerebral Edema: The 
Relationship to Trauma, Hypertensive Disease and Binswanger's Encephalopathy. J 
Neuropathol Exp Neurol. 1963; 22: 500-11. 
30. Braffman BH, Zimmerman RA, Trojanowski JQ, Gonatas NK, Hickey WF and 
Schlaepfer WW. Brain MR: pathologic correlation with gross and histopathology. 1. Lacunar 
infarction and Virchow-Robin spaces. AJR Am J Roentgenol. 1988; 151: 551-8. 
31. Potter GM, Chappell FM, Morris Z and Wardlaw JM. Cerebral perivascular spaces 
visible on magnetic resonance imaging: development of a qualitative rating scale and its 
observer reliability. Cerebrovasc Dis. 2015; 39: 224-31. 
32. Groeschel S, Chong WK, Surtees R and Hanefeld F. Virchow-Robin spaces on 
magnetic resonance images: normative data, their dilatation, and a review of the literature. 
Neuroradiology. 2006; 48: 745-54. 
33. Doubal FN, MacLullich AM, Ferguson KJ, Dennis MS and Wardlaw JM. Enlarged 
perivascular spaces on MRI are a feature of cerebral small vessel disease. Stroke. 2010; 41: 
450-4. 
34. Heier LA, Bauer CJ, Schwartz L, Zimmerman RD, Morgello S and Deck MD. Large 
Virchow-Robin spaces: MR-clinical correlation. AJNR Am J Neuroradiol. 1989; 10: 929-36. 
35. Zhu YC, Tzourio C, Soumare A, Mazoyer B, Dufouil C and Chabriat H. Severity of 
dilated Virchow-Robin spaces is associated with age, blood pressure, and MRI markers of 
small vessel disease: a population-based study. Stroke. 2010; 41: 2483-90. 
36. Maclullich AM, Wardlaw JM, Ferguson KJ, Starr JM, Seckl JR and Deary IJ. 
Enlarged perivascular spaces are associated with cognitive function in healthy elderly men. J 
Neurol Neurosurg Psychiatry. 2004; 75: 1519-23. 
37. Zhu YC, Dufouil C, Soumare A, Mazoyer B, Chabriat H and Tzourio C. High 
degree of dilated Virchow-Robin spaces on MRI is associated with increased risk of 
dementia. J Alzheimers Dis. 2010; 22: 663-72. 
38. Wuerfel J, Haertle M, Waiczies H, et al. Perivascular spaces--MRI marker of 
inflammatory activity in the brain? Brain. 2008; 131: 2332-40. 
39. Weller RO, Djuanda E, Yow HY and Carare RO. Lymphatic drainage of the brain 
and the pathophysiology of neurological disease. Acta Neuropathol. 2009; 117: 1-14. 
40. Iliff JJ, Wang M, Zeppenfeld DM, et al. Cerebral arterial pulsation drives 
paravascular CSF-interstitial fluid exchange in the murine brain. J Neurosci. 2013; 33: 
18190-9. 
41. van Dijk EJ, Breteler MM, Schmidt R, et al. The association between blood pressure, 
hypertension, and cerebral white matter lesions: cardiovascular determinants of dementia 
study. Hypertension. 2004; 44: 625-30. 
233 
 
42. Wardlaw JM, Allerhand M, Doubal FN, et al. Vascular risk factors, large-artery 
atheroma, and brain white matter hyperintensities. Neurology. 2014; 82: 1331-8. 
43. Pantoni L, Garcia JH and Gutierrez JA. Cerebral white matter is highly vulnerable to 
ischemia. Stroke. 1996; 27: 1641-6; discussion 7. 
44. Petito CK, Olarte JP, Roberts B, Nowak TS, Jr. and Pulsinelli WA. Selective glial 
vulnerability following transient global ischemia in rat brain. J Neuropathol Exp Neurol. 
1998; 57: 231-8. 
45. Potter GM, Doubal FN, Jackson CA, Sudlow CL, Dennis MS and Wardlaw JM. 
Lack of association of white matter lesions with ipsilateral carotid artery stenosis. 
Cerebrovasc Dis. 2012; 33: 378-84. 
46. Kwon HM, Lynn MJ, Turan TN, et al. Frequency, Risk Factors, and Outcome of 
Coexistent Small Vessel Disease and Intracranial Arterial Stenosis: Results From the 
Stenting and Aggressive Medical Management for Preventing Recurrent Stroke in 
Intracranial Stenosis (SAMMPRIS) Trial. JAMA Neurol. 2016; 73: 36-42. 
47. Ibayashi S, Nagao T, Kuwabara Y, Sasaki M and Fujishima M. Mechanism for 
decreased cortical oxygen metabolism in patients with leukoaraiosis: Is disconnection the 
answer? Journal of Stroke and Cerebrovascular Diseases. 2000; 9: 22-6. 
48. Kuwabara Y, Ichiya Y, Sasaki M, et al. Cerebral blood flow and vascular response 
to hypercapnia in hypertensive patients with leukoaraiosis. Ann Nucl Med. 1996; 10: 293-8. 
49. Farrall AJ and Wardlaw JM. Blood-brain barrier: ageing and microvascular disease--
systematic review and meta-analysis. Neurobiol Aging. 2009; 30: 337-52. 
50. Abbott NJ. Inflammatory mediators and modulation of blood-brain barrier 
permeability. Cell Mol Neurobiol. 2000; 20: 131-47. 
51. Fornage M, Chiang YA, O'Meara ES, et al. Biomarkers of Inflammation and MRI-
Defined Small Vessel Disease of the Brain: The Cardiovascular Health Study. Stroke. 2008; 
39: 1952-9. 
52. Al-Solaiman Y, Jesri A, Zhao Y, Morrow JD and Egan BM. Low-Sodium DASH 
reduces oxidative stress and improves vascular function in salt-sensitive humans. J Hum 
Hypertens. 2009; 23: 826-35. 
53. de Roos A, van der Grond J, Mitchell G and Westenberg J. Magnetic Resonance 
Imaging of Cardiovascular Function and the Brain: Is Dementia a Cardiovascular-Driven 
Disease? Circulation. 2017; 135: 2178-95. 
54. Garcia-Polite F, Martorell J, Del Rey-Puech P, et al. Pulsatility and high shear stress 
deteriorate barrier phenotype in brain microvascular endothelium. J Cereb Blood Flow 
Metab. 2017; 37: 2614-25. 
55. Tan Y, Tseng PO, Wang D, et al. Stiffening-induced high pulsatility flow activates 
endothelial inflammation via a TLR2/NF-kappaB pathway. PLoS One. 2014; 9: e102195. 
56. Aribisala BS, Wiseman S, Morris Z, et al. Circulating inflammatory markers are 
associated with magnetic resonance imaging-visible perivascular spaces but not directly with 
white matter hyperintensities. Stroke. 2014; 45: 605-7. 
57. Aribisala BS, Morris Z, Eadie E, et al. Blood pressure, internal carotid artery flow 
parameters, and age-related white matter hyperintensities. Hypertension. 2014; 63: 1011-8. 
58. Jolly TA, Bateman GA, Levi CR, Parsons MW, Michie PT and Karayanidis F. Early 
detection of microstructural white matter changes associated with arterial pulsatility. Front 
Hum Neurosci. 2013; 7: 782. 
59. Webb AJ, Simoni M, Mazzucco S, Kuker W, Schulz U and Rothwell PM. Increased 
cerebral arterial pulsatility in patients with leukoaraiosis: arterial stiffness enhances 
transmission of aortic pulsatility. Stroke. 2012; 43: 2631-6. 
60. Mitchell GF, van Buchem MA, Sigurdsson S, et al. Arterial stiffness, pressure and 
flow pulsatility and brain structure and function: the Age, Gene/Environment Susceptibility--
Reykjavik study. Brain. 2011; 134: 3398-407. 
61. Poels MM, Zaccai K, Verwoert GC, et al. Arterial stiffness and cerebral small vessel 
disease: the Rotterdam Scan Study. Stroke. 2012; 43: 2637-42. 
234 
 
62. Stivaros SM and Jackson A. Changing concepts of cerebrospinal fluid 
hydrodynamics: role of phase-contrast magnetic resonance imaging and implications for 
cerebral microvascular disease. Neurotherapeutics. 2007; 4: 511-22. 
63. Kellie G. An account of the appearances observed in the dissection of two of three 
individuals presumed to have perished in the storm of the 3d, and whose bodies were 
discovered in the vicinity of Leith on the morning of the 4th, November 1821 : with some 
reflections on the pathology of the brain. Transactions of the Medico-Chirurgical Society of 
Edinburgh. 1824; 1: 84-196. 
64. Bateman GA, Levi CR, Schofield P, Wang Y and Lovett EC. The venous 
manifestations of pulse wave encephalopathy: windkessel dysfunction in normal aging and 
senile dementia. Neuroradiology. 2008; 50: 491-7. 
65. Naish JH, Baldwin RC, Patankar T, et al. Abnormalities of CSF flow patterns in the 
cerebral aqueduct in treatment-resistant late-life depression: a potential biomarker of 
microvascular angiopathy. Magn Reson Med. 2006; 56: 509-16. 
66. Jeerakathil T, Wolf PA, Beiser A, et al. Stroke risk profile predicts white matter 
hyperintensity volume: the Framingham Study. Stroke. 2004; 35: 1857-61. 
67. Yata K and Tomimoto H. Chronic cerebral hypoperfusion and dementia. Neurol 
Clin Neurosci. 2014; 2: 129-34. 
68. Stroup DF, Berlin JA, Morton SC, et al. Meta-analysis of observational studies in 
epidemiology: a proposal for reporting. Meta-analysis Of Observational Studies in 
Epidemiology (MOOSE) group. JAMA. 2000; 283: 2008-12. 
69. Bailey EL, Smith C, Sudlow CL and Wardlaw JM. Pathology of lacunar ischemic 
stroke in humans--a systematic review. Brain Pathol. 2012; 22: 583-91. 
70. van der Veen PH, Muller M, Vincken KL, et al. Longitudinal relationship between 
cerebral small-vessel disease and cerebral blood flow: the second manifestations of arterial 
disease-magnetic resonance study. Stroke. 2015; 46: 1233-8. 
71. Bisschops RHC, Van Der Graaf Y, Mali WPTM and Van Der Grond J. High total 
cerebral blood flow is associated with a decrease of white matter lesions. J Neurol. 2004; 
251: 1481-5. 
72. Ten Dam VH, Van Den Heuvel DMJ, De Craen AJM, et al. Decline in total cerebral 
blood flow is linked with increase in periventricular but not deep white matter 
hyperintensities. Radiology. 2007; 243: 198-203. 
73. van Es AC, van der Grond J, ten Dam VH, et al. Associations between total cerebral 
blood flow and age related changes of the brain. PLoS One. 2010; 5: e9825. 
74. Vernooij MW, van der Lugt A, Ikram MA, et al. Total cerebral blood flow and total 
brain perfusion in the general population: the Rotterdam Scan Study. J Cereb Blood Flow 
Metab. 2008; 28: 412-9. 
75. Claus JJ, Breteler MMB, Hasan D, et al. Vascular risk factors, atherosclerosis, 
cerebral white matter lesions and cerebral perfusion in a population-based study. Eur J Nucl 
Med. 1996; 23: 675-82. 
76. Kimura N, Nakama H, Nakamura K, Aso Y and Kumamoto T. Effect of white 
matter lesions on brain perfusion in alzheimer's disease. Dement Geriatr Cogn Disord. 2012; 
34: 256-61. 
77. Yamaji S, Ishii K, Sasaki M, et al. Changes in cerebral blood flow and oxygen 
metabolism related to magnetic resonance imaging white matter hyperintensities in 
Alzheimer's disease. J Nucl Med. 1997; 38: 1471-4. 
78. Schuff N, Matsumoto S, Kmiecik J, et al. Cerebral blood flow in ischemic vascular 
dementia and Alzheimer's disease, measured by arterial spin-labeling magnetic resonance 
imaging. Alzheimer's and Dementia. 2009; 5: 454-62. 
79. Kawamura J, Meyer JS, Ichijo M, Kobari M, Terayama Y and Weathers S. 
Correlations of leuko-araiosis with cerebral atrophy and perfusion in elderly normal subjects 
and demented patients. J Neurol Neurosurg Psychiatry. 1993; 56: 182-7. 
235 
 
80. Kobari M, Meyer JS, Ichijo M and Oravez WT. Leukoaraiosis: Correlation of MR 
and CT findings with blood flow, atrophy, and cognition. AJNR Am J Neuroradiol. 1990; 11: 
273-81. 
81. Nezu T, Yokota C, Uehara T, et al. Preserved acetazolamide reactivity in lacunar 
patients with severe white-matter lesions: 15 O-labeled gas and H 2 O positron emission 
tomography studies. J Cereb Blood Flow Metab. 2012; 32: 844-50. 
82. Zheng LS, Xu J and Wang JP. Quantitative evaluation of regional cerebral blood 
flow in patients with silent Leukoaraiosis. [Chinese]. Chinese Journal of Clinical 
Rehabilitation. 2006; 10: 80-2. 
83. Ramli N, Ho KL, Nawawi O, Chong HT and Tan CT. CT perfusion as a useful tool 
in the evaluation of leuko-araiosis. Biomed Imaging Interv J. 2006; 2. 
84. Cui BW, Qi X and Guo HZ. Comparative study on the cerebral hemodynamics 
changes between Leukoaraiosis and Binswanger disease. [Chinese]. Chinese Journal of 
Clinical Rehabilitation. 2003; 7: 3460-1. 
85. O'Sullivan M, Lythgoe DJ, Pereira AC, et al. Patterns of cerebral blood flow 
reduction in patients with ischemic leukoaraiosis. Neurology. 2002; 59: 321-6. 
86. Yao H, Yuzuriha T, Fukuda K, et al. Cerebral blood flow in nondemented elderly 
subjects with extensive deep white matter lesions on magnetic resonance imaging. J Stroke 
Cerebrovasc Dis. 2000; 9: 172-5. 
87. Markus HS, Lythgoe DJ, Ostegaard L, O'Sullivan M and Williams SCR. Reduced 
cerebral blood flow in white matter in ischaemic leukoaraiosis demonstrated using 
quantitative exogenous contrast based perfusion MRI. J Neurol Neurosurg Psychiatry. 2000; 
69: 48-53. 
88. Oishi M and Mochizuki Y. Differences in regional cerebral blood flow in two types 
of leuko- araiosis. J Neurol Sci. 1999; 164: 129-33. 
89. Hatazawa J, Shimosegawa E, Satoh T, Toyoshima H and Okudera T. Subcortical 
hypoperfusion associated with asymptomatic white matter lesions on magnetic resonance 
imaging. Stroke. 1997; 28: 1944-7. 
90. Kobayashi S, Okada K and Yamashita K. Incidence of silent lacunar lesion in 
normal adults and its relation to cerebral blood flow and risk factors. Stroke. 1991; 22: 1379-
83. 
91. Fazekas F, Niederkorn K, Schmidt R, et al. White matter signal aities in normal 
individuals: Correlation with carotid ultrasonography, cerebral blood flow measurements, 
and cerebrovascular risk factorsbnormal. Stroke. 1988; 19: 1285-8. 
92. Kimura M, Shimoda K, Mizumura S, et al. Regional cerebral blood flow in vascular 
depression assessed by 123I-IMP SPECT. J Nippon Med Sch. 2003; 70: 321-6. 
93. Fu J, Tang J, Han J and Hong Z. The reduction of regional cerebral blood flow in 
normal-appearing white matter is associated with the severity of white matter lesions in 
elderly: A xeon-ct study. PLoS ONE. 2014; 9. 
94. De Bastos-Leite AJ, Kuijer JPA, Rombouts SARB, et al. Cerebral blood flow by 
using pulsed arterial spin-labeling in elderly subjects with white matter hyperintensities. 
American Journal of Neuroradiology. 2008; 29: 1296-301. 
95. Miyazawa N, Satoh T, Hashizume K and Fukamachi A. Xenon contrast CT-CBF 
measurements in high-intensity foci on T2-weighted MR images in centrum semiovale of 
asymptomatic individuals. Stroke. 1997; 28: 984-7. 
96. Tzourio C, Levy C, Dufouil C, Touboul PJ, Ducimetiere P and Alperovitch A. Low 
cerebral blood flow velocity and risk of white matter hyperintensities. Ann Neurol. 2001; 49: 
411-4. 
97. Heliopoulos I, Artemis D, Vadikolias K, Tripsianis G, Piperidou C and Tsivgoulis G. 
Association of ultrasonographic parameters with subclinical white-matter hyperintensities in 
hypertensive patients. Cardiovasc Psychiatry Neurol. 2012. 
236 
 
98. Isaka Y, Okamoto M, Ashida K and Imaizumi M. Decreased cerebrovascular 
dilatory capacity in subjects with asymptomatic periventricular hyperintensities. Stroke. 
1994; 25: 375-81. 
99. Alosco ML, Brickman AM, Spitznagel MB, et al. Cerebral perfusion is associated 
with white matter hyperintensities in older adults with heart failure. Congest Heart Fail. 
2013; 19: E29-E34. 
100. Ott BR, Faberman RS, Noto RB, et al. A SPECT imaging study of MRI white matter 
hyperintensity in patients with degenerative dementia. Dement Geriatr Cogn Disord. 1997; 
8: 348-54. 
101. Bernbaum M, Menon BK, Fick G, et al. Reduced blood flow in normal white matter 
predicts development of leukoaraiosis. J Cereb Blood Flow Metab. 2015; 35: 1610-5. 
102. Kraut MA, Beason-Held LL, Elkins WD and Resnick SM. The impact of magnetic 
resonance imaging-detected white matter hyperintensities on longitudinal changes in 
regional cerebral blood flow. J Cereb Blood Flow Metab. 2008; 28: 190-7. 
103. Wagner M, Helfrich M, Volz S, et al. Quantitative T2, T2*, and T2' MR imaging in 
patients with ischemic leukoaraiosis might detect microstructural changes and cortical 
hypoxia. Neuroradiology. 2015; 57: 1023-30. 
104. Huynh TJ, Murphy B, Pettersen JA, et al. CT perfusion quantification of small-
vessel ischemic severity. AJNR Am J Neuroradiol. 2008; 29: 1831-6. 
105. Crane DE, Black SE, Ganda A, et al. Grey matter blood flow and volume are 
reduced in association with white matter hyperintensity lesion burden: A cross-sectional 
MRI study. Front Aging Neurosci. 2015; 7. 
106. Zonneveld HI, Loehrer EA, Hofman A, et al. The bidirectional association between 
reduced cerebral blood flow and brain atrophy in the general population. J Cereb Blood 
Flow Metab. 2015; 35: 1882-7. 
107. Schmidt R, Ropele S, Enzinger C, et al. White matter lesion progression, brain 
atrophy, and cognitive decline: The Austrian Stroke Prevention Study. Ann Neurol. 2005; 
58: 610-6. 
108. Ryu WS, Woo SH, Schellingerhout D, et al. Grading and interpretation of white 
matter hyperintensities using statistical maps. Stroke. 2014; 45: 3567-75. 
109. Ostergaard L, Engedal TS, Moreton F, et al. Cerebral small vessel disease: Capillary 
pathways to stroke and cognitive decline. J Cereb Blood Flow Metab. 2016; 2: 23. 
110. Liem MK, Lesnik Oberstein SA, Haan J, et al. Cerebrovascular reactivity is a main 
determinant of white matter hyperintensity progression in CADASIL. AJNR Am J 
Neuroradiol. 2009; 30: 1244-7. 
111. Bahrani AA, Powell DK, Yu G, Johnson ES, Jicha GA and Smith CD. White Matter 
Hyperintensity Associations with Cerebral Blood Flow in Elderly Subjects Stratified by 
Cerebrovascular Risk. Journal of Stroke and Cerebrovascular Diseases. 2017; 26: 779-86. 
112. Hashimoto T, Yokota C, Koshino K, et al. Cerebral blood flow and metabolism 
associated with cerebral microbleeds in small vessel disease. Annals of Nuclear Medicine. 
2016; 30: 494-500. 
113. Liu J, Zhao H, Gao M, Xie H, Lu R and Liang X. Arterial spin labeling and DTI in 
evaluation on cerebral perfusion and white matter of cerebral small vessel disease patients. 
[Chinese]. Chinese Journal of Medical Imaging Technology. 2016; 32: 1170-4. 
114. Van Dalen JW, Mutsaerts HJMM, Nederveen AJ, et al. White matter hyperintensity 
volume and cerebral perfusion in older individuals with hypertension using arterial spin-
labeling. American Journal of Neuroradiology. 2016; 37: 1824-30. 
115. Hanaoka T, Kimura N, Aso Y, et al. Relationship between white matter lesions and 
regional cerebral blood flow changes during longitudinal follow up in Alzheimer's disease. 
Geriatrics and Gerontology International. 2016; 16: 836-42. 
116. Nylander R, Fahlstrom M, Rostrup E, et al. Quantitative and qualitative MRI 
evaluation of cerebral small vessel disease in an elderly population: a longitudinal study. 
Acta Radiol. 2017: 284185117727567. 
237 
 
117. Fazekas F, Kleinert R, Offenbacher H, et al. Pathologic correlates of incidental MRI 
white matter signal hyperintensities. Neurology. 1993; 43: 1683-9. 
118. Fazekas F, Kleinert R, Roob G, et al. Histopathologic analysis of foci of signal loss 
on gradient-echo T2*-weighted MR images in patients with spontaneous intracerebral 
hemorrhage: evidence of microangiopathy-related microbleeds. AJNR Am J Neuroradiol. 
1999; 20: 637-42. 
119. Shi Y and Wardlaw J. Update on cerebral small vessel disease: a dynamic whole-
brain disease. Stroke and Vascular Neurology. 2016; 2: 83-92. 
120. Mitchell GF. Effects of central arterial aging on the structure and function of the 
peripheral vasculature: implications for end-organ damage. J Appl Physiol (1985). 2008; 
105: 1652-60. 
121. Gosling RG and King DH. Arterial assessment by Doppler shift ultrasound. Proc R 
Soc Med. 1974; 67: 447-9. 
122. Mok V, Ding D, Fu J, et al. Transcranial doppler ultrasound for screening cerebral 
small vessel disease: A community study. Stroke. 2012; 43: 2791-3. 
123. Battal B, Kocaoglu M, Bulakbasi N, Husmen G, Tuba Sanal H and Tayfun C. 
Cerebrospinal fluid flow imaging by using phase-contrast MR technique. Br J Radiol. 2011; 
84: 758-65. 
124. Bateman GA. Pulse-wave encephalopathy: A comparative study of the 
hydrodynamics of leukoaraiosis and normal-pressure hydrocephalus. Neuroradiology. 2002; 
44: 740-8. 
125. Beggs CB, Magnano C, Shepherd SJ, et al. Dirty-Appearing White Matter in the 
Brain is Associated with Altered Cerebrospinal Fluid Pulsatility and Hypertension in 
Individuals without Neurologic Disease. Journal of Neuroimaging. 2016; 26: 136-43. 
126. Shi Y, Thrippleton MJ, Makin SD, et al. Cerebral blood flow in small vessel disease: 
A systematic review and meta-analysis. J Cereb Blood Flow Metab. 2016; 36: 1653-67. 
127. Tanaka T, Shimizu T and Fukuhara T. The relationship between leukoaraiosis 
volume and parameters of carotid artery duplex ultrasonographic scanning in asymptomatic 
diabetic patients. Computerized Medical Imaging and Graphics. 2009; 33: 489-93. 
128. Ternifi R, Cazals X, Desmidt T, et al. Ultrasound measurements of brain tissue 
pulsatility correlate with the volume of MRI white-matter hyperintensity. Journal of 
Cerebral Blood Flow and Metabolism. 2014; 34: 942-4. 
129. Turk M, Zupan M, Zaletel M, Zvan B and Oblak JP. Carotid arterial hemodynamic 
in ischemic levkoaraiosis suggests hypoperfusion mechanism. European Neurology. 2015; 
73: 310-5. 
130. Biedert S, Forstl H and Hewer W. Multiinfarct dementia vs Alzheimer's disease: 
Sonographic criteria. Angiology. 1995; 46: 129-35. 
131. Kidwell CS, El-Saden S, Livshits Z, Martin NA, Glenn TC and Saver JL. 
Transcranial doppler pulsatility indices as a measure of diffuse small-vessel disease. Journal 
of Neuroimaging. 2001; 11: 229-35. 
132. Sanchez-Perez RM, Hernandez-Lorido R, Castano P, Diaz-Marin C, Carneado-Ruiz 
J and Molto-Jorda J. Evaluation of hemodynamic parameters by transcranial Doppler in 
patients with leukoaraiosis. [Spanish]. Revista de Neurologia. 2003; 37: 301-11. 
133. Rodriguez I, Lema I, Blanco M, Rodriguez-Yanez M, Leira R and Castillo J. 
Vascular retinal, neuroimaging and ultrasonographic markers of lacunar infarcts. 
International Journal of Stroke. 2010; 5: 360-6. 
134. Purkayastha S, Fadar O, Mehregan A, et al. Impaired cerebrovascular 
hemodynamics are associated with cerebral white matter damage. Journal of Cerebral Blood 
Flow and Metabolism. 2014; 34: 228-34. 
135. Sargento-Freitas J, Felix-Morais R, Ribeiro J, et al. Different locations but common 
associations in subcortical hypodensities of presumed vascular origin: Cross-sectional study 
on clinical and neurosonologic correlates. BMC Neurology. 2014; 14 (1) (no pagination). 
238 
 
136. Sanahuja J, Alonso N, Diez J, et al. Increased burden of cerebral small vessel disease 
in patients with type 2 diabetes and retinopathy. Diabetes Care. 2016; 39: 1614-20. 
137. Smith EE, Vijayappa M, Lima F, et al. Impaired visual evoked flow velocity 
response in cerebral amyloid angiopathy. Neurology. 2008; 71: 1424-30. 
138. Hiroki M, Miyashita K, Yoshida H, Hirai S and Fukuyama H. Central retinal artery 
Doppler flow parameters reflect the severity of cerebral small-vessel disease. Stroke; a 
journal of cerebral circulation. 2003; 34: e92-4. 
139. Del Brutto OH, Mera RM, De La Luz Andrade M, Castillo PR, Zambrano M and 
Nader JA. Disappointing reliability of pulsatility indices to identify candidates for magnetic 
resonance imaging screening in population-based studies assessing prevalence of cerebral 
small vessel disease. Journal of Neurosciences in Rural Practice. 2015; 6: 336-8. 
140. Ghorbani A, Ahmadi MJ and Shemshaki H. The value of transcranial Doppler 
derived pulsatility index for diagnosing cerebral small-vessel disease. Adv Biomed Res. 
2015; 4: 54. 
141. Han SW, Song TJ, Bushnell CD, et al. Cilostazol decreases cerebral arterial 
pulsatility in patients with mild white matter hyperintensities: Subgroup analysis from the 
effect of cilostazol in acute lacunar infarction based on pulsatility index of transcranial 
doppler (ECLIPse) study. Cerebrovascular Diseases. 2014; 38: 197-203. 
142. Bettermann K, Slocomb JE, Shivkumar V and Lott MEJ. Retinal vasoreactivity as a 
marker for chronic ischemic white matter disease? Journal of the Neurological Sciences. 
2012; 322: 206-10. 
143. Henry-Feugeas MC, Roy C, Baron G and Schouman-Claeys E. Leukoaraiosis and 
pulse-wave encephalopathy: Observations with phase-contrast MRI in mild cognitive 
impairment. Journal of Neuroradiology. 2009; 36: 212-8. 
144. Wahlin A, Ambarki K, Birgander R, Malm J and Eklund A. Intracranial pulsatility is 
associated with regional brain volume in elderly individuals. Neurobiol Aging. 2014; 35: 
365-72. 
145. Zhang CE, Wong SM, Uiterwijk R, et al. Intravoxel Incoherent Motion Imaging in 
Small Vessel Disease: Microstructural Integrity and Microvascular Perfusion Related to 
Cognition. Stroke. 2017; 48: 658-63. 
146. Adams HP, Jr., Bendixen BH, Kappelle LJ, et al. Classification of subtype of acute 
ischemic stroke. Definitions for use in a multicenter clinical trial. TOAST. Trial of Org 
10172 in Acute Stroke Treatment. Stroke. 1993; 24: 35-41. 
147. Stoquart-ElSankari S, Baledent O, Gondry-Jouet C, Makki M, Godefroy O and 
Meyer ME. Aging effects on cerebral blood and cerebrospinal fluid flows. J Cereb Blood 
Flow Metab. 2007; 27: 1563-72. 
148. Wagshul ME, Eide PK and Madsen JR. The pulsating brain: A review of 
experimental and clinical studies of intracranial pulsatility. Fluids Barriers CNS. 2011; 8: 5. 
149. Michel E and Zernikow B. Gosling's Doppler pulsatility index revisited. Ultrasound 
Med Biol. 1998; 24: 597-9. 
150. Czosnyka M, Richards HK, Whitehouse HE and Pickard JD. Relationship between 
transcranial Doppler-determined pulsatility index and cerebrovascular resistance: an 
experimental study. J Neurosurg. 1996; 84: 79-84. 
151. Beasley MG, Blau JN and Gosling RG. Changes in internal carotid artery flow 
velocities with cerebral vasodilation and constriction. Stroke. 1979; 10: 331-5. 
152. Jiang J, Strother C, Johnson K, et al. Comparison of blood velocity measurements 
between ultrasound Doppler and accelerated phase-contrast MR angiography in small 
arteries with disturbed flow. Phys Med Biol. 2011; 56: 1755-73. 
153. Seitz J, Strotzer M, Schlaier J, Nitz WR, Volk M and Feuerbach S. Comparison 
between magnetic resonance phase contrast imaging and transcranial Doppler ultrasound 
with regard to blood flow velocity in intracranial arteries: work in progress. J Neuroimaging. 
2001; 11: 121-8. 
239 
 
154. Makedonov I, Black SE and Macintosh BJ. BOLD fMRI in the white matter as a 
marker of aging and small vessel disease. PLoS One. 2013; 8: e67652. 
155. Rivera-Rivera LA, Turski P, Johnson KM, et al. 4D flow MRI for intracranial 
hemodynamics assessment in Alzheimer's disease. J Cereb Blood Flow Metab. 2016; 36: 
1718-30. 
156. Bouvy WH, Geurts LJ, Kuijf HJ, et al. Assessment of blood flow velocity and 
pulsatility in cerebral perforating arteries with 7-T quantitative flow MRI. NMR Biomed. 
2016; 29: 1295-304. 
157. Kiviniemi V, Wang X, Korhonen V, et al. Ultra-fast magnetic resonance 
encephalography of physiological brain activity - Glymphatic pulsation mechanisms? J 
Cereb Blood Flow Metab. 2016; 36: 1033-45. 
158. Stoquart-Elsankari S, Lehmann P, Villette A, et al. A phase-contrast MRI study of 
physiologic cerebral venous flow. J Cereb Blood Flow Metab. 2009; 29: 1208-15. 
159. Pourcelot L. Applicaitions cliniques de l'examen Doppler transcutane. Coloques de 
l'Inst Natl Santé Rech Med. 1974; 34: 213-40. 
160. Chen CH, Nevo E, Fetics B, et al. Estimation of central aortic pressure waveform by 
mathematical transformation of radial tonometry pressure. Validation of generalized transfer 
function. Circulation. 1997; 95: 1827-36. 
161. Butlin M and Qasem A. Large Artery Stiffness Assessment Using SphygmoCor 
Technology. Pulse (Basel). 2017; 4: 180-92. 
162. Steppan J, Barodka V, Berkowitz DE and Nyhan D. Vascular stiffness and increased 
pulse pressure in the aging cardiovascular system. Cardiol Res Pract. 2011; 2011: 263585. 
163. Jenkinson M and Smith S. A global optimisation method for robust affine 
registration of brain images. Med Image Anal. 2001; 5: 143-56. 
164. Tustison NJ, Cook PA, Klein A, et al. Large-scale evaluation of ANTs and 
FreeSurfer cortical thickness measurements. Neuroimage. 2014; 99: 166-79. 
165. Avants BB, Epstein CL, Grossman M and Gee JC. Symmetric diffeomorphic image 
registration with cross-correlation: evaluating automated labeling of elderly and 
neurodegenerative brain. Med Image Anal. 2008; 12: 26-41. 
166. Freedman D, Pisani R and Purves R. Statistics. New York: W. W. Norton, 2007. 
167. Avants BB, Tustison NJ, Wu J, Cook PA and Gee JC. An open source multivariate 
framework for n-tissue segmentation with evaluation on public data. Neuroinformatics. 
2011; 9: 381-400. 
168. Fazekas F, Chawluk JB, Alavi A, Hurtig HI and Zimmerman RA. MR signal 
abnormalities at 1.5 T in Alzheimer's dementia and normal aging. AJR Am J Roentgenol. 
1987; 149: 351-6. 
169. Walker PG, Cranney GB, Scheidegger MB, Waseleski G, Pohost GM and 
Yoganathan AP. Semiautomated method for noise reduction and background phase error 
correction in MR phase velocity data. J Magn Reson Imaging. 1993; 3: 521-30. 
170. Ku JP, Elkins CJ and Taylor CA. Comparison of CFD and MRI flow and velocities 
in an in vitro large artery bypass graft model. Ann Biomed Eng. 2005; 33: 257-69. 
171. Wendt RE, 3rd, Rokey R, Wong WF and Marks A. Magnetic resonance velocity 
measurements in small arteries. Comparison with Doppler ultrasonic measurements in the 
aortas of normal rabbits. Invest Radiol. 1992; 27: 499-503. 
172. Seitz J, Strotzer M, Wild T, et al. Quantification of blood flow in the carotid arteries: 
comparison of Doppler ultrasound and three different phase-contrast magnetic resonance 
imaging sequences. Invest Radiol. 2001; 36: 642-7. 
173. Spilt A, Box FM, van der Geest RJ, et al. Reproducibility of total cerebral blood 
flow measurements using phase contrast magnetic resonance imaging. J Magn Reson 
Imaging. 2002; 16: 1-5. 
174. Wahlin A, Ambarki K, Hauksson J, Birgander R, Malm J and Eklund A. Phase 
contrast MRI quantification of pulsatile volumes of brain arteries, veins, and cerebrospinal 
240 
 
fluids compartments: repeatability and physiological interactions. J Magn Reson Imaging. 
2012; 35: 1055-62. 
175. Piechnik SK, Summers PE, Jezzard P and Byrne JV. Magnetic resonance 
measurement of blood and CSF flow rates with phase contrast--normal values, repeatability 
and CO2 reactivity. Acta Neurochir Suppl. 2008; 102: 263-70. 
176. Huang TY, Chung HW, Chen MY, et al. Supratentorial cerebrospinal fluid 
production rate in healthy adults: quantification with two-dimensional cine phase-contrast 
MR imaging with high temporal and spatial resolution. Radiology. 2004; 233: 603-8. 
177. Unal O, Kartum A, Avcu S, Etlik O, Arslan H and Bora A. Cine phase-contrast MRI 
evaluation of normal aqueductal cerebrospinal fluid flow according to sex and age. Diagn 
Interv Radiol. 2009; 15: 227-31. 
178. Schrauben EM, Johnson KM, Huston J, et al. Reproducibility of cerebrospinal 
venous blood flow and vessel anatomy with the use of phase contrast-vastly undersampled 
isotropic projection reconstruction and contrast-enhanced MRA. AJNR Am J Neuroradiol. 
2014; 35: 999-1006. 
179. Zivadinov R, Galeotti R, Hojnacki D, et al. Value of MR venography for detection 
of internal jugular vein anomalies in multiple sclerosis: a pilot longitudinal study. AJNR Am 
J Neuroradiol. 2011; 32: 938-46. 
180. Niggemann P, Seifert M, Forg A, Schild HH, Urbach H and Krings T. Positional 
venous MR angiography: an operator-independent tool to evaluate cerebral venous outflow 
hemodynamics. AJNR Am J Neuroradiol. 2012; 33: 246-51. 
181. Wentland AL, Wieben O, Korosec FR and Haughton VM. Accuracy and 
reproducibility of phase-contrast MR imaging measurements for CSF flow. AJNR Am J 
Neuroradiol. 2010; 31: 1331-6. 
182. Tawfik AM, Elsorogy L, Abdelghaffar R, Naby AA and Elmenshawi I. Phase-
Contrast MRI CSF Flow Measurements for the Diagnosis of Normal-Pressure 
Hydrocephalus: Observer Agreement of Velocity Versus Volume Parameters. AJR Am J 
Roentgenol. 2017; 208: 838-43. 
183. Tang C, Blatter DD and Parker DL. Accuracy of phase-contrast flow measurements 
in the presence of partial-volume effects. J Magn Reson Imaging. 1993; 3: 377-85. 
184. Sudlow CL and Warlow CP. Comparable studies of the incidence of stroke and its 
pathological types: results from an international collaboration. International Stroke Incidence 
Collaboration. Stroke. 1997; 28: 491-9. 
185. Staals J, Makin SD, Doubal FN, Dennis MS and Wardlaw JM. Stroke subtype, 
vascular risk factors, and total MRI brain small-vessel disease burden. Neurology. 2014; 83: 
1228-34. 
186. Rost NS, Rahman RM, Biffi A, et al. White matter hyperintensity volume is 
increased in small vessel stroke subtypes. Neurology. 2010; 75: 1670-7. 
187. Bergsneider M, Alwan AA, Falkson L and Rubinstein EH. The relationship of 
pulsatile cerebrospinal fluid flow to cerebral blood flow and intracranial pressure: a new 
theoretical model. Acta Neurochir Suppl. 1998; 71: 266-8. 
188. Doepp F, Schreiber SJ, von Munster T, Rademacher J, Klingebiel R and Valdueza 
JM. How does the blood leave the brain? A systematic ultrasound analysis of cerebral 
venous drainage patterns. Neuroradiology. 2004; 46: 565-70. 
189. Buijs PC, Krabbe-Hartkamp MJ, Bakker CJ, et al. Effect of age on cerebral blood 
flow: measurement with ungated two-dimensional phase-contrast MR angiography in 250 
adults. Radiology. 1998; 209: 667-74. 
190. Lemogoum D, Flores G, Van den Abeele W, et al. Validity of pulse pressure and 
augmentation index as surrogate measures of arterial stiffness during beta-adrenergic 
stimulation. J Hypertens. 2004; 22: 511-7. 
191. O'Rourke MF, Staessen JA, Vlachopoulos C, Duprez D and Plante GE. Clinical 




192. McEniery CM, Yasmin, Hall IR, et al. Normal vascular aging: differential effects on 
wave reflection and aortic pulse wave velocity: the Anglo-Cardiff Collaborative Trial 
(ACCT). J Am Coll Cardiol. 2005; 46: 1753-60. 
193. Janner JH, Godtfredsen NS, Ladelund S, Vestbo J and Prescott E. Aortic 
augmentation index: reference values in a large unselected population by means of the 
SphygmoCor device. Am J Hypertens. 2010; 23: 180-5. 
194. Scheel P, Ruge C and Schoning M. Flow velocity and flow volume measurements in 
the extracranial carotid and vertebral arteries in healthy adults: reference data and the effects 
of age. Ultrasound Med Biol. 2000; 26: 1261-6. 
195. Lassen NA. Cerebral blood flow and oxygen consumption in man. Physiol Rev. 
1959; 39: 183-238. 
196. Strandgaard S. Cerebral blood flow in the elderly: impact of hypertension and 
antihypertensive treatment. Cardiovasc Drugs Ther. 1991; 4 Suppl 6: 1217-21. 
197. Xu TY, Staessen JA, Wei FF, et al. Blood flow pattern in the middle cerebral artery 
in relation to indices of arterial stiffness in the systemic circulation. Am J Hypertens. 2012; 
25: 319-24. 
198. Kwater A, Gasowski J, Gryglewska B, Wizner B and Grodzicki T. Is blood flow in 
the middle cerebral artery determined by systemic arterial stiffness? Blood Press. 2009; 18: 
130-4. 
199. Mitchell GF, Lacourciere Y, Arnold JM, Dunlap ME, Conlin PR and Izzo JL, Jr. 
Changes in aortic stiffness and augmentation index after acute converting enzyme or 
vasopeptidase inhibition. Hypertension. 2005; 46: 1111-7. 
200. Nichols WN, O'Rourke MF and Vlachopoulos C. McDonald's Blood Flow in 
Arteries Theoretical, experimental and clinical principles 6th ed. London: Arnold, p. 200. 
201. Fantin F, Mattocks A, Bulpitt CJ, Banya W and Rajkumar C. Is augmentation index 
a good measure of vascular stiffness in the elderly? Age Ageing. 2007; 36: 43-8. 
202. Nakano T, Munakata A, Shimaura N, Asano K and Ohkuma H. Augmentation index 
is related to white matter lesions. Hypertens Res. 2012; 35: 729-32. 
203. Barnes JN, Harvey RE, Zuk SM, et al. Aortic hemodynamics and white matter 
hyperintensities in normotensive postmenopausal women. J Neurol. 2017; 264: 938-45. 
204. Arba F, Mair G, Carpenter T, et al. Cerebral White Matter Hypoperfusion Increases 
with Small-Vessel Disease Burden. Data From the Third International Stroke Trial. J Stroke 
Cerebrovasc Dis. 2017; 26: 1506-13. 
205. Bilston LE, Fletcher DF, Brodbelt AR and Stoodley MA. Arterial pulsation-driven 
cerebrospinal fluid flow in the perivascular space: a computational model. Comput Methods 
Biomech Biomed Engin. 2003; 6: 235-41. 
206. Gutierrez J, Elkind MS, Cheung K, Rundek T, Sacco RL and Wright CB. Pulsatile 
and steady components of blood pressure and subclinical cerebrovascular disease: the 
Northern Manhattan Study. J Hypertens. 2015; 33: 2115-22. 
207. Yakushiji Y, Charidimou A, Hara M, et al. Topography and associations of 
perivascular spaces in healthy adults: the Kashima scan study. Neurology. 2014; 83: 2116-23. 
208. Blanco PJ, Müller LO and Spence JD. Blood pressure gradients in cerebral arteries: 
a clue to pathogenesis of cerebral small vessel disease. stroke and Vascular Neurology. 
2017; 2: e000087. 
209. Starr JM, Wardlaw J, Ferguson K, MacLullich A, Deary IJ and Marshall I. Increased 
blood-brain barrier permeability in type II diabetes demonstrated by gadolinium magnetic 
resonance imaging. J Neurol Neurosurg Psychiatry. 2003; 74: 70-6. 
210. Hu X, Alwan AA, Rubinstein EH and Bergsneider M. Reduction of compartment 
compliance increases venous flow pulsatility and lowers apparent vascular compliance: 
implications for cerebral blood flow hemodynamics. Med Eng Phys. 2006; 28: 304-14. 
211. Greitz D, Greitz T and Hindmarsh T. A new view on the CSF-circulation with the 




212. Moody DM, Brown WR, Challa VR and Anderson RL. Periventricular venous 
collagenosis: association with leukoaraiosis. Radiology. 1995; 194: 469-76. 
213. Blair G, Appleton JP, Law ZK, et al. Preventing Cognitive Decline and Dementia 
from Cerebral Small Vessel Disease: The LACI-1 Trial. Protocol and statistical analysis plan 
of a phase IIa dose escalation trial testing tolerability, safety and effect on intermediary 
endpoints of isosorbide mononitrate and cilostazol, separately and in combination. Int J 
Stroke. In press. 
214. Jespersen SN and Ostergaard L. The roles of cerebral blood flow, capillary transit 
time heterogeneity, and oxygen tension in brain oxygenation and metabolism. J Cereb Blood 
Flow Metab. 2012; 32: 264-77. 
215. Mestre H, Kostrikov S, Mehta RI and Nedergaard M. Perivascular spaces, 
glymphatic dysfunction, and small vessel disease. Clin Sci (Lond). 2017; 131: 2257-74. 
216. Dufouil C, de Kersaint-Gilly A, Besancon V, et al. Longitudinal study of blood 
pressure and white matter hyperintensities: the EVA MRI Cohort. Neurology. 2001; 56: 921-
6. 
217. Dufouil C, Chalmers J, Coskun O, et al. Effects of blood pressure lowering on 
cerebral white matter hyperintensities in patients with stroke: the PROGRESS (Perindopril 
Protection Against Recurrent Stroke Study) Magnetic Resonance Imaging Substudy. 
Circulation. 2005; 112: 1644-50. 
218. Weber R, Weimar C, Blatchford J, et al. Telmisartan on top of antihypertensive 
treatment does not prevent progression of cerebral white matter lesions in the prevention 
regimen for effectively avoiding second strokes (PRoFESS) MRI substudy. Stroke. 2012; 43: 
2336-42. 
219. Chen Y, Shen F, Liu J and Yang G. Arterial stiffness and stroke: de-stiffening 
strategy, a therapeutic target for stroke. Stroke and Vascular Neurology. 2017; 2: 65-72. 
220. Turner ST, Fornage M, Jack CR, Jr., et al. Genomic susceptibility loci for brain 
atrophy in hypertensive sibships from the GENOA study. Hypertension. 2005; 45: 793-8. 
221. Ovbiagele B, Diener HC, Yusuf S, et al. Level of systolic blood pressure within the 
normal range and risk of recurrent stroke. JAMA. 2011; 306: 2137-44. 
222. Sabayan B, van Vliet P, de Ruijter W, Gussekloo J, de Craen AJ and Westendorp 
RG. High blood pressure, physical and cognitive function, and risk of stroke in the oldest 
old: the Leiden 85-plus Study. Stroke. 2013; 44: 15-20. 
223. ten Dam VH, van den Heuvel DM, van Buchem MA, et al. Effect of pravastatin on 
cerebral infarcts and white matter lesions. Neurology. 2005; 64: 1807-9. 
224. Bath PM and Wardlaw JM. Pharmacological treatment and prevention of cerebral 
small vessel disease: a review of potential interventions. Int J Stroke. 2015; 10: 469-78. 
225. Tanaka M, Sugawara M, Ogasawara Y, Izumi T, Niki K and Kajiya F. Intermittent, 
moderate-intensity aerobic exercise for only eight weeks reduces arterial stiffness: evaluation 
by measurement of stiffness parameter and pressure-strain elastic modulus by use of 
ultrasonic echo tracking. J Med Ultrason (2001). 2013; 40: 119-24. 
226. Tabara Y, Yuasa T, Oshiumi A, et al. Effect of acute and long-term aerobic exercise 
on arterial stiffness in the elderly. Hypertens Res. 2007; 30: 895-902. 
227. Tang A, Eng JJ, Krassioukov AV, et al. Exercise-induced changes in cardiovascular 
function after stroke: a randomized controlled trial. Int J Stroke. 2014; 9: 883-9. 
228. van Dijk EJ, Prins ND, Vrooman HA, Hofman A, Koudstaal PJ and Breteler MM. 
Progression of cerebral small vessel disease in relation to risk factors and cognitive 
consequences: Rotterdam Scan study. Stroke. 2008; 39: 2712-9. 
229. Rehill N, Beck CR, Yeo KR and Yeo WW. The effect of chronic tobacco smoking 
on arterial stiffness. Br J Clin Pharmacol. 2006; 61: 767-73. 
230. Shah RS and Cole JW. Smoking and stroke: the more you smoke the more you 
stroke. Expert Rev Cardiovasc Ther. 2010; 8: 917-32. 
231. Verro P, Gorelick PB and Nguyen D. Aspirin plus dipyridamole versus aspirin for 
prevention of vascular events after stroke or TIA: a meta-analysis. Stroke. 2008; 39: 1358-63. 
243 
 
232. Sandner P, Hutter J, Tinel H, Ziegelbauer K and Bischoff E. PDE5 inhibitors beyond 





List of Published papers 
1. Shi Y, Thrippleton MJ, Makin SD, et al. Cerebral blood flow in small vessel disease: A 
systematic review and meta-analysis. J Cereb Blood Flow Metab. 2016; 36: 1653-67.  
2. Shi Y and Wardlaw J. Update on cerebral small vessel disease: a dynamic whole-brain 
disease. Stroke and Vascular Neurology. 2016; 2: 83-92. 
3. Shi Y, Thrippleton MJ, Marshall I et al. Intracranial pulsatility in patients with cerebral 
small vessel disease: a systematic review. Clin Sci (Lond). 2018; 132: 157-171. 
4. Thrippleton MJ, Shi Y, Blair G, et al. Cerebrovascular reactivity measurement in cerebral 
small vessel disease: Rationale and reproducibility of a protocol for MRI acquisition and 
image processing. Int J Stroke. 2017; In press. 
5. Blair G, Appleton JP, Law ZK, Doubal F, Flaherty K, Dooley R, Shuler K, Richardson C, 
Hamilton I, Shi Y, Stringer M, Boyd J, Thrippleton MJ, Sprigg N, Bath PM and Wardlaw J. 
Preventing Cognitive Decline and Dementia from Cerebral Small Vessel Disease: The 
LACI-1 Trial. Protocol and statistical analysis plan of a phase IIa dose escalation trial testing 
tolerability, safety and effect on intermediary endpoints of isosorbide mononitrate and 
cilostazol, separately and in combination. Int J Stroke. doi: 10.1177/1747493017731947 
 
Copies of the above-listed papers will be presented in the following pages. Permissions to 
use these publications in this thesis which is authored by myself were already obtained from 





Cerebral blood flow in small
vessel disease: A systematic
review and meta-analysis
Yulu Shi1,2, Michael J Thrippleton1, Stephen D Makin1,3,
Ian Marshall1, Mirjam I Geerlings4, Anton JM de Craen5,y,
Mark A van Buchem6 and Joanna M Wardlaw1
Abstract
White matter hyperintensities are frequent on neuroimaging of older people and are a key feature of cerebral small
vessel disease. They are commonly attributed to chronic hypoperfusion, although whether low cerebral blood flow is
cause or effect is unclear. We systematically reviewed studies that assessed cerebral blood flow in small vessel disease
patients, performed meta-analysis and sensitivity analysis of potential confounders. Thirty-eight studies (n¼ 4006) met
the inclusion criteria, including four longitudinal and 34 cross-sectional studies. Most cerebral blood flow data were from
grey matter. Twenty-four cross-sectional studies (n¼ 1161) were meta-analysed, showing that cerebral blood flow was
lower in subjects with more white matter hyperintensity, globally and in most grey and white matter regions (e.g. mean
global cerebral blood flow: standardised mean difference0.71, 95% CI 1.12, 0.30). These cerebral blood flow
differences were attenuated by excluding studies in dementia or that lacked age-matching. Four longitudinal studies
(n¼ 1079) gave differing results, e.g., more baseline white matter hyperintensity predated falling cerebral blood flow (3.9
years, n¼ 575); cerebral blood flow was low in regions that developed white matter hyperintensity (1.5 years, n¼ 40).
Cerebral blood flow is lower in subjects with more white matter hyperintensity cross-sectionally, but evidence for falling
cerebral blood flow predating increasing white matter hyperintensity is conflicting. Future studies should be longitudinal,
obtain more white matter data, use better age-correction and stratify by clinical diagnosis.
Keywords
Cerebral blood flow, cerebral small vessel disease, white matter hyperintensities, systematic review, meta-analysis
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Introduction
White matter hyperintensities (WMHs) are commonly
seen on brain magnetic resonance imaging (MRI) in
older people and are considered as one of the core neu-
roimaging findings of cerebral small vessel disease
(SVD). They are defined as patchy or confluent hyper-
intensities on T2-weighted or FLAIR images, without
cavitation, in subcortical white or deep grey matter
regions.1 WMHs are associated with increasing age
and vascular risk factors such as hypertension and dia-
betes.2 Although the aetiology is not completely under-
stood, chronic hypoperfusion is thought to be a key
mechanism,3 perhaps resulting from narrowing of the
arteriolar lumena secondary to lipohyalinosis and arter-
iolosclerosis. Based on this theory, mechanically
induced hypoperfusion models, for example, partial
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or complete carotid artery occlusion, are used to create
pathology that appears to mimic human SVD.
However, no direct association between carotid artery
stenosis and lacunar stroke or WMH has been found in
human studies.4
Additionally, the relationship between cerebral
blood flow (CBF) and WMH is not consistent across
human studies. In some cross-sectional studies, low
CBF was significantly related to more WMHs, whereas
in other studies, no such relationship was found.5,6
These studies had different study designs, sample sizes
and locations where low CBF was detected and most
studies were cross-sectional. There are few longitudinal
studies. Thus it is unclear whether there is causal rela-
tionship between low CBF and WMHs in humans, or
whether there is region specificity.
We sought to establish if WMH was related to
changes in CBF levels, or whether differences in CBF
might be related to potential confounders such as age
and tissue loss. We systematically reviewed the avail-
able longitudinal and cross-sectional studies in humans,
performed a meta-analysis of cross-sectional studies to
assess the overall effect size of CBF differences by
WMH burden in different brain regions, assessed
study quality and performed sensitivity analyses on
important confounders.
Methods
We performed this review according to guidelines7 and
a pre-specified protocol. We conducted a literature
search of MEDLINE and EMBASE from 1946 up to
December 2015, using the Ovid Web Gateway. We used
exploded headings related to Small Vessel Disease and
Cerebral Blood Flow with the Boolean operator AND
[Supplementary methods]. English and non-English lit-
erature were sought. Additional records were identified
by hand searching from January 1990 to December
2015 of Stroke and Journal of Cerebral Blood Flow &
Metabolism. We also checked references cited in
reviews and primary papers.
Eligibility criteria
We sought longitudinal and cross-sectional pri-
mary research studies assessing CBF in subjects with
cerebral SVD.8 Studies measuring cerebral blood flow
velocity (CBFv) using Doppler ultrasound techniques
were also considered eligible. We excluded studies
targeting unilateral or bilateral severe carotid stenosis
or occlusion, studies in children, animal studies, dupli-
cate publications, conference abstracts and cross-
sectional studies from which we could not extract
either absolute values of CBF or correlation/regression
coefficients.
Data extraction and analysis
We screened all potentially relevant full papers and
extracted data using a standardised form. All data
were cross-checked by a second reviewer (JMW).
From those that met the inclusion criteria, we extracted
data on study population characteristics, study design,
SVD and CBF measurement techniques and units. We
assessed the study quality using a checklist devised on
the basis of the Strengthening the Reporting of
Observational Studies in Epidemiology statement
(www.equator-network.org) and checklist in a previous
paper,9 including factors such as study population and
bias controlling (Supplementary Table S1).
For cross-sectional studies which reported means
and standard deviations (S.D.s) of CBF, we extracted
data on CBF in disease and control groups or accord-
ing to SVD burden. Means and S.D.s were extracted
from text or tables where available, or from graphs
where necessary. For cross-sectional studies where
only qualitative data for association between CBF
and WMH were available, we included the studies in
the review but not in the meta-analysis: we noted the
statistical methods, coefficients, P values and other cov-
ariates included in regression.
For longitudinal studies, we also listed follow-up dur-
ations and primary results extracted from the papers,
and contacted the authors to request unpublished data
on baseline and follow-up CBF and WMH volume.
Data transformation and analysis
All studies reporting means and S.D.s were included for
meta-analysis. For studies that divided patients into more
than two grades of WMH severity, we combined the
means and S.D.s of groups to create a single pair-wise
comparison [Supplementary methods]. As most studies
measured CBF in several regions of interest (ROIs),
such as different grey matter and white matter regions,
we conducted subgroup analysis by brain region. Due to
various units of CBF being used in different papers, we
calculated the standardised mean differences (SMDs) and
95% confidence intervals (CI) for comparisons using a
random-effects model. Sensitivity analyses were carried
out for subjects with/without dementia and by age match-
ing between study groups, as both strongly influence
CBF. Meta-analyses were conducted using the
Cochrane Collaboration’s Review Manager (Revman
Version 5.3). We assessed for heterogeneity by calculating
the I2 statistic and publication bias using a funnel plot.
Results
A total of 2843 publications were initially identified, of
which 75 were potentially eligible and were selected for
1654 Journal of Cerebral Blood Flow & Metabolism 36(10)
further review. We ultimately included 38 articles and
excluded (Figure 1): conference abstracts (6), those
where we were unable to access the full text (6) or that
had no analysable data (18), duplicate publications
including the same participant population (3) and stu-
dies of severe carotid stenosis or occlusion (4). Note that
although presence of arterial diseases was an inclusion
criterion of Second Manifestations of ARTerial disease-
magnetic resonance (SMART-MR) study, carotid arter-
ial stenosis or occlusion was not one of the criteria: here
patients with carotid artery stenosis were included, but
they only represented a small proportion of participants,
thus we included the study10 in our review. The 38 stu-
dies included a total of 4006 participants: 4/38 were lon-
gitudinal and 34/38 were cross-sectional.
Some papers are from the same studies: van der
Veen et al.10 and Bisschops et al.11 from the SMART-
MR study; ten Dam et al.12 and van Es et al.13 from the
Prospective Study of the Elderly at Risk (PROSPER)
trial; Vernooij et al.14 and Claus et al.15 from the
Rotterdam Scan Study. We were careful to count
each participant only once in any analysis.
Characteristics of included studies
Cross-sectional studies. Thirty-four cross-sectional studies
were included (Table 1). 24/34 were suitable for meta-
analysis. 6/24 studies used patients with dementia plus
WMH as disease groups. Of these six studies, two
included Alzheimer’s disease (AD),16,17 the other four
focused on vascular dementia including subcortical vas-
cular dementia,18 multi-infarct dementia (MID),19,20
and Binswanger’s disease (BD).5 AD diagnosis used
the criteria of the National Institute of Neurological
Figure 1. PRISMA flow diagram of literature search.
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measuring CBF CBF units
Longitudinal studies (4)
Bernbaum et al.43 40 High risk TIA or minor
ischemic stroke
61.0 11.0 DCS PWI ml/100 g/min
van der Veen et al.10 575 Manifest arterial diseasesa 57.0 10.0 Phase-contrast MRI ml/100 ml/min
Kraut et al.44 74 Progressive WMH 70.0 6.9 PET Not shown
Stable WMH 67.1 7.0
ten Dam et al.12 390 History of vascular
disease or were at
increased vascular risk
75.0 3.2 Phase-contrast MRI ml/min
Cross-sectional studies (34)
Cognitive impairment/dementia (6)
Kimura et al.16 98 Late-onset AD with WMH 78.6 5.1 SPECT ml/100 g/min
AD without WMH 77.4 5.0
Schuff 200918 26 Subcortical vascular dementia 77.0 8.0 ASL ml/100 g/min
Cognitively normal 73.0 8.0




Yamaji 199717 32 AD with WMH 71.6 3.1 PET ml/100 ml/min
AD without WMH 71.0 4.3
Kawamura et al.19 40 MID 64.4 10.2 Xenon CT ml/100 g/min
No WMH 67.2 10.5
Kobari et al.20 20 MID 68.1 12.0 Xenon CT ml/100 g/min
Neurologically normal controls 52.3 5.7
No cognitive impairment (18)
Wagner et al.45 36 Extensive WMH 71.0 ASL ml/100 g/min
No or mild WMH 67.0
Fu et al.33 56 WMH Grade 3b 68.1 8.1 Xenon CT ml/100 g/min
WMH Grade 2 68.9 7.7
WMH Grade 1 64.5 5.8
WMH Grade 0 65.3 6.3
Nezu et al.21 18 Lacunar stroke with
severe WMHs




Huynh et al.36 35 TIA with moderate to
severe WMH
77.1 6.0 CT perfusion ml/100 g/min
TIA with mild WMH 62.6 16.3
De Bastos-Leite
et al.34
21 WMH Grade 3b 77.7 5.7 ASL ml/100 ml/min
WMH Grade 2 74.4 4.6
WMH Grade 1 74.0 5.0
Zheng et al.22 35 Asymptomatic WMH 69.7 8.9 SPECT ml/g/min
No WMH 67.1 6.9
Ramli et al.23 42 Leukoaraiosis on CT 70.19 CT perfusion ml/100 g/min
No leukoaraiosis on CT 69.86
Kimura et al.32 20 Depression (remission)
with WMH
78.5 5.1 SPECT ml/100 g/min
77.4 5.0
(continued)









measuring CBF CBF units
Depression (remission)
without WMH
Cui et al.24 98 WMH 70.0 TCD, SPECT cm/s
No WMH 66.0
O’Sullivan et al.25 36 WMH 68.9 9.2 PET ml/100 g/min
No WMH 72.7 7.7
Yao et al.26 10 Extensive WMH 75.0 5.0 Xenon CT ml/100 g/min
No WMH 72.0 5.0
Markus et al.27 17 Leukoaraiosis 63.3 12.3 MRI contrast ml/100 g/min
No leukoaraiosis 68.3 7.3
Oishi and Mochizuki28 45 WMH 66.8 8.4 Xenon CT ml/100 g/min
No WMH 65.1 8.5
Hatazawa et al.29 33 Asymptomatic WMH 71.3 8.6 PET ml/100 ml/min
No WMH 68.5 10.2
Miyazawa et al.35 135 WMH Grade IVc 71.90 8.17 Xenon CT ml/100 g/min
WMH Grade III 69.00 8.08
WMH Grade II 67.30 9.87
WMH Grade I 64.20 5.55
WMH Grade 0 57.3 12.0
Kuwabara et al.6 24 Hypertensive with moderate
to severe leukoaraiosisc




Normotensive control 60.0 12.0
Kobayashi et al.30 246 Apparent PVWMH 67.0 6.1 Xenon CT ml/100 g/min
No or mild PVWMH 60.0 8.2
Fazekas et al.31 23 WMH 58.8 5.3 Xenon CT ml/100 g/min
No WMH 58.2 2.8
Studies only showing correlation coefficients (10)
Crane et al.47 26 Mild to severe WMH 73.3 8.8 ASL ml/100 g/min
Alosco et al.40 69 Heart failure with WMH 68.55 8.07 Ultrasound Doppler cm/s
Heliopoulos et al.38 52 Hypertension with WMH 71.4 4.5 Ultrasound Doppler cm/s
van Es et al.13 447 Cerebrovascular risk factors
without major neurological
deficits
75.0 3.0 Phase-contrast MRI ml/min, ml/100 ml/min
Vernooij et al.14 892 Population-based 67.5 5.5 Phase-contrast MRI ml/100 g/min
Bisschops et al.42 228 Manifest arterial diseasesa 59.0 Phase-contrast MRI ml/min
Tzourio et al.37 628 Population-based 68.9 2.9 Ultrasound Doppler m/s
Ott et al.41 40 Mixed dementia 72.8 8.7 SPECT %rCBF relative to cerebellum
Claus et al.46 60 Non-demented WMH 65.0–85.0d SPECT %rCBF relative to cerebellum
Isaka et al.39 28 Cerebrovascular risk factors
without neurological deficits
67.8 Xenon CT ml/100 ml/min
S.D.: standard deviation; CBF: cerebral blood flow; TIA: transient ischemic attack; DCS-PWI: dynamic susceptibility contrast perfusion-weighted
imaging; MRI: magnetic resonance imaging; AD: Alzheimer’s disease; MID: multi-infarct dementia; BD: Binswanger’s disease; WMH: white matter
hyperintensity; SPECT: single-photon emission computed tomography; ASL: arterial spin labelling MRI; PET: positron emission tomography; TCD:
transcranial Doppler; CT: computed tomography; PVWMH: periventricular white matter hyperintensity; rCBF: regional cerebral blood flow. aIncludes
manifest coronary artery disease, cerebrovascular disease, peripheral arterial disease or an abdominal aortic aneurysm. bFazekas WMH score. cSelf-
designed scoring system for WMH. dAge range.
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and Communicative Disorders and Stroke, and
the Alzheimer’s disease and Related Disorders
Association (NINCDS/ADRDA) for probable AD.
Vascular dementia diagnosis varied: CT/MRI evidence,
DSM-III-R criteria,5,19,20 Hachinski ischaemia scores19
and the criteria of the State of California Alzheimer’s
Disease Diagnostic and Treatment Centres.18 In the 18/
24 studies of non-demented subjects, 11 compared CBF
between subjects having WMHs and normal controls
with no or mild WMHs,21–31 one study performed the
comparison between patients with depression (DSM-IV
criteria) plus WMHs vs no WMHs,32 and the other four
papers examined the differences in CBF across grades
of WMH severity.6,33–35 Of these four studies, two used
Fazekas WMH rating scores,6,35 the other two used a
self-designed rating systems similar to Fazekas’s
method.33,34 Two studies recruited patients with acute
ischemic symptoms: in Nezu et al.,21 patients presented
with minor ischemic stroke and brain scans were per-
formed at least 3 weeks after onset; Huynh et al. only
included TIA patients and brain scans were done
acutely.36
In the other 10/34 studies which only reported asso-
ciation analysis, two were population-based stu-
dies,14,37 the other nine hospital-based studies
included patients with cerebrovascular risk fac-
tors,13,38,39 heart failure,40 dementia41 and manifest
arterial diseases.42
Longitudinal studies. Four longitudinal prospective stu-
dies, including 1079 participants, were included
(Table 1). Three were hospital-based10,12,43 and one
from a population-based aging study.44 Among these
four studies, Bernbaum et al. recruited participants who
presented acute minor stroke symptoms or transient
ischemic attack (TIA) and had baseline MRI within
48 h after the onset.43 The other three studies did not
include acute patients. The follow-up durations ranged
from 1.5 to 7.7 years. Kraut et al. compared the pat-
terns of long-term CBF change in patients with pro-
gressive WMHs to those with stable WMHs,44
whereas the other three studies performed regression
analyses between CBF and WMH data without subdi-
viding patient groups.10,12,43
Quality assessment. The average study quality score was
6/9. Scores were mainly lost for not reporting the drop-
outs (25/38), no adjustment or matching for risk factors
(including age) (17/38), not reporting expertise of image
observers (20/38) and not using blinding (25/38)
(Supplementary Figure S1).
Assessment of CBF measurement methods. Three studies
used phase-contrast MRI,10,12–14,42 seven used positron
emission tomography (PET),5,6,17,21,25,29,44 six used
single-photon emission computerised tomog-
raphy,15,16,22,24,32,41 two used MRI contrast,27,43 two
used arterial spin labelling (ASL)-MRI,18,45 nine used
Xenon-CT19,20,26,28,30,31,33,35,39 and two used CT perfu-
sion23,36 to assess CBF. Four studies measured CBFv in
the middle cerebral arteries using transcranial Doppler
ultrasound.24,37,38,40
Meta-analysis of differences in CBF by WMH burden
Meta-analysis using SMD in CBF was only possible for
24 cross-sectional studies. Twenty-two brain regions
were extracted, but sufficient data were available from
only 11 regions which were used by at least three studies
and were selected for the primary meta-analysis. These
included: global brain mean CBF, basal ganglia, cor-
tical grey matter (total, frontal, temporal, parietal and
occipital grey matter) and white matter (total, frontal
and occipital white matter, centrum semiovale). Most
data were available for grey matter; few studies pro-
vided white matter data.
Patients with more severe WMH had lower CBF than
patients with mild WMH, globally and in most grey and
white matter regions (e.g. mean global CBF: SMD
0.71, 95% CI 1.12, 0.30; total grey matter:
SMD 0.50, 95% CI 0.97, 0.03; total white matter:
SMD 1.16, 95% CI 1.08, 0.53; see Figure 2a and
b), except in basal ganglia (SMD 1.25, 95% CI 2.53,
0.30) and occipital white matter (SMD 0.45, 95% CI
0.96, 0.05) where the difference in CBF did not reach
significance. No studies in the meta-analysis separated
normal appearing white matter (NAWM) and WMH.
However, there was heterogeneity between studies for
most of these comparisons (Figure 2a and b) that was
not due to publication bias (funnel plot, Supplementary
Figure S2). One study found that CBF in patients with
lacunar lesions was lower than in those without, how-
ever, the result was not adjusted for WMH volume and
could not be meta-analysed.30
Sensitivity analysis of dementia and age. We repeated the
meta-analyses after excluding studies that included
patients with dementia and then further excluded stu-
dies without age-matching. In most grey and white
matter regions, the differences in CBF between subjects
with high and low WMH burdens attenuated and were
no longer significant, except for mean global brain CBF
and centrum semiovale. Most of the trends in the com-
parisons were still the same, apart from temporal grey
matter (Figure 3).
Only one study, Ibayashi et al., used hypertensive
but neurologically normal patients as the control
group, and found lower CBF in patients with
Binswanger’s dementia compared to the control
group;5 none of the other studies matched or adjusted
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Figure 2. (a) Forest plot showing standard mean differences in global and grey matter CBF in patients with WMH in dementia and non-
dementia studies. CBF in different brain regions was analysed in subgroups. (b) Forest plot showing standard mean differences in white
matter CBF in patients with WMH in dementia and non-dementia studies. CBF in different brain regions was analysed in subgroups.
CBF: cerebral blood flow; WMH: white matter hyperintensity.
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for vascular risk factors. Therefore, we were not able to
do a sensitivity analysis for vascular risk factors.
Hypertension is significantly more prevalent in patients
with more severe WMH.
Cross-sectional studies that provided data on
associations between CBF and SVD features
Among the 10 cross-sectional papers which only per-
formed association analysis, three studies did not find
association between CBF and WMH burden.39,41,46
Four studies reported that CBF was negatively related
to WMH severity.11,13,14,47 Negative correlation
between WMH features and CBFv was found in three
studies, of which one assessed CBFv in internal carotid
arteries,38 and the other two in middle cerebral
arteries.37,40 Among all 10 studies, six adjusted for cov-
ariates such as age, gender and other vascular risk fac-
tors (Table 2).11,37,40,46–48
Longitudinal studies
In longitudinal studies, the largest study (575 subjects),
van der Veen et al., found that high WMH volume at
baseline was significantly associated with falling CBF
over 3.9 years follow-up.10 ten Dam et al. demonstrated
in 390 subjects that a decline in global CBF over 2.75
years was associated with a progression in periventricu-
lar WMH (PVWMH) but not in deep WMH
(DWMH).12 A small study (n¼ 40) found low CBF in
regions that developed WMH over 1.5 years follow-up
(Table 3).43 In contrast to the other findings of falling
CBF over time, Kraut et al. demonstrated in 74 subjects
that CBF increased in some brain areas (right inferior
temporal gyrus, right anterior cingulate and the left
superior temporal gyrus) over 7.7 years in patients
with progressive WMH.44 Falling CBF was observed
more in the posterior regions including right inferior
parietal lobule and right occipital pole but was not spe-
cifically associated with WMH change.
Discussion
WMHs are often considered to be a consequence of
chronic hypoperfusion. However, while our review of
all available published and some unpublished data
show that high WMH load is associated with lower
CBF, they do not strongly support causation. In
cross-sectional studies, low CBF was observed in
most of the patients with more WMHs. However the
association was damped after removing non-age
matched subjects and those with dementia, which sug-
gests that the underlying association is between reduced
CBF and age or dementia rather than just WMH. One
Figure 2. Continued.
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longitudinal study (n¼ 575) also showed a correlation
between high baseline WMH volume and decrease in
CBF over time, questioning whether a CBF decline
causes the tissue loss or vice versa.10
The strengths of this systematic review include the
use of well-established guidelines for meta-analysis,
cautious exclusion of duplicate data, thorough analysis
of different study types and sensitivity analysis of clin-
ically important subgroups. Some studies provided
more than one comparison but we avoided double-
counting the total number of participants. We used
every piece of data we could obtain. Studies that
recruited subjects with AD, heart failure and depression
but compared CBF between patients with and without
SVD were also included. Moreover, we included papers
in non-English languages, including three papers in
Chinese. As most studies measured regional CBF in
different brain areas, we carefully chose regions that
were mentioned by at least three studies to obtain
robust SMDs in meta-analyses.
There are some limitations of the review which in
most part reflect the limitation of the literature. First,
there are differences between studies in terms of study
design and imaging methods which we tried to harmon-
ise to enable comparisons. Longitudinal studies were
rare. Data for white matter regions such as centrum
semiovale or immediate periventricular white matter
were limited or lacking. CBF was obtained by different
techniques and varied by technique. However, it is
important to note that meta-analysis compares the
magnitude of association within one study with that
within the others, rather than making direct
Figure 3. Sensitivity analysis: SMDs of CBF in different brain areas in patients with moderate to severe WMH against those with
negative to mild WMH. In each brain area, we showed the SMD of CBF in all studies, after excluding dementia studies and furthermore
excluding studies without age-matching [number of studies] (number of participants).
SMD: standard mean difference; CBF: cerebral blood flow; GM: grey matter; WM: white matter; WMH: white matter hyperintensity;
CI: confidence interval.
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comparisons of CBF between studies. There are also
differences in patient populations: most studies chose
patients without neurological symptoms or from com-
munity-based populations, whereas three studies
recruited patients with acute onset of TIA or minor
stroke. Two studies used acute brain MRI as baseline
imaging.36,43 Image analysis methods differed and few if
any studies differentiated normal tissue from WMH in
the ROIs, thus including more tissue affected by lesions
in subjects with high WMH burdens than with few
WMH – an obvious confound if measuring CBF.
Second, as some studies divided subjects into different
severity groups, we converted them into pair-wise com-
parisons in the form of low WMHs versus high WMHs.
Therefore, it is possible that disease groups in the ori-
ginal pair-wise studies might include some patients with
mild lesions. Third, the sample sizes of the studies
included in meta-analyses were small – the whole ana-
lysis of 24 studies included 1161 patients (mean 48/
study or 24/group). Only a few studies used age-
matched controls. Patients with more severe WMHs
were in general significantly older than those who had
mild or no WMH, introducing an obvious confound;
we addressed this in sensitivity analyses but these were
underpowered for meta-regression. In addition, only
one study matched for important confounders like vas-
cular risk factors so that sensitivity analysis for risk
factors was not possible, and of course hypertension
was generally more prevalent in severe WMH groups.
Moreover, data for other imaging changes like lacunes
or lacunar lesions are lacking.30
The meta-analysis demonstrated that CBF measured
concurrently was significantly lower in patients with
more severe WMH. Cross-sectional studies which
only did regression/correlation analyses also showed
an association between high WMH burden and low
CBF. However, the differences between groups in
most brain regions were largely attenuated by excluding
dementia and non-age-matched studies, except global
mean CBF and CBF in centrum semiovale which
remained significant and the point estimate did not
move. These results suggest that disease severity and
age confound the relationship between WMH and
CBF, which was again supported by results from lon-
gitudinal studies showing that high burden of WMH
predated falling CBF.10 Additionally, in regression/cor-
relation-only cross-sectional studies where a negative
association between WMH and CBF was found, the
correlation tends to be significant in more severe
patients.37
These results indicate that the reduced CBF in
patients with WMH might reflect a reduction in the
blood supply required by the tissue, due to reduced
neuronal activity, or atrophy with fewer cells. As
most included studies recorded CBF in cortical grey
matter, these associations between reduced CBF and
cortical atrophy should not be overlooked. Cortical
atrophy is known to occur with the aging process.
Results from a large cohort study demonstrated that
baseline brain atrophy predicted decline in total CBF
over time.49 There are many imaging studies reporting
an association between cortical atrophy and WMH
severity.50 However, there is little information about
cortical volume from included studies. Although data
for white matter are limited, CBF in frontal and occipi-
tal white matter regions changed in the similar way as
in grey matter. Results in DWMH and in PVWM dif-
fered: a longitudinal study showed that decreasing CBF
over time was related to progression of PVWMH rather
than to that of DWMH,12 which is in agreement with a
cross-sectional study showing depressed CBF only in
NAWM in periventricular regions.25 The contradictory
results from white matter indicate that there might be
differential vulnerability for DWMH and PVWMH as
these two brain areas are on different sections of the
arteriolar tree.25 However, such a suggestion is not sup-
ported by available data – studies indicate that
PVWMH and DWMH are on a continuum in terms
of location.51
The limitation of resting CBF is that it only provides
information of a cut-off time point at which CBF might
still to be relatively preserved or compensated especially
in the early stage of disease.52 One of the included studies
showed a reduced CBF response to hypercapnia in non-
demented hypertensive patients with leukoaraiosis while
resting CBF was shown to be unaffected.6 Reduced cere-
bral vascular reactivity (CVR) represents the dilatory
ability of brain vessels, has been suggested as an alter-
native mechanism of SVD. Risk factors such as hyper-
tension alter the structure of penetrating arterioles by
promoting lipohyalinosis and vessel wall thickening,
which has led to the suggestion that cerebral arterioles
might become stiffer and thus cause a decrease in vaso-
dilatory capacity. Evidences from other studies also sug-
gest that the reduction in CVR might play a critical role
in the disease process of SVD.53 Further studies are
required to investigate how blood flow responsiveness
(not just resting CBF) varies across different tissues
(NAWM, WMHs and grey matter), and how it changes
across the course of the disease.
In conclusion, despite large heterogeneities across
included studies and the cross-sectional nature of
most studies, this systematic review showed that CBF
was negatively related to WMH severity. Our results
suggest that hypoperfusion in the whole brain and
low cortical blood flow is more likely a consequence
of WMH than the cause. However, whether WMH is
due to focal ischemia in particular white matter tissues
and whether development of PVWMHs and DWMHs
differs in mechanisms still remain unanswered. This
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systematic review emphasises that more data are needed
for white matter, especially separate data for NAWM
and WMH. Future studies should obtain longitudinal
data from white matter as well as grey matter, have
larger sample sizes, include appropriate control
groups, stratify by and adjust for important cofounders
such as age, important risk factors like hypertension,
clinical diagnosis (including the type of dementia if rele-
vant), by different features and severities of SVD and
by cognitive status. In addition, if studying patients
with acute stroke, it would be better to avoid the
acute phase after stroke for imaging assessments to
avoid effects of the acute stroke interfering with the
study of WMH. Moreover, investigation of alternative
mechanisms such as impaired CVR and effects of
blood–brain barrier changes should be pursued in par-
allel with CBF measurement to provide new perspec-
tives on treatment for SVD.
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Cerebral small vessel disease (CSVD) is a very
common neurological disease in older people. It
causes stroke and dementia, mood disturbance and
gait problems. Since it is difficult to visualise CSVD
pathologies in vivo, the diagnosis of CSVD has relied
on imaging findings including white matter
hyperintensities, lacunar ischaemic stroke, lacunes,
microbleeds, visible perivascular spaces and many
haemorrhagic strokes. However, variations in the use
of definition and terms of these features have probably
caused confusion and difficulties in interpreting results
of previous studies. A standardised use of terms
should be encouraged in CSVD research. These CSVD
features have long been regarded as different lesions,
but emerging evidence has indicated that they might
share some common intrinsic microvascular
pathologies and therefore, owing to its diffuse nature,
CSVD should be regarded as a ‘whole-brain disease’.
Single antiplatelet (for acute lacunar ischaemic stroke)
and management of traditional risk factors still remain
the most important therapeutic and preventive
approach, due to limited understanding of
pathophysiology in CSVD. Increasing evidence
suggests that new studies should consider drugs that
target endothelium and blood–brain barrier to prevent
and treat CSVD. Epidemiology of CSVD might differ in
Asian compared with Western populations (where most
results and guidelines about CSVD and stroke
originate), but more community-based data and
clear stratification of stroke types are required to
address this.
INTRODUCTION
The term ‘cerebral small vessel disease
(CSVD)’ refers to a syndrome of clinical and
imaging findings that are thought to result
from pathologies in perforating cerebral
arterioles, capillaries and venules. CSVD
causes up to 45% of dementia, and accounts
for about 20% of all stroke worldwide, 25%
of ischaemic (or lacunar strokes), of whom
about 20% are left disabled.1 Cognitive
impairment, depression and gait problems
are also frequently seen in patients with
CSVD. The prevalence of lacunar stroke may
be higher in patients in China where recent
studies have suggested that lacunar infarction
accounts for 38–46% of ischaemic stroke.2 3
Generally, including in this review, CSVD is
used to describe a series of imaging changes
in the white matter and subcortical grey
matter, including recent small subcortical
infarct, lacunes, white matter hyperintensities
(WMHs), prominent perivascular spaces
(PVS), cerebral microbleeds (CMBs) and
atrophy.4 Usually, recent small subcortical
infarcts cause acute stroke symptoms,
whereas other CSVD lesions are clinically
more insidious and thus referred to as
‘silent’ lesions. However, the definitions and
terms of these lesions have varied greatly
among studies. For example, a recent review
identified 159 different names for recent
small subcortical infarcts, but these names
like ‘lacunar infarct’ were also frequently
used to describe lacunes4 5 that were not
necessarily related to symptoms and might
have been due to haemorrhage. The substan-
tial variation in the use of these terms has
probably contributed to confusion and diffi-
culties in interpreting previous research.
Therefore, in 2013, an expert workgroup on
CSVD proposed a list of standard terms to
help avoid confusion and suggests that CSVD
researchers should be encouraged to apply
these terms in future studies.4 We will also
use these terms in this review.
The different features of CSVD have long
been regarded as different types of tissue
changes. However, recent studies show that
these features are correlated, are more likely
to share common diffuse intrinsic small
vessel pathologies, and are probably also
more ‘dynamic’ than previously thought.
Advances in imaging techniques have
brought new insights into mechanisms of
CSVD. In this review, we will summarise find-
ings in recent clinical studies on CSVD,
discuss CSVD mechanisms and explore emer-
ging prevention and treatment options.
Clinical lacunar stroke
A lacunar clinical syndrome could be due to
either ischaemia or a small haemorrhage.6
Many haemorrhagic strokes in older people
are also due to CSVD pathology.1 In this
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review, we will focus mainly on ischaemic CSVD.
Lacunar ischaemic stroke is defined as a stroke that is
attributable to a recent small infarct <1.5 (or some say
2) cm diameter in the white matter, basal ganglia, pons
or brainstem, and is consistent with a lacunar clinical
syndrome.7 It is commonly attributed to an abnormality
in a single small deep perforating (or lenticulostriate)
artery. On MRI, an acute lacunar infarct is shown as
hyperintense on diffusion-weighted imaging (DWI),
hypointense on an apparent diffusion coefficient map,
hyperintense on T2-weighted and fluid-attenuated inver-
sion recovery (FLAIR), hypointense on T1 and hypoatte-
nuated on CT (figure 1). It can be rounded, ovoid or
tubular.4 Generally, the Oxfordshire Community Stroke
Project (OCSP) classification, which uses only clinical
features to diagnose the stroke subtype, can predict cor-
rectly the size and location of a recent brain infarct on
imaging in 75–80% of patients with stroke.8 However, up
to 20% of acute lacunar infarcts can present with cor-
tical symptoms, and conversely cortical infarcts can
present with lacunar syndromes.9 One explanation is
that lacunar infarcts closer to the cortex are more likely
to cause cortical symptoms.9 Therefore, in studies where
stroke diagnosis relied mainly on the clinical presenta-
tions, this ‘mismatch’ may have added ‘noise’. Thus, in
epidemiology, mechanistic studies or clinical trials, it is
important to verify stroke lesions using sensitive imaging
wherever possible.
However, even with sensitive imaging like DWI, about
30% of patients with clinically definite stroke did not
show any recent ischaemic change on MRI;10 when fol-
lowed up for a year, the DWI-negative patients had just
as much recurrent stroke, dependency and cognitive
impairment as the DWI-positive patients. Therefore,
negative DWI/MRI cannot exclude stroke diagnosis.
Rapid access to scanning after stroke onset can increase
the chance of positive findings.11 It is also noteworthy
that DWI-positive lesions can be clinically ‘silent’, for
example, (1) as a second silent acute infarct in patients
presenting with stroke due to another acute symptomatic
infarct, or (2) in patients with acute haemorrhagic
stroke, and (3) in patients with severe WMHs who did
not have any overt stroke symptoms.12
In some clinical stroke classifications such as the Trial
of Org 10172 in Acute Stroke Treatment (TOAST) or
the ASCO (A: atherosclerosis; S: small-vessel disease; C:
cardiac pathology; O: other causes), another term ‘small
vessel/artery disease’ rather than ‘lacunar stroke’ is used
to represent a stroke that is supposed to be due to a
small artery occlusion. However, these classifications use
risk factors to decide the stroke subtype, not just the
clinical presentation, so as to distinguish ‘small vessel/
artery disease’ from strokes caused by large artery ath-
erosclerosis, cardiac emboli or other unknown reasons.
However, a small embolus, or atheroma in the middle
cerebral artery (MCA) or perforating arterioles can all
Figure 1 STRIVE, STandards for Reporting and Imaging of Small Vessel Disease: example findings (upper), schematic
representation (middle) and a summary of imaging characteristics (lower) of MRI features for changes related to small vessel
disease.4 DWI, diffusion-weighted imaging; FLAIR, fluid-attenuated inversion recovery; SWI, susceptibility-weighted imaging;
GRE, gradient-recalled echo.
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block the perforating arteriole, and any of these can
cause a lacunar ischaemic stroke (see figure 2).
Therefore, it might be better to focus on the clinical
presentation to assign the stroke syndrome and separ-
ately focus on the risk factors for patient management.
Risk factors and causes of lacunar infarcts
Four possible main aetiologies for lacunar ischaemic
stroke have been proposed (figure 2): atheroma of
parent arteries (usually MCA) or perforating arterioles,
embolism from the heart or carotid arteries, and intrin-
sic small vessel disease (lipohyalinosis or fibrinoid necro-
sis). Atheroma in MCA appears to cause <20% of
lacunar ischaemic stroke. In the Warfarin Aspirin
Symptomatic Intracranial Disease (WASID) trial, only
11% (38/347) of all patients with stroke were lacunar
type,13 which is surprising if MCA stenosis is supposed to
be a common cause of lacunar stroke. A recent study
also did not find any association between lacunar stroke
and MCA stenosis.14 A systematic review of Asian studies
showed that parent artery atherosclerosis accounted for
20% of single lacunar infarcts in anterior circulation ter-
ritory; however, these hospital-based studies were rather
small (n=71–118) and some were even retrospective.15
Larger and tubular lacunar infarcts might be more likely
to be caused by proximal artery diseases.16 However, the
results of both our study and the Secondary Prevention
of Small Subcortical Stokes Trial (SPS3) suggest that it is
not possible to identify the cause of a particular recent
lacunar ischaemic stroke based on its size, shape or
location.17 18
Evidence for embolism as a common cause for
lacunar ischaemic stroke is limited. Presence of cardi-
oembolic sources was found significantly less often in
lacunar than in non-lacunar ischaemic stroke.19 20 Few if
any associations were found between ipsilateral carotid
stenosis and lacunar ischaemic stroke or other features
of CSVD.21 22 In primate models, <6% of emboli
injected into carotid arteries entered the lenticulostriate
arteries, while the majority entered the cortical arter-
ies.23 Lacunar ischaemic strokes in the basal ganglia
were marginally more often associated with embolism
than those in the centrum semiovale (11% vs 3%,
respectively), but the overall rate of known embolic
sources in symptomatic lacunar ischaemic stroke was
very low (11%).18
Intrinsic small vessel pathologies remain the most
common cause of lacunar ischaemic stroke, although
the underlying mechanism is unclear. Fisher attributed
the lipohyalinosis in small arteries to hypertension.
However, the diagnosis and treatment of hypertension
were less good when Fisher was working in the 1950s
and 1960s and he may have seen some particularly
severe cases of hypertension. Now, epidemiology data
show that hypertension is equally common in non-
lacunar as in lacunar ischaemic stroke;19 and many
patients with lacunar stroke are normotensive. Similarly,
other traditional risk factors like diabetes mellitus,
Figure 2 Four possible mechanisms that cause a lacunar infarct (from bottom to top): (A) an embolus from the big arteries or
cardiac sources goes up to MCA and ends up entering and occluding lenticulostriate arteries, resulting in a lacunar lesion in
basal ganglia; (B) if the atheroma in the parent artery (ie, MCA) is positioned at the opening of its penetrating branches, it could
lead to an acute occlusion of one or several penetrating arteries, hence causing a lacunar infarct; (C) a lacunar infarct could also
be due to atheroma in the perforating artery if an acute occlusion happens; (D) intrinsic small vessel disease may lead to diffused
disrupted blood–brain barrier. If this happens at an arteriolar level, plasma fluid components would enter and deposit in the
vessel wall, resulting in narrowing of the arteriolar lumen, vessel wall thickening and eventually a secondary luminal occlusion
and traditional infarct. MCA, middle cerebral arteries.
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hypercholesterolaemia and smoking were as frequent in
lacunar stroke as in other ischaemic strokes.24 Risk
factor profiles of lacunar stroke seemed different in
China, but it might be too early to say so. The Beijing
stroke registry (n=1184) showed a higher proportion of
hypertension in lacunar (acute stroke symptoms+subcor-
tical lesion <2 cm diameter on acute CT/MRI) than in
non-lacunar stroke after adjusting for age and gender.3
Some other studies had similar findings, but the stroke
diagnosis varied: in some studies, the differentiation
between lacunar stroke and ‘large artery atherosclerosis’
stroke relied only on lesion size, and clinical classifica-
tion included risk factors.25 26 Additionally, most studies
were hospital-based. Hence, population scale data on
lacunar stroke are lacking. It is important to distinguish
lacunar stroke from other subtypes because of the mech-
anism, hence prevention and treatment might differ.
More data and careful separation of lacunar stroke from
other subtypes are required in future studies.
Clinically ‘Silent’ CSVD
White matter hyperintensities
WMH of presumed vascular origin are very common in
older individuals and regarded as typical signs of CSVD.
Symptoms of WMH develop insidiously, such as cognitive
impairment, dementia and depression,1 but it almost
triples the risk of stroke, doubles the risk of dementia
and increases the risk of death.27
WMHs are usually symmetrically and bilaterally distrib-
uted in the white matter including the pons and brain
stem, and also occur in deep grey matter. They appear
hyperintense to the normal brain on T2 or FLAIR MRI
(figure 1), and can be patchy or confluent depending
on their stage in development and severity.
Owing to limited pathology studies, the underlying
pathology of WMH remains imprecise. Demyelination,
loss of oligodendrocytes and axonal damage were often
reported. Diffusion tensor imaging studies provided
indirect evidence for axonal damage and impaired
white matter integrity in WMH.28 Indeed, recent evi-
dence indicates that WMHs are rather heterogeneous,
perhaps reflecting different disease stages. Reduced
density of glia and vacuolation were observed in severe
WMH suggesting end stage disease.29 Autopsy MRI
studies also found oedema that suggests leakage of fluid
from an impaired blood–brain barrier (BBB) in and
around WMH.30 31 Although these ‘white’ lesions have
until now been treated as if they were all the same, dif-
ferent degrees of ‘whiteness’ might indicate different
‘stages of formation’—some very white WMHs are prob-
ably at the end stage of disease and irreversible once
demyelination or axonal damage has happened; some
perhaps less white lesions might be reversible if they are
mainly interstitial fluid (ISF) imbalances before perman-
ent tissue damage has occurred. These observations
remain to be confirmed in larger studies. These micro-
structural changes happen in WMH, and are also
present in normal appearing white matter (NAWM).32 33
The white matter integrity in NAWM declines with
increasing closeness to the edge of WMH32 and with
more severe WMH.34
Multiple mechanisms underlying WMH such as
incomplete infarct, chronic hypoperfusion and venous
collagenous have been proposed, but evidence for each
is limited. In a pathology study (n=15), no incomplete
infarct was found in WMH.29 Though many cross-
sectional studies have found low cerebral blood flow
(CBF) to be associated with higher WMH burden, the
causality between low CBF and WMH is unclear.35 A lon-
gitudinal study (n=575) showed that more severe base-
line WMH predated CBF decline over time rather than
falling CBF predating WMH progression.36 In a post-
mortem study, some non-inflammatory, periventricular
venulopathy was observed in periventricular WMH, sug-
gesting that venous collagenosis might cause tissue
damage by vasogenic oedema and impede ISF circula-
tion.31 However, this theory remains to be confirmed in
in vivo studies. Impaired BBB was noted in WMH areas
in autopsies,29 30 which was corroborated by studies
using cerebrospinal fluid (CSF)/plasma albumin ratio37
and MRI.38–41 It is hypothesised that the disrupted BBB
would result in leakage of fluid, plasma components and
cells and eventually lead to perivascular inflammation,
demyelination and gliosis. Indeed, the formation of
WMH is likely to be multifactorial. Hypoperfusion,
venous pathologies and BBB impairment might all play
critical roles in WMH initiation or progression and inter-
act with each other, but which one is the key initial
factor remains unknown.
Lacunes
The term ‘lacune’ was used by Fisher to describe a small
fluid cavity in the brain which he thought was a healed
lacunar infarct. Therefore, in CSVD research, it is very
common that terms like ‘lacunar infarction’, ‘lacunar
stroke’ and ‘silent brain infarct’ were used to refer to
the CSF-filled cavities on brain MRI or autopsy.42 In fact,
lacunes are not always ‘ischaemic’. They can also be the
residual lesion of a small haemorrhage43 (figure 3).
Also, it is common that many non-cavitated lacunar
ischaemic strokes were not counted as ‘lacunar infarcts’.
Therefore, in order to avoid more confusion, the term
‘lacune of presumed vascular origin’ was proposed to
replace ‘lacune’ and the term ‘lacunar infarct’ should
NOT be used to describe ‘lacunes’ any more.
Lacunes of presumed vascular origin are round or
ovoid, subcortical, fluid-filled cavities with a diameter of
3–15 mm. These can occur without any prior symptoms,
but can also result from a previous acute small subcor-
tical infarct or haemorrhage4 (figure 1). PVS could also
mimic lacunes when they are more than 3 mm in diam-
eter.44 Large PVS might have also been miscounted as
lacunes in many studies.42 Lacunes usually present as a
hypointense ‘hole’ on FLAIR surrounded by a hyperin-
tense rim which can help its differentiation from PVS.
However, the rim can be absent in some cases and PVS
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within extensive WMH areas may appear as if sur-
rounded by hyperintensities, so the insistence on a rim
to differentiate lacunes from PVS is not helpful in prac-
tice. Nonetheless, it is important to distinguish between
lacunes and PVS if possible, on size at least, because
they represent different pathologies as well as differ in
clinical associations and implications.
Although many lacunes might have lacked acute symp-
toms, when present in larger numbers they are associated
with dementia, cognitive impairment, gait disturbance and
increased risk of stroke.5 45 46 In the general elderly popu-
lation, the prevalence of lacunes ranges from 8% to 28%
(mean age=50–75 years).5 A systematic review suggests that
silent brain infarcts (another term sometimes used for
lacune) are more prevalent in the Asian than in the
non-Asian population.47 However, it is noteworthy that
most of these Asian studies were hospital-based, whereas
all non-Asian studies were community-based; therefore,
more relevant comparisons are needed to determine if
the prevalence of lacunes and other CSVD features does
differ between world regions and ethnic groups.
Perivascular spaces
PVS are the extension of subarachnoid spaces that sur-
round cerebral microvessels.48 They are fluid-filled
spaces that follow the course of a vessel through the
brain parenchyma.48 PVS are usually microscopic and
not detected on CT or conventional MRIs. When
enlarged, PVS are commonly seen as hyperintense on
T2 MRI, either punctuate with a diameter <3 mm if
imaged perpendicular to the course of the vessel, or
linear if imaged parallel to the course of the vessel49
(figure 1). PVS are most frequent in the inferior parts
of the basal ganglia and centrum semiovale but can also
occur in the brainstem. Though 3 mm has generally
been considered as the cut-off diameter for distinguish-
ing PVS from lacunes,44 occasional PVS could be larger
and even cause a mass effect.4 PVS usually do not have a
hyperintense rim on T2-weighted or FLAIR unless
passing through a WMH area, which can help the dis-
crimination between PVS and lacunes.
Whether PVS should be regarded as ‘lesions’ is still
controversial, as their clinical significance remains
Figure 3 Example of MRIs of a lacune from a haemorrhagic source (A,B), and from a lacunar infarct (C, D). D (the DWI) is from
the acute presentation (i.e. within a few days of the stroke), and C (the FlAIR) is weeks to months later when the lesion has
cavitated. DWI, diffusion-weighted imaging; FLAIR, fluid-attenuated inversion recovery; SWI, susceptibility-weighted imaging.
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unclear. Although a few PVS can be normal,50 numbers
of PVS increased with advancing age and other features
of CSVD.51–54 In some studies, more PVS were associated
with increased risk of dementia or worse cognitive func-
tion or hypertension.44 55 56 The mechanisms under-
lying enlarged PVS are not well understood. In normal
ageing and other neurological diseases like multiple
sclerosis, PVS are associated with inflammatory
markers.57 In CSVD, it might be a sign of impaired
BBB.39 There is also a hypothesis that visible PVS are
associated with a blockage of drainage of ISF,58 which
might be attributed to increased vessel stiffness, as arter-
ial pulsatility is thought to be a key driver of ISF drain-
age.59 They may also be a key conduit for drainage of
brain interstitial metabolic products that occurs during
sleep.60
Cerebral microbleeds
CMBs are regarded as small round and homogeneous
foci of hypointensity on T2-weighted (gradient echo)
MRI and susceptibility-weighted imaging (figure 1). In
the very few studies of radiological–pathological correl-
ation, perivascular hemosiderin-laden macrophages were
found to underlie most of the CMBs shown on MRI.
Other possible pathologies include old haematomas,
intact erythrocytes and, very rarely, vascular pseudocalci-
fication, microaneurysm and distended dissected
vessels.61 Lipofibrohyalinosis and amyloid angiopathy are
the most common vascular findings in relation to CMB.
These two vasculopathies are thought to have different
patterns of CMB distribution: CMBs in the basal ganglia,
thalamus, brainstem and cerebellum are typically attribu-
ted to lipofibrohyalinosis, whereas amyloid angiopathy is
more associated with lobar CMBs.62 However, some
studies suggest that there may be more overlap and
larger studies are awaited to confirm the specificity of
CMB distribution for particular pathologies.
Most CMBs are asymptomatic; they can be found in
healthy adults but are more often a marker of vascular
risk factor exposure or amyloid deposition.63 In addition
to its potential association with stroke, CMBs also con-
tribute to cognitive impairment and dementia, and to
transient neurological deficits.64 The prevalence of
CMBs detected in community-dwelling participants in
the Rotterdam Scan study (n=3979, mean age=60.3
years) and AGES-Reykjavik study (n=1962, mean age=76
years) was 11.1–15.3%65 66 and increased with age.66 In
patients with ischaemic stroke and non-traumatic intra-
cerebral haemorrhage, the prevalence of CMBs could
be as high as 33.5–67.5%.63 It seems that CMBs may be
more common in the Asian than in the non-Asian popu-
lation. However, the differences might be due to a
higher proportion of hypertensive patients recruited in
these Asian studies or more hospital-based than commu-
nity studies.
It is unclear whether CMBs increase the risk of haem-
orrhage in patients receiving antiplatelet or anticoagu-
lant or thrombolytic therapy and further discussion is
outside the ischaemic focus of this review. We refer the
reader to recent reviews on this topic63 67 and note that
randomised trials are needed to answer these questions.
Risk factors and causes of ‘silent’ CSVD
Increasing age is significantly associated with CSVD fea-
tures; thus, age has to be controlled for while interpret-
ing relevant studies. Modifiable risk factors including
hypertension, hypercholesterolaemia, smoking and dia-
betes mellitus are also thought to be key risk factors in
the pathogenesis of CSVD, particularly hypertension.
However, the relationship between these risk factors and
CSVD is complex. Lipohyalinosis, the typical vascular
changes of CSVD, has long been thought to result from
hypertension. The theory is supported by clinical evi-
dence showing that hypertension is more prevalent in
patients with WMH and that higher blood pressure was
associated with more severe WMH.68 A recent study
shows that vascular risk factors and large artery disease
explained only 2% of the variance in WMH, leaving
98% of the variance unexplained, providing further evi-
dence that WMHs are mostly non-atheromatous.69 This
finding may give a clue as to why risk factor modifica-
tions so far have very limited effects on preventing
WMH progression. Other important risk factors for
CSVD include other high-risk lifestyles: lack of exercise,
poor diet and smoking. High salt intake is associated
with more severe WMH through causing high blood
pressure, as well as by having direct effects on the endo-
thelium.70 Current smoking is also an independent pre-
dictor of WMH progression71 and is associated with a
high burden of combined CSVD features.72 Lack of
exercise is a risk factor for having more WMH in later
life, although it is not clear if active exercise pro-
grammes reduce WMH risk.73
CSVD as a ‘whole-brain disease’
Common small vessel pathologies and BBB impairment
were found in clinically evident and covert CSVD fea-
tures, suggesting that CSVD should be regarded as a
whole-brain disease rather than be treated separately as
individual conditions. Small penetrating vessels and the
endothelium, which forms the BBB, are diffuse in the
brain. Various studies also demonstrate that all these
CSVD features were associated with each other: patients
with small vessel stroke (TOAST classification) or
lacunar stroke (OCSP classification) had more WMH
than those who had other stroke subtypes;74 75 more
than 90% of incident lacunes appeared at the edge of
WMH or had a partial overlap with WMH in 365 patients
with Cerebral Autosomal-Dominant Arteriopathy with
Subcortical Infarcts and Leukoencephalopathy
(CADASIL);76 visible PVS were frequently seen in
patients with lacunar stroke, WMH and lacunes; CMBs
were also associated with WMH and lacunar stroke.63
When counting the presence of any CSVD as the total
CSVD score, patients with lacunar stroke had a
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significantly higher CSVD burden than those with cor-
tical stroke.72
Why do some CSVD lesions cause stroke while others
are ‘silent’? One explanation is the locations of lesions.
A study using probability mapping shows that lesions
presenting with stroke were predominantly located in or
near the primary motor and sensory tracts, whereas
silent lesions were mostly in the basal ganglia and
centrum semiovale away from these main tracts.77
Another explanation could be the levels of vessels where
the vascular pathologies happened. In general, dis-
rupted BBB would enable plasma fluid components and
blood cells to enter the vessel wall, leading to disintegra-
tion of the vessel wall and fibrin deposition. If this
happens at arterioles where there is smooth muscle, the
components deposited in the arteriolar wall could result
in dilation and narrowing of the vessel lumen and vessel
wall thickening, which would eventually precipitate
inflammation, platelet adhesion, luminal occlusion and
thus traditional infarct. However, at the capillary level
where there is no smooth muscle between the epithe-
lium and brain tissue, the leaky BBB would cause direct
damage in the tissue, such as oedema and demyelin-
ation in white matter tracts. Further studies to assess
changes over time in lesion development and symptoms
are required to find out the reasons.
CSVD as a ‘dynamic disease’
There is increasing evidence showing that CSVD is more
dynamic than originally thought. Lesions progress over
time and the long-term outcome and impact on brain
damage vary. Cavitation is not the only fate of acute
lacunar ischaemic stroke.78 An acute lacunar ischaemic
stroke can also disappear or resemble a WMH (figure 4).
In a prospective study (n=90), definite cavitation (ie, that
looked like a lacune) was only present in 20% of patients,
and was marginally associated with increasing time from
stroke onset to follow-up scans. A large proportion of
lacunar lesions remained looking like WMH. Thus, only
calculating cavitated lacunes could lead to a large under-
estimation of lacunar ischaemic stroke burden. Similarly,
WMH burden is likely to be overestimated without previ-
ous scans of index stroke lesions.
The evolution of WMH also varies. The single stron-
gest predictor of WMH progression is high baseline
WMH,79 80 with little progression in punctate WMH but
rapid progression in confluent WMHs.81 The Austrian
Stroke Prevention Study, a community-based study,
Figure 4 Long-term appearances of lacunar infarcts (arrows: old stroke lesion on the follow-up scans). DWI, diffusion-weighted
imaging; FLAIR, fluid-attenuated inversion recovery; WMH, white matter hyperintensity.
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reported WMH progression in about 18% of participants
with vascular risk factors.79 WMH can also cavitate to
take on the appearance of lacunes and they can also
disappear—these dynamic features are only now being
realised. Though early microstructural impairment
could be detected in NAWM contouring WMH, not all
NAWM will eventually develop into WMH.82 The level of
NAWM deterioration was also strongly associated with
WMH severity, regardless of distance from the WMH.32
The variance in long-term changes of CSVD lesions
might reflect different pathologies underlying the
similar appearance on imaging, for example, reversible
lacunar ischaemic stroke lesions versus those that cavi-
tated, or NAWM in patients with mild WMH versus in
extensive WMH. Serial imaging studies using advanced
techniques like cerebral vascular reactivity, BBB and CBF
imaging and use of higher fields, for example, 7 tesla
MRI might help differentiate these changes.83
Treatments for CSVD
Management of traditional risk factors is still the main
approach for treating or preventing CSVD, despite the
fact that most of these treatments have not yet shown
ideal effects on long-term outcome. Antihypertensive
treatment produced contradictory results: it reduced
WMH progression in some observational studies84 but
showed little or no effects in randomised controlled
trials.85 86 Although hypertension has been reported to
be highly associated with CSVD, other factors may be
involved or be influenced by genetic factors,87 yet more
evidences are required. Likewise, most lipid-lowering
treatment had neutral results in preventing WMH, like
pravastatin.88 Post hoc analysis of a 2-year follow-up study
from Hong Kong showed that statins might be able to
delay WMH progression in patients with severe baseline
WMH.89 Statins might also have other therapeutic
effects including anti-inflammatory and proendothelial
activities.90 Likewise, subgroup analysis of the VITAmins
TO Prevent Stroke (VITATOPS) MRI substudy shows
that vitamin B supplementation may reduce WMH pro-
gression in patients with severe baseline CSVD.91
Studies of treatment specifically targeting lacunar
stroke are limited.90 Apart from the SPS3 trial, there are
very few clinical trials of antiplatelets where the results
were reported by stroke subtype, and, except trials of
cilostazol92 93 which has weak antiplatelet effects,94 are
especially scarce in Asian populations. Although some
trials reported the proportion of lacunar stroke in their
study population, the diagnostic criteria varied consider-
ably and the results were not always reported by sub-
group. A systematic review of randomised trials found
that any single antiplatelet appeared beneficial for sec-
ondary prevention of lacunar stroke,95 but the SPS3 trial
showed that long-term dual antiplatelet treatment
doubled the risk of bleeding without reducing the risk of
stroke recurrence in patients with recent lacunar stroke.
Also, blood pressure lowering did not show significant
reduction in recurrent lacunar stroke in the SPS3 trial,
although it was consistent with a modest benefit.96
Prevention and treatment of CSVD in the future
should consider targeting the BBB, brain endothelium
and microvascular function. There are multiple poten-
tial endothelial targets, such as the nitric oxide/cyclic
guanylate monophosphate (cGMP) system and prosta-
cyclin/cyclic AMP (cAMP) system.90 Therefore, interven-
tions that could induce cAMP or cGMP or reduce their
degradation appear promising. There are several
licensed drugs that have these properties like some
nitric oxide donors and phosphodiesterases-5 inhibi-
tors,90 while others are still in development. More
experimental studies should be encouraged. However, in
the meantime, management of these traditional risk
factors according to guidelines should still be encour-
aged except to avoid long-term dual antiplatelet drugs.
In conclusion, CSVD is not just a collection of individual
brain lesions, but is both a ‘dynamic’ and ‘whole-brain’
disease. All CSVD subtypes might share some common
intrinsic CSVD aetiologies. Some pathological changes at
the early stage of the disease could be reversible, but will
gradually worsen and become irreversible as the damage
in vessels and tissues accumulates. Modification of trad-
itional risk factors and a healthy lifestyle are currently the
most important prophylactic and therapeutic approaches
for CSVD indefinitely and until more specific treatments
are available. Apart from the trials of cilostazol which have
mostly been conducted in China or Japan, in general,
large clinical trials of CSVD treatments targeting the Asian
population are lacking, especially in lacunar stroke.
Community-based studies of CSVD prevalence and pro-
gression are also needed to determine if prevalence genu-
inely differs in different world regions or ethnic groups.
Future studies in CSVDs should stratify by stroke subtype
and by MRI diagnosis and measure risk factors carefully.
Clinical trials and experimental studies targeting endothe-
lium and BBB integrity should be pursued.
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Growing evidence suggests that increased intracranial pulsatility is associated with cerebral
small vessel disease (SVD). We systematically reviewed papers that assessed intracranial
pulsatility in subjects with SVD. We included 27 cross-sectional studies (n=3356): 20 used
Doppler ultrasound and 7 used phase-contrast MRI. Most studies measured pulsatility in
the internal carotid or middle cerebral arteries (ICA, MCA), whereas few assessed veins or
cerebrospinal fluid (CSF). Methods to reduce bias and risk factor adjustment were poorly
reported. Substantial variation between studies in assessment of SVD and of pulsatility in-
dices precluded a formal meta-analysis. Eight studies compared pulsatility by SVD severity
(n=26–159, median = 74.5): arterial pulsatility index was generally higher in more severe
SVD (e.g. MCA: standardized mean difference = 3.24, 95% confidence interval [2.40, 4.07]),
although most did not match for age. Seventeen studies (n=9–700; median = 110) per-
formed regression or correlation analysis, of which most showed that increased pulsatility
was associated with SVD after adjustment for age. In conclusion, most studies support a
cross-sectional association between higher pulsatility in large intracranial arteries and SVD.
Future studies should minimize bias, adjust for potential confounders, include pulsatility in
veins and CSF, and examine longitudinal relationship between pulsatility and SVD. Agree-
ment on reliable measures of intracranial pulsatility would be helpful.
Introduction
Cerebral small vessel disease (SVD) is responsible for up to 45% of dementia and approximately 20% of
all stroke worldwide [1,2]. SVD is mainly diagnosed on brain imaging, based on various features such as
white matter hyperintensities (WMH), perivascular space (PVS), microbleeds, lacunes, and recent small
subcortical (lacunar) infarcts. Although each individual imaging feature might represent different under-
lying tissue changes, evidence from autopsy and clinical studies indicate that these features are all related
to pathologies in brain small vessels [2]. For example, though white matter changes could be seen in other
conditions such as multiple sclerosis, WMH of presumed vascular origin are the most typical and known
SVD changes. They are usually symmetrically and bilaterally distributed in subcortical areas, and various
theories have been proposed to explain the small vessel pathology and how this affects the brain [2].
Ageing and hypertension are important risk factors for SVD [3], both of which are associated with loss
of elasticity in the arterial walls. Growing evidence has shown a relationship between increased aortic
pulsatility and lacunar infarcts or WMH volume [4,5]. It is hypothesized that the stiffened vessel walls
would be less able to dampen the systemic arterial pressure pulse via the Windkessel effect, leading to
high pulsatility being transmitted into the brain and causing or exacerbating small vessel damage, such as
endothelial dysfunction and blood–brain barrier (BBB) impairment [6].
Cerebrovascular pulsatility is also an important driving force of the cerebrospinal fluid
(CSF)–interstitial fluid (ISF) exchange via the glymphatic system in the perivascular spaces, which
is essential for clearing metabolic and other waste products from the brain [7,8]. Altered pulsatility and
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abnormality in the PVS might cause or accelerate glymphatic dysfunction and aggregation of waste products such as
Aβ, other proteins or cell debris, which is related to age-related neurodegenerative diseases and SVD [8]. Thus, for
several reasons, increased intracranial pulsatility might be an important underlying mechanism of SVD. However, so
far very few clinical studies have assessed pulsatility directly in the intracranial vessels [9,10].
Doppler ultrasound and magnetic resonance imaging (MRI) are two main techniques that could measure intracra-
nial pulsatility. Doppler ultrasound measures real-time blood flow velocity in the large arteries, mainly internal carotid
arteries (ICA) and middle cerebral arteries (MCA). Pulsatility is generally calculated using Gosling’s equation (pul-
satility index, PI = (peak systolic velocity − peak diastolic velocity)/mean velocity)). Phase-contrast MRI can quantify
fluid velocity and flow in the intracranial arteries, veins, and CSF. It has mostly been used in disorders such as hydro-
cephalus that present with abnormal CSF dynamics [11] with few studies in SVD. Some MRI studies used a similar
equation (flow was used instead of velocity) to calculate the pulsatility in the vessels, but indices reported for CSF pul-
satility vary [9,10]. It is unclear which measures are most relevant and reliable for quantifying intracranial pulsatility
in patients with SVD.
Furthermore it is unclear if high pulsatility and SVD were both simply the result of exposure to vascular risk
factors, since some studies did not adjust for age or important risk factors when assessing the relationship between
intracranial pulsatility and SVD [9]. Also, WMH are commonly used by studies to represent SVD burden [12-14],
and it is unknown whether high pulsatility was also related to other features of SVD, such as lacunar stroke or PVS.
In order to provide a complete summary of all knowledge to date on intracranial pulsatility in SVD patients, we
systematically reviewed papers that measured cerebral pulsatility in SVD with a view to performing a meta-analysis.
We aimed to determine if there was an association between intracranial pulsatility and SVD, the magnitude of any
association, whether pulsatility predicted SVD progression longitudinally, and if any individual SVD features were
more strongly associated with pulsatility than others.
Methods
We performed this review according to the MOOSE guidelines for meta-analysis of observational studies [15]. We
conducted a literature search of Ovid MEDLINE and Embase from 1946 up to April 2017 using the Ovid Web Gate-
way. We searched terms related to pulsatility and SVD in all contents of the papers using the strategy: “Pulsatility”
or “Resistance” or “Velocity” or “cerebrospinal fluid pulsatility” or “Phase-contrast MRI” and “Cerebral small vessel
disease” or “White matter hyperintensities” or “Leukoaraiosis”. English and non-English literatures were sought. Ad-
ditional records were identified by hand from relevant reviews, primary papers, and from the authors’ publication
lists. We defined SVD features according to the STRIVE Guideline [16].
Eligibility criteria
We included papers that reported primary results of studies that fulfilled all the following criteria: (1) recruited par-
ticipants with SVD features; (2) assessed resting-state intracranial pulsatility (including ICA) using any imaging tech-
nique; (3) assessed the relationship between intracranial pulsatility and SVD. We only included studies that focused
on sporadic SVD in this review as the mechanisms for hereditary SVDs might differ. We excluded review papers,
abstracts, and papers that used pharmacological, CO2 or other stimulus without providing pre-stimulus data.
Data extraction
We extracted data on participant characteristics, study design, MRI or Doppler technicalities, location, and type of
pulsatility indices assessed. For studies that compared pulsatility between groups and reported means and standard
deviations, we extracted the results of the comparisons from text or tables where available, or from graphs where
necessary; for those that performed association analysis such as correlation or regression models, we extracted the
statistical methods, coefficients, P values, and confounding factors or co-variates (if any) that were adjusted for. For
studies that performed both non-adjusted and adjusted analysis, we only included the adjusted results. We assessed
the study quality using a checklist that includes factors such as study population and methods for bias controlling
(Supplementary Table S1).
Statistical analysis
We displayed the results of comparisons between groups using forest plots in the Cochrane Collaboration’s Review
Manager (Revman Version 5.3) and used standardised mean difference (SMD) to represent the difference between
groups. We did not include data from studies that did not provide standard deviations (s.d.), because the SMD is ines-
timable without s.d.. In this review, we were not able to perform robust meta-analyses because of the limited data and
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Figure 1. PRISMA flow diagram of literature search and its results
the large heterogeneity in study population and pulsatility measures. Therefore, in the forest plot we did not calculate
overall effect sizes. For studies that divided patients into more than two grades of WMH severity, we combined the
means and s.d.s of PI from patients who had similar severity of SVD to create a single pair-wise comparison using for-
mulae from the Cochrane handbook (Supplementary Equation S1) [17]. For example, we created new groups “mild
WMHs” by combining groups of Fazekas score 0 to 1, and “severe WMHs” from Fazekas score 2 to 3.
Results
The search strategy identified 518 papers, of which 48 were potentially eligible and 27 were ultimately selected for
further review (Figure 1). We excluded reviews (3), drug trials without providing baseline information on pulsatility
and SVD (2), hereditary SVD study or non-relevant analysis (8), studies that used stimulus only (2) or did not assess
intracranial pulsatility (6). One MRI study compared CSF pulsatility between patients with late-life depression and
age-matched healthy volunteers, but we included the results in the forest plot because patients had higher WMH
burden than the healthy volunteers and late-onset depression is associated with SVD [18].
Characteristics of included studies
Twenty-seven studies (n=3356) were included, of which 20 used ultrasound [12,14,19-36] and 7 used MRI to measure
pulsatility [9,10,13,18,37-39], 26/27 were cross-sectional and one was a clinical trial of cilostazol [35] from which we
only extracted the data obtained at baseline.
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Figure 2. Regions of interest for flow measurement used in phase-contrast MRI studies included in this review.
*Anders Wåhlin et al. [39] selected the vertebral arteries instead of the basilar artery.
Doppler ultrasound studies
Table 1 summarises patient characteristics from 20 ultrasound studies (n=2935) with sample sizes ranging from 9 to
700 (median = 107). Fourteen used WMH (if MRI used for structural brain imaging) or white matter hypoattenuation
(if CT used) to represent SVD burden. Two studies included patients with stroke: one compared pulsatility between
lacunar and non-lacunar ischaemic stroke [25], and one compared pulsatility between patients with lacunar stroke
(according to Trial of ORG 1072 in Acute Stroke Treatment (TOAST) classification) and age- and sex-matched healthy
controls [32]. One study included patients with multi-infarct dementia [22] and one recruited patients with cerebral
amyloid angiopathy (CAA) [31] (Table 1).
Three studies assessed pulsatility in the ICA (cervical), seventeen in the MCA, one in the basilar artery, one in
the posterior cerebral artery (PCA), and one in the central retinal artery. Most studies calculated PI using Gosling’s
equation. One study measured brain tissue pulsatile movement [20].
MRI studies
Patient characteristics and scanner information of seven MRI studies (n=421, range 35–101, median = 51) are shown
in Table 2. Three studies recruited patients with dementia or cognitive impairment, including idiopathic dementia
[9], Alzheimer’s disease [13], vascular dementia [13], and mild cognitive impairment [37]. Only one reported the
diagnosis criteria for Alzheimer’s disease and vascular dementia [13]. One study recruited patients with late onset
major depressive disorder [18]. Three studies recruited healthy volunteers (age range: 43–82, 18–75, and 62–82 years)
[10,38,39] (Table 2).
All seven studies used phase-contrast MRI. Four studies used 1.5 Tesla and three used 3 Tesla scanners. All
studies used retrospective gated phase-contrast MRI: four used peripheral pulse- and two used electrocardiogram
(ECG)-gating; four studies reported the numbers of time points measured per cardiac cycle, among which three used
32 whereas one used 16 time points (Table 2).
There were large differences between studies as to where flow was measured. Figure 2 shows the regions of inter-
ests used in these studies. Six included the ICA(s) [9,10,13,37-39]; in posterior circulation five chose the basilar artery
[9,10,13,37,38] and one selected the vertebral arteries [39]; four studied pulsatility in the venous sinuses [9,13,37,38];
six measured CSF flow, among which one selected the cervical subarachnoid spaces [39], one selected tentorial in-
cisura [13], and four measured the cerebral aqueduct [10,18,37,38]. In total, three studies measured flow or pulsatility
across the cerebral arteries, veins, and the CSF system concurrently [13,18,37] (Figure 2).
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Table 1 Patient characteristics of ultrasound studies
First author Year Subjects/Disease Sample size Group Age +− s.d.(years) Vessels of interest
Jordi Sanahuja [30] 2016 Type 2 diabetes 202 Higher SVD score (n=21) MCA
Lower SVD score (n=181)
Oscar H. Del Brutto
[33]
2015 Community 70 Mild WMH (n=42) 72.2 +− 5.5 MCA, vertebral artery
77.4 +− 7.34
Abbas Ghorbani [34] 2015 Patients who had SVD
on imaging
104 Patients who had WMH or
lacunar infarct on MRI
68.4 MCA
Patients who had no lesion
on MRI
62.6
Monika Turk [21] 2014 Leukoraiosis 96 Leukoaraiosis (n=52) 54.9 +− 8.3 ICA





2014 Lothian birth cohort
1936
700 – 70 ICA




2014 Patients who visited
neurosonology lab
439 – 63.47 +− 14.94 MCA
Sushmita Purkayastha
[28]
2014 Patients with vascular
risk factors
48 – 75+−7 MCA
Sang Won Han [35] 2014 Lacunar stroke 130 – 64.7 MCA
Alastain J.S. Webb
[27]
2012 TIA or minor stroke 110 Fazekas 3 (n=25) 74.9 +− 7.9 MCA
Fazekas 2 (n=24) 68.5 +− 11
Fazekas 1 (n=21) 66.5 +− 12
Fazekas 0 (n=30) 53 +− 15
Vincent Mok [26] 2012 Community 205 With severe WMH 74 +− 6 MCA
without severe WMH 69 +− 6
Ioannis Heliopoulos
[14]
2012 Hypertensive patients 52 – 71.4 +− 4.5 MCA
Kerstin Bettermann
[36]
2012 Patients with WMH 26 Patients with WMH 63.5 +− 11.25 MCA
Control without WMH 55.07 +− 7.91
Iria Rodriguez [25] 2010 Ischaemic stroke 186 Lacunar (n=35) 69.7 +− 10.8 MCA
Non-lacunar (n=151) 71.6 +− 8.1
Tomotaka Tanaka [19] 2009 Diabetic patients 122 Hypertensive (n=43) 66.9 +− 9.8 ICA
Non-hypertensive (n=79) 62.0 +− 11.0
Eric E. Smith [31] 2008 CAA 20 CAA (n=11) 73.5 +− 7.4 Basilar artery
Healthy volunteers (n=9) 70.9 +− 7.9
Chelsea S. Kidwell [23] 2001 Retrospective review in
patients who had both
TCD and MRI
55 – 62 (range 28–98) MCA
Rosa M.
Sánchez-Pérez [24]





116 – 74.44 +− 6.35 MCA
Masahiko Hiroki [32] 2002 Stroke 167 Small vessel disease (TOAST)
(n=103)








Abbreviations: AD, Alzheimer’s disease; CAA, cerebral amyloid angiopathy; ICA, internal carotid artery; MCA, middle cerebral artery; MRI, magnetic
resonance imaging; SVD, small vessel disease; TCD, transcranial Doppler; TIA, transient ischaemic attack; WMH: white matter hyperintensities.
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Table 2 Patient characteristics and scanner information of MRI studies
First author Year
Subjects/
Disease Sample size Groups Age (years)
Scanner
and




























































































































Young (n=19) 27.5 +− 4.4
Continued over
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Table 2 Patient characteristics and scanner information of MRI studies (Continued)
First author Year
Subjects/
Disease Sample size Groups Age (years)
Scanner
and





























Abbreviations: AD, Alzheimer’s disease; CSF, cerebrospinal fluid; ECG, electrocardiogram; TE, Echo time; TR, repetition time; Venc, velocity encoding
parameter; WMH, white matter hyperintensities.
Quality assessment
The average quality score of 27 studies was 6.85/10. 26/27 studies were prospective. However, seven studies did not
report participants’ demographic information or general health condition. Only about half of the studies adjusted or
matched for risk factors (15/27) or reported the expertise of observers of structural MRI (15/27). Less than half of the
studies reported dropout (12/27) or use of blinding in structural image analysis (11/27) (Supplementary Figure S1).
Result of comparisons of pulsatility measures
Doppler ultrasound studies
Three studies (n=356, median = 96) compared arterial PI between patients with different WMH severities. One
study examined the ICA, one chose MCA, and one chose both MCA and basilar artery. PI was generally higher in
patients with more severe WMH in the ICA [21], MCA [22,26], and the basilar artery [22] (e.g. in MCA: SMD = 3.24,
95% confidence interval (CI) [2.4, 4.07]), although the result for ICA did not reach statistical significance (SMD =
0.38, 95% CI [−0.02, 0.79] [21]). 2/3 of the studies were age-matched [21,22], one of which also matched for gender
[21] (Figure 3A).
Two studies looked at other SVD features. One study (n=167) showed that patients with lacunar stroke (TOAST)
had higher PI in the central retinal artery compared with age- and sex-matched heathy controls (SMD = 0.35, 95%
CI [0.03, 0.66]) [32] (Figure 3B). One study of CAA (n=20) found that patients with CAA had a significantly higher
PI in PCA than non-age-matched healthy elderly controls (SMD = 1.07, 95% CI [0.12, 2.03]) [31] (Figure 3C).
MRI studies
Three phase-contrast MRI studies (n=124, median = 50) performed comparisons of cerebrovascular or CSF pulsatil-
ity between patients with different WMH severities. None of these studies corrected for age. The indices for pulsatility
included PI, stroke volume, and delay between waveform peaks. The trend in all the comparisons is that higher arte-
rial or venous PI (e.g. arterial PI: SMD = 0.93, 95% CI [0.40, 1.47] [9]), larger arterial or venous or CSF stroke volume
(e.g. CSF stroke volume: SMD = 1.58, 95% CI [0.64, 2.52] [13]) was associated with more WMH, although some
results did not reach a statistical significance (e.g. venous PI: SMD = 0.18, 95% CI [−0.33, 0.69] [9]) (Figure 3D).
Two studies (n=110) calculated the delay between waveform systolic peaks. There was no significant difference in
arterial-venous (n=60, SMD = 0.95% CI [−0.51, 0.51]) [13] or arterial-aqueduct peak delays (n=51, SMD = 0.49,
95% CI [−0.07, 1.06]) [18] between different severities of WMH (Figure 3E).
Results of studies that performed regression or correlation analysis
Table 3 summarises studies that performed regression or correlation analysis, including 13 Doppler ultrasound
(n=9–700, median = 116) and three MRI studies (n=35–100, median = 37). 14/16 studies adjusted for co-variates,
of which 12 included age. No studies adjusted for blood pressure although five considered history of hypertension.
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Figure 3. Forest plots of studies that compared pulsatility (using Doppler ultrasound or MRI) between SVD and control
groups; *indicates studies that matched for age
(A–C): Pulsatility was measured by Doppler ultrasound. (A) Comparison of vascular pulsatility between patients with severe and mild
white matter hyperintensities (WMH). (B) Comparison of central retinal artery pulsatility between patients with SVD-stroke (TOAST
classification) and healthy volunteers. (C) Comparison of posterior cerebral artery pulsatility between patients with cerebral amyloid
angiopathy (CAA) and healthy volunteers. (D and E): Pulsatility was measured by phase-contrast MRI. (D) Comparison of vascular
or CSF pulsatility between patients with severe and mild WMH. (E) Comparison of flow waveform peak delays between patients
with severe and mild WMH. It is worth noting that, in forest plot (E), shorter peak delay is suggested by the authors to represent
higher intracranial stiffness.
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2014 700 Multiple variable regression WMH volume ∼
ICA PI




2009 122 Multivariate regression analysis WMH volume ∼
ICA PI
not shown >0.05 Age
MCA
Oscar H. Del Brutto
[33]
2015 70 Generalised linear model WMH severity ∼
MCA PI
β = 0.065, 95%
CI[−0.084, 0.177 ]











2014 439 Multiple ordinal regression DWMH score ∼
MCA PI
OR 17.994, 95% CI
[6.875, 47.11]








PVH score ∼ MCA
PI





OR 11.844, 95% CI
[4.486, 31.268]
<0.001





2014 48 Multivariable linear regression WMH/ICV ∼ MCA
PI
OR 1.25, 95% CI
[0.14, 2.09]
<0.01 Age, sex, race, DM,
HBp
Alastain J. S. Webb
[27]
2012 110 Ordinal regression WMH score ∼
MCA PI
β = 4.33 P=0.037 Age, sex, physiology
Vincent Mok [26] 2012 159* Multiple logistic regression Severe WMH (vs
without severe
WMH) ∼ MCA PI






2012 52 Multivariable regression WMH score ∼
MCA PI
β = 0.262 P=0.025 Age, sex, BMI, HBp,
DM, hyperlipidaemia,
smoking
Iria Rodriguez [25] 2010 186 Multivariate logistic analysis Lacunar infarct (vs
non-lacunar) ∼
MCA PI







2003 116 Multiple linear regression Leukoaraiosis
severity score ∼
MCA PI
β = −0.108 0.353 Age, sex, vascular
risk factors, cognitive
performance, blood
flow velocity in MCA
Chelsea S. Kidwell
[23]
2001 55 Multivariate regression WMH score ∼
MCA PI










ρ = −0.86 <0.001 No
WMH volume ∼
Mean BTD
ρ = −0.72 <0.001 No
MRI studies
Clive B. Beggs [10] 2016 101 Multiple linear regression total WMH volume
∼ CSF peak
negative velocity
β = −124.903 P=0.041 Age
Anders Wåhlin [39] 2014 37 Ordinary linear regression Total brain volume
∼ arterial PI
β = −0.42 P<0.01 Age, ICV, arterial net
flow
Total brain volume
∼ CSF flow volume
pulsatility
β = −0.44 P<0.01 Age, ICV, arterial net
flow
Continued over
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not shown P>0.05 Age
WMH volume ∼ PI
in arteries or
venous sinuses
not shown P>0.05 Age
Abbreviations: BMI, body mass index; BTD, brain tissue displacement; CI, confidence interval; CSF, cerebrospinal fluid; DM, diabetes mellitus; DWI,
diffusion-weighted imaging; DWMH, deep white matter hyperintensities; HBp, hypertension; ICA, internal carotid artery; ICV, intracranial volume; IMT,
intima-media thickness; MCA, middle cerebral artery; OR, odds ratio; PI, pulsatility index; PVH, periventricular white matter hyperintensities; SD, standard
deviation; WMH, white matter hyperintensities.
*The original sample size of this study [26] was 205 but only 159 participants were included in the analysis.
Eight studies used visual rating scores to assess SVD burden, whereas the other eight measured WMH or brain vol-
ume, among which one used manual ROIs [38], one used semi-automated [10] and six used automated masks. Only
2/6 of the papers using automated masks reported that the masks were manually checked [35,39].
Doppler ultrasound studies
Two studies measured ICA and eleven measured MCA. Most studies (apart from two [19,24]) reported a signifi-
cant association between increased ICA or MCA PI and more WMH after adjustment for age. One (n=186) found
that higher MCA PI was predictive of having a lacunar infarct (vs other types of infarct) [25]. One paper (n=159)
mentioned that they did not find significant associations between MCA PI and microbleeds or lacunes, although no
detailed information was provided [26].
One study (n=9) found that higher brain tissue displacement, which was used for representing brain tissue pul-
satility, was significantly correlated with larger WMH volume, however it did not adjust for any co-variates [20] (Table
3).
MRI studies
All three MRI studies adjusted for age. Two assessed WMH volume showing that increased WMH volume was sig-
nificantly associated with higher CSF systolic peak velocity in one study (n=101, β = − 124.903, P=0.041) [10], but
not with arterial or venous pulsatility (pulse amplitude, pulse width or PI) in the other (n=35) [38].
One study (n=37) found that increased arterial PI and cervical CSF pulsatility were associated with smaller brain
volume in healthy volunteers [39] (Table 3).
Discussion
We identified 27 studies that assessed intracranial pulsatility in relation to SVD features including 3356 subjects. Most
studies found a significant association between increased intracranial pulsatility and SVD. However, these studies
showed considerable heterogeneity with regard to participants’ clinical characteristics, adjustment for co-variates,
image acquisitions and processing, vessels or regions of interest studied, and pulsatility measures used. About half
of the studies gave little detail on control of bias, such as use of blinding. We were not able to perform a formal
meta-analyse due to the substantial heterogeneities and limited data, although we were able to calculate summary
statistics for WMH and pulsatility for some studies.
The limitations of the literature include that SVD features differed or were assessed differently across studies. Most
studies used WMH volume or semi-quantitative score to represent SVD burden. Only half of the papers reported the
expertise of the observers doing the SVD rating. Semi-quantitative scales and volumes of WMH were shown to be
closely correlated and nearly equivalent in estimating WMH burden [40,41]. However, volumetric methods might
be more sensitive in detecting subtle WMH differences [42] and may require smaller sample sizes in longitudinal
studies [43], but are more difficult to undertake and require more resources than visual rating in a large-scale study
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with follow-ups. Many studies used automated approaches to measure WMH volume but very few reported whether
the WMH masks were manually checked, but failure to check increases errors. So far there is no automated method
that can identify WMH without any manual input [44]. Two studies used recent small subcortical (lacunar) ischaemic
stroke as the SVD feature: one referred to subcortical infarct on imaging whereas one used the definition of “small
vessel disease” in the TOAST classification. Although there is overlap between the two definitions, they are different:
“small vessel disease” in TOAST involves clinical features and consideration of vascular risk factors and does not
necessarily need imaging evidence [45]. Studies that assessed pulsatility in relation to other SVD features including
lacunes [26], microbleeds [26], or atrophy [39] were scant and lacked details of analysis. So far no clinical studies
have reported the relationship between cerebrovascular pulsatility and PVS visibility. Enlarged PVS is one of the
most consistent imaging findings of SVD, but the underlying pathophysiology remains unknown. Increasing evidence
suggest that altered cerebrovascular pulsatility might affect the ISF–CSF exchange and impede the clearance of toxic
solutes through the perivascular glymphatic system, which might possibly result in enlarged PVS [7,46]. Thus future
SVD studies should consider including PVS especially when investigating the role of cerebrovascular pulsatility in
SVD.
A third of papers provided little detail on patients’ demographic or health characteristics. Age and blood pressure
are thought to influence intracranial pulsatility [47,48] and are also important risk factors of SVD [2] and should be
adjusted for in relevant studies. Most studies that performed correlation or regression analysis have adjusted for age,
but in studies that performed comparisons of WMH, patients with more severe WMH were significantly older than
those with mild WMH [9,27,36,37]. Blood pressure also changes with age, but very few studies accounted for blood
pressure in their analyses although some included history of hypertension as a co-variate.
Indices used to represent pulsatility also varied. Most studies focused on the ICA or MCA. When calculating vascu-
lar PI, both MRI and ultrasound studies applied Gosling’s equation. However, some MRI scanners only collected flow
values at 16 time points in the cardiac cycle [18,37], meaning that low temporal resolution might affect the accuracy
of the PI value as the peak flow might have been missed. In studies that used Doppler ultrasound, another source
of variability is inherent when using the technique, including the dependency on the skills of ultrasound technicians
and the positioning of the probe. Although the reliability of Gosling’s PI in representing vascular resistance has been
questioned [49], there is evidence that ICA and MCA PI are well correlated with cerebrovascular reactivity measured
using CO2 stimulus or invasive monitoring [50,51]. One study used a novel ultrasound technique to measure brain
tissue pulsatile movement, but it only had nine participants and the validity still needs to be tested [20].
Apart from including large arteries, four MRI studies also considered pulsatility in veins and CSF. As the volume
inside the cranium is fixed, the venous system and CSF are also important components in compensating for arterial
pressure [52]. Two studies calculated venous PI [9,38] and one measured venous stroke volume [13]. CSF pulsatility
assessment varied in terms of both locations and indices. There is so far no accepted definition of pulsatility in CSF,
although stroke volume seemed to be the most used. Future studies need to test the reliability of different measures and
also select ones that provide more relevant measurements about pulsatility. In addition, one MRI study measured the
delay between arterial peak and venous sinus peak [13] whereas another looked at the delay between arterial blood
and aqueduct CSF pulsations [18]. These two measures also might be non-comparable, as it is suggested that CSF
pulse through the aqueduct is associated with capillary expansion whereas the venous pulse at neck level relates more
directly to the arterial expansion [52]. So far no studies have measured pulsatility in vessels more downstream than
MCA or PCA due to the limitations of the methodology, such as the spatial resolution or the sequences of the MRI
scanner. Future SVD studies could consider techniques such as 4D phase-contrast MRI or 7-T MRI which enables
flow assessment in multiple vessels including perforating arteries [53,54], or blood-oxygenation-level-dependent MRI
or ultra-fast magnetic resonance encephalography which could measure pulsatility in brain tissues [55,56].
Despite these heterogeneities, in general, most cross-sectional studies found that arterial or venous pulsatility was
associated with worse SVD, although the relationship could be confounded by risk factors, particularly age and blood
pressure. For ICA, one community based-study (n=700) with all participants aged 70 years that adjusted for age and
other medical co-variates, found increased ICA PI to be independently associated with larger WMH volume [12],
whereas in another study of diabetic patients (n=122) the significance of the association disappeared after adjustment
for age [19]. The relationship between increased MCA PI and WMH or lacunar infarct was found in most studies after
adjustment for confounding factors. We are unable to draw conclusions on the relationship between CSF pulsatility
and WMH because of different indices and locations used by each study, but the trend seems to be that larger CSF
stroke volume is related to more WMH. It was also impossible to conclude if any specific SVD features are more
associated with pulsatility due to the very limited data on any features other than WMH.
This is the first paper to comprehensively summarize studies that measured intracranial pulsatility in relation to
SVD. The strengths included a systematic search including papers in non-English languages and a careful assessment
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of all included studies. However, we were not able to perform a meta-analysis due to many sources of heterogeneity,
or to pool the results of association analyses as regression analyses were performed differently in each study.
In conclusion, most of the data support a cross-sectional association between SVD and higher pulsatility in large in-
tracranial arteries such as MCA and ICA, although whether a specific SVD feature is more related to high intracranial
pulsatility remains unknown, and it is not known if high pulsatility leads to more WMH or the opposite. Therefore,
methodologically robust longitudinal studies are required to help establish cause and effect, such as measuring both
WMH and intracranial pulsatility at baseline and follow-up. The sample size and follow-up duration of the longitudi-
nal study might partly depend on the baseline WMH burden and which method of WMH estimation is used (visual
rating or volumetric quantification), since baseline WMH burden is an important predictor for WMH progression
and should be accounted for in the study design and analysis [57]. Ultimately, randomized clinical trials of agents
to reduce vessel stiffness will be required to determine if reduction in pulsatility (as a measure of stiffness) prevents
SVD progression. Doppler ultrasound might be affordable and easy to use when measuring pulsatility, but it has only
limited access to individual vessels and requires experienced technicians. MRI techniques enable assessment of pul-
satility in multiple and smaller vessels and in different types of brain tissues, which therefore should be encouraged in
future studies. Agreement on reliable measures of intracranial pulsatility is also needed to allow for better comparison
between studies, especially for CSF pulsatility. Future studies should clearly define participants’ clinical features, use
blinding, improve expertise in SVD assessment, and adjust for relevant co-variates.
Clinical perspectives
• Increasing evidence suggest that high intracranial pulsatility might be an underlying mechanism of
small vessel disease (SVD).
• Most studies support a cross-sectional association between higher pulsatility in large intracranial
arteries and white matter hyperintensities, but there are substantial variations between studies in
pulsatility indices, and there is lack of longitudinal data and studies on other important SVD features
such as perivascular spaces.
• Our results suggest that increased intracranial pulsatility might play an important role in the patho-
physiology of SVD. However, future studies should minimize bias, adjust for potential confounders,
include pulsatility in veins and CSF, and examine longitudinal relationship between pulsatility and
SVD.
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Cerebrovascular reactivity measurement
in cerebral small vessel disease: Rationale
and reproducibility of a protocol for MRI
acquisition and image processing
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Abstract
Background: Impaired autoregulation may contribute to the pathogenesis of cerebral small vessel disease. Reliable
protocols for measuring microvascular reactivity are required to test this hypothesis and for providing secondary
endpoints in clinical trials.
Aims: To develop and assess a protocol for acquisition and processing of cerebrovascular reactivity by MRI, in subcor-
tical tissue of patients with small vessel disease and minor stroke.
Methods: We recruited 15 healthy volunteers, testing paradigms using 1- and 3-min 6% CO2 challenges with repeat
scanning, and 15 patients with history of minor stroke. We developed a protocol to measure cerebrovascular reactivity
and delay times, assessing tolerability and reproducibility in grey and white matter areas.
Results: The 3-min paradigm yielded more reproducible data than the 1-min paradigm (CV respectively: 7.9–15.4% and
11.7–70.2% for cerebrovascular reactivity in grey matter), and was less reproducible in white matter (16.1–24.4%
and 27.5–141.0%). Tolerability was similar for the two paradigms, but mean cerebrovascular reactivity and cere-
brovascular reactivity delay were significantly higher for the 3-min paradigm in most regions. Patient tolerability
was high with no evidence of greater failure rate (1/15 patients vs. 2/15 volunteers withdrew at the first visit).
Grey matter cerebrovascular reactivity was lower in patients than in volunteers (0.110–0.234 vs. 0.172–0.313%/mmHg;
p< 0.05 in 6/8 regions), as was the white matter cerebrovascular reactivity delay (16.2–43.9 vs. 31.1–47.9 s; p< 0.05 in
4/8 regions).
Conclusions: An effective and well-tolerated protocol for measurement of cerebrovascular reactivity was developed
for use in ongoing and future trials to investigate small vessel disease pathophysiology and to measure treatment effects.
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Introduction
Cerebral small vessel disease (SVD) accounts for 20–
25% of strokes and increases the risk of cognitive
impairment, disability, and dementia. The pathogenesis
is poorly understood but there is evidence of a role for
increased vessel stiffness;1,2 it is hypothesized that
affected arterioles do not vasodilate efficiently in
response to demand for increased blood flow, leading
to secondary ischemic damage.3 Impaired cerebrovas-
cular reactivity (CVR) has been reported in Alzheimer’s
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dementia4 and cerebral amyloid angiopathy.5 As a
result, there is growing interest in endothelial dysfunc-
tion as a therapeutic target for treating SVD and clin-
ical trials of licensed drugs with relevant modes of
action (e.g. Cilostazol and isosorbide mononitrate;
https://clinicaltrials.gov/ct2/show/NCT02481323) and
antihypertensive drugs have recently commenced at
our center and elsewhere.
Clinically feasible and reliable non-invasive methods
for assessing microvessel reactivity would provide
mechanistic insight and secondary endpoints in trials
of drugs to prevent and reverse SVD. Transcranial
Doppler ultrasound combined with a hypercapnic or
pharmacologic challenge is well-established, and
has been used to show reduced CVR in age-matched
subjects with white matter hyperintensities (WMH)
and similar vascular risk factors,6 but only provides
information on blood flow in a chosen large artery.
In contrast, MRI permits CVR measurement through-
out the brain using blood oxygenation level dependent
(BOLD) imaging or arterial spin labelling (ASL)
in response to a respiratory challenge. However,
although CVR MRI has been widely used to
study large artery diseases such as Moyamoya and car-
otid stenosis,7,8 the technique has infrequently been
applied in the study of SVD.9–14 Although the aims,
methods, and findings of these studies were varied,
Uh et al.14 reported a reduction in CVR both
in WMH compared with normal-appearing WM
(NAWM) and in the NAWM of subjects with greater
WMH burden. This suggests a potentially valuable
role for CVR measurement as a secondary endpoint
in clinical trials of drugs for SVD prevention and
reversal.
The aim of our work was to develop and pilot a
robust, reliable, and well-tolerated protocol for repro-
ducible and tolerable measurement of CVR in patients
presenting with minor ischemic stroke, with emphasis
on measurements in subcortical regions of the brain.
The minor stroke population allows both assessment
of CVR in relation to stroke etiology (SVD versus
large artery disease) and CVR in relation to specific
SVD radiological features, which while more common
in SVD stroke are prevalent in stroke patients
regardless of stroke etiology.15,16 We tested two
different hypercapnia paradigms with BOLD MRI,
with repeat scanning to measure reproducibility,
and recorded tolerability and symptoms associated
with the procedures. In addition, we developed
an image analysis protocol for measuring CVR in
multiple grey matter (GM) and white matter (WM)
brain areas relevant to SVD, including subcortical
GM, deep WM, and periventricular regions, deriving




We recruited healthy volunteers, who were asked to
attend two CVR scanning sessions, and patients with
a history of minor stroke, who were invited to a single
scanning session. The study was conducted following
Research Ethics Committee approvals (ref. 14/HV/
0001 and 14/EM/1126) and according to the principles
expressed in the Declaration of Helsinki. All subjects
gave written informed consent.
Healthy volunteers were recruited from the sur-
rounding area, excluding any potential participants
having cardiovascular or respiratory illness, hyperten-
sion, migraine, anxiety disorders, and panic attacks; we
also excluded those with a known family history of
intracranial aneurysm, subarachnoid hemorrhage,
arteriovenous malformation as well as those with
contraindications to MRI.
Patients were recruited from the in- and out-patient
stroke service as described previously.17,18 We recruited
patients presenting with a new clinical diagnosis of
minor ischemic stroke, i.e. that was non-disabling,
and also from our register of patients with a clinical
diagnosis of minor non-disabling ischemic stroke in
the past five years. ‘‘Non-disabling’’ was defined as
not requiring assistance in activities of daily living.
We included those with diabetes, hypertension, and
other vascular risk factors as long as these were well
controlled. We excluded patients with unstable hyper-
tension, unstable diabetes, other neurological disorders,
significant cardiac or respiratory illness or other life
threatening medical conditions. We also excluded
patients unable to give consent, with contraindications
to MRI, and who had hemorrhagic stroke (but not
hemorrhagic transformation of an infarct).
Participants were administered CO2 in medical air at
a concentration of 6% via a disposable anesthetic face
mask (Intersurgical, Wokingham, UK) for a test period
prior to entering the scanner in order to familiarize
them with the respiratory challenge and related equip-
ment, and to monitor them for anxiety and other symp-
toms. Anecdotally, it has been reported that a 4% CO2
gas mixture is noticeably better tolerated compared
with 6% CO2, though a smaller vasodilatory effect is
expected. Therefore, we used simple randomization to
allocate the first 10 patients to either 4% CO2 or 6%
CO2 to assess the impact on procedure tolerability and
aid in the planning of future studies; patients but not
researchers were blinded to CO2 concentration.
Magnetic resonance imaging
During CVR MRI, subjects wore a unidirectional
breathing circuit (Figure 1) designed by the University
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of Aberdeen and Intersurgical (Wokingham, UK; prod-
uct code: 2013018) that enabled administration of air or a
gas mixture containing 4 or 6% carbon dioxide; the
circuit was open to room air via a length of anesthetic
breathing circuit (with a volume greater than tidal
volume (350ml)) that served as a gas reservoir and
ensured participant safety when the cylinder gas flow
rate was insufficient or turned off. To ensure that accur-
ate concentrations of CO2 were administered, two cylin-
ders of certified, medical grade gas mixtures were used,
containing 6% CO2, 21% O2, 73% N2, and 4% CO2,
21% O2, 75% N2, respectively (BOC Special Products,
UK). The CO2 gas mixture was administered to volun-
teers using both a ‘‘1-min’’ (four 1-min blocks of air
alternated with three 1-min blocks of CO2)
19 and a
‘‘3-min’’ (three 2-min blocks of air interleaved with two
3-min blocks of CO2)
20 paradigm; as the results showed
improved reproducibility with the latter, the 3-min para-
digm alone was used for patient CVR scans. We mea-
sured vital signs (peripheral oxygen saturation, blood
pressure, heart rate, end-tidal CO2 (ETCO2), and respira-
tory rate) using a CD-3A CO2 sensor (AEI Technologies,
Pittsburgh, USA) and MR patient monitors (Millennia
3155A and Magnitude 3150 MRI; Invivo, Best,
The Netherlands). Gas cylinders and CO2 sensors were
positioned in the MR control room; tubes and sample
lines entered the scanner room via a waveguide.
Magnetic resonance imaging was acquired with a 1.5
Tesla MRI scanner (Signa HDxt, General Electric,
Milwaukee, WI) using an 8-channel phased-array
head coil. BOLD images were acquired every 3 s
during the CVR scan using axial single-shot gradient
echo echo-planar imaging (GE-EPI; TR/TE¼ 3000/
45ms, 90 flip angle, 25.6 25.6 cm field of view
(FoV), 64 64 acquisition matrix, 36 4mm contigu-
ous slices), including eight dummy scans prior to the
start of the gas paradigm.
For minor stroke patients, axial T2-weighted (T2W;
TR/TE¼ 7000/90ms, 24 24 cm FoV, Propeller acqui-
sition with matrix size 384, 1.5 signal averages,
36 4mm contiguous slices), axial fluid-attenuated
inversion recovery (FLAIR; TR/TE/TI¼ 8000/100/
2000, 24 24 cm FoV, 320 256 acquisition matrix,
36 4mm contiguous slices), gradient echo (GRE;
TR/TE¼ 900/15ms, 20 flip angle, 24 24 cm FoV,
384 256 acquisition matrix, 36 4mm contiguous
slices) and 3D T1-weighted imaging (T1W; inversion
recovery-prepared spoiled gradient echo (SPGR), sagit-
tal acquisition, TR/TE/TI¼ 9.6/4.0/500ms, 8 flip
angle, 25.6 25.6 cm FoV, 192 192 acquisition
matrix, 160 1.3mm slices). For healthy volunteers,
T2W and T1W structural images only were obtained
using similar parameters.
Participants were asked to rate the tolerability of the
CVR procedure on a four-point scale (‘‘intolerable,’’
‘‘not very tolerable,’’ ‘‘tolerable,’’ or ‘‘very tolerable’’)
and healthy volunteers were asked which of the two
paradigms was more tolerable.
Figure 1. (a) CVR MRI breathing circuit, designed by the University of Aberdeen and Intersurgical (Wokingham, UK). Red and
blue arrows indicate the flow of inhaled and exhaled gas respectively. 1¼ oxygen tubing for gas delivery; 2¼ open-ended reservoir
tube; 3¼ anaesthetic face mask; 4,5¼ one-way valve; 6¼ exit port for exhaled gas; 7¼ gas sampling line. (b) Photograph showing
subject positioned in the head coil with the breathing circuit and patient monitoring equipment in place.
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Image processing and analysis
End-tidal CO2. ETCO2 values were obtained using the
Millenia monitor with 1-s temporal resolution and
stored digitally. For patients and a subset of the volun-
teers, CO2 waveforms generated by the CD-3A sensor
were recorded digitally with a sampling rate of 20.s1;
these were converted to ETCO2 profiles using in-house
Matlab code for identifying peaks in CO2 concentration
corresponding to end-tidal values (MathWorks, Inc.,
MA, USA), which were temporally aligned with the
Millenia ETCO2 profile. The CD-3A sensor was cali-
brated prior to each scan using room air and the certi-
fied gas mixtures, and readings from this device were
used for determining CVR in patients; since most of the
volunteers were measured using the Millenia monitor,
ETCO2 readings were calibrated against the CD-3A
device in a subset of volunteers so that data for patients
and volunteers could be compared.
CVR. A range of parameters and quantification
methods have been proposed for CVR measurement,
including linear regression with21 and without19 a
tissue-dependent delay, parameterization of the
ETCO2-BOLD response curve,22 frequency-domain
analysis,23 and fitting the signal response using a non-
linear model.24 We chose to use linear regression with a
variable CVR delay, since this method is relatively
computationally efficient and there is good evidence
for a tissue-dependent delay in the BOLD response to
CO2.
21 The BOLD signal was regressed with an intercept
against ETCO2 and scan number (to account for linear
signal drift). The CVR (units %/mmHg) is the regression
coefficient corresponding to the ETCO2 regressor, with
the latter shifted by the delay that minimizes the residual
sum of squares, and is expressed as a percentage of the
mean signal during the first 45 s of the paradigm. CVR
and CVR delay were calculated in a voxel-wise manner
to generate parameter maps using the mean signal for
each ROI. CVR delay values were adjusted by þ4 s
to account for the time delay between exhalation and
detection of CO2 concentration changes.
Image pre-processing. MR images were converted from
DICOM to NIFTI format using SPM8 (Wellcome
Department of Imaging Neuroscience, London, UK);
BOLD dummy scans recorded prior to the start of the
paradigm were discarded and the remaining volumes
were spatially aligned to the mean volume using the
two-pass procedure in SPM8. T1W images were co-
registered to the T2W images using rigid-body registra-
tion and the transformation between the T2W and mean
BOLD image spaces was determined (FSL FLIRT25).
Regions of interest. The contrast-to-noise ratio of the
BOLD signal for individual voxels is generally small,
resulting in somewhat noisy parameter maps, particu-
larly in the WM.23 Many studies have employed auto-
matically generated tissue masks as regions of interest
(ROIs) to increase the contrast-to-noise ratio and
improve the model fitting, though such an approach
does not provide regional information and assumes a
global CVR delay. We therefore selected an intermedi-
ate approach, using ROIs to reduce the influence of
noise21 while retaining region- and tissue-specific infor-
mation. Sixteen ROIs were chosen to sample WM and
subcortical GM brain areas affected by SVD in add-
ition to two cortical GM ROIs (Figure 2). First, an
axial slice intersecting the basal ganglia was chosen
and ROIs covering the caudate heads, thalamus, and
putamen were drawn. A second slice superior to the
basal ganglia showing the lateral ventricles was
chosen for WM (periventricular, frontal and posterior)
and cortical GM (frontal and parietal lobe) ROIs.
Finally, a slice superior to the lateral ventricles was
selected and ROIs covering the centrum semiovale
were drawn. For each slice, the ROIs were extended
to cover the same regions or structures on a neighbor-
ing slice to increase the signal-to-noise ratio (for frontal
and posterior WM ROIs, three neighboring slices were
used). For patients, stroke lesions (as identified on the
FLAIR image) were excluded from the ROIs. Finally,
the ROIs were overlaid on the co-registered CVR maps;
voxels covering midline hyperintensities on the CVR
maps corresponding to blooming around the large
veins and venous sinuses were excluded to reduce the
influence of large vessels.
Statistical analysis
Descriptive statistics in the text are presented as
mean standard deviation. Differences within and
between the participant groups were tested in Matlab
using the t-test, assuming unequal variance for
unpaired data and with p< 0.05 (two-sided) as the sig-
nificance threshold. Reproducibility was measured
using variance component analysis in Matlab (anovan
function) and illustrated using Bland–Altman plots.26
The standard deviations resulting from this procedure
are presented as coefficients of variation (CVs), i.e. nor-
malized to the mean (averaged first over both visits and
then over subjects).
Results
Compliance, tolerability, and symptoms
Among the 15 healthy volunteers (mean age 33.8 9.5,
range 22–50 years; 27% female), CVR scans were
obtained in 13/15. Two subjects withdrew before data
were collected (one tolerated the pre-scan CO2 test run
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but experienced claustrophobia shortly after entering
the scanner and a second experienced anxiety during
the pre-scan CO2 test run); 11 of the 13 volunteers
scanned agreed to be scanned on a second occasion
(one had left the area, a second was excluded due to
anxiety during the first visit); one of the repeat scans
was halted due to sustained tachycardia that was likely
caused by anxiety exacerbated by head cold symptoms
(the subject had rated the first scan ‘‘very tolerable’’).
Two scans were interrupted due to scanner failure; at
two of the visits, the start time was not recorded, pro-
viding CVR but not CVR delay values. Most of the
Figure 2. (a) Regions of interest for a healthy volunteer, (b) CVR magnitude (%/mmHg) and (c) CVR delay (s) parameters maps at
the slice level shown by the right hand image in (a); both parameter maps were generated using BOLD data smoothed using a
4 mm full width at half maximum Gaussian kernel (note that ROI data were generated from unsmoothed data). (d–e) BOLD MRI
signal (dotted line) and model fit (solid line) for the (d) right putamen and (e) right centrum semiovale ROIs. The signal drift visible
in (d–e) is accounted for by a term in the model.
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CVR scans (11/15 for visit 1, 9/12 for visit 2) were rated
as either ‘‘tolerable’’ or ‘‘very tolerable’’ (Figure 3).
Volunteers had a range of previously described
hypercapnia-related symptoms: respiratory symptoms
(variously reported as shortness of breath, breathing
resistance etc.; n¼ 12 of 24 CVR scanning sessions
initiated), anxiety (n¼ 2), and temporary nausea, par-
aesthesia, confusion and blurred vision (n¼ 1). Three
participants had transient tachycardia apparent from
physiological monitoring data. No symptoms were
reported following 10 of the scans. One subject
reported the 3-min paradigm as more tolerable, while
two subjects preferred the 1-min paradigm and one sub-
ject chose a different paradigm at either visit; the
remainder had no preference.
Among the 15 patients (mean age 66.4 8.1, range
53–77 years; 20 % female), 14/15 completed CVR scan-
ning, compared with 13/15 for the volunteers (one sub-
ject tolerated the hypercapnic challenge outside the
scanner but was unable to tolerate MRI due to claus-
trophobia), all of whom rated the procedure as ‘‘toler-
able’’ or ‘‘very tolerable’’ (Figure 3). Five patients
reported no hypercapnia symptoms, while others
reported respiratory symptoms (n¼ 9), anxiety (n¼ 1)
and paraesthesia (n¼ 1). Tolerability was similar
among the 10 patients randomized to different CO2
concentrations: patients administered 4% CO2 rated
the scans as very tolerable (n¼ 2), tolerable (n¼ 2) or
intolerable (n¼ 1; experienced claustrophobia as noted
above), while those administered 6% CO2 rated the
scans as either very tolerable (n¼ 4) or tolerable
(n¼ 1). Since similar CVR values were observed
(Figure 4(e) and (f)) with greater changes in ETCO2
for 6% versus 4% CO2 administration (12.8 3.7 vs.
8.0 1.0mmHg, p< 0.01), the higher CO2 concentra-
tion was used for subsequent patient scans.
Patients had a range of radiological SVD features
including lacunes (60%), cerebral microbleeds (6.7%),
enlarged perivascular spaces (PVS; basal ganglia PVS
scores: 1 (40%), 2 (40%), 3 (20%); centrum semiovale
PVS scores: 0 (0%), 1 (33.3%), 2 (6.7%), 3 (46.7%), 4
(13.3%)), and WMH (perventricular Fazekas scores: 0
(6.7%), 1 (60%), 2 (33.3%); deep WM Fazekas scores:
0 (13.3%), 1 (66.7%), 2 (20%)).
Comparison of paradigms and reproducibility in
healthy volunteers
CVR and CVR delay measurements for each ROI are
shown in Table 1 and Figure 4(a) and (b). Average CVR
was significantly greater for the 3-min versus the 1-min
paradigm for all ROIs (0.041–0.313 vs. 0.021–0.251%/
mmHg respectively, p< 0.05); the average CVR delay
was similar in most GM ROIs, but was longer for the
3-min paradigm in WM ROIs. Inter-visit coefficients of
variation (CV; Table 2) were lower for the 3-min paradigm
in most ROIs (7.9–15.4% vs. 11.7–70.2% respectively for
CVR in GM). Large or negative variance estimates were
found in some ROIs for the 1-min paradigm; inspection of
the Bland–Altman plots (Supplementary Figures 1 to 4)
and individual model fits showed these data to be affected
by outliers caused by the periodicity of the 1-min para-
digm; as illustrated in Supplementary Figure 5, the algo-
rithm fits some noisy data by reversing the sign of the fitted
CVR while increasing the CVR delay by 60 s. This effect
was not seen for the 3-min paradigm due to the lower
frequency of the stimulus.
Regional CVR in healthy volunteers and patients
Table 1 and Figure 4(c) and (d) compare CVR
and CVR delays obtained in volunteers and patients,
Figure 3. Tolerability of CVR scanning for healthy volunteers and patients. Charts indicate the tolerability ratings given at each
visit by participants.
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Figure 4. Mean (a) CVR and (b) CVR delay values in healthy volunteers for the 1-min and 3-min CO2 paradigms, averaged first
over visits and secondly over subjects. (c–d) compare mean (c) CVR and (d) CVR delay values for healthy volunteers and patients,
obtained using the 3-min gas paradigm. (e–f) compare mean (e) CVR and (f) CVR delay for patients scanned using 4% (n¼ 4) and
6% (n¼ 10) CO2 gas mixtures. ‘‘*’’ indicates a significant difference (p< 0.05) between paradigms, between patients and volun-
teers, or between CO2 concentrations; error bars indicate the standard deviation after averaging over visits (part (a) only).
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measured using the same 3-min CO2 paradigm. Mean
CVR was higher for healthy volunteers in most GM
ROIs (0.172–0.313 vs. 0.110–0.234%/mmHg); CVR
was lower in WM regions, where mean values were
similar for volunteers and patients (0.035–0.124%/
mmHg). The CVR delay was similar for patients and
volunteers in GM (1.3–14.5 s); in some WM ROIs, the
CVR delay was significantly greater for healthy volun-
teers than for patients (16.2–43.9 vs. 31.1–47.9 s).
Discussion
Several cerebrovascular vasodilatory stimuli and para-
digms have been presented in the literature but rarely
tested in our patient population. Our first aim was
therefore to select a suitable stimulus for studies of
cerebral SVD and minor stroke. A range of methods
have been proposed, including simple respiratory chal-
lenges such as breath-holding and hyperventilation,
pharmacologic stimuli such as acetazolamide, inspired
gas challenges, and automated systems for targeting
precise changes in end-tidal gas concentration. We
selected a hypercapnic challenge because CO2 is
endogenous, simple to administer and measure using
widely available equipment, and safe to inhale at low
concentrations. A fixed-inspired CO2 challenge was
chosen as a compromise between experimental preci-
sion and ease of implementation for use in multicenter
clinical studies: unlike an acetazolamide injection, a
CO2 stimulus is easily administered and quickly
reversed; hyperventilation and breath-hold challenges
require less equipment but rely on a higher degree of
Table 1. Mean CVR and CVR delay measurements in healthy volunteers and patients
CVR (%/mmHg) CVR Delay (s)
Healthy volunteers Patients Healthy volunteers Patients
region 1 min 3 min 3 min 1 min 3 min 3 min
FCGM 0.193 (0.053) 0.230a (0.056) 0.110b (0.042) 9.9 (2.6) 11.9a (3.0) 10.0 (6.4)
PCGM 0.251 (0.053) 0.313a (0.064) 0.234b (0.079) 12.7 (3.0) 14.5a (3.5) 14.3 (6.2)
LCH 0.147 (0.063) 0.172a (0.050) 0.124b (0.064) 11.9 (8.0) 11.0 (2.9) 1.3b (11.7)
RCH 0.142 (0.060) 0.174a (0.050) 0.120b (0.055) 11.2 (8.4) 10.5 (2.7) 4.1 (13.3)
LP 0.151 (0.067) 0.188a (0.072) 0.139 (0.046) 11.4 (8.0) 10.0 (2.9) 11.4 (4.3)
RP 0.164 (0.082) 0.207a (0.097) 0.144 (0.054) 10.8 (8.0) 9.7 (2.9) 10.7 (5.7)
LT 0.197 (0.045) 0.250a (0.061) 0.163b (0.063) 10.3 (3.1) 13.3a (3.0) 11.3 (5.3)
RT 0.208 (0.060) 0.270a (0.116) 0.158b (0.058) 10.3 (3.2) 12.9a (3.9) 11.4 (5.1)
LCS 0.021 (0.014) 0.041a (0.015) 0.040 (0.024) 28.0 (18.0) 47.9a (19.6) 26.2b (20.2)
RCS 0.022 (0.016) 0.045a (0.013) 0.038 (0.013) 30.8 (18.8) 43.3a (23.0) 43.9 (23.9)
LPVWM 0.076 (0.046) 0.124a (0.055) 0.090 (0.042) 20.3 (8.1) 31.1a (10.1) 21.8b (9.0)
RPVWM 0.063 (0.020) 0.101 a (0.031) 0.092 (0.047) 19.9 (6.1) 34.0a (8.9) 24.1b (8.1)
LFWM 0.028 (0.023) 0.055a (0.032) 0.038 (0.016) 27.7 (17.4) 34.5 (28.4) 28.9 (36.3)
RFWM 0.024 (0.023) 0.053a (0.015) 0.035b (0.021) 32.2 (26.2) 41.6 (20.5) 16.2b (20.5)
LPWM 0.026 (0.022) 0.047a (0.014) 0.060 (0.025) 24.3 (17.0) 47.8a (18.6) 41.8 (21.7)
RPWM 0.031 (0.028) 0.061a (0.019) 0.063 (0.020) 29.7 (23.3) 46.0a (18.7) 41.6 (24.0)
Note: Healthy volunteer measurements were first averaged over both scans.
aIndicates a significant difference between 1-min and 3-min paradigms.
bIndicates a significant difference between patients and healthy volunteers (3-min paradigm; p< 0.05).
RPWM/LPWM: right/left posterior WM; RFWM/LFWM: right/left frontal WM; RPVWM/LPVWM: right/left periventricular WM; RCS/LCS: right/left
centrum semiovale; RT/LT: right/left thalamus; RP/LP: right/left putamen; RCH/LCH: right/left caudate head; PCGM: posterior cortical GM; FCGM:
frontal cortical GM.
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participant cooperation, and with breath holding it is
difficult to monitor the participant’s physiological par-
ameters non-invasively. The benefits and drawbacks of
different CVR challenges,24,25 and other practical
aspects of CVR measurement in clinical research,27
have been discussed in detail elsewhere. We chose to
use a 6% CO2 concentration in medical air since we
measured similar CVR values and tolerability with
greater ETCO2 and signal changes with this gas mixture
in a randomized comparison with 4% CO2. Carbogen
(CO2 and O2 with no nitrogen) gas mixtures have also
been used for measuring CVR but the effects on the
BOLD signal via changes in CBF and other mechan-
isms are more complex.28 The experiments performed
here could also be performed using a computerized
system for prospective targeting of ETCO2 values,
subject to sufficient patient cooperation, availability
of specialized equipment and provided a calibration
step is performed before CVR scanning; such an
approach should result in a more reproducible stimulus
with better correspondence between ETCO2 and arter-
ial PaCO2.
29
Comparing two previously published hypercapnia
paradigms, we found the paradigm based on 3-min
CO2 spells to be more reliable than a 1-min paradigm
for measuring CVR and the CVR delay. This is partly
because more signal is collected during the 3-min para-
digm (12min vs. 7min total duration). Another factor
is the longer repetition period of the 3-min paradigm,
which reduces the likelihood of selecting the ‘‘wrong’’
minima as illustrated in Supplementary Figure 5. Such
errors were observed in a small number of cases only
Table 2. Coefficients of variation (%) resulting from variance component analysis of healthy volunteer data for both CO2 paradigms
CVCVR (%) CVCVR Delay (%)
1 min 3 min 1 min 3 min
region Subject Visit Subject Visit Subject Visit Subject Visit
FCGM 28.1 15.1 21.5 10.7 23.6 20.8 25.2 16.1
PCGM 16.8 17.1 15.2 15.4 16.1 23.1 5.3 30.9
LCH 29.0 49.6 27.6 7.9 - 120.7 23.2 23.6
RCH - 70.2 27.6 8.7 - 128.6 20.6 25.1
LP 26.0 51.9 31.1 13.6 - 126.4 27.6 16.0
RP 36.5 52.4 39.5 8.7 - 126.0 32.2 7.3
LT 20.9 17.6 22.0 9.3 28.5 18.6 20.7 15.7
RT 30.3 11.7 40.5 11.2 24.3 26.8 25.3 19.8
LCS 69.0 34.0 31.0 18.3 71.5 19.9 31.0 25.2
RCS 53.7 67.4 25.0 17.5 51.4 37.1 47.8 19.5
LPVWM 58.8 31.7 47.0 18.3 32.3 17.1 24.0 23.0
RPVWM 25.7 27.5 26.0 16.1 14.4 32.2 24.9 10.5
LFWM 17.6 113.9 46.6 17.4 32.4 63.3 66.3 42.9
RFWM - 141.0 21.2 22.3 46.1 75.0 33.1 35.4
LPWM - 125.1 25.2 24.4 38.8 61.6 22.1 37.7
RPWM 85.0 38.5 23.2 22.2 66.2 18.6 32.3 25.9
Note: The ANOVA procedure yielded negative variance component estimates in some ROIs for the 1-min paradigm; these values, which may be caused
by outliers as described in the text, are not shown and are indicated by ‘‘-’’.
RPWM/LPWM: right/left posterior WM; RFWM/LFWM: right/left frontal WM; RPVWM/LPVWM: right/left periventricular WM; RCS/LCS: right/left
centrum semiovale; RT/LT: right/left thalamus; RP/LP: right/left putamen; RCH/LCH: right/left caudate head; PCGM: posterior cortical GM; FCGM:
frontal cortical GM.
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due to the use of pre-scan ETCO2 data, which negates
the periodicity of the paradigm; such errors could be
further suppressed by further constraining the per-
mitted delay values, but this would potentially bias
the results, particularly in regions, voxels, or patients
with slow CVR response (the group of greatest interest)
and appropriate arbitrary limits would be difficult to
determine a-priori without further knowledge of
human cerebrovascular biology. We also found that
CVR and the CVR delay were on average greater for
the 3-min paradigm, with the difference more pro-
nounced in WM ROIs. This observation suggests that
the linear regression model is an incomplete description
of the BOLD response to changes in ETCO2. Improved
fitting will likely result from convolving the ETCO2
regressor with an impulse response function21 or by
permitting multiple (e.g. fast and slow) components to
the response in any given tissue. However, the ideal
approach is yet to be determined and the inclusion of
additional fitting parameters would increase the com-
putational burden and likely reduce the precision of
other parameters. Further investigation is required to
determine the optimal approach and care should be
taken when comparing CVR values between studies.
In general, data were more reproducible for GM than
WM ROIs, which is expected due to the greater CBF in
GM. The tolerability was similar for the two paradigms
tested. Healthy volunteers had a similar rate of hyper-
capnia-related symptoms to patients but, on average,
found the CVR procedure less tolerable compared
with patients; this may be due to the administration
of two CVR paradigms per session in volunteers, or
due to healthy volunteers being less accustomed than
patients to medical procedures. Encouragingly, all
patients who underwent CVR scanning described the
experience as either ‘‘tolerable’’ or ‘‘very tolerable.’’
In an analysis of 434 CVR scans across multiple patient
groups, Spano et al.30 also reported a high success rate
for examinations using a prospective ETCO2 targeting
approach, with CVR maps generated for 83.9% of
scans.
There are limited data on the reproducibility of
BOLD CVR in the literature. Goode et al.,31 using
10% CO2 (9min paradigm duration at 1.5T) reported
coefficients of variation for CVR of around 25% in
whole-brain GM and WM regions,31 comparable to
our findings. Kassner et al.32 reported higher reprodu-
cibility (6.8% and 9.9% in GM and WM, respectively,
at 1.5T) using a paradigm of around 12-min duration,32
attributing this to more precise control of the ETCO2
stimulus through use of a rebreathing circuit; the use of
whole-brain ROIs and a constant CVR delay would
also likely influence their findings.
The voxel-wise BOLD signal response to hypercap-
nia typically has low contrast-to-noise ratio,
particularly in the WM, resulting in noisy parameter
maps. As a result, several previous studies have used
whole-brain tissue masks, but this precludes region-spe-
cific information needed for studies of SVD, which pri-
marily affects periventricular WM, deep WM, and
subcortical GM. We therefore selected an intermediate
approach, averaging signal over ROIs to reduce param-
eter uncertainty while retaining region-specific informa-
tion. This approach also permits manual exclusion of
the large draining veins and sinuses, which have a sig-
nificant influence on the signal in surrounding voxels
due to the ‘‘blooming’’ effect. Despite this approach,
reproducibility was lower in ROIs with low CVR; use
of higher field MRI (e.g. 3T) should in principle permit
increased reproducibility in these regions.
In common with previous volunteer studies, we
found CVR to be greater in GM than in WM. Few if
any studies have specifically measured subcortical GM
CVR, which we found to be comparable to that in cor-
tical GM. CVR values measured using the 1-min CO2
challenge in GM and WM had similar magnitude to
those reported by Thomas et al.21 using the same para-
digm. Within the WM, CVR was greater in periven-
tricular ROIs than in the deep WM areas, which may
be due to inclusion in the ROI of the draining veins
surrounding the lateral ventricles (it being very difficult
to ensure that no draining veins have been included).
Also, in agreement with Thomas et al., we report a
delay of approximately 20 s between the BOLD
responses in GM and WM; this difference was greater
still using the 3-min paradigm. Sam et al.13 also
observed differences between GM and WM in addition
to reporting data for WMH, which were found to have
reduced CVR and increased delay compared with
normal-appearing WM. It is noted that the speed and
magnitude of the WM response could be influenced by
a steal effect by the faster-responding GM in addition
to differences in intrinsic tissue properties such as cere-
bral blood volume and vasodilatory function.33
BOLD CVR was on average greater in healthy vol-
unteers than in patients for most ROIs. Since the pri-
mary purpose of this work was to develop and assess
protocols, the groups were not matched for age or vas-
cular risk factors. However, the difference is consistent
with the expected reduction in vasoreactivity both with
ageing34,35 (patients were older than the healthy volun-
teers) and cerebrovascular disease.6,14 More surpris-
ingly, the CVR delay was shorter for patients in most
ROIs. Thomas et al. also reported a longer CVR delay
in young versus older participants, though neither
group comprised patients.
Other aspects of the BOLD CVR examination
protocol, not addressed in this work, should also be
considered for CVR studies in SVD. While a field
strength of 1.5 T, as used in this work, has the benefit
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of wide availability in clinical settings, 3T scanning
would likely increase reproducibility as a result of
higher signal- and contrast-to-noise ratio for BOLD
MRI; adverse susceptibility effects including blooming
artefacts around the large veins are also greater at 3 T,
but this can be mitigated by increasing bandwidth and
reducing voxel size, which will also reduce partial
volume effects on CVR values, particularly in small
structures and lesions. We also did not address the opti-
mization of MR acquisition parameters, using, as in
most CVR studies, ‘‘standard’’ BOLD fMRI values
for the echo time and repetition time. The choice of
echo time affects the signal-to-noise ratio, sensitivity
to deoxyhaemoglobin, and other aspects of the acqui-
sition protocol. Ravi et al.36 proposed the use of a
shorter echo time to suppress negative CVR values
that were attributed by the authors to displacement of
CSF by dilated vessels. Finally, the increasing availabil-
ity of simultaneous multislice and other parallel ima-
ging techniques on commercial MR scanners will
facilitate higher spatial and/or temporal resolution in
future studies.37 The ‘‘HARNESS’’ (Harmonising
Brain Imaging Methods for Vascular Contributions
to Neurodegeneration) collaboration, currently in pro-
gress, and ongoing discussions within the wider CVR
community, should result in further recommendations
and guidance relevant to the conduct of CVR experi-
ments in SVD research.
In conclusion, the protocol described herein will
permit further investigation of the relationship between
cerebral SVD burden and subcortical CVR in cross-
sectional studies of patients presenting with minor
ischemic stroke, cognitive impairment, and CADASIL
(INVESTIGATE-SVDs: ISRCTN1051422). Since the
progression of WM changes visible by structural MRI
is typically slow,38 this protocol will also be used to
provide intermediary end-points in clinical trials of
drugs to prevent and reverse SVD (LACI-1:
ISRCTN12580546, TREAT-SVDs: NCT03082014).
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Protocol
Preventing cognitive decline and
dementia from cerebral small vessel
disease: The LACI-1 Trial. Protocol and
statistical analysis plan of a phase IIa dose
escalation trial testing tolerability, safety
and effect on intermediary endpoints of
isosorbide mononitrate and cilostazol,
separately and in combination
Gordon W Blair1,2,3, Jason P Appleton4, Zhe Kang Law4,5,
Fergus Doubal1,2,3, Katie Flaherty4, Richard Dooley4,
Kirsten Shuler1,2,3, Carla Richardson4, Iona Hamilton1,2,3,
Yulu Shi1,2,3, Michael Stringer1,2,3, Julia Boyd6,
Michael J Thrippleton1,2,3, Nikola Sprigg4, Philip M Bath4
and Joanna M Wardlaw1,2,3
Abstract
Rationale: The pathophysiology of most lacunar stroke, a form of small vessel disease, is thought to differ from large
artery atherothrombo- or cardio-embolic stroke. Licensed drugs, isosorbide mononitrate and cilostazol, have promising
mechanisms of action to support their testing to prevent stroke recurrence, cognitive impairment, or radiological
progression after lacunar stroke.
Aim: LACI-1 will assess the tolerability, safety, and efficacy, by dose, of isosorbide mononitrate and cilostazol, alone and
in combination, in patients with ischemic lacunar stroke.
Sample size: A sample of 60 provides 80þ% power (significance 0.05) to detect a difference of 35% (90% versus 55%)
between those reaching target dose on one versus both drugs.
Methods and design: LACI-1 is a phase IIa partial factorial, dose-escalation, prospective, randomized, open label,
blinded endpoint trial. Participants are randomized to isosorbide mononitrate and/or cilostazol for 11 weeks with dose
escalation to target as tolerated in two centers (Edinburgh, Nottingham). At three visits, tolerability, safety, blood
pressure, pulse wave velocity, and platelet function are assessed, plus magnetic resonance imaging to assess cerebro-
vascular reactivity in a subgroup.
Study outcomes: Primary: proportion of patients completing study achieving target maximum dose.
Secondary: symptoms whilst taking medications; safety (hemorrhage, recurrent vascular events, falls); blood pressure,
platelet function, arterial stiffness, and cerebrovascular reactivity.
Discussion: This study will inform the design of a larger phase III trial of isosorbide mononitrate and cilostazol in lacunar
stroke, whilst providing data on the drugs’ effects on vascular and platelet function.
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Introduction and rationale
Cerebral small vessel disease (SVD) is a common dis-
order that affects small perforating arterioles in the
brain’s deep white and gray matter.1 It causes 25% of
ischemic strokes (‘‘lacunar’’ stroke), intracerebral hem-
orrhage, vascular and many mixed dementias, gait and
bladder dysfunction.1,2 Cardioembolism and athero-
thromboembolism are uncommon in lacunar stroke
and SVD, respectively. Although the pathophysiology
remains poorly understood, endothelial dysfunc-
tion,1,3,4 inflammation,3,5 blood–brain barrier failure,6
and impaired vasoreactivity4,7 have been demonstrated.
There is no specific secondary prevention for lacunar
stroke, SVD-associated dementia, or progression of
SVD lesions on neuroimaging.1 We recently summar-
ized available drugs with potentially relevant
actions and identified two agents that seemed worthy
of further testing: isosorbide mononitrate (ISMN) and
cilostazol.8
ISMN, a nitric oxide (NO) donor, is commonly used
in angina. NO levels are reduced in acute, 9 chronic10
and possibly in lacunar stroke.11 NO has many poten-
tially beneficial effects for SVD including improved
vasoreactivity, neuroprotection, and anti-inflammatory
effects.8 In the Efficacy of Nitric Oxide in Stroke
(ENOS) trial, the NO donor glyceryl trinitrate admin-
istered within 6 h of all types of stroke, improved
cognitive test scores at 90 days.12 However, there are
few data on ISMN in lacunar stroke in part because
ischemic heart disease, for which ISMN is licensed, is
relatively infrequent in those with SVD.13
Cilostazol is a phosphodiesterase 30 inhibitor,8
mainly used for peripheral vascular disease in Europe
and North America,14 but more widely used for cere-
brovascular disease prevention in Asia-Pacific coun-
tries. Cilostazol has mild antiplatelet effects plus
several potentially beneficial effects for SVD including
improved blood–brain barrier integrity, vasodilatory
and anti-proliferative activity, improves oligodendro-
cyte maturation and hence myelination,15 and reduces
white cell chemotaxis.8 In models, it improved motor
and cognitive function, and reduced infarct volume16
and in human lacunar stroke it improved middle cere-
bral artery pulsatility index.17 Over 6000 patients, many
with lacunar stroke, have been included in trials of
cilostazol in secondary stroke prevention mostly in
Asia-Pacific countries (Figure 1); a meta-analysis of
these suggested that cilostazol reduces recurrent
stroke.18–21
There is little experience of ISMN in lacunar stroke,
cilostazol is rarely used for stroke prevention in Europe
or the Americas. There are no data on the effects of
cilostazol when combined with ISMN yet the effects
are potentially synergistic.8
Therefore, the Lacunar Intervention Trial-1
(LACI-1) will test ISMN and cilostazol, alone and
combined, in patients with lacunar ischemic stroke, to
assess their tolerability, safety, and efficacy on mechan-
istic endpoints including cerebrovascular reactivity
assessed using magnetic resonance imaging (MRI).
Treatment will be given in addition to current guide-
line-based post-stroke secondary prevention. LACI-1
will inform the design of a larger trial to test ISMN
and cilostazol effects on recurrent vascular events, cog-
nition, disability, death, and SVD lesion progression on
MRI (LACI-2). LACI-1 was designed through a UK
National Institute for Health Research Stroke Research
Network Expert Writing Group.
Methods
Design
Phase IIa, partial factorial, dose-escalation, prospect-
ive, randomized, open label, blinded endpoint
(PROBE) trial conducted in two UK centers
(Edinburgh, Nottingham).
Participants are randomized in a 1:1:1:1 ratio
into four groups: cilostazol alone; ISMN alone;
cilostazol and ISMN combined, started immediately
(with ISMN given first); and cilostazol and ISMN com-
bined, start delayed for three weeks (cilostazol first)
(Figure 2). The delayed start group also provides a
‘‘no drug’’ comparison group during the first three
weeks.
Participants take trial medication for 11 weeks. The
dose is increased, in weekly increments over two to
three weeks as tolerated, sustained until eight weeks
post-randomization, then decreased gradually over
two weeks and stopped (Supplementary Information
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gives medication by study week). The escalating dose is
designed to reduce potential adverse effects following
initiation of cilostazol and is standard for ISMN.
Gradual dose reduction aims to prevent large hemo-
dynamic changes on cessation of medication.
Patient population
Inclusion:
1. Mild symptomatic ischemic lacunar stroke in the
past four years, compatible with a clinical lacunar
stroke syndrome, with brain MRI or CT scanning
showing a symptomatic small subcortical (lacunar)
infarct (<20mm), or if no recent relevant infarct is
visible, that excluded other cause for symptoms.
Clinical or imaging evidence of a prior non-
lacunar stroke is not an exclusion as long as the
randomizing clinician is confident that the non-
lacunar stroke is not responsible for the index lacu-
nar stroke symptoms.
2. Age 35 years.
3. Independent in activities of daily living (modified
Rankin Scale of 2) and able to give informed
consent.
Exclusion:
1. Other significant neurological illness since the inci-
dent stroke.
2. Age< 35 years.
3. Montreal Cognitive Assessment (MoCA)< 20.
4. Requiring assistance with activities of daily living
(modified Rankin Scale 3).
5. Active cardiac disease.
6. Carotid stenosis> 50% (NASCET criteria) on the
side of the symptomatic stroke lesion requiring
urgent intervention. Note: successfully treated car-
otid artery stenosis may be included.
7. Definite indication for, or contraindication to,
cilostazol or ISMN.
8. Unable to swallow.
9. Bleeding tendency.
10. Unlikely to comply with trial medication based on
past history or lifestyle.
11. Planned surgery during the trial period.
12. History of intracranial hemorrhage (but not
asymptomatic hemorrhagic transformation of an
infarct).
13. Other life threatening illness.
14. History of drug overdose, attempted suicide or sig-
nificant active mental illness.
15. Pregnant or breastfeeding women.
16. Women of childbearing age not taking
contraception.
17. Use of prohibited medications (anticoagulants,
phosphodiesterase 50 inhibitors, macrolides, keto-
conazole, itraconazole, omeprazole).
18. Creatinine clearance< 25ml/min.
19. Hepatic impairment.
20. Current enrolment in another Clinical Trial of
Investigational Medicinal Product (CTIMP).
Randomization
Baseline information is entered on a password-pro-
tected website (https://nottingham.ac.uk/nszwww/
prev-svd/). Once checked and complete, a computer
algorithm randomizes participants at a 1:1:1:1 ratio to
a study group. Randomization is minimized on age
/>70 years, SVD severity on brain scanning (SVD
score />2),22 systolic blood pressure />140mmHg
and time after stroke />100 days.
Figure 1. Meta-analysis of trials of cilostazol for secondary stroke prevention.31–35
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Figure 2. Flow chart of study procedures.
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Intervention
The starting dose for cilostazol is 50mg twice daily,
increasing to 100mg twice daily (target dose). The start-
ing dose of ISMN is 25mg once daily increasing to
25mg twice daily (target dose). Participants allocated
to both drugs aim to attain the same target doses as
for the drugs alone (dose schedules in Supplementary
Information). Unused tablets are returned to Pharmacy
for counting and destruction at the end of the 11-week
period.
Primary outcome
The proportion of participants achieving target
dose assessed by alternate weeks structured question-
naire, supplemented by diary and Pharmacy tablet
count.
Secondary outcomes
1. Symptoms (headache, nausea, diarrhea, vomiting,
bleeding) recorded by structured questionnaire.
2. Safety (systemic or intracranial bleeding, recurrent
vascular events, death).
3. Blood pressure.
4. Platelet function (P-selectin flow cytometry).23
5. Systemic arterial stiffness (pulse wave velocity and
pulse wave analysis using the SphygmoCor tono-
metry device).
6. In a subgroup recruited in Edinburgh, cerebrovas-
cular reactivity (CVR)7 in white matter and cere-
brospinal fluid and blood pulsatility, assessed
using MRI. Acquisition details are provided in
the Supplementary Information.
Blinding
The processing and analysis of CVR, platelet function,
pulse wave velocity, blood pressure, and all tablet
counts, study questionnaires and compliance data will
be performed blind to treatment allocation. Apart from
the study research fellow and research nurse, other staff
performing the above assessments will not be aware of
the treatment allocation, particularly during image ana-
lysis, blood tests and follow-up data analysis. When
talking to participants, the tablets will only be referred
to as ‘‘A’’ or ‘‘B’’ to facilitate patients’ understanding
of procedures.
Data monitoring committee
An independent data monitoring committee (DMC) is
established, chair Prof. Colin Baigent (Oxford).
Sample size
A sample size of 55 provides 80% power (signifi-
cance 0.05) to detect a difference of 90% versus 55%
(i.e. an absolute difference of 35%) between those
reaching target doses on one drug versus both drugs;
i.e. we expect that 35% fewer patients will tolerate both
versus one of the two drugs and the sample size is set to
be able to detect that difference. For CVR, lacunar
stroke patients have impaired middle cerebral artery
vasoreactivity on transcranial Doppler ultrasound
with an effect size of 25%, standard deviation (SD) of
40%.4 Little data exist on CVR measured by blood
oxygen level dependent (BOLD) MRI in lacunar
stroke.7 The 40-participant sample in Edinburgh will
allow detection of a relative difference in CVR of
25% (4% versus 3% signal; with estimated common
SD of 40%) between no treatment and target dose of
both drugs, significance 0.05 and power 0.80.
Allowing for losses, 60 participants will be recruited
in total.
Analyses
Image processing. Structural MR images will be scored
for SVD lesion burden using validated scales24 and pro-
cessed to generate tissue segmentation maps using vali-
dated software.25 CVR (% signal change/mmHg
change in end-tidal CO2) will be determined by multiple
linear regression of the BOLD MRI signal time course,
with the end-tidal CO2 and time (to account for scanner
drift) as regressors, for specific tissue regions for com-
parison of trial drugs and doses.
Statistical. We will compare cilostazol versus none,
ISMN versus none, and cilostazol and ISMN given
immediately versus both given after a delay (the
delayed start provides a drug-free control period;
having two groups that both get both drugs compares
drug initiation with one versus the other drug). We will
compare symptoms, blood pressure, arterial stiffness,
platelet function, and CVR by treatment allocation.
The primary outcome (proportion of participants
achieving target dose) will be assessed using binary
logistic regression with adjustment for minimization
factors; age, SVD score, systolic blood pressure, and
time from stroke to randomization (days). The second-
ary outcomes will be assessed using binary logistic
regression for binary variables, multiple linear regres-
sion for continuous variables and Cox proportional
hazards regression for variables which have a time-
until-event component. As data are collected over an
11-week period, time trends will also be examined.
Data tables and figures summarizing the main
planned comparisons are provided in the
Supplementary Information.
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Study organization and funding
The study is funded by The Alzheimer’s Society and
will be performed in the Centre for Clinical Brain
Sciences and Edinburgh Clinical Trials Unit,
University of Edinburgh and the Stroke Trials Unit,




LACI-1 follows participants intensively over 11 weeks
including 3 research clinic visits (to assess BP, platelet
function, arterial stiffness, CVR, and symptoms) and 5
telephone follow-ups (to assess side-effects and guide
dose escalation). The intense follow-up provides data
on dose escalation and safety to inform a future larger,
pragmatic, phase III trial with less frequent follow-up.
PROBE design
The PROBE design blinds the main study outcomes
whilst maintaining feasibility of dose escalation.
A double-blind design proved to be impractical as
there is no matching placebo for either study drug.
Furthermore, masking by over-encapsulation was
impractical and prohibitively expensive when combined
with dose escalation. Complicated arrangements for
dispensing multiple bottles of study drug, with different
dose combinations, were required, with high risk of
reduced compliance, confusion, and incorrect medica-
tion. The PROBE design is well established26 and the
Figure 3. Mechanistic endpoints (intermediary outcomes) assessing brain and systemic vascular function in response to cilostazol
and isosorbide mononitrate. (a) Brain—CVR MRI scans. The dark blue areas indicate the least reactive tissues, and the bright red
areas are the most reactive tissues. (b) Carotid and vertebral arteries—phase contrast MRI scan, which also measures intracranial
arterial, venous sinus and CSF flow. (c) Systemic arteries—aortic and radial artery pressure waveforms and pulse wave velocity.
(d) Platelet function is assessed with P-selectin flow cytometry.
International Journal of Stroke, 0(0)
6 International Journal of Stroke 0(0)
study has been designed and staffed appropriately to
maintain investigator blinding at the point of outcome
assessment.
Factorial design
The factorial design compares each drug to no drug and
also combination therapy to no therapy. The ‘‘delayed
start’’ group provides a modified ‘‘no-drug’’ control
group as these participants do not receive medication
for the first three weeks after randomization so are
not on any medication at the second visit (week 3).
They start medication following the week 3 visit,
creating a more efficient design, as all participants
receive study drug and tests the effect of which drug
is commenced first in the combination groups
(Supplementary Information). Randomization using
minimization increases statistical power.
Dose escalation
The common side-effects of both study drugs (ISMN:
headache; cilostazol: headache, palpitations) are usu-
ally encountered soon after starting the medication.
Slow dose escalation at treatment initiation is widely
used to lessen these side-effects. However, evidence
for this comes from a single non-randomized study27
and personal experience. Dose escalation of dipyrid-
amole, a phosphodiesterase 50 inhibitor with a similar
pharmacodynamics profile to cilostazol, did not reduce
headache in a blinded randomized comparison.28
LACI-1 will provide objective evidence on the fre-
quency of common inception side-effects to inform a
larger pragmatic trial at up to 20 sites to select the
regimen that best balances simplicity with tolerability
and compliance.
Mechanistic endpoints
Stroke recurrence, whilst a significant problem follow-
ing lacunar stroke, occurs relatively infrequently
and late, whilst radiological progression of SVD is rela-
tively slow.29 Hence large trials with long follow-up
periods are required to detect treatment effects. To
enhance information on pharmacological effects of
cilostazol and ISMN at these doses, we will use mech-
anistic vascular function endpoints (Figure 3): changes
in CVR measured using hypercapnic challenge BOLD
MRI scans,7 and changes in arterial, venous, and cere-
brospinal fluid flow characteristics measured using
phase-contrast MRI; improvement in systemic vascular
stiffness using pulse wave velocity (SphygmoCor tono-
metry device); and alteration in platelet function will
test effects on platelet activation and provide safety
data.30
Bleeding
Cilostazol (but not ISMN) has a low risk of bleeding, a
potential interaction with the background antiplatelet
medication that patients will be taking. One of the aims
of LACI-1 is to assess whether bleeding is enhanced
when patients take these combinations of antiplatelet
agents.
Summary and conclusions
LACI-1 will provide data on tolerability, safety and
surrogate efficacy markers for cilostazol and ISMN in
patients with lacunar stroke, and will inform the design
of a larger pragmatic phase III study.
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